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Abstract
Background
The incidence of upper gastrointestinal cancer is increasing in the United Kingdom [1]. Radical 
resection of the tumour remains the most common curative intent treatment. Patients undergoing 
resections for malignancy are often malnourished [2-8].
Much research [5, 9-11] has indicated that malnutrition impedes surgical recovery. Therefore it 
would seem logical that the use of nutritional support may improve clinical outcome and aid 
recovery. There are two methods for delivering nutritional support, enterally and parenterally. 
Early enteral nutrition after major surgery has been advocated as an option for improving the 
clinical outcome of patients undergoing major cancer resections [12-16]. However, a meta­
analysis [17] has suggested the current evidence is inconclusive. Traditionally, the majority of 
patients are starved for prolonged periods [18].
Aims
The aim of the randomised controlled trial presented in this thesis was to determine if early 
enteral nutrition, compared with the traditional management, improved clinical outcome.
Methods
Ninety-six patients were recruited in this analysis, over a 3-year period. There were 2 groups; one 
group received Early Enteral Nutrition (EEN group), which was delivered via a jejunostomy. The 
other group was managed with traditional, standard management (STD group), until it was 
deemed safe by the operating surgeon to commence oral diet and fluids.
Outcomes
The primary outcome of the trial was length of hospital stay. In addition, there were several 
secondary outcomes, including the development of major and minor complications, nutritional 
parameters, health related quality of life and a cost comparison.
Results
Median length of hospital stay for the standard group was 20 days (Range 14-28 days); and for 
the enteral nutrition group 16 days (Range 13-222 days) Mann Whitney U=822.5, p=0.021. Major 
complications were less frequent in the enteral nutrition group.
Summary of Results STD group 
(N-42)
EEN group 
(N=54)
Test Statistic 
(P)
Length of Hospital (days) 20 16 U=822.5 (0.021)
Anastomotic leak % (N) 16.6 (7) 1.8(1) Chi= 6.73 (0.01)
Wound infection %(N) 28.5(12) 5.5 (3) Chi =16.3 (0.0001)
Chest Infection % (N) 21.4 (9) 9.3 (5) Chi =6.03 (<0.05)
There were no statistically significant differences in health related quality of life between the 
groups. The enteral nutrition group EEN resulted in a cost saving of £1241 (£828-£5,315) per 
patient.
Conclusion
This was an early analysis of an ongoing trial. The results at present indicate that the use of Early 
Enteral Nutrition maybe clinically effective, maybe cost effective, and may reduce a patients’ 
duration of hospital stay. However, full conclusions cannot be made until the close of the main 
trial.
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Introduction
Upper Gastrointestinal Cancers (UGI) are a major cause of death in the UK 
accounting for approximately 19,000 deaths per annum [1]. Surgical resection of 
the tumour has long been considered to be the only hope of a cure [19]. Upper 
Gl resection for malignancy is a major surgical procedure, and is associated with 
high morbidity and a well recognised in-hospital mortality rate [19-39].
Patients admitted for UGI resection are often malnourished [2-8]. Nutritional 
support remains the only modality capable of correcting and treating malnutrition 
[40]. However, traditional post-operative management of the patient after UGI 
resection often involves a prolonged period of ‘nil by mouth’, with only 
intravenous fluid therapy. Nutritional support is ad hoc, is often delayed and 
generally relies on parenteral nutrition (PN).
PN involves the delivery of nutrients directly into the systemic circulation, 
therefore bypassing the gastrointestinal tract (GIT). The use of enteral nutrition 
(EN) involves the delivery of nutrients via the GIT. It is hypothesised that EN may 
help to preserve GIT function and structure [41-45], having a central role in gut 
mediated immunity [46, 47]. Conversely, PN is associated with impaired GIT 
function and structure [48-51].
Studies have concluded that EN is superior to PN in improving clinical outcome 
[52-57] [58]. Length of hospital stay (LOHS) was reduced in the EN groups as 
compared to the PN groups in two RCTs [58] [52].
It is hypothesised that these benefits are further enhanced if EN is used 
immediately after the initiation of an acute phase response, for example after 
major surgery. Therefore, the use of immediate EN or early EN (EEN) seems 
optimal.
However, the benefits of EEN over standard post-operative management i.e. nil 
by mouth (typically for 7-10 days [59, 60]), has not been demonstrated 
adequately in clinical trials [17]. A meta-analysis [17] concluded that EEN might 
reduce the rate of post-operative infections and duration of hospital stay. This
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analysis highlighted the problems with the previous trials, including small sample 
size, defective randomisation, varied methods of EN (jejunostomy, oral diet, oral 
supplements and nasogastric tube feeding), heterogeneous surgical procedures, 
and failure to evaluate the health related quality of life (HRQoL) of patients 
following discharge. They concluded that an adequately powered multi-centre 
randomised trial is necessary to assess EEN and standard management in 
patients undergoing elective Gl surgery.
Furthermore, the only route for the delivery of EEN following radical upper 
gastrointestinal resectional surgery is into the small intestines below the newly 
formed anastomosis. There are two options, nasojejunal tube or feeding 
jejunostomy. Nasojejunal tubes have been shown to be unreliable and 
uncomfortable for patients [61, 62]. Feeding jejunostomy, is however an invasive 
procedure. Previous studies have reported major complication rates ranging from 
0-40%, directly attributed to the feeding jejunostomy [63-75]. Therefore, the 
contemporary view is that the use of EEN should not become routine post­
operative clinical practice, until proven safe, feasible and effective in improving 
clinical outcome in an adequately powered randomised controlled trial.
The aim of the randomised controlled trial presented in this thesis, is to compare 
the use of EEN versus standard post-operative management i.e. nil by mouth, 
taking into consideration the limitations with the previous trials.
Chapter 1 of this thesis is the literature review. It will commence with a review of 
the incidence, aetiology, symptoms and treatment options for the three types of 
UGI cancers studied in this thesis. The first section will end by detailing why this 
patient cohort was considered important for study.
The causes of malnutrition, along with the consequences of malnutrition, will be 
covered in the following section. Discussions as to why these issues are relevant 
for the patient undergoing major UGI resectional surgery for cancer will be 
described.
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This will be followed by a review of the clinical studies on nutritional support in 
the surgical patient. However, it will be evident that the literature to date is 
inadequate to promote the routine use of enteral nutritional support in surgical 
patients.
Chapter 2 will contain the methods used in the randomised controlled trial (RCT) 
which forms the basis of this thesis.
Chapter 3 and 4 will present the results and discussion of the results in the 
context of the previous literature. Conclusions will be drawn and suggestions for 
further studies will be outlined.
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1.0 Literature Review
The literature review will include the following,
1. A discussion of upper gastrointestinal (UGI) cancers, detailing the incidence, 
aetiology and treatment options for oesophageal, gastric and pancreatic cancers.
2. An overview of the incidence, causes and consequences of malnutrition. The 
consequences of malnutrition are wide ranging and include physiological and 
clinical consequences that may affect outcome in surgical patients.
3. The literature review will then explore the range of nutritional assessment 
techniques available to ascertain malnutrition.
4. The penultimate section will provide an extensive review of the clinical trials 
that have been conducted in the field of surgical clinical nutrition. The 
organisation of these trials into logical sections was difficult as there was 
variation in types of nutritional support delivered, by varying routes, to different 
groups of patients and varying choices of outcomes measures.
5. Finally, the literature review will debate the key components of high quality 
clinical trials. It will detail the frameworks available to ensure researchers 
conduct and report robust clinical trials.
1.1 Upper Gastrointestinal Cancers
1.1.0 Introduction
Cancer is a major contributor to death across the world. It is predominantly a 
disease of later life with more than 70% of cancers occurring in people over the 
age of 60 years [1].
Upper Gastrointestinal (UGI) cancers are common throughout the world. Each 
year, UGI cancers cause nearly 1 million deaths (World Health Organisation, 
1998). The incidence and mortality of the different subtypes of UGI cancers are 
changing rapidly in many parts of the world. It is thought that environmental 
factors may be responsible for this. Social and cultural behaviour such as
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smoking, alcohol, obesity, and social deprivation are contributory factors. Recent 
links with genetics are also being investigated and explored.
The incidence of cancer is increasing in the United Kingdom (UK). Cancer 
accounts for 28% of all deaths in males and 23% in females in 2003 [1]. Survival 
depends on the type of cancer, with five-year survival reported to be very low for 
cancers of the pancreas, lung, oesophagus and stomach. The range of survival 
for these cancers has been reported as 2-15% for patients diagnosed in England 
in 1998-2001 [1]. Colon cancer in contrast has a 5-year survival of around 50%, 
cancers of the bladder, cervix and prostate 53-71% and breast cancer (80%). 
However, overall survival has improved for most cancers in both sexes since the 
early 1990s [1].
The next section will summarise the epidemiology, incidence, aetiology, clinical 
features and treatment of UGI cancers. For the purpose of the thesis UGI will be 
considered to include oesophageal, gastric and pancreatic cancers.
1.1.1 Oesophageal Cancer
1.1.1.1 Epidemiology
Oesophageal cancer is the 7th most common cancer worldwide and accounts for
355,000 deaths annually (5.4% of all cancer deaths) [76]. Studies have revealed 
a wide geographical variation in incidence of carcinoma of the oesophagus. The 
highest incidence in the world is in China where it is the most common single 
cause of death accounting for more than 100 cases per 100,000 people per 
annum. Elsewhere incidence varies from less than five per 100,000 in whites in 
the USA to 26.5 per 100,000 in some regions of France [77].
In the UK, oesophageal cancers represent 1.9% of all cancers [78]. In the 1990s 
there were 7000 new cases of oesophageal cancers and 6,700 deaths reported 
per year. Incidence is rising both in the UK and worldwide [26]. This is 
particularly true for adenocarcinomas. Incidence is higher in men than women, 
with 12.6 men and 5.9 women per 100,000 presenting respectively per year in 
the UK [1]. Patients typically present with a mean age of 69 years for men and 
75 for women [1].
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Oesophageal cancer is the 9th most common cancer in men in Wales and 13th in 
women for the period 1993-2002 [79]. The incidence of oesophageal cancer in 
Wales is increasing; in 1993 a total of 334 patients were diagnosed, this 
increased to 443 people in 2003. The ratio of males to females was 1.44 in 1993 
and 1.34 in 2003 [79]. Locally in Wales, Methyr Tydfil has the highest incidence 
for both males and females.
There has been a marked increase in the incidence of adenocarcinomas of the 
distal oesophagus and or gastric cardia which is thought to be a distinct disease 
entity [80] . Similarly, the incidence of squamous cell carcinomas has increased 
but this increase is not as dramatic as the increase for adenocarcinoma [80].
1.1.1.2 Aetiology
In the Western world alcohol is a major risk factor for oesophageal cancer [81, 
82]. The mechanism by which it increases the risk of cancer is not known, 
however poor diet associated with increased alcohol consumption may be a 
factor, as well as the irritation of the mucosal lining leading to increased cell 
division and spontaneous mutation. Lack of fruit and vegetables with the 
subsequent lack of vitamin A, C and riboflavin are all associated with an increase 
in squamous cell carcinoma [83-85].
Tobacco is also a major risk factor. Alcohol and tobacco appear to act in synergy 
to increase the rate of carcinogenesis [86]. Ingestion of pickled vegetables [87], 
increasing obesity, Barrett’s oesophagus [88] and achalasia [89, 90] are all risk 
factors [91].
Oesophageal cancer is more common in areas of greater social deprivation [92], 
likewise 5 year survival has been reported to be better in patients from less 
deprived areas [93].
1.1.1.3 Clinical Features
Early oesophageal cancer may go unnoticed. Dysphagia is the most common 
symptom. Difficulty is initially experienced on swallowing solids, then semi-solids 
and finally liquids. Most cancers involve at least a 4cm length of the oesophagus
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before diagnosis, and the typical patient will have had 3-6 months of dysphagia 
before first contacting a physician [94].
Therefore an inevitable consequence is a reduced dietary intake and subsequent 
weight loss. Weight loss, may be exacerbated by the metabolic effects of the 
tumour itself. Pain is uncommon and if it occurs is a late manifestation.
1.1.1.4 Surgical Resection for Oesophageal Cancers
Potentially curative resection involves resection of an appropriate length of the
oesophagus along with any involved stomach and lymphatics. Restoration of 
continuation is typically achieved by the transposition of the stomach to form an 
oesophago-gastric anastomosis.
Several surgical options are available:
1. McKeown (1974) [22] developed a subtotal oesophagectomy performed 
through a midline incision and a right thoracotomy. In addition, a cervical incision 
is made to complete the cervical anastomosis. This is usually performed for 
cancers involving the upper oesophagus.
2. Ivor-Lewis (1946) [23] popularised an oesophagectomy technique involving a 
subtotal oesophago-gastrectomy performed through a midline incision to enable 
mobilisation of the stomach. Typically resection involves removal of about one 
fifth of the stomach. In addition, a right thoracotomy is performed providing 
access to the oesophagus to complete the anastomosis. This became known as 
the Ivor-Lewis oesophagectomy.
3. The Transhiatal oesophagectomy was popularised in the USA and Brazil by 
Orringer in the mid 1980s [24, 25]. It involves opening the abdomen through a 
midline incision (without thoracotomy) and the oesophagus is resected in the 
chest through the diaphragmatic hiatus. Stomach or colon for reconstruction is 
then passed through the posterior mediastinum to the neck where it is 
anastomosed to the upper oesophagus through a cervical incision [26]. This is 
typically used for cancers of the lower oesophagus.
4. Over the past few years minimally invasive oesophagectomy using endoscopic 
instruments has been introduced into oesophageal cancer surgery. This
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procedure is used for early tumours and performed by endoscopic mucosectomy 
or mucosal ablation techniques [95],
Patients after oesophagectomy are prone to developing major complications, 
which include: haemorrhage, infection, thromboembolic disease and
cardiovascular problems. Pulmonary complications may range from a simple 
chest infection to pneumonia, pulmonary collapse, persistent pneumothorax, 
haemothorax or damage to the trachea or bronchus. Extensive 
lymphadenectomy can affect pulmonary lymphatic drainage, which can 
predispose to pulmonary oedema [27-38]. Anastomotic leak is a serious 
complication post-operatively; it can be attributed to a technical error if it 
develops within 72 hours post-operatively. According to UK guidelines the 
incidence of anastomotic leak ideally should not exceed 5% for UGI resections 
[39]. Other complications such as chylothorax (occur in 2-3 % of resections), 
laryngeal nerve palsy and anastomotic strictures are also often reported. Hospital 
mortality should be less than 10% [19].
Prognosis is dependent on the depth of invasion of the tumour (T stage), the 
presence of nodal metastases (N stage) and the ratio of involved to removed 
lymph nodes. Five-year survival is reported to be 5-10% [19].
1.1.1.5 Adjuvant, Neo-Adjuvant Chemotherapy and Chemoradiation
Evidence supporting the use of adjuvant chemotherapy is limited [19]. However,
the use of neo-adjuvant chemotherapy was studied by the MRC Oesophageal 
Working Party (OE02 study) in 2002 [96]. The authors concluded that neo­
adjuvant chemotherapy, i.e. 4-cycles of cisplatin and 5-fluorouracil every 3 weeks 
followed by surgical resection was superior to surgery alone in improving two- 
year survival. Following this study, it was recommended that neo-adjuvant 
chemotherapy be used for all operative patients with the exception of T1 stage 
tumours to improve survival. However, a Cochrane review by Malthaner et al 
(2006) [97] of eleven randomised trials involving 2019 patients, concluded that 
preoperative chemotherapy plus surgery may offer a survival advantage
8
compared to surgery alone for resectable thoracic oesophageal cancer, but the 
evidence remains inconclusive.
The use of chemoradiation in improving survival was suggested in a 
retrospective study by Crosby et al (2004) [98]. The authors concluded that 
definitive chemoradiation for inoperable oesophageal cancer led to a median 
overall survival of 26 months, with advancing stage of disease correlating 
positively with prognosis. Interestingly, a subgroup analysis of patients who did 
not proceed to resection secondary to co-morbidities rather than tumour stage 
had a median survival of 40 months. The results of this study indicate that the 
use of definitive chemoradiation may lead to a similar survival rate as resectional 
surgery with curative intent.
A French study, Bedenne et al (2007) [99] of patients with potentially curative, 
operable thoracic oesophageal cancer (stage T3N0-1M0). Patients received two 
cycles of cisplatin and 5-fluorouracil and concomitant radiotherapy. Patients, who 
responded to this regimen, were then randomised to either surgery or additional 
chemoradiation. The authors concluded that there were no differences in survival 
at two years between the two randomised groups. This study did not evaluate 
health related quality of life.
There is no consensus to suggest that radiotherapy in isolation is beneficial in 
oesophagectomy patients [100].
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1.1.2 Stomach Cancer
1.1.2.1 Epidemiology
Gastric cancer is one of the prominent causes of death from malignant disease 
[101]. The incidence worldwide is 11 people per 100, 000 (World Health 
Organisation, 1998). There are wide international variations in incidence. It is 
common in Japan, South America and Eastern Europe, occurs with intermediate 
frequency in Western Europe, and is uncommon in the USA. In addition to 
international variations, the incidence varies within countries (World Health 
Organisation, 1998).
It is primarily a disease in the older adult with over 80% of patients presenting 
being over 65 years [102]. The incidence is twice as high in males as females 
[101].
Gastric cancer is relatively common in the UK, with a reported incidence of 
15/100,000 people per annum in 2004 [19]. It is reported that there are 10,000 
new cases and 7,500 deaths per annum.
Incidence is correlated with low socio-economic status. In the UK, the areas with 
a high incidence include South Wales, Scotland and the Midlands. The incidence 
in Wales, of stomach cancer, is however falling [79].
Males have a higher incidence than females, with new cases reported as 420 for 
males and 247 for females per annum in the UK [19]. The mortality rate from 
gastric cancer in Wales, however, exceeds that of the UK. With 34 deaths per 
100 000 males, compared with 23 deaths per 100 000 reported in the UK [79].
Delays in diagnosis are common, and as many as one in three patients in Britain 
continue to present with advanced, incurable disease. Survival has improved 
over the past 10 years in Wales, with one-year survival reported as 33% for the 
period of 1995-1999 [79]; compared to 1990-1994 when it was 25.78%.
1.1.2.2 Aetiology
The aetiology of gastric cancer is multifactorial. There are a few definite pre- 
malignant conditions and risk factors. These include: a gastric polyp, pernicious 
anaemia [103, 104], autoimmune and environmental gastritis, gastric surgery
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[104] for benign conditions, gastric mucosal dysplasia, cigarette smoking, long 
standing dyspepsia and genetic factors.
Dietary factors may also be important. A reduced intake of fresh fruit and 
vegetables, leading to a reduced intake of carotene, vitamin C and E are risk 
factors [105]. Dietary nitrates and nitrites, and excessive salt intake [106] are 
also linked [105]. In 1994, WHO declared Helicobacter pylori [107-109] to be a 
Grade 1 carcinogen for gastric adenocarcinoma and mucosa associated 
lymphoid tumours of the stomach [110]. The incidence of cancer of the stomach 
is increased in first degree relatives of patients [111].
1.1.2.3 Clinical Features
There has been a change in anatomical distribution with an increasing trend for 
tumours to be located in the proximal stomach and cardia [112, 113] [114] as 
opposed to the distal stomach.
It is a difficult disease to diagnose early, because of the time lag between the 
commencement of the growth, and the appearance of symptoms, and also 
because of diversity in its presentation. Yet, the key to improving the outcome of 
gastric cancer is early diagnosis [105].
1.1.2.4 Gastric Surgical Resection
For those patients who are fit enough, surgical resection is the only option for a 
cure in gastric cancer. The extent of the disease at presentation determines the 
extent of the resection. It is reported that in the West, patients often present late 
with gastric cancer, and hence the cure rate is low [115].
The two most appropriate operations for gastric cancer are a radical subtotal 
distal gastrectomy for the lower one third of the stomach and a total gastrectomy 
for tumours of the middle and upper third.
Studies in Japan have demonstrated improved survival if patients undergo a D2 
or ‘systemic lymphadenectomy’ or D3 ‘extended lymphadenectomy’ [116].
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1.1.2.5 Neo adjuvant chemotherapy in stomach cancer
In the past, the role of adjuvant therapy for gastric cancer was indefinite.
However, two randomised controlled trials have shown the survival benefit of 
adjuvant oncological treatment. The Amercan Intergroup (0116 trial) [117] 
concluded that adjuvant chemoradiation therapy prior to resection was superior 
to surgery alone. The European MAGIC trial [118] showed improved survival 
and disease-free survival with pre-operative chemotherapy epirubicin, cisplatin, 
and 5-FU (ECF) given every 3 weeks pre- and post-operatively compared to 
surgery alone.
1.1.3 Pancreatic Cancer
Pancreatic cancer remains one of the major challenges in surgical oncology, it is 
termed ‘the Everest of solid tumours’ and challenges the whole of the multi­
disciplinary team [119].
1.1.3.1 Aetiology
Little is known about the aetiology of pancreatic cancer [120]. However, tobacco 
smoking is associated with a doubling of the risk of pancreatic cancer, 
accounting for 30% of cases [121-130].
Other aetiological factors have been suggested. These include, a limited 
consumption of fruit and vegetables [131], alcohol, high protein and fat diets, 
high coffee consumption, diabetes mellitus, pernicious anaemia and previous 
gastric surgery [132]. Chronic pancreatitis is thought to be a pre-malignant 
condition, increasing cancer risk by 5-15 fold [129, 133]. Genetic links have also 
been reported [134-142]. Recently, certain occupational groups such as 
chemical and petrochemical, dye and rubber industry workers are thought to be 
at greater risk [143].
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1.1.3.2 Incidence
Carcinoma of the pancreas remains a deadly disease [79]. Incidence has 
increased over recent decades, and is highest in Western countries. 
Approximately 7,200 new cases of pancreatic cancer are diagnosed per year in 
the UK and Ireland [1, 144]. For the period of 1992-2002 the incidence of 
pancreatic cancer has remained stable. Pancreatic cancer is predominantly a 
disease of the elderly with 80% of cases reported in patients aged 60-80 years 
[145] [146] . The rate of pancreatic cancer is higher in men than women 
generally in the UK. In Wales, however, the incidence is similar in men and 
women with 202 males diagnosed per annum in Wales and 220 females [79].
Pancreatic cancer has a very poor prognosis and has the lowest survival 
amongst all the UGI cancers. One year relative survival is 13.60% for 1990-1994 
and 14.11% from the period of 1995-1999 [79].
1.1.3.3 Clinical Features
The most common type of pancreatic cancer is ductal adenocarcinoma, which 
accounts for over 90% of all tumours. Eighty to ninety percent of tumours present 
in the head of the gland but metastasis is common [147]. There are also many 
other rare types of endocrine and exocrine tumours [132].
1.1.3.4 Surgical Resection
The most common surgical procedure is Pylorus Preserving 
Pancreaticoduodenectomy (PPPD). Five-year survival is poor approximately 
10% post procedure [148, 149]. There are also more radical surgical options 
available such as total pancreactectomy and portal vein excision [150-152]. The 
surgical resection is complex and it is not uncommon in spite of adequate 
preoperative staging, to discover at open laparotomy distant metastases or local 
spread, which preclude the operation proceeding. Complication rates of 
resectional surgery are high when compared to other operations [153], although 
mortality rates have fallen. Reoccurrence of the tumour even after curative intent 
surgical resection is common [153].
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1.1.4 The Management of Upper Gastrointestinal Cancers
The patients presenting with UGI cancers are, by and large, elderly. They 
typically present with multiple pre-existing co-morbidities, this contributes to the 
risks for undergoing resectional surgery [20, 21].
The presence of the underlying cancer produces immunological, physiological 
and metabolic consequences, often rendering the patient debilitated. Particularly 
there may be nutritional inadequacies. Some patients may have received neo­
adjuvant chemotherapy, which may compromise a patient’s nutritional and 
immunological status prior to surgery. All these factors will be discussed later in 
the literature review.
Operations with curative intent for UGI cancers are prolonged and technically 
demanding. They involve extensive dissection of the tumour and often-complex 
reconstruction. There is the potential for rapid blood loss, intraoperative cooling 
and fluid shifts.
Post-operatively, conventional management has involved a prolonged period of 
‘nil by mouth’ until the integrity of the newly formed anastomosis is confirmed 
radiologically. The use of this practice, in conjunction with the complex metabolic, 
endocrine and neuroendocrine responses, affect fluid balance, insulin resistance 
and pain. All these complicate and intensify the complexity of post-operative 
recovery in these patients. Maintenance of systemic circulation and ventilation 
are complex post-operation, and these patients tend to be managed on critical 
care units.
Of all the elective complex major operations, the procedure of resections for UGI 
cancers are associated with the highest risk of septic related complications and 
mortality [154]. Nutrition has long been reported to influence clinical outcome 
[155]. Any treatment that can potentially improve clinical outcome, whilst 
improving quality of life, is beneficial. However despite this, the nutritional 
management of these patients’ remains an area of controversy, with some 
studies showing evidence of benefits from perioperative nutritional support and 
others showing no or an equivocal effect. These will be discussed at length in 
section 1.6.
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1.1.5 Summary of Section
Cancer is a major contributor to death across the world with UGI cancers 
accounting for 1 million deaths worldwide.
This section has provided an overview of the increasing incidence of UGI 
cancers both across the UK and locally in Wales. The aetiological factors for the 
development of UGI cancers are diverse with nutritional factors being stated as 
central to the disease origin.
What is apparent is that UGI cancers have clinical consequences which impact 
directly on patients’ nutritional status and food intake.
Coupled with the treatment modalities of surgery and chemotherapy, it is 
inevitable that patients with UGI cancers are at risk of developing malnutrition. 
Thus the next section will detail the physiological and clinical manifestations of 
malnutrition. It will also outline the causes and incidence of malnutrition in 
particular relating to the surgical patient.
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1.2. Malnutrition: Incidence and Causes
1.2.0 Introduction
Malnutrition has long been considered to have an adverse effect on the surgical 
outcome in patients with benign and malignant disease. In 1936, Studely [9] 
highlighted the relationship of pre-operative weight loss and surgical outcome. 
Patients who had lost more than 20% of their usual body weight prior to surgery 
suffered a 33% mortality rate. This was compared to 4% mortality in patients with 
a weight loss between 15% and 20%. The conclusion, from this study, was that a 
weight loss exceeding 15-20%, deleteriously affected surgical outcome, and 
prognosis. Subsequently, much evidence has been published identifying the 
effects of malnutrition on physiological outcome.
This section will review the literature regarding the extent, causes and 
consequences of malnutrition in hospital patients, with an emphasis on surgical 
patients.
1.2.1 The Extent of Malnutrition
Malnutrition literally means bad, or faulty, nutrition. It is an ‘umbrella’ term, 
encompassing all types of nutritional disorders such as obesity, macronutrients 
and micronutrient deficiencies. There is no consensus definition of malnutrition. 
For the purpose of this thesis, however, malnutrition will be defined as:
“A state in which a deficiency of nutrients such as energy, protein, vitamins and 
minerals causes measurable adverse effects on body composition, function and 
__________________________ clinical outcome._”__________________________
Stroud (2006) page 3 [40]
Malnutrition is a public health problem, affecting 5% of the total population in the 
United Kingdom [102, 156]. Florence Nightingale, in 1859, was one of the first to 
draw attention to the problem of malnutrition in hospitals. She reportedly stated
16
that patients are often ‘Starved in the midst of plenty’ [157]. Yet, nearly 150 years 
later, malnutrition in hospital is still a major cause for concern [40]. A systematic 
review, by Stratton et al (2000) [158], re-analysed many of the studies published 
reporting the percentage of patients with malnutrition in the general hospital 
population. The incidence of malnutrition varied from 5-64% depending on the 
criterion used to define malnutrition. Theses studies are summarised in table 
1.2 .1 .
Table 1.2.1 Studies published to date using standardised anthropometric criteria
Author Criterion Percentage 
of patients
Anderson et al (1984) 
[159]
BMI < 20
Weight Loss > 4.5 kg
30
Kamath (1986) [160] Low albumin, Hb or TLC 58
Corish and Kennedy 
(2000) [161]
BMI <20 16
Larsson et al (1994) 
[162]
Weight loss >10% 29
Kyle (2001) [163] BMI <18 kg m2
Index of fat free mass
A combination of anthropometric indices
9
31
11-45
Naber et a/(1997)[164] NRI moderate or high risk 57
Audivert (2000) [165] BMI <28 kg m2
A combination of anthropometric indices 
below 15th centile
33
Braunschweig et al 
(2000) [166]
All these studies used a combination of 
anthropometric, biochemical and or 
immunological indices
20-58
Landi (2000) [167] Comparison with IBW 
BMI<21.7 kg m2
16.2
27.3
McWhirter and 
Pennington (1994) [163, 
168-171]
BMI 20 kg m2 and TSF or MAMC <15th 
centile
40
Harrison et al (1997) 
[172]
A variety of nutrition risk scores 50-64
(BMI= body mass index; IBW- ideal body weight; kg= kilograms;
Hb= haemoglobin; TLC=total lymphocyte count; NRI= nutrition risk index)
Cancer, increases the risk of malnutrition [4, 173]. The type and site of the 
tumour, stage of disease, and the treatments performed all affect the extent of 
malnutrition in cancer patients [174]. The reported incidence of malnutrition for
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gastrointestinal (GIT) surgical patients, with benign disease, ranged from 6% 
[175] to 87% in patients with GIT cancer [2-8].
A summary of the studies that reported the incidence of malnutrition in cancer 
patients is presented in table 1.2.2.
Table 1.2.2 The Incidence of malnutrition in Gastrointestinal Cancer Patients
Author (year) Incidence Criterion used to Define 
Malnutrition
Persson et al (1999) 
[8]
80% UGI cancers Subjective Global 
Assessment (SGA)
DeWys et al (1980) 
[176]
Pancreatic cancer 83% 
Oesophageal cancer 87% 
Gastric cancer 65%
Weight loss > 5% in 6 
months
Riccardi and Allen 
(1999) [94, 1771
UGI cancers 70% 10% weight loss over 4 
months
Daly et al 
(2000)[1771
Oesophageal cancer 57% Involuntary weight loss
Martin et al (1999) 
[178]
Oesophageal Cancer 58% Involuntary weight loss
Saito et al (1990) 
[179, 180]
Oesophageal Cancer 81.2% 
Gastric Cancer 64%
Abnormal levels of at least 
one of: body weight, TSF, 
MAMC, albumin
Rey-Ferro et al 
(1997) [1811
Gastric Cancer 63% NRI less than 97.5
Larrea et al (1992) 
[182]
Oesophageal Cancer 78.9% Not reported
Sitges-Serra et al 
(1990) [183]
N=84 Oesophageal Cancer 
58%
TSF below 5th percentile 
Albumin >35g/l, involuntary 
weight loss
Thoresen et al 
(2002)[184]
Belghiti et al (1987) 
[185]
Bozzetti et al (1989) 
[1861
N=46 Gl cancers 83% 
N=24 Gl cancers 63% 
N=14 Gl cancers 30%
Unintentional weight loss 
Weight loss > 10%
BMI >18
(NRI-nutrition risk index; TSF-Tricep skinfold thickness; BMI body mass index; MAMC- 
mid arm muscle circumference)
To summarise so far, malnutrition is thought to affect 5% of the total population 
with the incidence increasing to between 9-58% in hospitalised patients and
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increasing to 58%-90% in patients with UGI cancers. The negative impact of 
malnutrition on surgical outcome has long been considered.
1.2.2 Causes of Malnutrition in the Surgical Patient
This section will outline the causes of malnutrition in the surgical patient with 
cancer. The causes will be classified into cancer related factors, surgical related 
factors and lack of nutritional support.
1.2.2.1 Cancer Related Factors 
Anorexia
Anorexia or loss of appetite is a prominent clinical feature of acute or chronic 
disease. It is thought to be responsible for malnutrition in 15-40% of upper 
gastrointestinal (UGI) cancer patients, at presentation [187].
It seems ironic that anorexia often occurs when the body’s’ energy requirements 
are elevated i.e. in response to an acute phase response, however, the affect of 
anorexia can either be deleterious or beneficial, depending on the timing, onset 
and duration of the anorexic period.
The initiation of anorexia may be based on evolution. Does anorexia, and hence 
the reduction in the ‘hunger’ feeling, eliminate the necessity to search and 
scavenge for food? This may limit the energy expenditure from heat loss, from 
bodily movement, and also reduces the risk of further harm to occur, when the 
individual is incapacitated as a result of infection or injury. Following on from this 
theory, animal studies have suggested that ‘force feeding’ is detrimental in the 
short term, inducing infective complications [188].
However, prolonged anorexia, will inevitably lead to starvation and malnutrition, 
the consequences of which are described later in this chapter.
The physiological origins of anorexia are complex. Pro-inflammatory cytokines 
are central in the development of anorexia. The cytokines, lnterleukin-1 (IL-1),
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Tumour necrosis factor-alpha (TNF-alpha)[189], IL-6 [190], interferon [191] and 
IL-8 [192] are reported to be released in response to the presence of microbial 
products. These subsequently activate monocytes and macrophages, through 
surface proteins such as CD11B and CD14. Also, cytokines in particular IL-1 
alpha and beta, are thought to target central and peripheral nervous system 
phenomena, these include:
1. The hypothalamus-feeding centre and activation of the pituitary-adrenal axis.
2. The prostaglandin dependent mechanisms;
3. The modifications of neurotransmitter production;
4. The gastrointestinal tract (leading to inhibition of gastric motility, decreased 
gastric emptying, and modulation of intestinal motility
5. Endocrine response (affecting corticotrophin releasing factor, cholecystokinin, 
glucagon and insulin)
Malhotra and Bird (1997) and Chang and Bistrian (1998) [193, 194]
Other possibly factors leading to anorexia in cancer patients are altered intestinal 
enzyme production, GIT motility and a feeling of fullness often attributed to 
delayed gastric emptying [195]. Iniu et al (1999) have also linked leptin and 
satietins to altered appetite and anorexia [199].
Changes in taste and smell perception, psychological factors, uncontrolled pain 
and therapy induced side effects all play a role in the aetiology of anorexia [196]. 
Taste changes, are often reported in cancer patients [195]. In particular, patients 
report a hypersensitivity to sweet flavours and bitter foods. This is thought to be 
secondary to the high concentrations of amino-acids, purines and polypeptides in 
the brain [195].
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Dysphagia
Riccardi and Allen (1999) [94] reported malnutrition in 70% of patients with UGI 
cancer cases on presentation. In most cases, weight loss was rapid, occurring 
over a period of less than four months. The main cause was progressive 
dysphagia, pain and/or anorexia. A similar review [197], suggested that 
dysphagia in patients with gastric or oesophageal cancers is the main 
determinant of malnutrition. Dysphagia in UGI cancer patients is usually the 
result of obstruction by the tumour, physically preventing food from entering the 
stomach.
Increased Energy Expenditure
Cancer may increase energy expenditure [198]. A study in rats demonstrated 
that transplanted tumour cells increased resting energy expenditure (REE) by 
40% [199].
In humans, patients with pancreatic cancer, had a higher REE (33 % higher) 
when compared to individuals without cancer [200] [201-203]. Other studies have 
also reported a higher REE (increased by 138-289 calories/day) in cancer 
patients [196, 204, 205]. Once again leptin secretion may have an impact on 
energy expenditure [199].
1.2.2.2 Surgical Factors
The Acute Phase Response (APR)
Surgery, like any injury to the body elicits a cascade of reactions termed the 
acute phase response (APR). This ‘stress’ response was first described in 1932 
[206, 207]. Subsequently, the endocrine aspects of the response were described 
in 1959, by Egdahl [208].
Recent understanding of cytokines has provided further insight into the complex 
mechanisms that initiate the APR. Cytokines are produced from activated 
leucocytes, fibroblasts and endothelial cells at the site of the injury. Among the 
initial cytokines released are IL-1 and TNF-alpha [209]. Within 30-60 minutes, 
these cytokines stimulate the production of IL-6, becoming sufficient in 
concentration after 2-4 hours, to stimulate the release of hormones-ACTH, ADH,
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and cortisol. These then lead to the cascade of hypercatabolism resulting in the 
catabolism of glycogen, adipose and muscle proteins.
C-reactive Protein (CRP), fibrinogen and other anti-proteinases are released 
following the serum changes in IL-6 and the APR [210, 211]. One study 
correlated circulating level of IL-6 to the severity of the surgical procedure [209]. 
Major Gl surgical procedures produce one of the greatest increases in IL-6 
production post-operatively [212]. If complications do not occur, the IL-6 levels 
typically start to decrease within 48-72 hours of the surgical procedure. IL-6 is 
considered a useful indicator of the overall APR as it correlates with hepatic 
production of acute phase response proteins and inversely with liver proteins 
such as albumin and transferrin [212].
Starvation after Surgery
It is traditional practice to withhold food, nutrients and oral fluid in the immediate 
post-operative period. This ‘starvation’ after surgery has a different metabolic 
response to that observed in ‘simple’ starvation. The two responses are 
summarised below.
The metabolic response to ‘simple’ starvation is aimed at the conservation of 
body tissues, whilst maintaining a constant supply of energy substrates to the 
vital organs. Basal metabolic rate is reduced. The complex physiological 
mechanisms and hormonal regulation lead to a reduction in insulin production, 
and a subsequent rise in glucagon production. The result is an increase in 
glycogen degradation with subsequent glucose release. After depletion of 
glycogen stores, protein and lean body tissues are converted to glucose by 
gluconeogenesis. Fatty acids, derived from the degradation of adipose tissue, 
produce an essential supply of ketones for utilisation by the brain for energy. It is 
this rise in ketones in the blood that ‘triggers’ the reduction in gluconeogenesis, 
leading to conservation of lean body mass preserving vital organ mass and 
organ function.
Healthy individuals can sustain extended periods of ‘simple’ starvation without 
permanent harm, because of these adaptive metabolic responses. However 
periods of starvation, after surgery or when the patient is ‘stressed’, are not
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characterised by the same metabolic response. On the contrary, starvation in the 
stressed patient, in the presence of an acute phase response, is characterised 
by an increased basal metabolic rate. At the same time, the process of 
ketogenesis and the subsequent production of ketones fail to suppress 
gluconeogenesis, and hence protein degradation and lean body mass is 
accelerated. Thus, starvation in a stressed patient leads to accelerated tissue 
loss and organ function, and impending malnutrition.
Insufficient Utilisation of Ingested Nutrients
Patients post-operatively develop a sequence of events similar to that seen in 
Type II diabetes. Patients develop insulin resistance. Patients therefore become 
‘inefficient’ and unable to utilise nutrients at the cellular level. Much research has 
focused on this over the last decade and is summarised in a review paper [213].
Maldigestion and Malabsorption
The normal GIT has an maximal absorptive capacity of 4500-7000kcals/day 
[214]. Pancreatic exocrine function is impaired in malnutrition, which inevitably 
leads to maldigestion and absorption [215]. Coupled with this, bacterial 
overgrowth and malnutrition can alter GIT motility and enzyme production [216], 
leading to malabsorption [217]. The overzealous use nutrition delivered into the 
GIT at this time may overwhelm the digestive and absorptive capacity of the GIT. 
If macronutrients delivered via the nutrition are not absorbed in the small 
intestines, they are subsequently fermented in the colon, causing diarrhoea 
[217]. Therefore the delivery of nutritional support in malnutrition requires specific 
attention.
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1.2.2.3 Lack of Nutritional Support
The use of nutritional support for patients undergoing major surgery is not routine 
in the peri-operative period. Standard post-operative management is to withhold 
oral diet and oral fluids (‘nil by mouth’), and maintain hydration status with the 
prescription of intravenous fluids, until the surgeon decides that oral diet and 
fluids can resume.
Butterworth et al (1974) [218] identified a number of reasons accounting for the 
suboptimal delivery of nutrition in surgical patients in hospitals. The reasons 
were:
1. The diffusion of responsibility of patient care between members of the 
multidisciplinary team
2. The failure to observe and monitor patient’s food intake
3. The withholding of meals because of diagnostic tests
4. The failure to recognise increased nutritional needs as a result of injury or 
illness
5. The failure to provide nutritional support after surgery and failure to appreciate 
the role of nutrition in the prevention and recovery from infection
6. The prolonged use of ‘nil by mouth’ and glucose and saline intravenous fluids 
in the post-operatively phase.
This study was conducted over 30 years ago. Many of the reasons highlighted 
are still issues of concern in UK hospitals today [40].
An audit in 1996 1 found that the mean duration ‘nil by mouth’ in adult 
gastrointestinal surgical patients was 10 days (range 1-40 days) in a Teaching 
Hospital. The clinical rationale for this practice was based on assumptions that 
the delivery of nutrition post-operatively was not safe, or clinically indicated, in 
the post-operative period.
219. Barlow, R., An audit o f  the length o f  time patients are starved on a Surgical Unit in a Teaching 
hospital. 1996, Cardiff and Vale NHS Trust.
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Since this, one published survey [220] and one unpublished survey 2 found that 
nutritional support practices for patients undergoing resection for upper 
gastrointestinal malignancy, across the UK post-operatively were ad hoc. The 
authors attributed this practice to the lack of robust clinical trials performed, and 
the subsequent lack of consensus as to what is the optimal modality for providing 
nutritional support (if at all), peri-operatively.
1.2.3 Summary of Section
The cause of malnutrition in patients undergoing surgery for cancer is 
multifactorial. This section has subdivided them into cancer related such as 
anorexia, altered metabolism and dysphagia; surgery related such as the acute 
stimulation of the inflammatory and acute phase response. Coupled with this is 
the post-operative starvation associated with the traditional management of 
patients following surgery.
The next section will discuss methods of assessing nutritional status and 
determining malnutrition.
59. Barlow, R., A survey o f  Peri-operative nutritional practices in NHS Trusts across the UK. 2003, 
Cardiff and Vale NHS Trust.
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1.3 Nutritional Assessment
1.3.0 Introduction
Many anthropometric, biochemical, immunological tests and body compositional 
analyses have been developed to assess patient’s nutritional status. However, 
no single parameter can fully characterise the extent of malnutrition, as there is 
currently no one anthropometric measurement that is considered to be 
completely reliable, as well as practical for use in the clinical setting. More 
precise techniques such as measurements of total body potassium or sodium or 
dual energy X-ray absorptiometry are not practical for use in the clinical area, 
being too cumbersome for use outside the laboratory research setting.
This section will detail the practical methods available for nutritional assessment 
of the surgical patient in a clinical setting, which are suggested to enable a 
reliable and effective nutritional assessment.
1.3.1 Weight
Body weight is the most practical and simple measure of the total body 
components. The measured weight can be compared with ideal and desirable 
weight ranges and previous weight [221]. However, body weight is not an 
accurate guide to depletion of body stores, so other measurements should be 
used.
1.3.1.1 Percentage Weight Loss
The use of percentage weight loss is essential as this may indicate the extent or 
duration of any underlying disease. Studely (1936) [9] indicated that surgical 
outcome was influenced by pre-operative percentage weight loss. This was also 
the finding of Roy et al (1985) [222], who found that weight loss of >6% of usual 
body weight accurately predicted morbidity and mortality in surgical patients. The 
accuracy of the prediction, does however, depend on the accuracy of the original 
weight before the onset of weight loss. Many patients can give some estimate of 
their weight when well, but the accuracy of this reported weight is questionable 
[223]. Nonetheless, various national reports, organisations and individual 
workers have provided a range of cut off values, which generally fall within the 5-
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10% range of weight loss over the previous 3-6 months [224-226]. There is a 
paucity of information as to why these cut off values were chosen, but it seems 
that clinical judgment was important.
1.3.1.2 Body Mass Index
The relationship of weight with height is also useful, as body size dictates 
expected body weight. The most commonly used index is the Quetelet index 
(1869), usually known as the Body Mass Index (BMI) [227]. It is calculated by 
dividing weight (kg) by height squared (m). Both weight and height 
measurements are non-invasive and relatively easy to obtain in healthy adults, 
however, older people may present with numerous medical and physical 
problems, making these measurements more difficult to obtain. For example, it is 
often impossible to measure accurately in the elderly due to mobility problems 
and kyphosis or scoliosis. In this situation measurements of other body 
segments can be used as an alternative. These include: knee height [228] which 
relies on measuring long bones that do not lose length over time in the same 
way as the spine.
BMI indicates chronic protein and energy status, whereas percentage weight 
loss indicates acute changes in protein and energy status. The usefulness of 
BMI is limited by poor sensitivity with respect to baseline assessment, particularly 
for overweight patients who can undergo significant change in nutritional status. 
Furthermore, co-morbid conditions that promote underhydration, oedema or 
ascites will confound the calculation [229, 230].
1.3.2 Determination of Body Stores
The loss of skeletal muscle is an important clinical indicator. The skeletal muscle 
mass constitutes 15,000 to 20,000 stored calories. A study [230] in surgical 
patients, illustrated that patients who have lost 30% of their total protein stores 
have visible tendons which are prominent for palpitation, additionally, the bony 
prominences of the scapula are evident.
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Skeletal muscle mass can degrade by 50-70% in severe malnutrition. Mid upper 
arm circumference (MUAC) is used to calculate mid upper muscle circumference 
(MUMC). This is used as a prediction of skeletal muscle reserves, and thus, an 
indication of residual amino acids source, available for times of stress and 
starvation.
Twenty-five to sixty percent of total body fat is located subcutaneously. Body fat 
can provide 50,000 to 140,000kcals in an adult. Gross loss of body fat can be 
observed, not only from the patients’ appearance, but also by palpating skinfolds 
between the thumb and finger. If the dermis can be felt a study revealed that this 
correlated with a percentage body fat of less than 10% [230, 231].
In addition, body fat estimation can be gained from measuring Tricep Skinfold 
Thickness (TSF) with skin calipers. Work has shown that TSF correlates well 
with total body fat [231]. However another study failed to demonstrate this 
correlation in severe malnutrition, presumably because of an abnormal 
distribution of fat [232].
In general, for all arm anthropometry, if measurement falls below the 10th 
percentile, it provides an indication of malnutrition or increased risk of developing 
complications. The most commonly used standards for triceps skinfold thickness 
and mid arm circumference are those reported by Jellife in 1966 [233]. However 
these are based on measurements of European male military personnel and low- 
income American women which are not considered representative of the general 
UK population, comparison and interpretation needs to be made with caution.
Interpretation of the data may be further limited by inter-rater variability. Hall et al 
(1980) [234], found inconsistencies when three different observers performed 
anthropometric measurements. The coefficient of variation was 4.7% for arm 
circumference and 22.6% for triceps skinfold thickness. Also, the time frame 
needed before changes in measurements reliably reflect alterations in 
physiological condition must also be considered as this is typically based on the 
assessor clinical judgment.
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1.3.3 Skeletal Muscle Function
The function of muscle is also an important clinical indicator [235]. Handgrip 
strength or Handdynanometry is a quick and easy objective test to perform. It 
measures the muscle function of the hand and arm. Its usefulness is limited 
however by the need for patient cooperation and the need to avoid use of 
analgesics and sedatives which impair patient response [229]. Changes in 
muscle function may precede body composition changes and may serve as an 
indicator of functional impairment at subclinical levels. Work from the Minnesota 
Experiments [236] studied healthy men over a 3 month period and showed that a 
10% weight loss over 3 months lead to a reduction in handgrip strength by 8- 
10% and this correlated with a reduction in physical strength. Research has 
shown that grip strength correlates well with indicators of muscle mass, such as 
mid-arm muscle circumference and creatinine-height index [237]. Several 
investigators have proposed hand grip strength as an indicator of 
malnutrition[235, 238] . All investigators recognise that handgrip alone is not 
sufficient to identify malnutrition; it needs to be used in conjunction with other 
indicators. However, Klidjian et al [237] did suggest that grip strength, alone, can 
be used as a predictor of malnutrition and used as a screen to identify patients in 
need of further assessment.
Hand-grip strength has also been demonstrated to be a useful test to predict 
post-operative complications in surgical patients [239] [240, 241].
Windsor and Hill (1988) [242] correlated hand grip strength with body protein 
levels. They concluded handgrip strength was superior to biochemical and 
anthropometric markers in the determination of malnutrition. This was also the 
findings of the study by Klidjian et al (1980) [237]; this study examined 225 
patients admitted for elective surgery and found that grip strength was a more 
sensitive indicator than weight loss, BMI, skinfold thickness, MUAC and serum 
albumin in predicting post-operative complications. They demonstrated that 29 
out of 44 patients who had grip strength less than 85% of normal developed 
post-operative complications whereas only 3/58 (5.1%) patients, who had pre­
operative handgrip strength above 85% of normal, developed complications.
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Two studies [243, 244] concluded that skeletal muscle function is sensitive to 
nutritional depletion and nutritional support. Humphreys et al (2002) concluded 
that hand grip strength predicted functional status in hospitalised patients. They 
were able to predict those patients who could not be discharged home and not 
able to perform their normal activities of daily living.
It could be considered that any intervention that can prevent decline or improve 
grip strength should have a significant impact on a patient’s health and well­
being.
1.3.4 Biochemical Assessment
The commonly used test to investigate suspected malnutrition is the 
measurement of serum proteins. Proteins that are commonly tested include; 
albumin, transferrin, thyroxine binding prealbumin and retinol binding protein, 
each having its own advantages and disadvantages. Albumin is probably the 
most commonly measured protein and is measured as part of routine clinical 
chemistry in hospitals [245].
Plasma protein synthesis is affected by malnutrition [246, 247] and two studies 
have shown that malnutrition was an important factor in the regulation of albumin 
synthesis [246, 248] [249]. However, other studies have not shown this, 
suggesting that chronic food deprivation does not result in hypoproteinaemia 
[250-254].
The reasons for the variation in studies is probably related to the multifactorial 
origin of hypoalbuminaemia [250-254]. Albumin has a half-life of 19 days and 
thus does not reflect short terms changes in protein status. Research has shown 
that although nutrition can contribute to changes in albumin concentrations, the 
most influential factor, is the metabolic response to stress [250, 251] infection 
[252, 253], burns [253], trauma and surgery [255, 256] all of which decrease 
plasma albumin. The reason for the decrease in serum proteins is mainly due to 
the increase in vascular permeability seen in catabolism, which occur in these 
clinical situations [254, 257, 258]. It is therefore inevitable that plasma albumin
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levels will not increase in ‘stressed’ patients, until the inflammatory response has 
decreased [258],
The was reflected in a prospective study [259, 260] of 79 patients who 
underwent oesophagogastric surgery. Serum concentrations of interleukin-6 (IL- 
6), total protein, serum albumin, serum CRP, cortisol and other nutritional 
parameters were measured peri-operatively. All serum nutritional parameters 
decreased in the initial three days after resection, and improved, returning to 
preoperative levels within two-three weeks. This was with the exception of iron, 
transferrin and TIBC, which all returned to normal about one month after surgery. 
The authors attributed the drop in protein status to the acute phase response.
Oedema is a problem in surgical patients [255] as it deleteriously affects clinical 
outcome. Kinney (1986) [260] demonstrated that oedema appeared when the 
patient had gained 10% of body weight in extracellular fluid expansion. Starker et 
al (1985) [261] studied the administration of total parenteral nutrition (TPN) post- 
operatively and found that half of the patients gained weight. The authors 
attributed this to changes in fluid balance. The subsequent increase in fluid load 
reduced protein concentration [262], presumably via a dilution effect.
Despite these factors, all of which make interpreting serum protein levels difficult, 
serum protein, in particular albumin continues to be used as a nutritional marker. 
Based on clinical evidence, the use of albumin should be re-considered to be an 
indicator of illness and poor prognosis, rather than nutritional state [254, 263, 
264].
A low serum albumin has been shown to predict complications and death post- 
operatively. Serum albumin concentration below 35g/l impairs the ability to 
withstand major illness, surgical intervention or a septic episode [240, 264, 265]. 
Gibbs et al (1999) [262] sought to evaluate the reliability of peri-operative 
albumin in predicting surgical outcome. They concluded that a drop in serum 
albumin from 46 to less than 21 g/l was associated with an increase in mortality 
rates from less than 1-29% and in morbidity rates from 10-65%. Therefore, when 
looking at albumin concentration changes in sick patients, any improvement may 
indicate an improved clinical status rather than a corrected nutritional status.
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Other proteins such as retinol binding protein, transferrin and pre-albumin have a 
shorter half life than albumin leading to the suggestion that they could be more 
sensitive indicators of nutritional depletion [256]. However, like albumin, they will 
also decrease in times of metabolic stress and can be affected by other factors 
discussed above [266] [259, 267].
1.3.5 Nitrogen Balance
Estimates of nitrogen balance provide information on whether a patient is in an 
anabolic or catabolic state [268]. Nitrogen balance is estimated by measuring the 
difference between the amount of nitrogen ingested and the amount of nitrogen 
excreted in urine, hair, sweat, faeces and skin as expressed in the following 
equation.
Nitrogen balance (g) = protein intake (g) / 6.25- urinary nitrogen (g) +4g losses.
Negative nitrogen balance in patients with surgical injuries, sepsis and other 
catabolic stresses reflects muscle protein catabolism. In clinical practice 
however, performance of nitrogen balance has limitations [269, 270] . In a study 
a positive nitrogen balance was reflected by a rise of pre-albumin in 88% of 
cases whereas a negative nitrogen balance was associated with a fall in pre­
albumin in 70% of cases [271]. Nevertheless, it remains a useful measure in 
clinical practice [268].
1.3.6 Dietary Assessment
Malnourished patients often have or have had a reduced food intake. Often the 
treatment of malnutrition is to ensure that food or nutritional support intake meets 
the patients’ requirements. An assessment of food intake is therefore important 
in not only identifying malnutrition, but also monitoring treatment.
Measurement of dietary intake is not a simple matter. For accuracy, techniques 
require a high degree of skill, care and dedication on behalf of the observer [272,
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273]. There are a variety of methods for assessing dietary intake including 24 
hour dietary recall and diet history which assess diet retrospectively, and dietary 
records, which may be either weighed or rely on estimated weights, to assess 
current intake.
A dietary history involves using a series of open and closed questions with 
regard to usual food intake. It should include questions on eating patterns and 
presence of symptoms that may affect food intake such as anorexia, nausea, 
vomiting, dysphagia, diarrhea, steatorrhoea, constipation, taste changes or 
increasing shortness of breath.
Studies conducted in an attempt to quantify the error in dietary assessment 
methods have found that most estimates using the 24-hour recall are accurate to 
±10% [274, 275].
1.3.7 Nutritional Assessment Indexes
Because no single parameter has been found that will identify all patients at 
nutritional risk, investigators have developed indices in an attempt to improve 
accuracy. The five most common criterion assessments used for surgical 
patients are outlined in table 1.3.1. These criterions are mainly used in the 
research setting.
The best available method for nutritional assessment is a carefully performed 
history and physical examination [7, 276-278].
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Table 1.3.1 Summary of Indexes
Index Authors Criteria Summary
Nutrition 
Risk Index 
(NRI)
Veterans
Affairs
(1991)
[278]
NRI=
(1.519x albumin, al '1) +(0.417 current weiaht X 100
usual weight 
NRI >97.5 borderline malnutrition 
NRI 83.5-97.5 mildly malnourished 
NRI <83.5 severely malnourished
Prognostic 
Nutritional 
Index (PNI)
Buzby and 
Mullen et al 
(1980) [7]
PNI (% risk)=
1.58-16.6(albumin gl'1)-0.78 (TSF, mm)-0.2 (transferrin, 
mg dl'1)-5.8 (delayed hypersensitivity graded 0-2.
PNI<40% low risk
PNI 40-50%intermediate risk
PNI >50% high risk
Nutritional 
Index (Nl)
Von
Meyenfeldt 
et al (1992)
[279]
Nl=
(0.14Xalbumin, gl1)+(0.03C%IBW)+(0.73XTLC 10 9 I'1 )- 
8.90.
Values less than 1.31 are in indicative of malnutrition.
Subjective
Global
Assessment
(SGA)
Detsky et 
al (1987) 
[225]
Five features:
1) Weight loss in 6 months
2) Dietary intake
3) Presence of GIT symptoms
4) Functional capacity
5) Metabolic demands
Maastrict 
Index (Ml)
De Jong et 
al (1988)
[280]
Ml=
20.68-(0.24 X albumin, gl'1)-(19.21 pre-albumin gl'1)-(1.86 
X TLC, 10 9)-1) -(0.04 X IBW)
Patients with a score less than 0 are considered 
malnourished
(TSF Tricep Skinfold thickness; IBW Ideal body weight; TLC total lymphocyte count)
1.3.8 Summary of Section
There are many methods available for determining and monitoring nutritional 
status. This section has provided an overview of these techniques. However, the 
important message, is that no one assessment parameter, in isolation, will 
accurately determine if a patient is malnourished, or at risk of malnutrition. There 
are several methods that are particularly useful in the surgical patient; these 
include percentage weight loss, body mass index (BMI), mid upper muscle 
circumference and handdynanometry or hand-grip strength.
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1.4 The Consequences of Malnutrition
1.4.0 Introduction
Starvation will lead to malnutrition and ultimately death. Malnutrition initially leads 
to an altered body composition, altered organ function and may therefore, have a 
significant effect on clinical outcomes. This section will explore this topic, 
outlining the generic consequences of starvation and describing how these 
effects influence surgical outcome.
1.4.1 Body Composition
Weight loss is the most prominent consequence of malnutrition. In cancer 
patients, weight loss is often the presenting symptom [176] with up to 66% of 
cancer patients reporting weight loss during the course of their disease [281]. It 
is reported that 45% of cancer patients have lost over 10% of their pre-illness 
weight at presentation [282].
Weight loss represents changes in body composition with all body stores, i.e. 
glucose, fat, fluid and protein stores being affected. Unlike glucose and fat, there 
is no inert protein store. Therefore, any depletion of body protein originates from 
lean body tissues, which will progressively impair organ function.
This alteration in physiological function is affected at certain percentage weight 
losses [236]. A summary of studies of percentage weight loss on physiological 
function is presented in table 1.4.1. It is apparent that as percentage weight loss 
increases, this is reflected by a negative affect on physiological function.
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Table 1.4.1 The Physiological Effects at Key Percentage Weight Losses.
Author Percentage 
weight loss
Physiological abnormality reported
Keys et al (1950) [236] 5% General apathy
Studely (1936) [9] 10% weight 
loss
Reduced hand grip by 8-10% and 
subsequent reduced physical strength
Selzer et al (1982)
Hill (1992), Peel (1997) 
[230, 283, 284]
10% weight 
loss
Increased post-operative 
complications
Winick (1994) [285] 18% weight 
loss
General physiological impairment
Russell et al (1983) 
[286]
20% weight 
loss
3-fold increase in mortality (23 % vs. 
7%)
Sitges-Serra et al 
(1990) T287]
35% weight 
loss
45% reduced cardiac output, EEG 
abnormalities
In previously healthy individuals, starvation (water only) for 5 days resulted in a 
weight loss of 5% when compared to their usual weight [288]. Therefore, 
according to the work by Keys et al (1950) [236] it would appear that these 
individuals should report a degree of general apathy. A similar percentage weight 
loss was reported in a study by Brunn et al (1999) [289] comprising of surgical 
patients who remained nil by mouth with intravenous fluids. Eighty-three percent 
of patients reported weight loss and 33% of patients lost more than 5% of their 
admission weight. A similar study [290] demonstrated the average weight loss 
was 5% in 10 days in Gl surgical patients who had standard management and 
no nutritional support. This was similar to the findings in oesophago-gastrectomy 
patients who received no post-operative nutritional support reported by Martin et 
al (1999) [170]. A post-operative weight loss was reported in 87% of cases; with 
21 % of patients losing more than 10% of their pre-operative weight.
Gianotti et al (2002) [291] examined patients undergoing elective surgery for 
carcinoma of the gastrointestinal tract. This study concluded that on average 
patients lost 4.8% of admission weight post-operatively. Thus, if the results of the 
studies presented in table 1.4.1 are considered, surgical patients who are kept 
have traditional management i.e. nil by mouth, must have deleterious 
physiological function.
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The next section will present an overview of the evidence of the effect of 
malnutrition on muscle loss and organ function.
1.4.2 Organ Function
1.4.2.1 Cardiac Function
Cardiac function is grossly impaired in malnutrition [292-295]. Cardiac failure has 
been shown to be the possible cause of death in severe malnutrition [292-294].
The above studies reported that malnutrition leads to a reduced ventricular mass 
and results in reduced cardiac output, bradycardia and hypotension [296].
1.4.2.2 Respiratory Function
Malnutrition, resulting from reduced protein ingestion directly affects protein 
synthesis in the respiratory muscles [296]. Morphological changes in the lung 
and diaphragm are reported in patients with mild/moderate malnutrition [297]. 
Ventilatory drive is impaired in malnutrition [298]. The same authors showed that 
clinical semi-starvation for 10 days in healthy subjects reduced hypoxic drive by 
42%, refeeding with nutritional support however, restored this response to 
normal.
The recruitment of macrophages into the lung and their subsequent activation is 
impaired in malnutrition. This has major impact on phagocytosis-a first line in 
pulmonary defense [296]. Cell mediated immunity is also impaired in the lung
[299]. These effects have implications for surgical patients, particularly patients 
who have undergone thoracic surgery and abdominal surgery. A reduced cough 
pressure leads to increased susceptibility to chest infections. Malnourished 
patients often require ventilatory support for longer and are more difficult to wean 
from a ventilator [300].
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1.4.2.3 Renal Function
The kidneys demonstrate little morphological or functional change in malnutrition
[300]. In progressive starvation, the kidneys lose their ability to concentrate urine 
in the renal medulla, which lowers the renal medullary concentration gradient 
with subsequent polyuria.
1.4.2.4 Liver Function
Liver function and the number of hepatocytes are not impaired until near death in 
total starvation. The liver initially loses glycogen and subsequently gains fat. As 
starvation proceeds liver fat is utilised for energy and liver proteins are converted 
to glucose [300].
1.4.2.5 Pancreatic Function
The pancreas atrophies in starvation altering pancreatic exocrine and endocrine 
function early on in starvation and malnutrition [215].
1.4.2.6 Gastrointestinal Tract Function
The gastrointestinal tract (GIT) has many functions, it absorbs nutrients, is 
metabolically active secreting endocrine and exocrine products, and forms a 
microbiological barrier between the environment and the systemic circulation.
The effect of nutritional depletion on the GIT has been the subject of numerous 
studies. What seems apparent is that the presence of nutrients in the GIT lumen 
is essential for intestinal mucosal growth and function through the activation 
trophic Gl hormones, the increase in intestinal blood flow and by the activation of 
the autonomic nervous system [301]. Malnutrition or nutritional depletion affects 
the Gl in several ways:
1. Nutrient absorption
2. Gl motility
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3. Immunological impairment.
These factors will be discussed in the next section.
Nutrient Absorption
Nutrient digestion and absorption are affected in malnutrition [302]. Loss of 
weight is associated with altered mucosal architecture. Acute starvation, fasting 
and malnutrition alter villi height in humans [303], cause atrophy and thinning of 
the mucosa which all lead to a reduced surface area available for absorption. 
Coupled with this, there is a decreased brush border enzyme activity [304] 
further exacerbating steatorrhoea and diarrhoea, and hence increasing nutrient 
loss [305, 306]. A subsequent reduction in gastric acid production can cause 
bacterial overgrowth which further prevents the nutrients absorption at their 
receptors sites along the GIT.
Gut barrier function
In times of nutritional depletion or malnutrition, the gut barrier is thought to 
atrophy. This was the suggestion of trial of the affects of total starvation and very 
low calorie diets on intestinal permeability [307]. The authors established that 
starvation and malnutrition impaired Gl permeability. They found an increased 
permeability to mannitol and lactulose after only short-term total starvation. The 
authors assumed that if increased permeability occurred to these molecules, 
then bacteria could follow the same route. However, a study in animals found 
that prolonged malnutrition did not lead to intestinal atrophy or bacterial 
translocation [308]. The same group did however find that bacterial translocation 
occurred in malnutrition only when the animals had developed an acute phase 
response (APR) [49]. Thus, malnutrition alone does not seem to cause 
translocation, but it does appear to render it more probable if it occurs in 
conjunction with a systemic insult. The effect of APR without malnutrition was not 
studied.
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A subsequent human study demonstrated that malnutrition did increase intestinal 
permeability in the presence of an APR [309]. This was reported by another 
study [310] who also concluded that increased intestinal permeability positively 
correlated with circulating IL-6 levels. Both authors of these studies hypothesised 
that the GIT is the driving force behind the metabolic response to injury. This will 
be detailed in the following sections.
Gut Associated Lymphoid Tissue (GALT)
Recent evidence has linked malnutrition and the absence of enteral nutrition to 
impaired GALT function [311]. GALT comprises of immune cells located in the 
Peyers patches and mesenteric lymph nodes and cells within the intestinal 
mucosa. The impairment of GALT by the absence of enteral nutrition is the 
hypothetical reason why enteral nutrition has been demonstrated in some clinical 
trials to reduced infectious complications [49, 312-314]. This will be discussed in 
greater detail in section 1.5.
1.4.2.7 Immunological Function
Malnutrition profoundly affects immunocompetence, affecting all aspects of the 
immune system [315] but seems to have a particular impact on the cell mediated 
activity [316, 317]. Malnutrition is probably the commonest cause of secondary 
immunodeficiency world wide and is not restricted to developing countries [318]. 
It is apparent that malnutrition deleteriously affects all aspects of immunity.
Malnutrition leads to Decreased lymphoid tissue
Decreased lymphocytes numbers 
Decreased humoral immunity 
Decreased cell m ediated immunity 
Decreased lymphocyte proliferation 
Decreased phagocyte function
Dowd et al (1984) [318]
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Deterioration in immune function negatively affects the ability to recover from 
surgery. Two studies [319, 320] demonstrated that a suppressed immunity lead 
to more post-operative septic complications and increased mortality. Therefore it 
seems likely that if malnutrition leads to impaired immunity, then it must too lead 
to impaired surgical outcomes. This will be discussed later in this section.
1.4.3 Psychological Function
Starvation and reduced food intake have been shown to increase anxiety, 
depression and other behavioural changes. Studies by Leyton (1946) [321] of 
prisoners of war, reported that the first response to starvation and the reduction 
in food was the loss of sense of well being often long before the feeling of 
‘hunger*. The more prolonged the starvation the more progressive the mental 
and physical lethargy became [321]. The Minnesota study [236] detailed the 
effects of prolonged food restriction (24 weeks) on depression score. It was 
concluded that food restriction lead to social isolation and depression, having a 
major impact on the individual’s quality of life.
In 1922, Sorokin working in Russia [322] concluded that,
“Starving individuals change ideals, convictions, beliefs, emotions and the whole 
outlook on life. Starvation mercilessly bps off the social garments and shows
man as a naked animal. ”
The mechanism for this impaired psychosocial function is secondary to reduced 
protein synthesis as a result of reduced protein ingestion. These alter 
neurotransmitter production [323].
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1.4.4 Health Related Quality of Life
A study [162] concluded that malnutrition led to significant impairment in health 
related quality of life (HRQoL). This study concluded that serum albumin, pre­
albumin and a weight loss of greater than 10% predicted a patient’s perception of 
life satisfaction.
A study by Ferguson and Capra (1998) [324] reviewed 456 admissions to a 
hospital in Australia and concluded that the patients with malnutrition reported 
reduced quality of life scores when compared to well nourished patients (p<
0.05). This study used The European Organisation for Research and Treatment 
of Cancer (EORTC) QLQ-C30.
Hammerlid et al (1998) [325] also looked at HRQoL and malnutrition in a group 
of patients with head and neck cancer. They found that malnutrition did not 
correlate with HRQoL. Following major surgery it is reported that patients 
experience a pronounced feeling of fatigue for one month. This fatigue correlates 
with nutritional status, and impaired muscle strength. One study in community 
patients post discharge who had undergone major surgery reported that 10% of 
patients who were well-nourished had become malnourished within 6 weeks of 
surgery [326, 327].
1.4.5 Wound Healing
Malnutrition and recent nutritional intake are key factors in the complex 
mechanism of wound healing [328]. Malnutrition has been linked to impaired 
wound healing in surgical patients [3, 328, 329]. Even acute starvation for a few 
days is detrimental to wound healing [330]. Goodson et al [331] showed that 
even a 1-2 day inadequate nutrient intake decreased hydroxyproline synthesis 
one of the main components of collagen.
Haydock and Hill (1987) [332] studied 36 surgical patients, divided on the basis 
of their pre-operative nutritional status to ‘normally nourished’,’ mildly 
malnourished’ and ‘moderately malnourished’. They found that wound strength
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was half the normal strength in patients who were even mildly malnourished. 
Pre-operative oral food intake is also important in wound healing as 
demonstrated by Windsor (1988) [333]. The authors’ found a positive correlation 
between pre-operative nutritional intake and improved post-operative wound 
healing. This is relevant, as in clinical practice it is not uncommon for patients in 
the week prior to surgical intervention to have numerous radiological 
interventions and hence prolonged periods of ‘nil by mouth’.
Few studies have looked specifically at anastomotic strength in surgical patients. 
A study of rats [334], concluded that hypoproteinaemia and weight loss 
correlated with the bursting strength of anastomosis. In patients with a low serum 
albumin there was an increased tendency for suture dehiscence [335]. However, 
albumin does not reflect nutritional status per se, but may reflect the 
inflammatory response, which as discussed may be influenced by nutritional 
status.
1.4.6 Malnutrition and Surgical Risk
Studely [9] described the effect of malnutrition on surgical outcomes in 1936. He 
concluded that malnutrition negatively impacts on surgical outcomes. Since this 
work, the clinical management of surgical patients has progressed, with the 
availability of prophylactic antibiotics, intravenous fluids and colloids, increased 
understanding of the use of anaesthetics and analgesics, specialist critical care 
units and an increased understanding of organ function peri-operatively.
However, the use of nutritional intervention in optimising surgical outcome 
remains controversial. Several prospective studies have indicated that patients 
undergoing surgery are at nutritional risk and this can have a deleterious effect 
on clinical outcome. A review of the studies is presented in the following section.
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1.4.6.1 Retrospective Studies
A study by Windsor (1988) [5] concluded that a pre-operative weight loss greater 
than 10% created a marked negative effect on liver, skeletal muscle, respiratory 
muscle and psychological function. These patients also developed more post­
operative complications when compared to patients without weight loss. In 
addition, the author suggested that the presence of hypoalbuminaemia might 
exacerbate further septic complications including pneumonia causing an 
increased time in hospital for patients.
Similar findings were demonstrated with a 20% weight loss. These patients had a 
three times more higher risk of dying then those who had no weight loss (23% 
versus 7%) [10]. Conti et al (1977) [11] demonstrated a higher morbidity and 
mortality rate in patients undergoing oesophago-gastrectomy with a weight loss 
greater than 15% compared to those with less than 15%. Once again sepsis 
was the main cause of morbidity and mortality in this study. The authors 
hypothesise that this may be related to the effect of malnutrition on the immune 
status of the patient and therefore may have an impact on the frequency of 
complications.
A study by Meijerink et al (1992) [336], analysed the additional risk to surgical 
patients undergoing major Gl surgery caused by suboptimal nutritional status. 
Well-accepted surgical risk factors such as age, co-morbidities, type and extent 
of surgical procedure, skill of the surgeon and the disease itself, were all 
significantly correlated with surgical outcome. Following multivariate regression 
analysis the severity of malnutrition was positively associated with the severity of 
the complication.
A summary of the cohort studies of the effect of malnutrition on surgical 
complications, clinical outcome and hospital mortality are presented in table 
1.4.2. All of the 6 studies [5, 7, 170, 337, 338] indicate that a weight loss of 
greater than 10% peri-operatively leads to more complications. Two studies link 
a weight loss greater than 10% to increase risk of death in major surgical 
patients [327] [338].
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Table 1.4.2 Summary of the cohort studies of the effect of malnutrition on surgical 
complications, clinical outcome and hospital mortality__________ _________
Authors Surgical
studies
Nutritional 
status pre- 
operatively
Increase in 
complication 
s
Increased
LOHS
Increased
mortality
Corish et 
al (1998) 
[327]
Major
cancer
surgery
Weight loss 
>10% in 6 
months
Yes Not reported Nor
reported
Braga et 
al (1995) 
[337]
Glcancer 
surgery
Weight loss 
>10% in 6 
months
Yes Yes Not
reported
Martin et 
al (1999) 
[170]
Cancer
surgery
Pre-op weight 
loss>12%
Yes Not reported Not
reported
Buzby et 
al (1980) 
[7]
Major
Surgery
PNI >50 Yes Yes Not
reported
Windsor 
et al 
(1988) 
[5]
Major Gl 
surgery 
(mixed)
Weight
loss>10%
Yes Yes Not
reported
Bozetti et 
al (2001) 
[338]
UGI
cancer
surgery
PNI >50 Yes Yes Yes
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1.4.7 The Economic Impact of Malnutrition
This section has so far reviewed the effects of malnutrition on physiological, 
psychological and social function. This next section will present a summary of the 
evidence on the effect of malnutrition on the cost of healthcare.
A study by Allison et al (1992) [339] concluded that patients with unintentional 
weight loss greater than 10% of their usual body weight have more 
complications, higher mortality, longer hospital stays and therefore use more 
healthcare resources than well nourished individuals. In the USA, individuals 
whose BMI falls outside the normal range have greater health care expenditure. 
In 1993, a calculation was made suggesting that healthcare expenditure 
increased progressively as BMI decreased, from $1850 for a woman with a BMI 
of 21 kg m2 to $2350 for a woman with a BMI 15 kg m2. In men the figure was 
more pronounced with BMI 21 kgm2 equating to $1300 and $3250 for a BMI of 
15 kg m2 [340].
The recently published NICE guidelines (2006) suggest that malnutrition costs 
the NHS £7.3 billion in actual expenditure per annum [341].
Other studies have shown that malnourished patients have higher hospital costs 
when compared to well-nourished patients [342] [343]. Robinson et al (1988) 
[342] concluded that malnourished patients had increased hospital costs $7,692 
per patient -compared to $5,142 for well-nourished patients.
Reilly et al (1988) [343] also concluded that malnutrition increased hospital costs. 
They found that the costs of treating infections in patients undergoing surgery for 
cancer increased costs by $12,542 per patient and more infections occurred in 
patients who were malnourished.
Other work has demonstrated that the duration post-operatively without 
adequate nutritional intake correlated with increased length of hospital stay [344].
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The same study [344] verified that malnourished patients had increased length of 
hospital stay when compared to well-nourished patients (23.5 days versus 16.5 
days p<0.01). Thus malnourished patients had a prolonged hospital stay by 50%.
To date, few studies have looked at the impact of malnutrition after discharge 
from hospital after surgical procedures. Linn et al (1984) [345] reported more 
infectious complications in the year post discharge if the patients were 
malnourished at the time of discharge after being hospitalised for surgical 
intervention. Another study, Friedmann et al (1997) [346], reported a higher risk 
of non-elective readmissions post discharge in patients with malnutrition at the 
time of discharge.
1.4.8 Summary of Section
This section has provided an overview of the effects of malnutrition on both 
physiological and psychological function. The effects of malnutrition on the 
gastrointestinal tract, immune and muscle function are important as these have 
an impact on the development of complications in terms of morbidity and 
mortality. Impaired wound healing and complications all lead to increase in LOHS 
and increased health care costs.
Malnutrition instigates a range of physiological and clinically relevant effects 
ranging from impaired organ function to increase mortality. Malnutrition can also 
increase hospital expenditure.
These effects all need to be taken into account in the design of clinical trial of 
nutritional support to determine functional, clinical and financial outcome 
indicators.
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1.5 Nutritional Support
1.5.0 Introduction
The first documented use of nutrition intervention in the treatment of sick patients 
dates back to the Ancient Egyptians. Wine, whey, milk and barley enemas were 
administered in an attempt to improve recovery [347].
In the late 18th century, John Hunter gave the earliest recorded enteral nutritional 
support, to a dysphagic patient after a stroke. The enteral feeding tube was 
made from a whale bone and eel skin and the ‘feed’ was squeezed into the 
stomach by a reservoir made out of pig bladder [347].
In the 19th century, it was common practice to withhold food or fluid in the febrile 
or ill patient. However, in the late 1890s after the discovery that a fever increased 
the metabolic rate by 40%, it was deemed important to ‘feed a fever’ [348].
In 1932, Sir David Cuthbertson [206] studied the effects of trauma and injury on 
protein homeostasis. He concluded that ill or injured patients were ‘catabolic’ with 
resulting progressive degradation of lean body mass. This was characterised by 
increased urinary nitrogen, proportionate to the severity of the injury. These 
studies formed the basis of the understanding of the relationship between 
surgical injury and the development of protein depletion.
In 1936, the relationship between surgical outcome and nutritional status was 
demonstrated by Studely [9]. He concluded that pre-operative percentage weight 
loss correlated with increased risk of death post-operatively. Other factors such 
as age, impaired cardiac and respiratory function, type of surgery, duration of 
surgical procedure and the surgeon performing the operation were not 
associated with changes to clinical outcome. He attributed this deleterious 
outcome to the impaired immune function which is typical in malnourished 
patients. He concluded that more patients could be saved, provided efforts are 
concentrated on the pre-operative preparation of those who have lost a great 
deal of weight [155].
Some years later, Cannon (1944) [349] demonstrated that reduced protein intake 
peri-operatively increased the incidence of post-operative infections. It was at
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this time that early case studies highlighted the feasibility of enteral nutrition post- 
operatively [350, 351]. Patients who received enteral nutrition had increased 
energy and protein intakes (3050-4700 calories and 17.7-28 grams nitrogen per 
day), reduced weight loss; maintenance of plasma proteins and preservation of 
lean body mass characterised by a reduced loss of urinary nitrogen as opposed 
to patients who remained nil by mouth [350, 351].
Dudrick et al (1968) [352] subsequently defined the method of delivering Total 
Parenteral Nutrition (TPN) demonstrating that puppies could be solely ‘nourished’ 
by its use in the late 1960s. Efforts by Wretlind (1972) [353] led to the rapid gain 
in popularity of TPN in surgical patients. Subsequently, the use of TPN has been 
used often without criticism as the optimum way of delivering nutrition to surgical 
patients. Little attention was made to EN in surgical patients until the last 5-10 
years when theoretical benefits of EN over TPN were suggested.
Over the last 40 years, numerous clinical nutrition trials in surgical patients have 
been conducted. These trials have often used functional endpoints; such as 
weight loss, muscle loss, reduced muscle strength, poor immunological status 
and impaired wound healing. These are deemed important as inadequacies in 
these may manifest in the development of complications, impairing clinical 
outcome. Thus, improvements in these functional or surrogate endpoints are 
often extrapolated to provide a prediction of clinical outcome.
The most common and best-studied method of treating malnutrition is the use of 
nutritional support; either oral supplements, liquid enteral feeds or parenteral 
nutrition [341]. Nutritional support provides macro and micronutrients. Other 
methods include fortifying foods so that meals are more nutrient dense. 
However, this method is not useful in patients who are unable to eat, such as 
after major GIT surgery.
This following section will firstly present the clinical trials of nutritional support 
which used surrogate and functional endpoints. It will then examine the evidence
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for the affect of nutritional support on clinical outcome in patients undergoing 
major surgery. It will scrutinise the use of both parenteral and enteral nutritional 
support, and how these impact on clinical outcome.
1.5.1 Nutritional Support: Impact on Nutritional Outcome
Functional or surrogates outcome markers have often been reported in clinical 
nutrition trials. These indicators are usually extrapolated to suggest either a 
benefit or detriment of nutritional support in patients.
The trials in this section are classified into the effect of nutritional support on:
1. Body weight,
2. Nutritional intake,
3. Body composition
4.Body functions, namely wound healing, immune function and gastrointestinal 
function.
1.5.1.1 Nutritional Support and Weight Loss
Ten studies have looked at the effect of nutritional support on weight loss, in 
patients undergoing major GIT surgery [13-16, 18, 354-358], three of these 
studies [354-356] have demonstrated that TPN post-operatively reduced weight 
loss. The other studies [15, 16, 357, 358] with the exception of one by Watters 
et al (1997) [14] concluded that enteral nutrition (EN) via a feeding jejunostomy 
attenuated weight loss in post-operative Gl surgical patients when compared to 
patients who received standard management i.e. nil by mouth and intravenous 
fluids.
Three trials have shown that EN was superior to maintain weight when compared 
to STD management. An RCT [15] showed no mean weight loss in the EN group 
(mean calories =1138/day for 5 days) versus a weight loss of 2kg (range 5.8kg 
loss to 0.5kg weight gain) in the standard management group.
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Hoover et al (1980) [357] concluded that in a population of 49 patients following 
UGI surgery, weight loss was lower in the EN group (0.02 kg after 10 days of 
1350 calories/day) as compared to the standard group (3 kg loss, nil by mouth 
until allowed to eat and drink.)
Ryan (1981) [18] showed that patients who received 1430 calories per day from 
EN compared with nil by mouth for 6.6 days lost less weight (3.7 kg) than 
controls (5.6 kg) for the first post-operative week. Interestingly none of the 
studies reported calorie intakes that exceeded 1400kcals/day.
One study by Muggia-Sullam et al (1985) [359] compared the efficacy of TPN 
and EN in maintaining body weight. The authors demonstrated that both 
modalities were equivalent in promoting nitrogen balance, preserving weight and 
promoting protein synthesis.
None of these trials addressed the issue of fluid balance and development of 
oedema as contributory factors for weight changes in surgical patients.
1.5.1.2 Nutritional Support and Nutritional Intake
Six studies [12, 16, 18, 357, 360, 361] have reported that EN increased 
nutritional intake in GIT patients post-operatively. This is not surprising as the 
control group remained ‘nil by mouth’ and hence had no nutritional intake until 
initiation of oral intake.
Enteral tube feeding bypasses both the cephalic and oral stages of digestion; 
therefore it is possible that disturbances in appetite sensations may occur. 
Subsequently, it is assumed that the use of nutritional support will delay or 
suppress a patient’s ability to resume oral food intake post-operatively, however 
this not supported by the findings of several RCTs [15, 18, 357, 361]. These 
studies concluded that food intake was similar (if not greater) for the patients who 
received EN as compared to STD management (nil by mouth). In an elegantly 
designed study, Bastow et al (1985) [362], the authors observed that overnight 
nasogastric feeding in patients with fractured neck of femur, was associated with 
a doubling of voluntary oral intake.
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The mechanism for this increase in oral food intake may be related to a 
modifying effect of EN on the inflammatory response [363]. However, studies in 
rats of TPN [364] and intragastric feeding [365] indicate that the continuous 
infusion of nutrients decreased spontaneous food intake, the decrease in food 
intake being proportional to the density and duration of nutrients infused. After 
cessation of either TPN or EN, food intake normalised within 3 days. The 
possible mechanism may centre on receptors in the portal vein that may detect 
the concentration of nutrients in the portal circulation, signaling via the vagus 
nerve to the hypothalamus. Increase nutrient concentration activates the efferent 
loop inducing a satiated feeling, hence reducing food intake, stimulating 
gastrointestinal motility and gastric emptying [366, 367].
1.5.2 Nutritional Support and Physiological Function
1.5.2.1 Nutritional Support and Muscle mass and Strength
As discussed, a reduction in muscle mass and strength in surgical patients
deleteriously affects the function of skeletal, cardiac and respiratory muscle.
Several studies have concluded that nutritional support post-operatively 
attenuates muscle and fat loss in surgical patients [13, 14, 16, 361, 368].
Carr et al (1996) [13] reported that surgical patients who received early EN for 
the first seven days post-operatively lost less muscle strength (using 
handdynanometry (HD)) compared to ‘nil by mouth’ and intravenous fluids (6.7kg 
weight gain versus 9.6 kg weight loss in the EN and control group respectively.)
However, this was not the finding of Watters et al (1997) [14], who reported no 
differences in muscle strength (using HD) in patients who received EN versus ‘nil 
by mouth’ in the first seven days post-operatively after major UGI surgery. The 
same RCT reported that post-operative vital capacity and forced expiratory 
volume in 1 (FEV1) was consistently lower in the EN group as compared to 
controls [14]. This impairment may have been related to the high incidence of 
abdominal distension (62%) that was attributed to the ‘aggressive’ enteral feed
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regimen (2500mls/day EN delivered by the second postoperative morning) used 
in the EN group.
Also, the majority of the STD group received their pain relief from epidurals 
compared to the EN group who received systemic opioids that are associated 
with altered Gl motility [369]. This may also have been a contributory factor in the 
abdominal distension in the EN group.
1.5.2.2 Nutritional Support and Immunological Function
Patients who become anergic after surgery have a very high death rate, mainly
due to infectious complications [319]. Nutritional support is thought to have a 
direct positive affect on immunological function. However, the impact of 
nutritional support on immunological function is not straightforward. Most studies 
have assumed that a reduction in infections reflects enhanced immune function 
rather than studying the affect of nutritional support on the immune system per 
se.
One study, did however conclude that TPN corrected anergy in malnourished 
cancer patients [370]. This was not the conclusions of a study by Beier- 
Holgerson et al [12], who investigated the effect of EEN versus placebo on cell- 
mediated immunity (CMI). Sixty patients were studied; patients were stratified for 
preoperative nutritional status. CMI tests were applied 2 days before surgery and 
days 1 and 5 postoperatively; the authors concluded there were no significant 
differences in CMI scores between the groups, likewise nutritional status did not 
appear to influence CMI.
More recently, RCTs have studied the role of immuno-nutrition in improving 
immunity. Cerra et al (1991) [371] conducted a randomised blinded prospective 
trial comparing two nutritionally complete enteral nutrition formulas, (one 
supplemented with arginine, menhaden oil, and RNA) on anergy and 
suppression of immune function in critical care patients. After 7-10 days of 
enteral nutrition in patients with persistent sepsis, both EN formulas achieved 
improved nitrogen balance and improved visceral proteins, yet there was no 
improvement in anergy [371].
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The effect of EN on the development of infections (in particular respiratory 
infections) has been reported by Kudsk et al (1996)[312]. This RCT compared 
enteral and parenteral nutrition and demonstrated that enteral nutrition reduced 
infection rates from 31% in TPN to 11% with enteral nutrition. There was no STD 
management group, however.
Human studies have concluded that patients who did not have EN had more 
MOFs [313], a less favourable prognosis [372] and have increased rates of 
septicaemia, in particular which stem from bacteria derived from the intestines 
[49, 314].
1.5.2.3 Nutritional Support and the Acute Phase Response
Similarly, EN is thought to modify the acute phase inflammatory response (APR)
[373-375]. Studies have illustrated that following initiation of EN, C-reactive 
protein synthesis is reduced with a subsequent improved liver synthesis of 
albumin and transferrin. These studies [374, 375] have suggested that EN 
modulates the acute-phase response while reprioritising visceral protein 
synthesis. Interestingly, a study by Kudsk et al (1998) [376] concluded that the 
patients most likely to benefit from EN were the most metabolically unstable 
patients with the highest APR.
The role of EN in attenuating the APR, was reflected in another study [377] of 
surgical patients. The authors concluded that nutritional support prevented early 
nitrogen loss after Gl surgery, suggesting that EN reduces catabolism. Similar 
findings were reported in two further RCTS [378] [379]. Hochwald et al (1997) 
[378] randomised patients to either EEN or STD post-operative management (IV 
fluids), with the aim of determining whether EEN improves visceral proteins in 
postoperative upper Gl cancer patients. The randomised groups were 
comparable at baseline for diagnosis, procedures, serum albumin and 
preoperative weight loss (n=29). The study concluded that EEN improved 
nitrogen balance (p<0.001). The authors suggested that reduction in catabolism 
of proteins, muscle and fat mass maybe secondary to an increased production of
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insulin (an approximate two-fold increase in insulin), which is an anabolic 
hormone. Singh et al (1998) [360] supported these findings. They concluded that 
patients who received EEN within 24 hours post-operatively were in a positive 
nitrogen balance on day 3 whereas the controls (nil by mouth) remained in a 
negative nitrogen balance for 10 days. Both these studies, give a possible insight 
into the mechanisms why enteral nutrition may contribute to a reduction in 
postoperative morbidity and mortality.
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1.5.2.4 Nutritional Support and Wound Healing
The studies of the role of nutritional support in wound healing in surgical patients 
are limited. Animal studies (rats) have shown that the use of EEN had a 
significant effect on wound collagen accumulation and therefore a higher wound 
tensile strength, in the earlier phase of healing as compared to PN [380].
Clinical trials from the 1980s, highlighted that malnourished patients (N=470) 
who received PN for 1 week post-operatively had improved collagen synthesis 
and wound healing when compared to standard management [332].
Similar findings were reported by Schroeder et al (1991) [16]. The authors in this 
study used EN in patients after Gl resection, and compared it to ‘nil by mouth’ 
and IV fluids. EN was continued until the patients were able to eat and drink 
normally. The results indicate improved collagen synthesis, stronger wound 
strength in the EN group. However, a small RCT by Sagar et al (1979) [15] 
refuted this. They concluded that EN versus STD management who compared 
enteral tube feeding and standard management and did not improve wound 
healing.
The role of EN post surgery in anastomotic healing has been studied more 
recently. A meta-analysis by Lewis et al (2001) [17] of 11 RCTs demonstrated 
that anastomotic dehiscence rates were reduced in patients receiving EN. This is 
consistent with the study by Braga et al (2001) [381] which reported an 
improvement in anastomotic healing in patients receiving EEN.
A study by Khalili et al (2001) [382] concluded that early post-operative EN 
increased intestinal anastomotic strength, even in the presence of sepsis. 
Enteral nutrition also reduced TNF-alpha, which corresponded with an 
improvement in healing of the anastomosis [382]. Despite these being relatively 
small studies the role of EN in anastomotic healing looks favourable.
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A study by Braga et al (2001) [381] also suggested that EEN was not detrimental 
for anastomotic healing even when an early direct passage of nutrients over a 
fresh intestinal suture has occurred. They studied 270 gastrectomised patients 
and did not observe any jejunal ileal anastomotic leaks even though patients 
were fed proximally to this via a nasojejunal enteral tube.
1.5.2.5 Nutritional Support and Gastrointestinal Tract
The role of nutritional support in the optimal function of the GIT has been a key
area of research over the past few decades. This section will present a review of 
the evidence to date. It will focus on the effect of nutritional support in the two 
main areas of controversy, namely GIT motility and GIT barrier function. A review 
of normal GIT motility is presented in appendix 1.1.
Gastrointestinal Motility
After Gl surgery, postoperative gastrointestinal dysfunction (PGID) or ileus is 
common, occurring in 90% of patients [383].
Livingston and Passaro (1990) [384] described ileus as,
"The inhibition of propulsive bowel motility, irrespective of pathological
mechanisms"
Ileus is characterised by the development of nausea, vomiting, delayed gastric 
emptying, bowel distension, decreased bowel sounds, delay in passage of stools 
and pain after a surgical procedure [385] [386]. Studies report that ileus 
increases patient suffering and increases the tendency for more complications, 
prolonging hospital stay [383, 387, 388]. The economic impact of ileus has been 
estimated to be $750 million to $1 billion in the United States in 1999 [389].
The pathogenesis of ileus is multifactorial, the origin is thought to stem from the 
high concentration of inflammatory mediators following any injury to the intestinal 
muscularis of the Gl tract. The cytokine cascade has been demonstrated by 
several studies [390-392]. Intestinal surgery activates the macrophage network in
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the intestinal luminal wall setting up an inflammatory reaction. These 
macrophages express CD11A and CD11b and CD18 and interleukins IL-1, IL-6 
and TNF alpha. These act locally to initiate morphological changes in the bowel 
wall. In addition, these immunological cells cause an increase in free radical 
production, disrupting the membrane ion-channels (potassium and calcium) that 
regulate smooth muscle contraction and rhythm. This results in a decrease in 
circular muscle contraction and a reduced intestinal transit time. Subsequently, 
systemic cytokines, prostaglandins and catecholamines are released which 
activate the autonomic nervous system. This produces the inhibitory effects of 
altered motility and reduced mesenteric blood flow [384, 393, 394].
Interestingly, the length of the surgical abdominal incision has not been shown to 
correlate with return of normal GIT function post-operatively [395]. Neither the 
extent nor the duration of the operation appeared to correlate with the severity 
and duration of ileus [396]
Many other factors affect PGID:
1. Neuropeptides in particular substance P and endogenous opioids are released 
in response to the pain of surgery and have been linked to post-operative ileus 
[397]. Opioids have a direct affect on gastric emptying and intestinal small 
muscle contractile activity [369]. The mechanism is complex. Opioids initially 
stimulate the Migrating Motor Complex (MMC) to increase contractile activity in 
the small bowel however; however, this is then followed by a prolonged period of 
atony leading to a reduced transit time. Likewise, it has an inhibitory effect on 
colonic motility [369].
2. The avoidance of general anaesthesia and analgesia is associated with a 
reduced incidence of PGID. A study has shown that epidural analgesia reduces 
PGID compared to opioids anaesthesia [398]
3. Post-operative fluid balance affects Gl motility. A positive fluid balance leads 
to interstitial oedema, which can lead to GIT oedema [255]. Lobo et al (2002)
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[399] concluded that fluid and sodium restriction in patients undergoing major 
colonic resection significantly reduced the duration of PGID. Maintaining optimal 
fluid status was shown to improve GIT perfusion and reduce PGID [400]. 
However, this was not the findings of a further study by Cook (1989) [401], which 
found that regulating fluid regimens did not have any effect on post-operative 
ileus.
4. Disturbances in acid-base balance, glucose or electrolytes affect PGID. 
Hypokalaemia, hyponatraemia, low serum magnesium levels and acidosis all 
cause delayed gastric emptying and ileus [402] presumably due to the direct 
alteration in cellular mechanics. One study attributed even relatively mild 
hyperglycemia and hypoglycemia to altered GIT motility [403].
5. There are many other factors, which have been linked to ileus such as nitric 
oxide, reserpine, calcitonin, nasogastric intubation, gum chewing, using 
laproscopic procedures, pharmacological agents such as non-steroidal anti­
inflammatory drugs (NSAIDS), prokinetics such as metaclopramide 
hydrochloride, erythromycin (a motilin receptor antagonist), cisapride (a serotonin 
antagonist), ceruletide (a peptide that may enhance intestinal motility) and 
octreotide a somatostatin analogues that inhibit the secretion of gastrointestinal 
hormones. These are all reviewed extensively by Mythen (2005) [383].
Enteral Nutrition and Its Effects on Gastrointestinal Motility
In surgical patients, it is thought that PGID prevents the safe delivery of EN. 
Barium studies demonstrated that small bowel motility continues in the post­
operative phase, with delayed gastric emptying, taking 24 to 48 hours to recover 
and colonic motility taking 3 to 5 days to return [384].
Some clinicians continue to use the traditional practice of auscultation of bowel 
sounds to gain information on intestinal function and motility. However, bowels 
sounds have not been shown to correlate with motor patterns of function or 
dysfunction [404-414]. To date, there are few non-invasive techniques available
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to quantify gastrointestinal motility. This is an important area of research, as the 
ability to determine adequate Gl motility would undoubtedly prevent patients 
suffering from a prolonged period ‘nil by mouth’.
The administration of EN has been shown to promote bowel function in three 
studies of post-operative surgical patients [12, 68, 415]. However, this was not 
seen in two RCTs, both of which concluded that EN did not alter bowel function 
post-operatively [16, 416].
To understand why these studies produced differing outcomes an understanding 
of normal GIT motility is essential (appendix 1.1). Normal Gl motility occurs in two 
states; fed state and fasting state [417].
The fed state. The efficient absorption of nutrients from chyme in the upper small 
intestine is dependent on repeated segmental peristaltic waves. These waves 
ensure the mucosa ‘dips’ into the chyme, promoting optimal absorption. At the 
same time, the villous contractions increase both blood and lymphatic flow to 
enhance the uptake of nutrients, resulting from digestion and absorption [418].
The fasting state. In the fasting state, small intestinal motility is characterised by 
periods of inactivity and activity. The migrating motor complex (MMC) occurs 4-6 
hours after ingestion of nutrients. It is characterised by 4 phases [419].
1. Phase I- a phase of inactivity
2. Phase ll-a period of irregular spike activity lasting for 30-40 minutes. 
Pressure activity increases during phase II
3. Phase III- intense contraction
4. Phase IV- pulsating waves of contraction
The whole cycle of activity migrates down the upper small intestines at 4-6 
minutes intervals. MMCs normally occur only in the fasting state and have the
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function of sweeping food and bacteria debris down the small intestine. MMCs 
typically do not occur until 4-6 hours after a meal [420].
The route, rate and concentration of nutrients delivered into the GIT produce 
differing Gl motility affects. Studies of gastric feeding delivered at a constant rate 
caused continuous gastric emptying. The rate of the gastric emptying was 
proportional to the EN infusion rate, caloric load and the osmolarity of the feed. 
However, when the feed rate exceeded 3kcaIs/minute, gastric emptying was 
impaired [421], increasing the risk of vomiting.
The effect of intragastric feeding on small intestinal motility was demonstrated in 
a study of healthy volunteers. Polymeric enteral feed was delivered continuously 
into the stomach via a nasogastric tube, at concentrations of 1 kcal per minute 
and 1.38 kcals per minute. Neither rate of the feed elicited the normal fed state 
motility response [214]. Propagating Migrating Motor Complexes (MMCs) were 
seen throughout both the infusions of the intragastric feed [422].
In contrast, when the feed was delivered into the duodenum a fed state motility 
pattern occurred, with abolition of the MMCs [214]. There was also an increase in 
colonic motility, with the increased nutrient delivery per minute [423]. Thus, post­
pyloric EN appears to be superior to gastric feeding in stimulating GIT motility.
One study [424], did however demonstrate that delayed gastric emptying 
occurred in patients who underwent pylorus-preserving 
pancreaticoduodenectomy (PPPD). All patients received a continuous jejunal 
infusion of EN. The reason for this could stem from the actual surgical procedure 
or could be attributed to the presence of high concentration of nutrients in the 
small bowel initiating an endocrine feedback mechanism, preventing further 
nutrients being decanted into the small bowel.
This section has provided evidence to suggest that when EN is delivered in 
clinical practice, the delivery of the EN should not be perceived as simplistic. 
Attention to the delivery of the EN, in particular to the feed rate, is important, as
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failure to increase the feed rate may not produce a post-prandial motility 
response. This will result in the prevention of a normal small bowel contraction 
and peristalses, resulting in undigested EN passing into the colon [417].
Gut Barrier Function
The primary role of the GIT mucosa is to act as a defense barrier, preventing 
bacteria and endotoxins from entering the systemic circulation. The small bowel 
has a constant exposure to multiple pathogens and so contains an extensive 
immunological system [425]. The ‘normal’ intestinal mucosa is lined with tight 
junctions between the mucosa cells, which prevent the movement of pathogens 
into the portal circulation via the paracellular channels [426]. In addition, a 
multitude of immunological cells are present in the intestinal wall.
It is hypothesised that during periods of ‘stress’, following the activation of a 
APR, disruption of the gut barrier function occurs [427-431]. Bacteria which are 
normally resident in the lumen of the intestines barrier, are able to migrate and 
act as sources of sepsis at distant sites [432, 433].
One published clinical trial studied GIT morphology and bacterial translocation in 
surgical patients [434]. The authors collected ileal serosal biopsies and an ileal 
mesenteric lymph node biopsy for culture, at the start of surgery. They concluded 
that translocation occurred in 10.3% of patients.
In section 1.4.2.5, the effect of malnutrition on GIT structure and function was 
discussed. Surgical patients traditionally have a period of ‘nil by mouth’ resulting 
in ‘bowel rest’. This bowel rest has been correlated with a reduction in mucosal 
mass of 50% and mucosal atrophy, occurring within days [435].
Similarly, failure to supply enteral nutrients as occurs with the use of TPN, 
caused a reduction in mucosal thickness, reduces villous height, increases 
gastrointestinal tract (GIT) oedema, reduces GIT permeability, alters GIT barrier 
function and leads to GIT mucosal atrophy with the subsequent increased 
bacterial translocation of luminal bacteria into the systemic circulation [48-51].
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Sedman et al (1994) [434] concluded there was, however, no correlation 
between 10 days of preoperative TPN and nutritional status and intestinal villous 
height and translocation in patients undergoing open laparotomy. Septic 
complications were twice as high in patients with bacterial translocation but the 
organisms causing the infection did not originate from the GIT lumen.
Similar mucosal changes as seen with TPN have been shown to occur with 
elemental enteral diets [436, 437]. Elemental enteral feed caused mucosal 
atrophy, decrease digestive and absorptive products which are important in the 
regeneration of GIT mucosal structure and GIT function [438]. Interestingly, 
whole protein enteral nutrition was considered superior to TPN and elemental 
diets, in maintaining GIT function and integrity. This was first published by Kudsk 
(1981) in laboratory studies [41] and Alexander (1980) in clinical studies [42]. 
These studies supported previous rat studies, which suggested that GIT mucosal 
atrophy occurs in the absence of enteral feeding [43, 44]. Enteral nutrition is 
thought to have a trophic effect on GIT structure and integrity, contributing to the 
maintenance of GIT barrier function and protecting against invasion by bacteria 
and toxins, with one study by Maxton et al (1989) [45] demonstrated no 
deterioration in GIT morphology post-operatively in surgical patients who 
received EN. This was however refuted in a study by Cummins et al (1995) [439]. 
This study demonstrated that there was no benefit of EN in preserving GIT 
morphology. This study did not however report when the delivery of EN was 
commenced after the operation. This is crucial as it is possible that EN is less 
effective after hypermetabolism has been initiated.
This crucial ‘window’ when EN delivery seems optimal was supported by an 
animal study by Mochizuki et al (1984)[427]. The authors concluded that if EN 
was commenced immediately, within 12 hours, after an injury, preservation of the 
GIT mucosal structure and attenuated the catabolic response occurred. If EN 
was delayed for 72 hours the animals developed a hypermetabolic state 
(characterised by increased stress hormone concentrations and increased 
oxygen consumption). All animals, in the delayed EN group, developed mucosal 
atrophy. The authors hypothesised that the hypermetabolic state may have
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originated from the intestines, caused by pathogens entering the systemic 
circulation by bacterial translocation.
It is apparent from the above that studying the role of nutrition, ‘nil by mouth’ or 
malnutrition on translocation in human studies is challenging. There are few 
published clinical trials. Several RCTs [440-442] have not demonstrated that EN 
was superior to TPN in maintaining GIT integrity and hence reducing GIT 
permeability. Brooks et al (1999) [440] examined patients (N=26) after resection 
of upper Gl cancer and compared EN via a needle catheter jejunostomy (NCJ) 
with standard care ( nil by mouth with IV fluids) and concluded that GIT 
permeability increased in all study patients post-operatively returning to normal 
day 5 postoperatively. All patients were well nourished preoperatively.
A RCT (N=67) compared the effect of EN and PN on GIT permeability [441] in 
patients undergoing major upper Gl surgery. Patients were randomised 
prospectively to receive either seven days postoperative EN (n=33) or TPN 
(n=34). The groups were matched for age, sex, nutritional status, surgical 
procedure and blood transfusions. The mean energy and nitrogen intake over 
the seven days was not significantly different between the two groups. The 
results show no significant difference in the incidence of non-infective 
complications or the number of total infection episodes between the two groups. 
EN once again did not significantly modulate GIT permeability determined by the 
lactose/mannitol test. Intestinal permeability was increased after surgery but 
returned to normal by day seven in both groups. Kompan et al (1999) [442] 
showed no benefit of EN over PN in altering post-operative Gl permeability in 
critical care surgical patients.
Alternatively, one RCT [13] demonstrated that EN as compared to TPN led to a 
significant reduction in GIT permeability and hence possibly improved GIT 
integrity in patients undergoing intestinal resection (p<0.05). There was a 
corresponding reduction in the development of infective complications. This trial 
has a small sample size but does infer that EN may ‘protect’ GIT morphology and 
maintain GIT integrity, preventing the translocation of pathogens, hence the
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reduced number of infective complications. The exact mechanism is only 
speculative, as the trial did not isolate systemic pathogens and mesenteric lymph 
node pathogens, which would have provided an insight into the mechanism of 
translocation. To date, there appears to be no consensus as to whether EN is 
superior to TPN in maintaining GIT barrier function as reported in two review 
papers [443, 444].
1.5.3 Nutritional Support and Health Related Quality of Life
As indicated in section 1.4.4 malnutrition impacts on health related quality of life 
(HRQoL). The World Health Organisation defines HRQoL as:
‘An individual’s perception of his or her position in life in the context of the 
culture and value systems in which he or she lives and in relation to goals, 
expectations, standards and concerns. It is affected in complex ways by 
the person’s physical health, psychological state, level of independence, 
social relationships and how the person relates to salient features of his or 
her environment. ’
(World Health Organisation, 1998) [445] pg 1569
It seems likely that if malnutrition negatively impacts on HRQoL, the use of 
nutritional support may subsequently improve HRQoL [446]. The body of 
evidence to date is however limited.
There is only one published RCT to date studying the effect of nutritional support 
on HRQoL in Gl surgical patients post-operatively. Beattie et al (2000)[447] 
conducted an RCT studying the effect of EN on nutritional status, morbidity and 
HRQoL in surgical patients, post-operatively. Patients were randomised to either 
a 1.5-kcal/ml oral supplements or standard management (nil by mouth). They 
concluded that the oral enteral supplements improved nutritional status, reduced 
complications and improved HRQoL (using the UK SF-36 questionnaire).
Similar improvements were reported in HRQoL in chronic illness [448] and in 
head and neck cancer surgical patients, who received nutritional support [449].
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1.5.4 Summary of Section
This section has detailed the history behind the delivery of nutrition to surgical 
patients in particular. It discussed how the use of nutritional support seems to 
have tangible benefits on surrogate endpoints such as maintaining weight, 
muscle mass and function, improving oral nutritional intake, promoting 
immunological function and the inflammatory response. These effects also 
appear to manifest in improved wound healing, improved GIT function, improved 
immunological outcome and improved HRQoL. The next section will explore the 
clinical trials comparing different nutritional support modalities, paying particular 
attention to improvements in clinical outcome in surgical patients.
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1.6 Nutritional Support and Clinical Outcome in Surgical 
Patients
1.6.0 Introduction
The previous section suggested that nutritional support alters physiological 
function. This has raised the expectations of clinicians working in the field of 
nutritional support to assume that nutritional support must therefore improve 
clinical outcome.
Twenty years ago, a review paper entitled ‘What supports Nutritional Support’ 
[450] concluded that the trials in nutritional support were not scientifically robust 
and adequately powered to produce a radical change in surgical clinical practice. 
Since this, subsequent trials, meta-analysis and systematic reviews of nutritional 
support (both EN and TPN) still remain inconclusive as to the optimal route of 
delivery of nutrition peri-operatively.
Some of the meta-analyses have combined trials of EN with other nutritional 
interventions such as oral diet and sip feeds [451, 452]. These reviews therefore 
have heterogeneous study populations, making the generalisability of the 
findings difficult. At the time of completion of this thesis there were no systematic 
reviews of peri-operative nutritional support in major upper gastrointestinal 
surgery in the Cochrane library.
1.6.1 Current Use of Nutritional Support in the United Kingdom
The use of nutritional support therefore remains a controversial post-operative, 
therapeutic intervention in surgical patients. Currently, its use remains ad hoc in 
many UK hospitals [59, 60]. Many patients remain ‘nil by mouth’ for the first week 
post-operatively. This may predispose patients to the effects of malnutrition and 
its subsequent patho-physiological consequences as discussed in section 1.3.
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Parenteral nutrition (PN) is a frequently used option for providing patients with 
nutritional support post-operatively. However, its use tends to be delayed and 
initiated only after the development of major surgical complications.
The next section will provide a review of RCTs and meta-analyses of nutritional 
support. It will be presented as follows:
1. Pre-operative nutritional support versus post-operative nutritional support
2. Enteral nutrition (EN) versus Parenteral Nutrition (PN)
3. Pre-operative PN versus STD hospital management
4. Post-operative PN versus STD hospital management
5. Peri-operative PN versus EN
6. Post-operative EN versus STD hospital management (i.e. nil by mouth and IV 
fluids).
1.6.2 Literature Search Strategy
The following databases were searched: Medline 1966-2008; CINAHL 1982- 
2008; EMBASE 1980-2008; Cochrane Library. The medical subject headings 
(MeSH) nutrition, nutrients, diet, nutritional support, feeding, feed, parenteral and 
enteral was used.
The search was limited to RCTs, meta-analyses and systematic reviews. The 
titles and abstracts were scanned to remove irrelevant papers. The search was 
further limited to the MeSH headings operative, surgical, surgery, resection and 
the text words clinical outcomes, morbidity, complications, hospital stay.
In addition, key RCTs reference lists were hand searched to determine any titles 
that were relevant. This produced:
1. 13 RCTS for perioperative TPN versus standard management
2. 13 RCTs for Enteral Nutrition versus Total Parenteral Nutrition
3. 13 RCTs for Enteral Nutrition versus Standard management
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The methodological quality criteria for reviewing the trials are presented in 
appendix I.II. In the following section, tables 1.6.1 to 1.6.4 include all RCTs 
conducted to date for the above classification. The RCTs are classified in the 
tables as follows:
* Poor quality trials. Inadequate power secondary to small sample size; failure to 
report stringent randomisation techniques i.e. reporting the methods of random 
sequence allocation and also methods of allocation concealment.
** High quality trial. Report allocation concealment and methods of determining 
random sequence were robust
*** Meta-analysis or systematic review of RCTs.
1.6.3 Pre-operative Nutritional Support versus Post-operative 
Nutritional Support
Studies have compared the use of pre-operative nutritional support versus post­
operative nutritional support. It is important prior to appreciate that a patient prior 
to surgery is metabolically very different from an immediate post-operative 
patient. Pre-operative patients are typically metabolically stable, however, 
patients who are to undergo surgery for a malignancy are arguably not 
metabolically stable, as the effects of cancer cachexia may alter metabolism. In 
contrast, patients in the immediate post-operative phase are catabolic, losing 
cellular protein, gaining extracelluar fluid and have a decreased plasma protein 
concentration, all mediated by the acute phase response (sections 1.2.2.1 and 
1.2 .2 .2 ).
1.6.4 Enteral Nutrition versus Parenteral Nutrition
To date, there appears to be no simple answer to the question of which is 
superior - parenteral or enteral nutrition. It is important to realise that there are 
fundamental differences between the two modalities.
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The obvious difference being that EN uses the GIT, therefore, it is assumed to be 
more ‘physiological’ than PN. Normal feeding in humans is associated with 
periods of high nutrient intake followed by periods of no nutrient intake. This 
results in a fed/fast cycle. Thus, the continuous infusion of nutrients either EN or 
PN is not ‘physiological’. Therefore, the rather simplistic view often perceived by 
many clinicians that enteral is a non-scientific or ‘basic’ modality for treatment is 
not so. A review of the studies of the comparing enteral and parenteral nutrition 
is outlined later in this section.
1.6.5 Peri-operative Parenteral Nutrition versus Standard 
Hospital care
Thirteen RCTs [278, 279, 354, 356, 453-461] and 2 meta-analysis [462, 463] 
have compared peri-operative PN (i.e. pre and post PN combined) versus STD 
hospital management. These are presented in table 1.6.1.
Seven studies [279, 354, 356, 456-459] concluded that patients who had peri­
operative PN developed fewer post-operative complications than the control 
group; in three of these studies [354, 457, 458] the difference was statistically 
significant. Two studies demonstrated a reduction in mortality [459, 461] with pre­
operative PN versus controls. The difficulty with critiquing these trials is the 
variation in the use and definition of STD management. This STD management 
could be ad hoc oral intake or enteral tube feeding. Thus, interpretation of these 
RCTs and meta-analysis must be with caution.
The Veterans Affair Administration [278] randomised peri-operative patients to 
either pre-operative PN for 7-15 days, which was continued for 3 days after 
surgery, or oral diet as tolerated. The oral intakes were not reported in either 
group. The results suggest no difference between the 2 groups in overall 
complication rates (22.5% vs. 24.6% NS) and mortality (13.5% and 10.5% N.S). 
However, more infectious complications occurred in the TPN group (14.1% vs.
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6.4%; p<0.01). Several causes may have contributed to the increased infection 
rates; the central venous catheter used to deliver the TPN, bacterial translocation 
or excessive calorie and glucose load precipitating hyperglycaemia. All of which 
have been suggested to increase bacterial infections. None of these were 
reported in the study.
The authors performed a sub-group analysis. The results of which indicate that 
patients with severe malnutrition who received TPN (N=50) reported significantly 
fewer non-septic complications (5% vs. 43% p=0.03) and total complications 
(21% vs. 47% p<0.05) as compared to STD hospital care. This study suggests 
that patients with severe malnutrition benefit from peri-operative TPN 
(manifested by a reduction in surgical morbidity) when compared to well- 
nourished patients. No benefit was noted in patients with mild or moderate 
malnutrition.
Three meta-analyses have pooled the data from these trials. One meta-analysis 
[462] concluded that pre-operative TPN improved morbidity and reduced post­
operative mortality as compared to patients receiving standard care (normal 
hospital diet as tolerated).
A more recent meta-analysis [463] of 27 RCTs of peri-operative TPN in adult Gl 
surgical patients reiterated these findings. It was concluded that TPN did not 
alter hospital mortality rates peri-operatively. However, there was a non­
significant reduction in post-operative total complications in the TPN group 
(Relative Risk 0.81 (95% Cl 0.65-1.01). The most significant reduction in 
complications was in patients with severe malnutrition (relative risk 0.52 
(95%CI=0.30-0.91)).
Another meta-analysis of 41 RCTs [464] in surgical patients in the peri-operative 
period concluded there is no benefit on post-operative mortality, clinical outcome 
or length of hospital stay in patients who receive TPN peri-operatively.
Details of the RCTs summarised above are listed in table 1.6.1.
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Table 1.6.1 A review of the Randomised Controlled Trial Peri-Operative Parenteral Nutrition versus Standard Hospital Diet
S tu d y M ethods P artic ipan ts In te rven tio n s O u tco m es R an d o m isatio n  M ethods
Bellantone 
e ta ! 1988  
[459]*
Prospective
randomised
trial
N =100
Various
Gastrointestinal 
diseases 
requiring surgical 
procedure
37%  of total patients 
w ere malnourished
2 groups
T P N  30 non protein calories 
/Kg/day
lipid 9kcals/kg/day
for 7 days versus standard
hospital diet
Septic Complications TP N  30%  
Control 35 .3%  (N .S)
Mortality 2 .5%  vs. 3 .9%
No difference in the 2 groups in terms 
of mortality and complication rates.
Patients were not stratified 
for nutritional status
No randomisation 
methods or allocation 
concealment reported
Bellantone 
et al 1988  
[460]*
Prospective
randomised
trial
Gastrointestinal 
diseases  
requiring surgical 
procedure 
100%  of total 
patients were  
malnourished
2 Groups
TP N  30 non protein calories 
/Kg/day
lipid versus standard 
hospital diet
Septic complications
TP N  14.8%  vs. Control 7 .8%
(P <0.001)
Mortality TPN  1.8%  vs. control 2 .2%
TP N  group had more 
septic complications but a 
trend towards lower 
mortality.
No randomisation 
methods or allocation 
concealment reported
Fan et al
1 9 8 9 *
[455]
Prospective 
randomised 
controlled trial
N =40
Oesophageal cancer
Patients were  
matched for age sex 
and nutritional 
status, tumour 
staging or histology.
77%  of patients were  
malnourished
2 groups
Pre -op TPN  >40 non 
protein calories/Kg/day for 
7-10  days versus hospital 
diet
Complications TP N  85%  vs. Control 
75%
(N .S)
TP N  group had a statistically 
significant improvement in weight gain 
but no differences in mortality
No randomisation 
methods or allocation 
concealment reported
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Table 1.6.1 A review of the Randomised Controlled Trial Peri-Ooerative Parenteral Nutrition versus Standard HosDital Diet
S tudy M ethods P artic ipan ts In terven tio n s O utcom es R and o m isa tio n  M ethods
Heatley et 
al 1979  
[354] *
Prospective 
randomised 
controlled trial
Patients were  
randomised 
based on odds 
and even year 
of birth
N =74
2 groups 
Gastric and 
oesophageal cancer
Randomised pre-op to 
either oral diet n=36 or oral 
diet and TP N  N=38. Study 
time was 7-10  days pre- 
operatively
Post-op complications: TPN  group = 
35.4%  Control group= 83%
W ound infection rates TPN  
group=7.7%  and 30.5%  in the study 
group (P <0.05)
Mortality rate was the sam e in both 
groups
Concluded that TPN  was not of benefit 
to out way the complications of the 
catheter.
The authors concluded 
that 25 /38  had to have 
TP N  catheters changed 
during the study period 
due to catheter 
complications.
Allocation Concealm ent 
not reported. 
Randomisation methods 
not robust.
Holter and 
Fischer 
1977  
*[356]
Prospective
Randomised
Trial.
Randomisation 
methods used 
random  
number tables
N =56 randomised to 
receive either pre-op 
TP N  or oral diet.
Patients were stratified for 
pre-operative nutritional 
status.
Post-op complications in malnourished 
patients reduced from 19.2 % to 
13.3%  (Not significant)
Study generally well 
designed but degree of 
type II error.
Allocation Concealm ent 
not reported
Meguid et 
al 1988  
[458] *
Prospective, 
randomised 
controlled trial
N= 160 100%  
malnourished. 
Patients with 
Gastrointestinal 
Cancers
Pre-operative TPN  35 Non 
Protein Calories/KG/day for 
8 days versus standard 
hospital diet followed by 
post-op TP N  in all patients
Post-op complication rate; TPN  N 
=10 /32  (31.3% )
standard group 19/34 (56% ) (p<0.03) 
Mortality TP N  3%  vs. 0%  in Control
Allocation Concealment 
not reported. 
Randomisation methods 
not robust.
Moghissi 
e ta ! * 
1977  
[457]
Prospective 
randomised 
controlled trial
N =22
Patients with 
oesophageal cancer 
(100%
2 groups patients were  
given either TP N  (40-50  
Non Protein 
Calories/kg/day) or
All patients in the pre-operative TPN  
group were in +ve nitrogen balance 
and patients on IV  fluids were in a -ve 
nitrogen balance.
Allocation Concealm ent 
not reported. 
Randomisation methods 
not robust.
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Table 1.6.1 A review of the Randomised Controlled Trial Peri-Ooerative Parenteral Nutrition versus Sta
Study Methods Participants Interventions Outcomes
malnourished) standard management Patients in the TPN had impro 
in wound healing but not signif 
TPN group 0% complications i 
control group had 80% complk 
rate (p<0.05)
Muller et 
al 1986 
[461]*
Prospective
randomised
trial.
N=125
Gastro/oesophageal 
Cancer surgery
2 groups
TPN (2400kcals) for 10 
days or oral diet as 
tolerated 
Equal number of 
malnourished patients in 
each group
Post-op Complications; TPN= 
Control = 11% (p<0.05) 
Mortality rates= TPN =3% Con 
11% (p<0.05)
Mullen et
al 1981
[454] [456] 
*
Prospective 
randomised 
controlled trial
N=145 with Gl 
malignancies
2 groups:
TPN group for 10 days or 
standard hospital diet. 
Patients were matched for 
nutritional status.
TPN had a significant reductio 
complications and mortality wh 
compared to oral diet
Smith and
Hartemink
etal 1985 *
[358]
Prospective 
randomised 
controlled trial
N=34.
All malnourished 
using the PNI 
(Mullen et al, 1979)
2 groups 
TPN group 50-60 
NPCs/KG/day for 6-14 days 
pre-op versus standard 
hospital diet pre-op
Major Complications rate; TPN 
Control Group= 35.3% (no sig] 
Mortality Rate TPN=5.9% and 
(no sig)
TPN did have a improvement i 
nutritional status (p<0.05)
Table 1.6.1 A review of the Randomised Controlled Trial Peri-Operative Parenteral Nutrition versus Sta
Study Methods Participants Interventions Outcomes
Thompson 
et al
1981(453]*
Prospective 
randomised 
controlled trial
N=21 100% 
Malnourished 
Patients with Gl 
cancer undergoing 
surgery
2 groups
TPN 40-50 NPCs/KG/day 
for 8-15 days pre-op versus 
group with standard 
hospital diet
Complications rates, TPN 16.7 
Control group 11.1% (N.S).
No change in mortality (0% TP 
0% Control)
Veterans 
Affair 1991 
[278]
*
Prospective 
randomly 
assigned to 2 
groups
Randomisation
methods used
computer
generated
random
sequence.
N=395
100% malnourished 
Undergoing 
laparotomy or non­
cardiac thoracotomy
2 groups
TPN 7-10 days before 
surgery and 3 days after 
wards
Control Group received 
Standard and IV fluids as 
needed. The control group 
could then start oral diet, 
TPN or TEN as required at
3 days post-op.
Post op Complications were sii 
both groups. (TPN 25.5% vs. 2 
The patients categorised as se 
malnourished had fewer non- 
infectious complications then c 
(5% vs. 43% p=0.03)
Von
Meyenfeldt
et a/1992 
[279] **
Prospective
randomised
trial
N=101 100% 
malnourished 
Gl cancer surgical 
patients
2 groups;
TPN 35-40 NPCs/KG/day 
for 10-23 days versus 
standard hospital diet and 
treatment
Complications rates;
TPN 12% vs. Control 14 % (N. 
No change in mortality (4% vs. 
N.S)
Study Methods Participants Interventions Outcomes
Heyland [463] *** Meta-analysis of 27 randomised controlled trials. N=2901
Adult Gl surgical patients. No effect of TPN when compared to conventional inten
rates.
Klein [462] *** Klein et al, 1997 pooled these results for a meta-analysis and found that the relati 
reduction in complications rates with pre-op TPN. (A reduction from 40%-30%). T 
and Enteral Nutrition (ASPEN) has recommended that the following patients may
1) Severely malnourished prior to surgery
2) Well nourished prior to surgery but undergo surgical treatment rendering them 
14 days 3) Well nourished but due to the developments of complications will fail t< 
10-14 days.
One flaw is they failed to define malnutrition and did not describe how nutritional s
* P o o r quality  trial design; i.e. sm all s am p le  s ize , no robust o u tco m e defin itions or tre a tm e n t allocatio i
**  C lin ical trials w ith a d e q u a te  p o w er and  co n c e a lm e n t a llocation  reported.
* * *  M e ta -a n a ly s e s
1.6.6 Post-operative Parenteral Nutrition versus Standard
Hospital Management
Eight RCTs [355, 356, 465-470] and three meta-analysis [329, 471, 472] have 
compared the use of post-operative TPN with standard hospital management. 
The reviews are presented in table 1.6.2.
The largest two trials Sandstrom et al (1993)[469] (N=300) and Brennan et al 
(1994) [470] (N=114) reported a significant increase in major post-operative 
complication rates with the use of post-operative TPN. Three RCTs [355, 356] 
[466] however did report a reduction in total complications with post-operative 
TPN. Reference needs to be made to the high incidence of general 
complications in both groups, with 90% of the controls developing complications 
in the RCT by Collins et al (1978)[355].
A meta-analysis by Torosian (1999) [471] who combined data from previous 
RCTs reports that there was an increased complication rate of 10% in major GIT 
surgical patients who routinely received post-operative TPN. The conclusion was 
that TPN routinely in the immediate post-operative period is contraindicated. 
Table 1.6.2 presents details of the RCTs to date of post-operative parenteral 
nutrition versus standard management. There are general inconsistent 
conclusions from each of the RCTs, therefore, a consensus of whether post­
operative parenteral nutrition is superior to standard management is not 
possible.
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Table 1.6.2 A review of the Randomised Controlled Trial comparing Post-operative Parenteral Nil 
Management
Study Methods Participants Interventions Outcomes
Brennan et 
al 1994 
[470] *
Prospective 
randomised 
controlled trial
N=117
100% pancreatic 
resection for 
cancer 
100%
malnourished
2 groups
TPN 30-35 Non Protein 
Calories/kg/day for 12 
days post-op versus 
standard group who 
received IV fluids until 
normal oral diet allowed
Total Complications
TPN 45 % versus Control group
22.8% (p<0.002)
Mortality increased 3-fold in patiei 
receiving post-op TPN
Collins et al 
1978 [355]*
Prospective
Randomised
Controlled
Trial
N=20 Major 
Surgical patients
2 groups
TPN 37 Non Protein 
Calories/kg/day for 13 
days post-op versus 
control group who 
received IV fluids
Total Complications
20 % TPN versus 90% Control
group (p<0.01).
Holter and 
Fischer 
1977 [356] *
Prospective
Randomised
Controlled
Trial
N=30 2 groups
TPN 30 Non Protein 
Calories/kg/day for 10 
days post-op versus 
control group received 
IV fluids
Total Complications
13.3 % TPN group versus 19.2%
Control group (N.S)
Jenson and 
Ginnerup 
1982 [466] *
Prospective
Randomised
Controlled
Trial
N=20 2 groups TPN for 6 days 
post-op versus control 
group who received IV 
fluids until oral diet
Pershaw et Prospective N=47 2 groups Total Complications
Table 1.6.2 A review of the Randomised Controlled Trial comparing Post-operative Parenteral Ni 
Management
Study Methods Participants Interventions Outcomes
al 1979 
[465] *
Randomised
Controlled
Trial.
100% elective 
colonic resection.
TPN 40 Non Protein 
Calories/kg/day for 5 
days post-op versus 
control group received 
IV fluids until oral diet
TPN 33.3 % versus Control group 
17.4% (N.S).
Reilly et al 
1990 [468] *
Prospective
Randomised
Controlled
Trial
N=28 2 groups
TPN 35 Non Protein 
Calories/kg/day for 7 
days post-op versus 
control group received 
IV fluids until oral diet
Nothing recorded for Complication 
rates only surrogate endpoints
Sandstrom 
et al 1993 
[469] *
Prospective 
randomised 
controlled trial
N=300. 
Emergency or 
elective major 
surgeries were 
eligible.
Various types of 
surgery.
2 groups
TPN 29 Non Protein 
Calories /kg/day for 9 
days post-op 
(commenced dayl post 
op) versus control group 
who received IV fluids
Total Complications
TPN 27.3 % versus control 16%
(p<0.05)
Woolfson 
and Smith 
1989 [467] *
Prospective 
double blind 
parallel study.
ISM 22 undergoing 
oesophago- 
gastrectomy or 
total cystectomy
2 groups
TPN 35 Non Protein 
Calories/kg/day for more 
than 6 days post-op 
versus control group 
who received IV fluids.
Total Complications
TPN 9.7 % versus Control group
6.7% (N.S)
Table 1.6.2 Characteristics of Meta-analyses comparing Post-operative Parenteral Nutrition and St 
(continued)
Torosian et al 
1999 [471]
Torosian 1999 combined the data from 8 trials to reveal an increase in complications (10%) in p 
post-operative TPN in patients undergoing Gl surgery. Therefore routine use of TPN post-opers
Campos and 
Meguid [329]
This was a meta-analysis of peri-operative nutritional support 
Date 1977-1991
N=22 prospective studies9/22 (40.9%) = pre-operative TPN vs. oral diet.
2/22 (9%) pre-operative TPN vs. EN 
4/22 (18.1%) post-operative EN vs. oral 
2/22 (9%) post-operative EN vs. oral 
5/22 (22.7%) EN vs. TPN
The authors assume that nutritional requirements are achieved in each group as this was not d(
Detsky et al 
[472]
Detsky 1987 carried out a meta-analysis of trials of peri-operative nutritional support. They cone 
supplementation did reduce morbidity (reduced by 21%) and reduced post-operative mortality b 
however patients who received parenteral nutrition had increase complications when compared 
nutritional support (TPN increased by 7%).
* P o o r quality  trial design; i.e. sm all sam p le  s ize , no robust o u tco m e defin itions or tre a tm e n t a llocation
**  C lin ical tria ls w ith a d e q u a te  p o w er and  c o n cea lm en t a llocation reported .
* * *  M e ta -a n a ly s e s
1.6.7 Peri-operative Enterai Nutrition versus Parenteral Nutrition
Over the last two decades, evidence has accumulated that EN may have 
advantages over PN. The advantages stem from the trophic effect of EN on the 
GIT. These have been discussed in section 1.5.1.5.
Recently published work by Kudsk (2002) [46] and Genton (2003) [47] have 
provided new insight into the protective mechanism of EN. The delivery of EN is 
thought to stimulate the production of neuropeptides produced by neurons 
located in the enteric nervous system. Neuropeptides are responsible for the 
initiating the cascade of cytokine and immunological response, in particular 
producing alterations in Gut Associated Lymphoid Tissue (GALT).
A study by Cunningham (1995) [473] reiterated this possible mechanism, 
demonstrating that lack of EN or the use of PN produced a reduction in 
cholecystokinin (CCK). CCK is a neuropeptide, which directly stimulates the 
enteric nervous system. Interestingly, when PN was supplemented with CCK 
prevention in changes in GALT occurred. Neuropeptides bind with immune cells 
located in the M-cells in the Peyers patches lining the distal small intestine, to 
heighten immune response. This has not been studied in humans as yet.
TPN also carries the risk of central venous catheter infection, alters liver function 
and has increased costs [40]. The recommendation for clinical practice should be 
to use EN (either oral or enteral tube feeding) in patients who require nutritional 
support, if the GIT tract is accessible and functioning. The problem with this 
statement centres on what constitutes and defines a functioning GIT tract. Many 
surgeons and clinicians consider that EN is not feasible, practical or safe in the 
early post-operative phase due to altered GIT motility and functioning. However, 
several cohort studies as presented in table 1.6.4 have demonstrated that EN is 
both practical and feasible in the early post-operative period. The next section 
will review the literature regarding the use of EN versus TPN post-operatively.
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To date, thirteen RCTS have examined the clinical outcome of patients who were 
randomised to receive either EN or TPN post-operatively [52-58, 279, 359, 361, 
381, 441, 474]. There are two meta-analyses [475, 476]. In seven RCTs, EN 
post-operatively delivered into the duodenum or jejunum was advantageous in 
improving clinical outcome when compared to PN post-operatively [52-57]. 
Length of hospital stay (LOHS) was reduced in the EN group as compared to the 
TPN group in two RCTs [58] [52]. Conversely, no difference in either clinical 
outcome or length of hospital was reported in three RCTs [279, 441, 474]. In 
another three studies, it was not possible to draw any conclusions as to the 
effect of EN on clinical outcome, as these studies reported nutritional outcomes 
only [359, 477, 478].
One of the limitations of many of the RCTs comparing EN and TPN is that the 
groups were not matched for isoenergetic and isonitrogenous feeding regimens 
post-operatively. A study [381] in patients (N=257) undergoing curative surgery 
for upper Gl cancer compared early EN (24.4 kcals/kg/day) with PN 
(23kcals/kg/day). No differences were reported between the two groups in the 
overall study population. In a sub group analysis of the malnourished patients 
(N=91)(weight loss greater than 10%) there was a trend towards a lower 
complication rate in the EN group (37.1%) as compared to the PN group (52%) 
(P=0.023). There was also a significantly shorter length of hospital stay in the EN 
group versus the PN group (p=0.042). The authors commented that EN was four 
times less expensive than PN. This study suggested that malnourished cancer 
patients undergoing major upper GIT surgery had an improved clinical outcome 
with early EN as opposed to TPN post-operatively.
The findings of the study by Braga et al (2001) [381] were similar to a large study 
(N=307) of patients with 13-14% weight loss undergoing major GIT resection for 
cancer [52], EN or PN was commenced on day 1 post-operatively. Mean energy 
intakes were 26kcals/Kg actual body weight per day and 1.4g amino acid per 
kg/day for both the PN and EN groups. EN reduced post-operative complications 
as compared to PN (EN 34% versus PN 49% (p=0.005; risk differential 15%
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p<=0.02). Length of hospital stay was also lower in the EN group, (13.4 days 
versus 15 days (p=0.009)). An important aspect of this study was that 8% of 
patients (N=14) did not tolerate EN post-operatively. All were subsequently 
commenced on TPN and analysed on an intention to treat basis.
The 2 meta-analyses, Moore et al (1992) [476] and Braunschweig (2001) [475] 
reported that EN improved clinical outcome when compared to PN. Moore et al 
(1992) [476] concluded that EN reduced septic complications when compared to 
PN (18% versus 35%; p=0.01), whilst Braunschweig (2001) [475] aggregated the 
results of 27 RCTs, to conclude there was a significantly lower risk of infections 
with EN than with PN (RR 0.64; Cl 0.54-0.76). Interestingly, a third group 
receiving standard care had lower rates of infection than the TPN group.
A review paper by Bozzetti et al (2002) [479] concluded that post-operative EN is 
considered to be superior to PN, however the EN had to be adequate providing 
an adequate nitrogen supply (1.4g amino acids/kg/d ay).
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Table 1.6.3 A review of the Randomised Controlled Trial comparing Post-operative Parenteral an
Study Methods Participants Interventions Outcomes
Aiko et al 
(2001) [58] 
*
Prospective
randomised
controlled
trial
Japan.
N=24
undergoing
oesophagecto
my
2 groups;
ETF (N=13) commenced on the 
1st post-op day vs. TPN (N=11). 
TPN and EN and TPN regimens 
were isocaloric and 
isonitrogenous
No differences in 
complications between tl 
groups
LOHS ETF 34 days vs. 1 
40 days
Baigrie et al 
(1996) [53]
*
Randomised
prospective
controlled
trial.
Australia 
(1992-1994). 
N= 97.
100%
oesophagecto 
my and 
gastrectomy.
2 groups.
TPN N= 50 EN N=47.
TPN via a central venous catheter 
commenced day 1 post-op 
EN via a jejunostomy (Witzel) 
commenced on day 3 post-op day 
using 5% dextrose. EN 
commenced day 4 at 100ml/hr.
Mortality rates TPN 12%
versus
TEN 8.5%
Major Complications TPf 
30%
versus TEN 19%
Minor complications TPIV 
22% versus 
EN 17% N.S.
Bower et al 
(1986) [54]
*
Prospective
Randomised
Controlled
Trial
N=20 100% Gl 
or HPB 
surgery
2 groups
EN N=10 NCJ and elemental feed 
commenced on Day 1 post-op for 
7 days per day or 
TPN N=10 1000-3000kcals via a 
CVP for more than 7 day
ETF had better outcome 
TPN
No statistical information 
paper
Cost implications: patien 
charges for TPN group 
$2312.57, TEN group 
$849.40.
Table 1.6.3 A review of the Randomised Controlled Trial comparing Post-operative Parenteral and
Study Methods Participants Interventions Outcomes
Bozzetti et al 
(2001) [52, 
381]
* *
Prospective
Randomised
Controlled
Trial
N=307
100%
malnourished
2 groups
ETF ISM 59 versus TPN N=158
Post-operative complicat 
ETF =34% versus TPN 4 
(p=0.005 Cl 0.53-0.90) 
LOHS
ETF 13.4 days vs. TPN 1 
days (p=0.009)
Braga et al 
(2001) [55] 
[381]
*
Italy
N=257
Gastric ISM 21 
Pancreas 
ISM 10 and 
N=26
Oesophagus.
2 groups EN (NCJ or NJT) N=126 
versus TPN N=131 
Both EN and TPN were isocaloric 
and isonitrogenous 
(25kcals/kg/day) and were 
continued unlit oral intake 
achieved 800 Kcals/day. ETF was 
commenced 6 hours post-op at 
10ml/hr
Total complications ETF 
35.7% versus TPN 40.4°/ 
(NS)
No difference in LOHS, 
mortality, and infectious ( 
non-infectious complicati 
TEN was four-fold less 
expensive than TPN ($25 
$90.60/day)
Braga et al 
(2001 )(b) 
[55]
*
Prospective
Randomised
Controlled
Trial
Italy
N=166
(55.4% Gastric 
and 44.6% 
Pancreas 
47% were 
malnourished.
3 groups
EN (standard) N=55
IMN (IMPACT immunonutrition)
N=55
TPN N=56
Overall infective complic< 
rate was 38.4% ETF vs. 
IMN vs. 42.8% TPN 
LOHS= EN 16.1=/-5.9 vs 
13.7 +/-4.8IMN vs. 17.5 
6.1 TPN.
Heylen et al 
(1987) [478] *
Prospective
Randomised
Controlled
Trial.
N=20
100% Total 
Gastrectomy.
2 groups
EN N=10 versus TPN N=10.
EN group had a NCJ. Elemental 
Feed (Vivonex) commenced 6 
hours after surgery in EN. TPN 
group commenced 6 hours post-
No catheter complication 
either group. Anthropomc 
measurements, lab and 
cellular immunity tests 
showed clinical benefit ol 
Low cost and easy nursir
Tahlp 1.6.3 A rpvipw of the Randnmisprl Controlled Trial cnmnarinn Pnst-nnprativp Parpnti
Study Methods Participants Interventions Outcomes
op. with EN
Lim et al 
(1981) [477]*
Prospective
Randomised
Controlled
Trial
N= 24 
100%
oesophageal 
or gastric 
resection for 
cancer
2 Groups
ENN= 12 TPN N=12
EN for 3 weeks via a gastrostomy
and TPN for 3 weeks
TPN group had higher w 
gain.
No significant difference: 
between the 2 groups
Muggia- 
Sullam et al 
(1985)
[359] *
Prospective
Randomised
Controlled
Trial
USA
N=15 100%
Abdominal
Resection
2 groups:
ENN=7 via a NCJ (elemental 
nutrition) vs. TPN (N=8)
EN group had no 
complications with NCJ 
No outcome data compa 
the 2 groups
Okabayashi 
eta l(2006) 
[56] **
Prospective
Randomised
Controlled
Trial
Japan 
N=39 
100% 
pancreatic 
resection for 
cancer
2 groups. All matched pre- 
operatively.
TPN for 7 days N=23 
EN(NCJ) day 1 post-op
Less pancreatic fistulas 
group 6.3% versus 39.1c 
LOHS
TPN 44.3+/-19 days ver? 
EN 31.7+/-8.8 days
(p=0.0011)
No differences in other 
postoperative complicate
Pacelli et al 
(2001) [474] *
Multicentre 
Prospective 
Randomised 
Control Trial
N=241 100% 
elective 
gastric, colon 
and pancreatic
2 Groups
EN group N=119, TPN group 
N=122. EN (NCJ) N=81 (68.1%) 
NJT N= 38 (31.9%)
Major Complications NS 
EN and TPN, (37.8% am 
39.3%).
No difference in
Study Methods Participants Interventions Outcomes
resection for 
cancer.
and TPN via central venous 
catheter. Feed delivered over 
8.7+/- 5.9 days.
postoperative mortality r« 
EN 5.9% and TPN 2.5%.
Reynolds et 
al (1997) 
[441] **
Prospective
randomised
Controlled
Trial
UK
N=67
100% Upper 
Gl Resection 
for cancer 
Patients were 
matched for 
demographics
2 Groups 
EN N=33 NCJ
TPN (peripheral catheter) N=34 
Feed delivered for 7 days post-op 
EN Osmolite at 30 ml/hr increased 
to 100ml/hr 
TPN 1800 NPCs/day
No differences in outcom
Sand et al 
(1997)[57] **
Prospective
Randomised
Controlled
Trial
N=29 100% 
UGI resection 
for Malignancy
2 groups
ETF N=13 (NJT) TPN N=16 
(central venous catheter).
Complications EN 38% 
versus 50% TPN (NS) 
No differences in LOHS.
Von
Meyenfeldt
(1992) [279] 
* *
Prospective
Randomised
Controlled
Trial
The
Netherlands. 
N=200 
100%- Gl 
surgery for 
cancer
Groups
1) TPN N=51 10 days of pre-op 
and post op TPN; 2) EN N=50 
pre-op either oral or NG; 3) 
Control group N=50 100% 
malnourished no nutrition pre/post 
op; 4) N=49 well nourished no 
pre/post- op nutrition
No differences in total 
complications between tf 
groups
Study Methods Participants Interventions Outcomes
Excluded
Studies
The following trials are excluded if they were not a RCT, or the sample population ws 
major Gl resection or were a meta-analysis
Adams et al 
[480]
A prospective randomised clinical trial in patients with multiple trauma of central total paren 
nutrition by jejunostomy N=23. Nutritional support began on the first post-operative day anc 
significant differences were detected between the 2 groups in age, sex, injury severity; hou 
prescription and complications rates were all comparable. The authors suggested that ETF 
with multiple traumas.
Braunschwei 
g et al [475]
Meta-analysis of enteral compared with parenteral nutrition. Twenty-seven studies in 1828 
showed a significantly lower relative risk of infection with tube feeding and standard care th 
is higher and risk of infection is higher with standard care than PN in malnourished populat
Fletcher et al 
[481]
A prospective randomised controlled trial of enteral nutrition given via a NGT commenced s 
versus conventional management receiving IV fluids in patients undergoing major aortic gr« 
between the groups in length of hospital stay and complications.
Kudsk et al 
[482]
This study investigates the importance of nutrient administration after blunt and penetrating 
to either enteral or parenteral nutrition within 24 hours of injury. Both feeds were identical ir 
carbohydrate.
The enteral group had significantly fewer pneumonias (11.9%-31% p<0.02) intra-abdomina 
p<0.04)
The benefit of enteral nutrition was more pronounced in the most severely ill patients.
Moore et al 
[483]
This meta-analysis combined data from 8 prospective RCTs (N= 230) designed to compare 
TEN (N=112) in reducing septic complication in patients undergoing surgery or admitted wi 
via NCJ (N=81) NGT/NJT (N=37). All received an elemental type feed. All TPN was standa 
demonstrated that EN patients had fewer septic complications when compared to TPN (181
* Poor quality trial design; i.e. small sample size, no robust outcome definitions or treatment allocation not defined. 
** Clinical trials with adequate power and concealment allocation reported.
*** Meta-analyses
1.6.8 Early Enteral Nutrition versus Standard hospital 
management
So far, comparisons of TPN (pre-operatively and post-operatively) and STD 
management have suggested that TPN is not beneficial unless the patient is 
severely malnourished (Veterans Affair study (1991) [278]. Subsequently, the 
comparison of TPN versus EN indicates that EN is superior in terms of improving 
clinical outcome, reducing LOHS and reducing costs as compared to TPN.
Several meta-analysis have suggested that normal food intake or EN may be 
beneficial in reducing infective complications and LOHS in general patients [17] 
[415, 484-486]. However, the issue of the early introduction of oral food intake in 
patients with an upper GIT anastomosis is not straightforward, with minimal data 
available on the introduction of oral food intake in patients undergoing 
oesophagectomy, gastrectomy and pancreactectomy. One study, Lassen et al 
(2005) [487] page 346 concluded that:
“ The paucity of evidence is reflected by the marked heterogeneity in practice 
across Surgical Units in Europe. Large groups of patients may be treated sub- 
optimally. Best perioperative care for these patients must be defined and 
documented. Especially, the role of early enteral/oral intake at will in upper Gl 
surgery needs to be clarified by sufficiently powered trials. ”
This review advocates the use of oral food at will, however certainly for many 
patients this may not be the preferred method. For patients the anorexia and lack 
of confidence with regards to eating certainly in the first few days post- 
operatively, is not a viable option. In these patients, the use of feeding 
jejunostomy, for immediate EEN may be the option in clinical practice. Studies 
have reported that immediate postoperative EN is safe, well tolerated and has 
advantages over traditional management with IV fluids or PN [13, 17, 57, 58, 
488, 489]. However, doubt remains as to its efficacy and effectiveness in clinical 
practice.
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A study has shown that jejunal EN increased GIT side effects, major 
complications and was associated with occasional fatal complications [66]. 
Conversely, a study illustrated that EN was not associated with any increased 
risk of aspiration pneumonia, abdominal distension, increased nausea or 
vomiting [490]. The section will discuss the feeding jejunostomy and review the 
cohort studies which have examined its use.
1.6.8.1 Feeding Jejunostomy
There are several methods of delivering EN post-operatively. Jejunostomy is a 
surgical procedure by which a tube is situated in the lumen of the proximal 
jejunum, primarily to administer nutrition, fluid and medication [491] reducing the 
need for central venous access for administration of nutrition and drugs.
The first jejunostomy for delivering nutrition was described by Busch in 1858 
[492]. Several other surgeons in the late 1800s’ [493-495] performed 
jejunostomies in patients with pyloric obstruction. One author [494] described,
“A mid-line was made and the jejunum brought into the wound. The jejunum was 
sewn to the wound with a double row of silk sutures. The patients received 
enemas of beef-tea and egg digested with Bengers’s liquor pancreaticus every 4 
hours, on day 2 the patients had injected digested beef tea and cream injected 
into the jejunostomy”
Surmay (1878,) page 325
The patient subsequently died 36 hours later. A few years later in 1892, Maydl 
[496] performed a roux-en-Y jejunostomy; this allowed a feeding tube to be 
inserted for the delivery of nutrition.
The most commonly described technique was the Witzel jejunostomy. This was 
actually first described by Eiselberg in 1895 [497] but as it was a modification of 
the Witzel gastrostomy [498], it was continued to be called the Witzel 
Jejunostomy.
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In 1973, Delany et al [73] inserted the first needle catheter jejunostomy (NCJ). 
They described the delivery of feeding and fluids via a NCJ in 42 patients 
undergoing UGI surgery).
Since this paper, many cohort and feasibility studies have reviewed jejunostomy 
feeding. Many reporting serious and occasionally life threatening complications 
[18, 63-65, 67, 70-72, 74, 75, 499-502]. A summary of these studies is presented 
in table 1.6.7.
A retrospective review by Adams (1986) [75] of jejunostomy feeding compared 
three types of feeding jejunostomy. The total number of major complications was 
high; ranging from 33% to 66.6%. The mortality rate attributed to all type of 
jejunostomy was 10%. The conclusion from this paper was that feeding 
jejunostomy is not indicated for patients post-operatively. However, comment 
must be made as to the exceptionally high complications and mortality overall, in 
this paper.
The complications seen with jejunostomy can be classified into mechanical, 
infectious, gastrointestinal, or metabolic.
1. Mechanical Complications such as tube dislocation, occlusion or migration
2. Surgical Complications such as cutaneous or intrabdominal abscesses, 
enterocutaneous fistulas, pneumatosis, small bowel obstruction, and intestinal 
ischaemia.
3. Infectious complications can occur such as aspiration pneumonia or 
contamination of the enteral feed.
4. Gastrointestinal intolerance to jejunal feeding is reported to be between 2.3% 
and 6.8% and include abdominal distension, colic, constipation, nausea, and 
vomiting.
5. Metabolic complications include hyperglycemia, hypokalaemia, water and 
electrolyte imbalance, hypophosphataemia, and hypomagnesaemia.
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The largest prospective study over nine years was reported by Braga et al (2002) 
[66]. They studied a series of 650 patients undergoing GIT surgery. All patients 
had either a Needle Catheter Jejunostomy (NCJ) (61.8%) or Naso-Jejunal 
feeding Tube (NJT) (38.2%). Severe jejunostomy related complications were 
noted in 1.7% of patients. Enteral nutrition related mortality was 0.1%. One 
patient who had a NJT died of aspiration/ respiratory failure, directly attributed to 
the enteral feed. Refractory intolerance of the enteral feed was reported in 48% 
of patients. The authors recommended the intolerance could be minimized with 
the slow increase in feed rate in the first post-operative week and close 
monitoring. They concluded that EEN is safe and well tolerated and was not 
detrimental to anastomotic healing. The authors suggested that any intolerance 
of EN is an early predictor of impeding post-operative complications.
Another prospective cohort study [65] of 84 patients post major upper GIT 
surgery, commenced feed at 30ml/hr with a slow increase of feed rate to a 
maximum of 90ml/hr. No major complications were reported with 20% of patients 
having minor symptoms such as distension, nausea or vomiting.
Biffi et al (200) [64] studied 80 UGI cancer surgical patients who all received EN 
commenced at 15 mls/hour. The authors concluded that 1.25% of patients had 
minor complications such as nausea and distension that resolved after transient 
reduction in feed rate. No major complications were reported. Sarr (1999) [69] 
reviewed 500 patients who all received NCJ. Major complications associated with 
the NCJ were 0.6%. Minor complications (nausea, vomiting and distension) were 
reported in 15% of patients. Positive reports of NCJ were also reported in a multi 
centred pilot study of 56 patients [68].
A study from the USA [503] had a 9% complication rate with the jejunostomy 
tube. This study did however use a Foley catheter as the tube of choice. A recent 
study from Ireland [70] prospectively studied 205 patients post oesophagectomy. 
They concluded that early EN via a NCJ was tolerated in 92% of patients. 
Patients were fed on average for 15 days with 26% requiring long term nutritional 
support i.e. for longer than 20 days. Serious complications were reported in 1.4%
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of patients all requiring re-laparotomy. There was one death directly attributed to 
jejunostomy feeding.
Table 1.6.4 below provides an overview of the studies of jejunostomy tube 
feeding. The percentages of major complications associated with the 
jejunostomy are presented, in addition to the fatal complications. Several of the 
studies used a Foley catheter for the jejunostomy tube. The percentages of 
major complications range from 0% to 40%. Mortality associated with the 
jejunostomy tube ranges from 0% to 10%.
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able 1.6.4 Review of Studies of Jejunostomy Tube Related Complications
Author N Major
Complication
Jej%
Minor
Complications
jejunostomy
(%)
Mortality 
associated with 
jejunostomy (%)
Type of Jejunostomy
Delaney et a / (1977) [73] 42 Not reported Not reported Not reported NCJ
Smith et a / (1985 )[358] 50 20/50 Not reported 1/50 NCJ
Adams e fa l(1986) [75] 73 40 10 10 Stamm(46)Maydl(9)Witzel (17)
Smith-Choban (1986) [500] 143 10/143 55 5/143 Foley catheter
Brandmair and Lehr (1988) [504] 40 45 Not reported Not reported
Gemt and Orringer (1994) [505] 523 2.1 2.1 Not reported Witzel style jejunostomy
Wakefield et al (995) [72] 58 0 2 0 NCJ-Fresenius freka
Myers et al (1995) [499] 2072 1.5 0.74 0.15 Not reported
Mercer and Mungara (1996)[488] 32 30 Not reported Not reported Foley catheter
Eddy et a / (1996) [63] 122 9.8 9.8 0 NCJ
Sonawane (1997) [71] 96 8.3 7.2 3.2 NS
Velez et al (1997) [68] 56 0 19.5 0 NCJ
Heslin e fa /(1997 ) [503] 160 4 9 0.5 Foley
Yagi (1999) [506] 78 0 3.8 0 Witzel type (silicon catheter)
Senkal et al (1999) [507] 154 Not reported 18.2 Not reported NCJ
Sarr 1999 [69] 500 0.6 15 0 NCJ
Biffi et al (2000) [64] 80 0 1.25 0 NCJ
Braga e ta l(2002) [66] 650 1.7 0.1 NCJ
Han-Geurts et al (2004) [67] 1,166 1.1 1 0.4 NCJ
Chin et al (2004) [65] 84 12.9 20 0 NCJ
Sica etal (2005) [74] 262 1.5 0.1 0 NCJ
Ryan et al (2006) [70] 205 1.4 0.5 NCJ
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A study of 1,166 patients undergoing upper Gl surgery had an overall post­
operative complication rate of 36%. The complication rate attributed to the 
jejunostomy was 1.1% of patients. Mortality attributed to the jejunostomy was 
0.4%. All these patients required re-laparotomy for intra-peritoneal leak [67].
Many of the studies above have made reference to the timings and increment of 
enteral feedings post-operatively. This was reiterated in a study by Holmes et al 
(1999) [508]. The authors suggested that the development of major jejunostomy 
related complications could be related to the feeding protocol used to initiate the 
feed. The authors concluded that too ‘aggressive’ feeding lead to GIT 
complications in particular ‘distension necrosis’. This is a potentially fatal 
condition requiring urgent re-laparotomy. Aggressive feeding was defined as 
achieving nutritional ‘goals’ within 24-36 hours post-operatively. Other factors 
include osmolarity of the enteral feed, bacteria contamination and bacteria 
overgrowth of the small intestine secondary to H2 antagonists. A systematic 
review by Melis et al (2006) [644] details these as possibly aetiological factors.
The studies that have reported major and often fatal complications with needle 
catheter jejunostomy are summarised in table 1.6.5.
Table 1.6.5 Summary of Studies reporting fatal complications with jejunostomy 
feeding_______________________________ _____________ __________________
Author Complications N with fatal 
complications
Comments
Gaddy e fa /(1 9 8 6 ) [509] Small bowel 
ischaemia
5 All had NCJ. and 
distension
Brenner and Schellham m er 
(1987) [510]
Small bowel 
necrosis
1 N =25 all post 
cystectomy
Rai et al (1996) [511] Small bowel 
necrosis
2 N =2 jejunostomy 
used not specified
Lawlor eta! (1998 ) [512] Small bowel 
necrosis
3 N =3 NCJ
Scaife etal (1999 ) [513] Small bowel 
necrosis
4 N =4 NCJ
Jorba etal (2000 ) [514] Small bowel 
necrosis
5 N =5 NCJ
Zern (1985) [515] Pneumatosis
Intestinalis
3 N =2 Foley catheter
Schloerb e t a l (2 0 0 4 )  [516] Small bowel 
necrosis
5 N =15 all had water 
post-operatively
Smith et a I (1985)[500] Small bowel 
necrosis
5 N =144 Foley catheter
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A study by Zapas et al (1996) [517] carried out a risk/benefit analysis comparing 
complication rates and avoidance of TPN, they concluded that the risk/benefit 
ratio was low and NCJ enteral nutrition was not to be recommended.
1.6.8.2 Nasojejunal (NJT) versus Needle Catheter Jejunostomy (NCJ) 
Nutrition
There is limited literature on the use of NJT vs. NCJ in clinical practice. One 
cohort review [66] of jejunal feeding showed that the NJT group (N=61%) had a 
higher rate of displacement and clogging than the jejunostomy catheter N=38.% 
(p=0.0005 and p=0.0007 respectively).
The main concern with the use of NJTs centres on patient compliance. It is 
reported that at least 50% of nasally passed tubes are voluntary or accidentally 
removed by the patients within a week of placement [61]. Patients also report 
that they found nasoenteral tubes to be more inconvenient and more 
uncomfortable than percutaneous tubes. This was despite the percutaneous 
tubes staying in situ for a longer period of time [62].
In patients undergoing pancreatic resection, a study [518] determined whether 
patients had reduced length of hospital stay who received double lumen 
gastrojejunostomy (GJT) tubes as compared to nasoenteral tubes. Insertion of a 
GJT was associated with a shorter length of hospital stay, reduced gastroparesis 
and was determined to be more cost effective.
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1.6.8.3 Review of Randomised Controlled Trials of Early Enteral Nutrition 
versus Standard Post-Operative Management
The above section presented a review of the cohort studies of the feasibility of 
feeding jejunostomy. It is still not apparent whether the introduction of EEN within 
24 hours of leaving the operating theatre improves clinical outcome and leads to 
a subsequent reduction in LOHS. The next section will examine the published 
RCTs to date.
Thirteen RCTs [12-16, 357, 358, 361, 483, 503, 518-521] have been published 
comparing EN versus STD post-operative management (nil by mouth) on the 
development of complications, clinical outcome and LOHS in patients 
undergoing major Gl resectional surgery.
Four RCTs concluded that EN was beneficial in improving clinical outcome as 
compared to STD management [12-16]. Patients who received EN had a shorter 
LOHS of 3.5-5 days [12, 15, 16, 483, 518]. However, other RCTs [13, 14, 357, 
358, 360, 416, 503, 519, 521] have refuted this. These studies have reported no 
reduction in LOHS with the use of early EN post-operatively.
Beier-Holgerson et al (1996) [12] (N=60) compared the use of EEN delivered via 
a NJT with Placebo (water). The author aimed to match the volumes delivered 
per day in each group. The study included all patients undergoing resection for 
Gl disease. The studies conclude that the EEN group had a 3.5 days reduction in 
LOHS, and a lower mortality rate than the placebo group.
With regards to the development of complications, they demonstrated that EEN 
group had fewer total complications and a significantly lower incidence of 
postoperative infectious complications (7%) compared with the control group 
(47%) (P<0.0009) [12]. This is a high complication rate in the placebo group.
The choice of STD group intervention is a concern in some RCTs. The STD 
treatment used in the study by Beier-Holgerson et al (1996) was 900 mis of 
hypotonic fluids infused into the small intestines on the day of surgery. This may 
have led to influx of systemic fluid back into the intestines, subsequently
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increasing pressure on the anastomosis, which may have had a contributory 
factor to the high incidence of complications in the STD group.
Heslin et al (1997) [503] conducted an RCT which examined the effect of EN on 
morbidity, mortality and LOHS in UGI cancer patients when given early 
postoperatively. After curative resection patients were randomised to receive 
either EN (n=97) or STD management, nil by mouth and intravenous fluids 
(n=98). There was a 5-6% preoperative weight loss in the sample suggesting 
some degree of malnutrition; serum albumin levels were within the normal range. 
No significant differences were reported in the two groups in relation to the 
incidence of major or minor complications, mortality rates or LOHS. Overall 
complication rate was 25% in both groups and overall mortality was 2.7%.
There were several confounding factors in this RCT. The patients randomised to 
EN group received approximately 30% of the planned EN goal in the first week. 
Post hoc analysis revealed that the EN group had more patients allocated who 
underwent surgical procedures with increased intra-operative duration time as 
compared to the standard group. Likewise, there were more patients who 
received neo-adjuvant chemotherapy allocated to the EN group. Thus the groups 
could be deemed non-equivalent for comparison. In summary, the results of this 
RCT need to be interpreted with caution, as the higher risk patients were 
allocated to the EN group.
The RCT by Watters et al 1997 [14] (N=40), also concluded that EEN was not 
superior to STD hospital management post-operatively. The results indicated that 
vital capacity, (which reflects respiratory muscle strength) was significantly lower 
in the EN group when compared to the unfed group postoperatively. The 
impairment was attributed to the high incidence of abdominal distension (62%) 
experienced in the EN group. This could have been related to the ‘aggressive’ 
feeding regimen of 2500 mls/day enteral feed to be delivered by day 2 post­
operatively. It may be that the abdominal distension affected diaphragm function.
Lewis et al (2001) (2001) [17] performed a meta-analysis and systematic review 
of 13 RCTs comparing any type of enteral feeding with nil by mouth management 
after elective gastro-intestinal surgery. The majority of the RCTs had
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heterogeneous samples or small size. The authors questioned the 
methodological quality of many of the studies included. The meta-analysis all 
included a range of routes of delivery of enteral nutritional support. In six studies, 
patients in the intervention group were fed directly into the small bowel, in five 
studies they were fed orally. The authors concluded that EN reduced LOHS by 1 
day, compared to standard management. Early feeding reduced the risk of any 
type of infection. Risk reductions were also seen in anastomotic dehiscence, 
wound infection, pneumonia, intra-abdominal abscess, and mortality, but these 
failed to reach significance. The risk of vomiting was higher in the EEN group.
The following tables discuss the RCTs comparing postoperative early enteral 
nutrition versus standard hospital management (i.e. nil by mouth) in patients 
undergoing major gastrointestinal resection. Meta-analyses and RCTs of other 
groups of surgery are presented in the excluded trials section that follows.
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Table 1.6.6 A review of the Randomised Controlled Trial comparing Postoperative Enteral N 
Management ( i.e. nil by mouth)
Study Methods Participants Interventions Outcomes
Beier- 
Holgerson 
et al (1996) 
[12]
* *
Randomised 
double blind 
prospective 
trial.
Informed 
written 
consent was 
obtained.
Denmark N=60. 
15% patients 
malnourished 
Placebo Group=30. 
Gastrointestinal 
diseases for bowel 
resection with an 
anastomosis, an 
enterostomy, a 
gastric or 
oesophageal 
resection were 
included.
Patients were 
stratified for pre- 
operative nutritional 
status.
All patients have a NJT
(Flocare).
EN (N=30) received nutridrink 
(Nutricia Clinical Care, 
Netherlands) 600mls day of 
operation.
Nutrition group= 30 NJT 
placed in 2nd-3rd jejunum. 
900 Kcals and 30g protein; 
day 1 post­
operative^ OOOkcals and 50g 
protein; day 2 post-operative 
1400kcals and 80g protein 
and day 3 1800kcals and 100 
grams protein;
Control Placebo 600mls ( 
water) increasing volume to 
10OOmls/day.
Major Complications 
EN 26% versus Placebo 63° 
(p=0.0089)
Infectious complications 
EN 6.6% versus Placebo 
46.6% (p=0.0009)
LOHS
EN 8 days versus Placebo 1 
days (p=0.08)
Mortality Rates
EN 6.6 % versus Placebo
group 13.3%
Economic:
EN 43.270 DKK versus 
Placebo group 58.385 DKK
Carr et al 
(1996) [13] 
*
Randomised
Controlled
Trial
UK N=30 
100% Elective Gl 
Resections
2 Groups
EN: ( n= 14) via a double 
lumen Medicina NJT 
commenced 2-3 hours post­
op
Control group: IV fluids ( N= 
14) until introduction of 
normal food.
No difference in LOHS (9.8 
days vs. 9.3 days); EN grouj 
appears to have maintained 
Nitrogen balance in first wee 
post-op. Intestinal permeabil 
reduced in the EN group 
(p<0.005). EN had less naus 
vomiting and distension than 
the IVI group (NS).
Table 1.6.6 A review of the Randomised Controlled Trial comparing Postoperative Enteral Nutrition vers
Study Methods Participants Interventions Outcomes
Heslin et al
(1997) [503] **
Randomised
Controlled
Trial
USA N=195 
100% Major UGI 
surgery with curative 
intent.
Oesophageal (N= 
23), gastric (N=75), 
pancreatic (N= 86) 
or bile duct (N=11) 
cancer.
2 Groups
EN group N= 97 Control 
group N= 98.
EN commenced 24 hours 
post-op via NCJ, aiming 
towards 25 kcal/ kg per day, 
continued until oral intake 
resumed.
Control patients had 
intravenous crystalloid 
solutions until commenced 
oral intake.
No differences in complicati< 
rates or mortality.
No difference on LOHS. 
Weight loss was the same ir 
groups, 5% EN and 6% 
Control.
Hoover et 
al (1980) 
[357] *
Prospective
Randomised
Controlled
Trial
USA.
100%
Oesophagectomy, 
gastroduodenal, 
biliary or pancreatic 
resections 
N=49
2 groups
ETF (N= 27) NCJ with 
elemental feed (Vivonex) 
commenced day 0 Feed rate 
commenced at 50mI/hr 
increasing to 125ml/hr for a 
minimum of 10 days 
Control (N=22) IV fluids until 
oral diet commenced.
No differences in complicate 
Improved nitrogen balance i 
the ETF group.
No weight loss ETF group 
compared to mean 4kg weig 
loss in Control group.
Mack et al A prospective USA N=59 2 groups LOHS EN=11.5 +/- 2.9 days
Table 1.6.6 A review of the Randomised Controlled Trial comoarino Postooerative Enteral Nuf
Study Methods Participants Interventions Outcomes
(2004) [518] 
* *
Randomised
Controlled
Trial
100% peri-ampullary 
tumours for PPPD 
19 patients palliative 
at surgery
EN group N=20 double 
lumen NJT
Control group N= 16 nil by 
mouth until oral diet
and control = 15.8 +/- 7.8 d£
p=0.01)
Hospital charges were 
$82,151+/-56,632 in control! 
and $52,589+/- $15,964 in tl 
EN (p=0.036)
Incidence of weight loss wa; 
similar in each group. 
Delayed gastric emptying in 
control group =25%
Moore and
Jones
(1986) [483] 
*
Prospective
Randomised
Controlled
Trial.
USA. N=75 Gl 
surgical Procedure 
Study duration was 
2 years.
N=75 consecutive 
admissions. 12 were 
excluded from 
analysis (6 re­
operations, 4 
deaths, and 2 
transfers to another 
hospital).
EN (N= 32) NCJ received 
elemental diet 18 hours after 
surgery and aiming for 3000 
Kcals/day by day3.
Control group (N=31) IVI 
fluids for 5 days and then 
TPN if no oral diet at that 
time.
Major complications in 15/3' 
(48%) of controls developed 
post-op complications.
14/31 (44%) had major 
complications. Septic morbic 
was greater in the control gr 
(29%) p<0.025.
LOHS was shorter in the EN 
(25.3+/-6.1 days) Control gn 
(28.6 +/-6.1 days). Hospital 
costs were higher in the con 
group $609,000 (mean 
$19,636+/-3,396) compared 
$505,000 (mean $16,280+/- 
$2,146).
Concluded that NCJ is safe, 
simple and feasible.
Page et al 
(2002) *
Prospective
Randomised
UK
N= 40 transthoracic
2 groups
EN group N=20 either NJT
No difference in morbidity, 
mortality or any parameters
Table 1.6.6 A review of the Randomised Controlled Trial comoarina Postooerative Enteral Nutrition ^
Study Methods Participants Interventions Outcomes
[521] Controlled
Trial.
oesophagectomy for 
cancer
Groups matched 
pre-operatively
(double lumen) or NCJ 
versus Control group N=20 
EN feed started day 1 post­
op at 25 ml/hr and increased 
every 4 hours until target 
volume was reached 
(35ml/kg body weight/day). 
Control group received IV 
fluids.
between the groups.
Sagar et al 
(1979)[15] *
Randomised
Controlled
Trial
UK
N=30.
100% GIT Resection
2 Groups
EN N=15 elemental diet via a 
double lumen into the 
stomach.
Control group N=15 Iv fluids 
and after 2 days oral fluids 
and 'light' diet on day 6.
LOHS
EN 14 days versus Control1 
days.
Total complications 
EN 3 % versus 5% (NS).
EN patients maintained their 
weight compared to controls 
(1.85kg)
EN had improved nitrogen 
balance compared to contro
Schroeder 
et al
("1981) [16] 
*
Randomised
Controlled
Trial
N=32
New Zealand 
100% Small or large 
bowel resection
2 groups
EN N =16 NJT feed given for 
56 hours post-op 
Control group N=16 IV fluids 
until oral diet
LOHS:EN 10 days versus 
Control group 15 days (NS) 
Complications: 4 % versus 7 
(NS).Higher wound healing 
rates in EN (NS)
Smith et al 
(1985) [358] 
*
Prospective
Randomised
Controlled
Trial.
100% elective GIT 
resection for 
malignancy or 
bypass
2 groups
EN N= 25 NCJ started 3 days 
post-op until oral intake 
adequate
No differences between the 
groups in total complications 
Failure due to catheter 
complications = 5/25 (20%)
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Study Methods Participants Interventions Outcomes
N=50 Duration =30 
months
Control Group N=25 IV fluids 
until adequate oral intake.
Failure due to intolerance = 
6/25 (24%)
14/25 successful feeding. 9/ 
failed enteral feed due to tut 
failure or intolerance.
No recommendation for EN
Swails et al
(1995) [522] 
*
Prospective
Randomised
Controlled
Trial
N=25 EN=13 started immediately 
after surgery and control 
group routine care and 
advancement to oral diet
No major complications 
associated with the feeding 
catheter.
A trend towards ETF having 
shorted LOHS N.S)
Watters et 
al [14]*
Prospective
Randomised
Controlled
Trial
N=47 UGI 
Randomised 
patients N=31. N=16 
not randomised as 
palliative at surgery. 
Groups matched at 
baseline
2 Groups
EN =13 NCJ 2 patients 
excluded in the EN group 
because of major 
complications, 
vs. Control=15 nil by mouth 
until oral diet commenced
EN group had decreases in 
vital capacity and FEV1 thar 
control patients.
EN not beneficial.
Yeung et al 
1979)[361]
*
Randomised
Controlled
Trial
N=40
100% GIT surgery
2 Groups EN N=20 elemental 
diet via NCJ versus control 
group N=20 intravenous 
fluids and nil by mouth
No change in groups for LOI 
or complications rates
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Study The studies below were excluded from the main table for the randomised controlled trials as th 
meta-analyses or non upper gastrointestinal surgery.
Beattie [447] Randomised controlled trial evaluating the use of enteral nutritional supplements in postoperat 
patients. N=101 (52 treatment group, 49 control group) admitted for elective gastrointestinal or 
group were provided with oral dietary supplements, 1.5 kcal/ ml and 0.06 g/ml protein and wen 
Control patients lost more weight. Anthropometry and QOL were similarly significantly different 
Incidence of complications differed between the groups, 13 controls, 6 in treatment group. Mor 
the control patients.
Concluded that postoperative nutritional supplementation improved nutritional status, QOL anc
Biffi et al [64] N=80 oncological Gl surgical patients. Age 18-75. Jejunostomy tube inserted as per Delaney [' 
scheduled surgical procedure. Nutrition was commenced at 15 ml/hr and increase over 5 days 
nutritional support for 14 days.
This paper demonstrated a 1.25 % early complication rate this was related to intolerance of the 
reducing the feed rate temporarily.
No late complications were demonstrated (12month fu) however no mention if the tube was in 
receiving nutritional support.
Braga et al 
[66]
Prospective study of 650 patients treated with EEN via a NCJ or NJT after major intestinal surj 
Jejunal feeding was started within 12 hours of surgery and increased by 20ml/hr daily until nuti 
61.8% of patients had a NCJ (Witzel technique) and 38.2% had NJT.
One patient aspirated with an NJT and subsequently died of respiratory failure.
Gl adverse effects occurred in 30% of patients. Emphasised the importance of keeping feed ra 
slowly.
4.6% of patients needed to switch to TPN. Low serum albumin correlated with refractory intole 
intolerance in 48% of patients represented a early symptoms of intra-abdominal complications. 
Concluded that EEN was safe and well tolerated and did not show any deleterious effect on an
Bufo et al 
[414]
Non-randomised uncontrolled trial of 38 patients undergoing colorectal surgery.
Supports the concept of early post-operative nutritional support. Speculation that early enteral 
reduces hospital costs. Details discussion of post-operative ileus and Gl motility post colorecta
Table 1.6.6 A Review of the Trials comoarina Postoperative Enteral Nutrition versus Standard Hos
Cerra et al 
[523]
Excluded as uses head injuries, long bone fractures N=9. Patients were classed as moderatel 
The study focused on small intestinal feeding in the presence of ileus and moderately high lev 
Poor study with small sample size, the paper does not give clear insight into objectives and oi
Chin et al 
[65]
York (UK). A prospective cohort study of 84 patients undergoing oesophagectomy, gastrectonr 
for cancer. All patients had a NCJ by one of 2 dedicated surgeons as per technique by Sarr (1 
needle catheter jejunostomy). The study was over 3 years. Feed was commenced within 24 h< 
increasing to requirements by day 3, a rate of 60-90mIs/hour. No patients had NCJ leakage th 
procedure related mortality.
Complications (14%) related to feeding were managed by reducing feed rates.
98% of patients started nutritional support on dayl post-op. Feed rate commenced at 30ml/hr. 
68% (N=57) achieved nutritional requirements in 3 days post-op.
No major complications or deaths were reported in the study.
Minor feeding related complications such as distension, nausea etc were 20%.
Conclusions are that NCJ is safe despite being an invasive procedure when practised in expei
DeGottardi 
et al [524]
N=100 had NCJ for post-operative enteral nutrition. 26 developed catheter related complicatio 
due to feed leakage. No patients died as a result.
N=18 developed nutritional related complications which resolved due to reducing the feed rate 
Concluded jejunostomy is safe and that complications can be reduced by meticulous insertion 
can reduce feed related complications.
Eddy et al 
(1996) [63]
N=122. Retrospective review of trauma patients. Complication rate of 14% (8% serious). Weal 
patients are prone to higher rate of complications associated with jejunostomy secondary to er 
the stoma site secondary to oedema due to acute post-injury response leading to leakage at tl
Farreras et 
al 2005 [525]
Barcelona, Spain.N=66 A prospective randomised double blind clinical trial. One group receive 
(Impact). Control group received standard enteral nutrition (Isosource). Concluded that immun 
surgical wound healing for patients undergoing gastrectomy and reduces general morbidity an 
infections.
Frankel and 
Florowitz 
(1989) [416]
N=50 randomised into two groups to assess the importance of the role of Moss Nasojejunal tu 
Treatment group had oesophago-gastric decompression and immediate post op enteral feedir 
treatment group, none in control. No difference in length of hospital stay or use of post op ana 
discharge complications in either group.
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Lewis et al
(2001) [17] ***
A meta-analysis and systematic review of RCTs comparing any type of enteral feeding with nil 
elective gastro-intestinal surgery. Heterogeneous RCTs and most very small and of doubtful m 
studies, patients in the intervention group were fed directly into the small bowel, in five studies 
reduced by 1 day in the EEN group.
Early feeding reduced the risk of any type of infection. Risk reductions were also seen in anast 
infection, pneumonia, intra-abdominal abscess, and mortality, but these failed to reach signifies 
higher in the EEN group.
Lobo et al 
2006 [526]
Randomised double blind RCT. N=120 Patients undergoing major resection for cancers of the 
stomach. Two groups. One group had NCJ and enteral nutrition versus NCJ and immunonutriti 
days. Feeding commence 4 hours post-operatively at 25 ml/hour on day 0, 50ml/hour on day 1 
groups.
Analysed 108 patients (54 in each group).
No difference in feed delivery in either group. Median LOHS was 14.5 days (12-23) in group A 
Infective complications were similar in both groups (44%).
Jejunostomy related complications were 50% in either group. Authors concluded no benefit wit
Mercer et al 
(1996) [488]
N=32 undergoing palliative or curative surgery for oesophago-gastric carcinomas. Prospective 
the early post-operative period. All patients had a Foley catheter type tube. There were no posl 
of jejunal feeding was 24 days. A cost of enteral nutrition was $188.71 per patient. 
Gastrointestinal complications occurred in 7 patients. Metabolic complications occurred in 3 pa 
Concluded that ETF is effective and safe and cheap. Excluded as not RCT
Ryan et al 
(1981) [18]
N=14 colorectal patients. RCTS 2 groups one enteral nutrition group and one control group rec 
complication in the nutrition group versus 43% in the control group.
Sarr et al 
(1999) [69]
A study of 500 consecutive cases in one hospital centre over a 10 year period. Insertion of NC, 
(0.006%) major complications in patients requiring surgical treatment.
Minor complications were shown in 15% of patients such as intolerance (diarrhoea and distens 
allow safer, cheaper and equally effective delivery of nutrition, compared to TPN after major ab
Senkal et al 
(2004) [527]
Prospective open clinical trial N=20 over 8 months. Cancer patients undergoing major elective 
3 hours after surgery at 20-30 ml/hr via a NCJ (not mentioned which one).
Total Kcals for 3 days = 500 Kcals/ day. On day 3 patients were additionally given (Reconvan F 
250kcal/500mls, glutamine, and nucleotides. Concluded that the 'new' feed as metabolically si
is well tolerated in surgical patients and provides a novel way to deliver conditional essential ni
Singh et al 
(1998) [360]
A 1 -year prospective study to investigate the feasibility and efficacy of immediate postoperative 
intestinal perforation and peritonitis. Treatment group N=21 (Witzel jejunostomy) received ente 
operatively. By day 3 they were receiving at least 2 litres of full strength feed for 24 hours/d. 
The two groups were comparable except for higher sepsis score in treatment group. Treatmen 
balance by day 3, the control group remained in negative nitrogen b balance throughout. Diarrl 
was easily resolved. Mortality rates were similar. Control group 22 septic complications compa 
Concluded that immediate post op feeding is feasible.
Smedley
[528]
ISM 79 were randomised to receive one of four groups:
1) no oral nutritional supplements
2) Pre-operative oral nutritional supplements
3) Pre and Post-operative nutritional supplements
4) Post-operative oral nutritional supplements
Results:No differences in outcome in terms of major complications, anthropometries and Q-o-l, 
complications and was deemed to be cost-effective.
Soop [529] N=18.Patients were randomised to receive either immediate post-operative enteral nutrition or 
for the first 3 days. Study focused on insulin resistance and post-operative nitrogen balance. C 
nitrogen balance and does not increase hyperglycaemia when compared to hypocaloric feeds.
Stewart
[415]
N=88 undergoing elective colorectal resection with anastomosis. Patients were randomised to 
post-op or nil by mouth (N=40) until passage of flatus or bowel motions.
The patients in each group were well matched for age, sex and type and duration of surgery. T 
tolerated a diet, passed flatus, used their bowels and were discharged home 2 days sooner (9
Torosian
[471]
Critical analysis of perioperative nutrition support for patients undergoing gastrointestinal surge 
parenteral nutrition both pre and post operatively. Four post op enteral nutrition trials were ana 
individual studies are not confirmed when analysing combined data from all studies; it revealed 
morbidity or mortality rates.
Velez [68] A multicentre pilot cohort study in patients undergoing Gl surgery with intestinal anastomosis, 
failed to meet the inclusion criteria due to mechanical tube issues.
EN was commenced in 46 patients within 24 hours. Feed type was a peptide based feed (Pepi 
well tolerated in the majority of surgical patients with a low incidence of complications and side
faster resolving of bowel function which may shorter LOHS.
Zapas [517] Carried out a benefit/risk analysis of prophylactic jejunostomy comparing complication rates, a 
N=92.
Concluded that benefit/risk ratio is low mainly for the significant rate of complications related tc
1.6.8.4 Cost Effectiveness comparison of enteral nutrition versus standard
management
Very few RCTs have been designed to compare the economic costs of using EN 
versus STD hospital management post-operatively. However, cost comparisons 
have been made several studies. These will be presented in this section.
A study from the USA by Hedberg et al (1999) [530] concluded that EN delivered 
via a needle catheter jejunostomy within 12 hours of major surgery (as compared 
to standard care) led to a cost saving of $4,450 per patient in the early EN group 
in patients post major GIT resection, as compared to STD care.
Beier-Holgerson and Boesby (1996) [12] demonstrated that the cost of providing 
EN to patients undergoing major resection for Gl cancer could deliver a potential 
cost saving of 50%; £1000 for EN patients and £2000 for STD patients, the costs 
were based on the differences in LOHS. This was reiterated by Carr et al 1996 
[13] who too surmised that the use of post-operative EN could lead to cost 
savings.
A systematic review and meta-analysis of the RCTs comparing any method and 
type of enteral feeding started after surgery with nil by mouth and standard 
management in elective gastrointestinal surgery was conducted in 2001 [17]. 
The authors concluded that early feeding was associated with a shorter length of 
hospital stay and reduced frequency of infections, the greatest reduction being in 
wound infections. They also surmised that cost savings could be achieved.
While the RCTs included were heterogeneous in clinical terms, the effect of early 
nutrition seemed to be homogenous. The authors conclude that there is little 
evidence that keeping patients 'nil by mouth' is beneficial. However, they 
recommended that an adequately powered RCT addressing the flaws and 
limitations in the RCTs to date should be conducted.
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1.6.9 Immuno-enhanced Enteral Nutrition
Most of the studies examining EN in postoperative patients have used standard 
enteral formulas. Recently, more studies have used formulas, with immune 
enhancing properties.
To date there has been 7 RCTs [291, 489, 507, 531-534] exploring this subject. 
Several studies have indicated that immuno-enhanced enteral nutrition was 
superior to enteral nutrition in lowering incidence of infections and complications. 
Daly et al (1995) [531] examined a formula supplemented with arginine, RNA, 
and omega-3 fatty acids in patients with upper Gl malignancies. Eighty-five 
patients were randomised to receive either a supplemented enteral formula or a 
standard enteral formula. Both groups had a similar calorie intake but nitrogen 
intake was significantly greater in the supplemented group. A lower incidence of 
infectious and wound complications was found in the supplemented group (11% 
vs. 37%) and length of stay was shorter. There was no control arm in the study 
that did not receive nutritional support in the study design.
McCarter et al (1997) [489] conducted a prospective study of 167 patients 
undergoing upper Gl surgery for carcinoma of the oesophagus, stomach and 
pancreas. Patients received a standard or supplemented formula via a 
jejunostomy postoperatively. The authors did not examine the occurrence of 
complications in the two groups but instead examined the tolerance of the 
enteral feeds. The majority of symptoms experienced were mild and included 
abdominal cramping, abdominal distension, nausea and diarrhoea. This is not 
attributed to the use of different formulas as no significant difference was found 
in tolerance of feed between the standard and immune enhanced formula group. 
The direct correlation between jejunal feeding and the occurrence of symptoms 
is not clear once again due to the absence of a control group without an enteral 
feed.
I l l
Braga et al (1998) [55] used an immune enhancing formula in 166 patients who 
underwent abdominal surgery for gastric or pancreatic cancer. Patients were 
randomised to TPN, standard enteral feeding or enteral feeding with the enriched 
formula. Greater than 10% weight loss in the preceding 6 months occurred in 78 
patients. There was a trend towards fewer infections in the EN group; it did not 
reach statistical significance, and the severity of infection was lower with the 
enhanced formula than with the TPN or standard enteral formula.
A study by Senkal et al (1999) [507] focused on providing immuno-nutrition to 
malnourished surgical patients. The authors found that immuno-nutrition given in 
the pre-operative period alone or in the pre and post-operative period improved 
clinical outcome and shortened hospital stay, when compared to standard 
enteral nutrition.
A series of more recent studies from Italy [291, 532-534] have provided more 
evidence of the benefits of perioperative enteral feeding. Preoperative oral 
feeding with an immune enhancing formula combined with postoperative jejunal 
feeding with the same formula in patients with Gl cancer resulted in a 
significantly reduced incidence of postoperative infectious complications [532, 
533]. Further studies were then conducted in malnourished and well-nourished 
patients. In malnourished patients the greatest benefit on the reduction of 
complications was achieved with an immune enhancing formula given peri- 
operatively [532]. In well-nourished patients the provision of an immune 
enhancing formula preoperatively alone was sufficient to significantly reduce 
infectious complications and length of postoperative stay [291].
A consensus from the USA recommended that patients undergoing major 
elective Gl surgery who were malnourished should receive early enteral nutrition 
using immune enhancing nutritional support. In a meta-analysis of 27 studies 
[535] immuno-nutrition was associated with a reduction in infectious 
complications, but no effect on mortality was demonstrated.
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One concern of these studies is that few opted for a control group using standard 
management alone. Most of the RCTs in which immunonutrition formulas were 
used have compared it with standard enteral nutrition. What is important, 
clinically, is how enteral feeding per se impacts on clinical outcome and LOHS. 
Following a detailed review of the literature this still remains a contentious issue.
1.6.10 Pre-operative Enteral Nutrition
Pre-operative EN in patients with gastrointestinal cancer has been evaluated in 
two RCTs [368] [279], both showing a benefit from using pre-operative enteral 
nutrition in improving clinical outcome post-operatively. In the study [368] pre­
operative enteral nutrition given orally significantly reduced post-operative 
complications from 30 % to 10 % when compared to standard hospital diet.
The enhanced recovery after surgery programme (ERAS) [536] has been widely 
studied. The optimising of nutrition support peri-operatively along with early- 
enforced mobilisation, adequate analgesia forms the basis of this programme. 
The evidence comes from colorectal surgery and has not as yet been evaluated 
in UGIT surgery. The ESPEN working group [537] provides a detailed review of 
this evidence to support this programme.
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1.6.11 Limitations with Clinical Trials in Nutritional Support in 
Surgical Patients
The reasons why previous studies remain inconclusive as to which is the optimal 
modality of managing patients post-operatively could be due to one of three 
factors:
1. The delivery of peri-operative nutritional support does not improve clinical 
outcome in any patients.
2. Peri-operative nutritional support does not improve clinical outcome in the 
patients studied to date.
3. Peri-operative nutritional support does improve clinical outcome but previous 
clinical trials have failed to demonstrate this. This could be secondary to the fact 
that previous studies were not designed to evaluate the efficacy in reducing 
complications.
The next section will discuss potential limitations in the trials to date.
Location of jejunal catheter in small bowel
It appears from reviewing the literature that many authors fail to highlight the 
exact location of the tube in the intestines. Smith et al (1985) [358] 
recommended placing the jejunal catheter at 70cms distal to the DJ flexture to 
prevent reflux of feeds into the proximal small bowel.
Position of the tube in the small bowel is essential for maximizing the absorption 
of nutrients. Also placing the jejunal catheter too distal or too proximal in the 
small bowel may lead to problems. Too distal may lead to proximal small bowel 
atrophy and hence translocation. Too proximal may lead to the reflux of feed, 
causing increased pressure on the newly formed anastomosis.
Time of Commencement of Enteral Nutrition
Many studies had varying commencement times for nutritional support post- 
operatively. Some studies commence enteral nutrition immediately after the 
patient returned from the operating theatre [12, 13]. Some started within 24 
hours [16, 503, 521], some commenced within 24-48 hours [357] and one
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commenced after 3 days [358]. In one paper it was actually unclear when EN 
was commenced. In comparison to the PN studies which all commenced PN 
within 24 hours of the patients returning from the operating theatre.
One study by Neumayer et al (2001)[538] summarised the important issues and 
concluded that for EN to be beneficial it needs to be both early (within 12 hours) 
and in sufficient rate and volumes. The authors of this research concluded this 
might be the reason why many trials do not show a difference between EEN and 
STD management.
Type of feeding used
In EN studies there is are wide variation in the types of EN used. There are many 
different commercial brands available; these can be categorized into whole 
protein, semi-elemental (pre-digested), elemental, disease specific and immuno- 
nutrition feeds. It is not clear from many studies, which type of feed was used, 
and whether the authors ‘tailored’ the feed type to the patient needs. Failure to 
‘tailor’ the feed type to the patient could predispose to increased development of 
complications.
Pre-operative nutritional status
It is clear from the literature that malnutrition predisposes an individual to 
alterations in physiological, psychological function and immune function as 
outlined in sections 1.4.2-1.4.4. It is essential that clinical trials studying peri­
operative nutrition have the same BMI and mean percentage body weight loss at 
baseline to ensure comparability of the randomised groups. It may be that 
malnourished patients respond better to nutritional support than ‘at risk’ or 
marginally malnourished patients [539].
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1.6.12 Consensus of Clinical Trials and Meta-analysis to date
Several national clinical guidelines on nutritional support have been published in 
different countries [537, 540]. These guidelines agree on many key elements, 
primarily if the GIT is functioning and the patients are high risk of malnutrition or 
are malnourished then EN should be used. Importantly, they all suggest that to 
date, the evidence is not adequately robust to provide a radical change in post­
operative practice. The meta-analyses
1.6.13 Summary of Section
This section has provided a robust literature review of the modalities available for 
the provision of nutrition to surgical patients; these include the use of parenteral 
or enteral nutrition, both of which have different physiological effects. The 
evidence to support their efficacy and effectiveness in the peri-operative 
management of surgical patients remains inconclusive.
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1.7 The Design of Clinical Trials
1.7.0 Introduction
Previous clinical trials of post-operative nutritional support (either enteral or 
parenteral) have fairly consistently demonstrated that nutritional support is 
superior to traditional, standard management i.e. nil by mouth with no nutritional 
support in maintaining nutritional status; namely measures of nutritional intake 
[12, 16, 18, 357, 360, 361], weight [13-16, 18, 354-358], nitrogen balance [378, 
379] and improved muscle strength and function [16, 361, 368] [13, 14].
Whilst improvement in nutritional status per se is a legitimate secondary goal of 
treatment it can hardly justify the substantial time and expense required 
providing these therapies, therefore it is imperative that trials study the effect on 
clinical outcome.
Section 1.6 provided a consensus view, that the use of nutritional support in 
surgical patients undergoing major UGI resection is not proven to be clinically 
beneficial in terms of optimising operative outcome and survival.
The necessity for evidence-based medicine over recent decades has meant 
there is a need for healthcare treatments to be examined for their efficacy. The 
efficacy of an intervention describes the therapeutic effect of the intervention 
under ideal circumstances. Effectiveness describes the benefit of an intervention 
compared with other interventions in routine clinical practice and efficiency is the 
benefit of an intervention compared to the resources it consumes.
So often in clinical nutrition trials, the nutritional intervention is tried on patients to 
determine its effect. These trials do not have a comparison group and are 
typically observational and uncontrolled [541].
The Randomised Controlled Trial (RCT) is considered the ‘gold standard’ 
comparative study design for evaluating the efficacy, the efficiency and the 
effectiveness of different healthcare interventions [542, 543].
A RCT has a minimum of two comparable groups. These groups are accurately 
assessed with regards to the outcome or effects of a new or existing intervention
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(the experimental variable). Typically, there is a comparison of the group 
receiving the ‘experimental’ intervention and the group receiving standard or 
conventional treatment. This group is often termed the control group.
RCTs are often considered one of the best ways of delivering clinically relevant 
results that can be extrapolated into clinical practice. The process of 
randomisation reduces selection bias which is considered to be the main source 
of bias in clinical research [544]. RCTs have been advocated by Verhagen et al 
(2001) [545] who suggested that RCTs increase the likelihood of the trial to 
generate unbiased results that are sufficiently precise and allow application in 
clinical practice.
There are limitations with RCTs, however, which are listed below:
1. In a RCT the results and data collected from the study sample are used to 
make inferences about the population of all such subjects. Thus, it is essential 
that the study sample adequately represent the population who would normally 
receive the treatment. Too restrictive eligibility criteria for inclusion in a trial may 
make the results difficult to extrapolate to the population. In addition, an 
unrepresentative sample may result from clinicians restricting which patients put 
forward to enter the study.
2. The trial setting may be atypical from that of usual clinical practice. The 
setting should be typical of the clinical environment and setting where the 
procedures and treatments are usually conducted.
3. There may be professional resistance to the concept, hypothesis and 
implementation of the study. Some clinicians may be unwilling to refer their 
patients into the study. Using restrictive eligibility criteria means the results are 
less generalisable. Some clinical staff may assume it is unethical to deny any
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patients the treatment because it is ‘believed’ by them to be better than 
‘standard’ treatment.
4. Trials, which have a small number of eligible subjects in the study population, 
may make a trial unethical in terms of the long and expensive period of the trial. 
The use of Multicentred trials may be advantageous, leading to an improved 
accrual rate. They have the advantage that patient accrual is quicker and the 
intended size is reached more quickly. The end result should be that a multi- 
centre trial reaches more reliable conclusions at a faster rate so that overall 
progress in the treatment of a disease is enhanced. By involving patients from 
several centres, any conclusions have a broader more representative base than 
can be reached in a single centre.
However, multi-centred RCTs have been criticised. The conduct of multi-centre 
trials involves complex administration and planning; they are expensive to run 
and therefore adequate funding is required. Seamless communication between 
the research team and clinical staff across the centres is essential. There may be 
fundamental differences in baseline care of the patients with differing outcomes. 
Therefore standardisation of intervention and education and training of clinical 
staff of trial procedures is paramount. The use of stratification based on each 
hospital centre can alleviate some of these problems and will be discussed later 
in this chapter.
5. Patient preference. Some patients may have a preconceived idea of what 
treatment option is likely to benefit them and therefore may demonstrate a 
preference leading to non-compliance of the treatment allocated. This may lead 
to the results being biased. Zelen’s design [546] aims to address these issues. 
Patients are randomised before they consent to take part in the clinical trial. Two 
types of the design exist: double and single consent. In the double consent 
version patients are initially offered the treatment to which they were randomised; 
however, if they decline the randomised treatment, they can then be offered
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alternative therapies including the experimental treatment. In the single consent 
version only patients offered the experimental treatment are told there is an 
alternative treatment (the control) available. Patients randomised to the control 
treatment are not allowed the experimental treatment (although they are given 
unhindered access to any usual treatment facilities). Analysis is undertaken with 
patients retaining their original assignment. There are reported problems with this 
design [546]. There is a view that these studies are unethical, introduce bias and 
require more subjects to be included in the study.
1.7.1 Contrasting Explanatory with Pragmatic Randomised 
Clinical Trials
There are two main types of RCTs [547]. Explanatory RCTs examine efficacy 
and pragmatic RCTs examine effectiveness. The next section will outline the 
contrasting principles differentiating these two types of trial.
1.7.1.1 Explanatory trials
These trials test scientific hypotheses. They examine the therapeutic benefit of a 
particular treatment. There is a strict protocol, with strict inclusion and exclusion 
criteria. These trials often have a placebo.
Outcomes are usually intermediate and based on the physiological and 
molecular origin of the intervention treatment. In view of these non clinical 
outcomes, there is doubt as to how well the results of these trials can be 
incorporated into clinical practice [547] [548],
1.7.1.2 Pragmatic trials
These trials tend to closely mimic typical clinical practice. They aim to examine 
the effectiveness of two interventions in clinical care. Instead of a placebo the 
control group receives usual care or standard care commonly used for that 
condition. Blinded allocation is usually not possible.
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Eligibility criteria should be used with minimal exclusion criteria to produce a 
heterogeneous representative group of subjects. Clinician and patient biases are 
not viewed as detrimental but accepted as part of the response to treatment. It is 
accepted that both treatment and control groups have placebo effects, which 
may be of differing magnitude. The treatment effect is taken as the difference 
between the two treatments reflecting the likely clinical response.
A primary outcome measure is used. This is supplemented with the use of 
secondary outcome measures, which are based on a wide range of 
assessments. The inclusion of a cost analysis and a report of health related 
quality of life are typical [549]. Results are usually reported on an intention-to- 
treat-basis [547, 548]. The RCT described in this thesis is a pragmatic trial.
1.7.2 Choice of intervention and Control Groups
For the trial to be ethical there must be clinical equipoise as to which is the 
optimum treatment before the trial commences. There must be doubt as to which 
arm of the study is superior, based on a critical review of existing literature.
In theory, the random allocation of patients to one of two groups should not 
disadvantage patients if true equipoise exists. However, true equipoise is 
affected by past experience, observational studies, from previous underpowered 
studies.
1.7.3 Sample Size and Power Calculation
Many RCTs identified in the review of the literature (chapter 1.6) have small 
sample sizes and often do not report the power calculation in their method 
section. The use of a power calculation provides a scientific basis for the 
number of subjects required to make up the sample size that is needed to reject 
the null hypothesis with a given level of confidence (usually 80%).
RCTs should be sufficiently large to demonstrate a high probability of obtaining a 
significant difference between the randomisation groups where real differences 
exists. Sample size calculations should always be reported [550].
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1.7.4 Randomisation
The selection of the randomisation groups is a primary factor in the design of a 
RCT [551]. Randomisation refers to the random allocation of the intervention 
group or ‘arm’ of the study to which the patient is to be distributed. It should be 
conducted in a way that each subject has an equal chance of being allocated to 
either group. Random allocation aims to reduce selection bias, by reducing the 
effects of extraneous variables. The reduction of extraneous variables increases 
the probability that the differences observed between the randomised groups, is 
due to the intervention. Pocock (1983) outlined the three main components of 
randomisation:
1) The generation of the random sequence
2) The concealment of the treatment allocation
3) Stratification
Pocock (1983) [552].
These will be discussed in turn in the next section.
1.7.4.1 Generation of the Random Sequence
There are several methods of preparing a list of random allocation to treatment. 
The key issue is that whichever method is used it should be reported and 
reproducible [550, 551].
Simple randomisation results in every participant in the study having the same 
chance of receiving either treatment option. The sequence can be generated 
using a random number table or computer-generated series of numbers [553]. 
The benefit of simple randomisation is that each treatment assignment is 
completely unpredictable. However, there is a chance that treatment allocation 
may be unequal, resulting in unequal randomisation group sizes.
Block randomisation ensures exactly equal treatment numbers are used at 
certain equally spaced points in the sequence of treatment assignment. To 
reduce again the issue of prediction of the sequence the blocks are usually
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reasonably large [552]. The method used for the current study was block 
randomisation.
1.7.4.2 Concealment of Treatment Allocation
This is a very important aspect of randomisation. If the allocation of the next 
patient is known in advance then this may affect the decision to enter that patient 
into the trial. Failure to adequately conceal the treatment allocation can lead to 
selection bias. A systematic review by Chalmers (1983) [554] reported that 
inadequate concealment lead to an exaggerated odds ratio of treatment effects 
by 30-40%.
The use of sealed opaque envelopes is commonly used but has been criticised 
as being inadequately secure [555]. Many large commercially funded trials use 
an independent third party preferably via telephone [550]. However this is often 
not practical for small budget clinical trials.
1.7.4.3 Stratification
In any RCT, the aim is to have treatments groups that are similar with regard to 
baseline patient characteristics. This is especially so for prognostic factors. The 
literature review is essential to determine these factors and these should be 
known prior to commencing the RCT.
Stratification allows the sample population to be separated into stratification 
groups or stratum, based on these factors. This ensures balanced allocation of 
important prognostic factors aiming to increase the sample’s precision. There are 
however disadvantages of using stratification. Stratification introduces increased 
complexity into the randomisation process potentially increasing the chance of 
errors. There may also be an uneven distribution of subjects across the stratum, 
resulting in an imbalance of subjects per treatment groups [552].
In multi-centre RCTs stratification is usually based on each hospital centre. This 
takes into account the differing healthcare delivery systems that may be present 
in each centre. For the purpose of this RCT, this was the only strata used. This is 
because if the number of strata increased, to stratify for a prognostic factor, this
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would have increased the number of patients to power the trial, ultimately 
increasing the duration of the trial. This would have had implications for funding.
1.7.5 Blinding
Blinding is separate from and should not be confused with allocation 
concealment. The theory behind blinding is that if a patient in a clinical trial is 
aware that he or she is in the treatment group there may be a psychological 
benefit affecting their response. The reverse may be true if the patient knows 
they are receiving standard care. The research team may also introduce bias; if 
they are aware of the treatment allocation they may often unintentionally follow 
up these patients more closely.
To reduce bias and if blinding was not possible in the intervention stage then 
blinding can occur at the data analysis stage. Blinding the statistician conducting 
the statistical analysis reduces potential bias.
1.7.6 Ethical Issues
A RCT is an experiment on human beings [541]. Therefore, there are several 
important ethical issues relating to the design and implementation of clinical 
trials. The ethical principle governing research is that patients should not be 
harmed as a result of participating in the research trial [556].
The dignity, rights, safety and well being of participants in a research trial must 
be of primary consideration [445]. The ethical committee provides independent 
expert opinion on whether the proposed research is ethical and respects the 
dignity, rights, safety and well being of participants.
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1.7.7 Frameworks for Conducting Clinical Trials
There are several frameworks, which provide guidance for the development and 
evaluation of complex interventions to improve heath, within the framework of a 
Randomised Controlled Trial (RCT). These will be discussed in the following 
section.
1.7.7.1 The Research Governance Framework
In 2002, The Research Governance Framework was published by the 
Department of Health [557]. Prior to this, the Medical Research Council (2000) 
[542] was the framework on which most UK clinical trials were based.
The Governance of NHS research aims to provide the public and key 
stakeholders with the confidence that high quality research will be conducted 
[557].
The Research Governance Framework outlines the key elements of a quality 
research trial to be:
1. That all participants in the clinical trial should be treated with respect. They 
should be treated with dignity, have their rights, safety and well-being considered 
to be the highest priority at all times during the conduct and follow up of the trial.
2. The development of the clinical trial must value the diversity within society, 
and consider this in the development and conduct of the clinical trial.
3. The Principal Investigator (PI) and the research team must demonstrate both 
personal and scientific integrity, during the conception and conduct of the trial.
4. The PI must be able to demonstrate strong leadership and be accountable for 
the delivery of the trial.
5. The organisation where the research is conducted must be able to provide 
clear and supportive management to the PI and the research team. This is 
typically the role of the Trust or organisation Research and Development 
Committee.
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1.7.7.2 CONSORT (Consolidated Standards of Reporting Trials) Guidelines
The CONSORT guidelines were developed to improve the reporting of clinical 
trials. Traditionally the reporting of clinical trials has been criticised [558, 559]. As 
a result, published and accepted standards, CONSORT, were developed to 
ensure the quality of reporting of RCTs [560]. Further updates have been more 
recently published [558, 559].
1.7.7.3 The Role of Clinical Research Guidelines in the United Kingdom
As discussed RCTs provide the best way of comparing the efficacy and 
effectiveness of different healthcare interventions, however this is only applicable 
if reporting is to a high standard. Readers should not have to infer what was 
probably done, they should be told explicitly. Robust methodology should be 
used and reported comprehensively. It seems reasonable to hope that, in 
addition to improved reporting, the wide adoption of these guidelines will improve 
the conduct of future research by increasing awareness of the requirements for a 
high quality study. The aim of the CONSORT statement means that the authors 
of clinical trials will have to report details of research methodology emphasizing 
the importance of adequately reporting the randomisation process [561]. The 
guidelines have been specifically developed to encourage transparency and 
reporting the methodology of clinical trials. The use of these guidelines will 
assist the investigators in the reporting of clinical trials. By using the CONSORT 
standards and flowchart for reporting clinical trials the authors will provide 
adequate data and information to allow the readers to decide if the study design 
was robust and sufficient to change their local clinical practice by incorporating 
the evidence into local policy and procedures.
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1.7.8 Summary of Section
This section has discussed the importance of RCTs in evaluating the efficacy, 
efficiency and effectiveness of differing healthcare interventions. It has outlined 
the benefits of using a pragmatic design in clinical trials, as they tend to closely 
mimic clinical practice. However, the limitations of RCTs were also outlined.
What is apparent is that they are several key aspects that need to be considered 
and implemented in order to produce high quality, robust clinical trials. These 
include the importance of an adequate sample size, rigorous randomisation 
techniques, the importance of concealment of treatment allocation, the use of 
stratification and blinding and their limitations. It also outlined the important 
ethical considerations that are required when conducting clinical trials.
This section ended with an outline of the two main frameworks used in the 
running and reporting of clinical trials. These are the research governance 
framework and the CONSORT (Consolidated Standards of Reporting Trials). 
These are essential frameworks in which to adhere to ensure excellent quality 
clinical trials.
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2. Original Work: A Randomised Controlled Trial of Early Enteral 
Nutrition versus Standard Management in patients undergoing 
Major Upper Gastrointestinal Resection for Malignancy
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2.1 Methods of the Main Study
2.1.0 Introduction
The need for the current study was apparent after recognition that post-operative 
nutritional practices were ad hoc in hospitals around the United Kingdom [59, 
220]. These practices involved the traditional practice of starvation with ‘nil by 
mouth’, parenteral and/or enteral nutrition. To date, the clinical evidence remains 
inconclusive as to which is the optimal post-operative management.
This chapter will present the aims, objectives and detail the choice of clinical 
outcomes and methods used for the RCT described in this thesis.
2.1.1 Aim of the Trial
The aim of the RCT was to compare the use of post-operative early enteral 
nutrition (EEN) delivered via a needle catheter jejunostomy with traditional, 
standard management (STD). Comparisons will be defined by measuring the 
length of hospital stay, the clinical outcome, the HRQoL and by differences in 
cost in patients undergoing major upper gastrointestinal resection for 
malignancy.
2.1.2 Primary (null) Hypothesis
Patients who receive early enteral nutrition (within 12 hours of leaving the 
operating theatre) compared to patients who receive standard management have 
no differences in their length of hospital stay.
2.1.3 Primary Objective
To determine the difference in length of hospital stay (LOHS), between the two 
randomised groups.
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2.1.4 Secondary Objectives
1. To determine if there was any difference in the development of major 
complications between the two groups.
2. To determine if there were any differences in readmission rates between 
discharge and 6 weeks and between 6 weeks and 12 weeks after discharge.
3. To examine the feasibility of EEN following major gastrointestinal surgery for 
malignancy.
4. To determine if there were any differences in nutritional outcome, for the two 
groups.
5. To report any differences in health related quality of life for the two groups 12 
weeks post operatively.
6. To estimate any differences in costs between the two groups
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2.1.5 Conceptual Map
Age
Tum our Stage
Psychological
influence
Factors influencing post­
operative outcome
Pre-operative Nutritional 
Status
Biochemical and 
immunological factors; 
glucose control, protein 
status
Operative factors: duration of operation, 
blood loss, and type of surgical procedure
EARLY ENTERAL 
NUTRITION
VERSUS NIL BY MOUTH
(STANDARD
MANAGEMENT)
Postoperative clinical management; fluid balance 
pain control, critical care management, 
mobilisation, use of appropriate antibiotics
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2.1.6 Choice of Clinical Outcomes
Prescott (1999) [550] suggested that it is beneficial to choose a primary outcome 
indicator and supplement this with a limited number of secondary outcomes, as 
was the case in the current RCT. Other alternatives in clinical pragmatic trial 
design can be to use a combination of multiple outcomes or endpoints to 
determine the efficacy and efficiency of the proposed interventions. The use of 
multiple endpoints can lead to Type I error due to over analysis of the data. The 
Bonferroni method [541] aims to adjust the statistical significance according to 
the number of tests performed on the same data set. However, this method has 
been criticised to be too conservative leading to Type II error. Pernerger et al 
(1998) [562] suggested that in order to avoid either a Type I or Type II error, the 
author should detail what statistical methods were used and discuss the 
interpretations of each results, allowing conclusions to be reached without the 
use of Bonferroni methods. This section will provide the justification for the 
choice of outcome made in this RCT.
2.1.6.1 The Primary Outcome-  Length of Hospital Stay
Studying clinical outcomes is an important aspect of evaluating healthcare
delivery. One outcome measure used in clinical trials is LOHS [563]. Length of 
hospital stay was selected as the primary outcome for the current RCT, to allow 
comparison with the previous enteral nutrition RCTs [12] [13, 503] and in a meta­
analysis [17] which have also used length of hospital stay.
To date there is no agreed definition of LOHS. Length of hospital stay has been 
defined as:
“The time from the date of the index operation to the date of discharge whether home, 
the transfer to a subacute service or death which ever comes first”
Collins et al (1999) [564] page 255
However, LOHS can be affected by many factors, including pre-operative age, 
physical status score, intra-operative factors such as blood loss, and duration of 
time in theatre, type of surgical procedure and the presence of co-morbidities. 
These factors have all been associated with prolonged LOHS [565, 566]. Post­
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operatively the development of major complications have also been correlated 
with prolonged LOHS [564]. In addition, social factors including patients waiting 
for transfer to convalescence healthcare organisations can also prolong LOHS. 
It was for this reason that for the purpose of this study LOHS was defined as:
The time from the day of the index operation to the date the operating surgeon 
decides the patients is medical fit for discharge
This definition takes into account any administrative factors that may prolong 
discharge for example waiting for social support packages. Similarly, LOHS can 
be subjective if robust criteria are not used to determine when patients are 
medically fit for discharge. For the purpose of this RCT the following discharge 
criteria was used to decide whether the patient was ready for discharge home.
Patient must be able to:
1. Get out of bed and mobilise
2. Prepare a drink or food.
3. Get to the lavatory in their home
Taking all this in this confounding factors into account, LOHS was still considered 
to be the most appropriate primary endpoint, for true comparison with the 
previous literature.
The use of LOHS as a primary outcome measure can be criticised if subjects are 
discharged back into the community with complications. Information on the 
number of hospital readmissions is essential to support the result of the 
differences in length of hospital stay. Data was for readmissions for all patients in 
the current RCT, between discharge and 6 weeks and 6 and 12 weeks post­
discharge.
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2.1.6.2 Secondary Outcomes
The Development of Major Complications
The development of major surgical complications can prolong length of hospital 
stay. Therefore the measurement of the occurrence of major complications is 
crucial. Surgical complications are associated with increased hospital costs and 
a reduction in a patient’s quality of life [564]. It is for this reason that healthcare 
organisations are focused on reducing the development of major and minor 
complications [564].
For the purpose of this study post-operative complications, both infective and 
non-infective, were diagnosed by nursing, surgical or critical care staff that were 
not directly involved with the trial. Consistency was ensured by clear definition of 
the major complications as outlined in table 2.2.1.
These definitions were based on the definitions used in a previous large clinical 
nutrition RCT [338]. In addition, the definitions were adapted to provide a 
consensus following discussion with Surgical and Critical Care colleagues.
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Table 2.2.1 The ClassilFication of in Hospital Major Complications
Type of Complications Signs of Symptoms of the presence of the 
Complications
Wound infection Any redness or tenderness of the surgical wound with a 
discharge of pus.
Abdominal Abscess Deep collection of pus located in the abdominal cavity.
Chest Infection Abnormal Chest X-Ray with pyrexia (>38 °C.) and WCC > 
12000 cells/ul +/- positive sputum.
Urinary Tract Infection >10 7 Micro-organism/ml of urine.
Septicaemia Two consecutive +ve blood cultures.
Open Abdominal Wound Surgical Wound gaping >3cm.
Post-operative Bleeding The Need for blood transfusion > 2 units.
Anastomotic Leak Any dehiscence of an anastomosis with clinical & radiological 
evidence
Respiratory Failure Presence of dysnopnea and respiratory rate >35/min or Pa 
O2 <70mmHg on air.
Circulatory Insufficiency Unstable blood pressure requiring use of extra fluids &/ or 
inotropes.
Renal Dysfunction Necessary haemodialysis/ filtration.
Hepatic dysfunction Increased serum bilirubin (50% above baseline).
Pancreatic Fistula Daily output of fluid >10mls from surgical drain with amylase 
content 5 times higher than serum.
Delayed Gastric Emptying The need for gastric decompression for 8 days, or more post­
op.
Multi-Organ Failure Two, or more, organ failures.
Systemic Sepsis Presence of Systemic Inflammatory Response Syndrome.
Deep vein thrombosis The development of a blood clot or thrombus within the 
vascular system confirmed by a Doppler Scan.
Pulmonary Embolism Presence of a thrombus in the pleural cavity diagnosed with 
a VQ scan or angiogram.
Cerebro-vascular accident The development of embolic, thrombotic or haemorrhagic 
vascular accident or stroke persistent for more than 24 hours
Return to theatre Return to theatre within 30days of the index operation.
Pleural Effusion The presence of fluid between the pleura and the chest 
cavity and lining of the lungs.
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Complication Ratios
A study by McAleese and Oldling-Smee (1994) [567] described the impact of 
major complications on length of hospital stay. The authors developed a 
calculation termed the ‘complication ratio’. This ratio is the factor that LOHS (in 
days) will be increased if a patient develops a complication compared with a 
patient who develops no complication. It is calculated using the following:
Complication ratio = Average LOHS (in days) with a particular complications
Average LOHS (in days) without that complication
According to this study [567] surgical complications in general increased a 
patient’s average length of hospital stay by a factor of between 3.3 and 4.4 times 
the routine inpatient period. For example if routine stay is 5 days and a patient 
develops a major complication then LOHS will be 16.5-22 days. The authors 
concluded that respiratory tract and wound infections were most likely to prolong 
LOHS. In addition, the authors isolated age as the most predictive variable with 
an age 60-69 years having the largest impact on development of complications.
Table 2.2.2 Complication Ratios for Key Surgical Procedures (McAleese and 
Oldling-Smee (1994)[567]________________________________________________
Type of Complication Complication ratio
All major complications 3.3-4.4
Infectious Complications
Wound Infection 2.43
Chest Infection 1.99
Non Infectious complications
Delayed gastric Emptying 3.4
Pleural effusion 1.99
Chylothorax NA
Anastomotic Leak 3.4
Abdominal dehiscence 1.85
Respiratory Failure 1.99
The complication ratios for infective and non-infective major complications were 
calculated for this RCT.
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The Development of Minor Complications
The presence of the following was recorded daily post-operatively, from the 
nursing and medical records. In addition the patient was asked to report and 
confirm the symptoms.
1) Nausea was defined as “the feeling that one is about to vomit” [568].
Patients were asked to report if they had complained of nausea in the previous 
24 hours. Any report was taken as confirmation of this symptom. However, the 
use of nausea is a subjective measurement. It is, however, an important clinical 
outcome indicator in post-operative patients [64, 65, 69]. For this RCT, the 
presence of nausea in the first post-operative week was considered important for 
comparison between the two randomised groups.
2) Vomiting was defined as “the reflex action of ejecting the contents of the 
stomach through the mouth” [568].
The actual volume of vomit was recorded from the nursing records in millilitres 
per day. The total volume was recorded per 24 hours; the presence of vomiting 
in the first post-operative week was used as an endpoint.
3) Abdominal distension.
The development of abdominal distension has been reported in several other 
RCTs. Patients were asked if they were complaining of abdominal cramping or 
distension. In addition, if the surgical team had documented in the medical 
records that the patient had reported these symptoms this was recorded in the 
trial documents.
4) Nasogastric Aspirates. This was defined as the volume of gastric or 
intestinal secretions that were withdrawn by aspiration of the nasogastric or 
gastrostomy tube per 24 hours
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5) Pain Score. This was recorded from the nursing records. The visual 
descriptive scale was used [569]. The rankings were categorised into mild, 
moderate or severe.
6) Bowel function. The following was the definition used to define bowel 
function for the purpose of this RCT.
Passage of flatus was defined as the patient reporting the passage of gas per 
rectum. The day this first occurred was recorded.
Passage of stool was defined as “the defaecation and evacuation of the 
bowels” [568].
Diarrhoea was defined “as the passage of loose or watery stools more 
frequently than 3 times per day” [568].
Ultrasound imaging of Gastrointestinal Motility
The use of ultrasound imaging (USS) was used to quantify the frequency of small 
bowel peristaltic waves. The principal investigator and a Senior Surgical 
Colleague performed the USS.
Methods
1. The USS imaging was performed on Day 1-2, and day 5-6 post- 
operatively.
2. The USS probe was placed on the patients’ abdomen in the left iliac fossa 
avoiding the surgical incision and wound.
3. The probe was held with moderate pressure.
4. The number of peristaltic waves per minute was counted on the screen 
and recorded.
5. In addition bowel sounds were quantified using auscultation. The following 
was recorded:
a. Absent
b. Sluggish
c. Normal
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d. Hyperactive
A member of the Surgical Team repeated this stage.
Fluid balance
Fluid balance has an important effect on clinical outcome and has been shown to 
increase the development of post-operative complications [570] [399]. Fluid loss 
and administration of intravenous fluid were recorded from the day of the 
operation, until day 9 post-operatively.
The fluid balance data was recorded from the patients nursing records. The 
nurse in charge of the patient completed all records every 12 hours on the ward 
and every hour on critical care units. The loss of fluid in the urine, drains, 
nasogastric aspirates, vomit and any faecal fluid was recorded as fluid output.
Fluid input was recorded as the volume of intravenous fluid, enteral feed and 
intravenous and enteral drug volume. All measurements were measured in 
millilitres.
The development of oedema was recorded as an important clinical outcome 
indicator. Oedema was defined as, “The presence of excessive amounts of fluid 
in the intercellular tissue spaces of the body, due to increased transudation of 
fluid from the capillaries.” [571].
The presence of oedema was determined by palpating the peripheries with a 
thumb. Oedema was recorded if an indentation remained when the thumb was 
removed after 5 seconds.
The Delivery of Early Enteral Nutrition
Several previous observational studies have suggested that enteral nutrition is 
safe and well tolerated in the post-operative phase [64, 65, 69]. Many of these 
trials were retrospective. This RCT aimed to collect data prospectively on the 
delivery of enteral nutrition.
Complications with the Needle Catheter Jejunostomy
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The presence of complications associated with the needle catheter jejunostomy 
was recorded daily during hospital admission. Complications such as catheter 
dislodgement, catheter blockage and catheter entry site infection were recorded. 
Other major and minor complications attributed to the jejunostomy which were 
documented in the medical notes, were also recorded.
The Volume of Enteral Nutrition
The volume and rate in millilitres per hour of enteral feed delivered each day was 
recorded from the nursing records. This was calculated on a daily basis as a 
percentage of nutritional requirements [572].
The number of patients who had their enteral feed stopped for more than 12 
hours was also recorded together with the reason why the feed was stopped.
Nutritional Outcomes
The following indices of nutritional status were chosen on the basis that they are 
objective, minimally invasive and easy to obtain [184].
There are many limitations associated with anthropometry (i.e. measurement) in 
clinical practice. These relate to the accuracy, reliability and sensitivity of the 
measurement. This section will outline the methods used to measure the 
nutritional parameters and will then present the measurement errors for each 
parameter.
Height
A measure of body size is needed to standardise measures such as weight, and 
height is a convenient measure to use.
Height was measured on a wall-mounted stadiometer on the ward or in the 
outpatient department. Shoes were removed and the subject was asked to stand 
up straight, looking straight ahead with the Frankfurt plane horizontal. The arms 
were relaxed at the sides, legs were straight and close together, and feet were 
flat with the heels almost together. The measurement was taken on a hard even 
floor surface and the subject were instructed to stand as tall as they could. The
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instrument was placed on the person’s head and, using the spirit level, held in a 
horizontal plane. The measurement was taken and then repeated; the two 
measurements had to be within 1cm of each other, if not a third was taken. An 
average was calculated of the two readings that were within 1cm of each other
Weight
Weight is a convenient and widely used method to assess overall body mass, 
energy balance and, in conjunction with height, to evaluate nutritional status. A 
loss of weight over time indicates a negative energy balance and weight gain 
indicates positive energy balance. As this thesis aims to investigate response to 
a nutritional intervention it is important to be able to identify a positive energy 
balance, which would suggest the intervention is successful.
Patients were weighed either in clinic, on a stand on Seca ward scales, which 
were recently calibrated, using the following methodology:
The scales were positioned near the subject but avoided resting against other 
furniture. The subject was in nightclothes or light day clothes, heavy items such 
as jumpers, dressing gowns, jackets and shoes were all removed. Pockets were 
checked for heavy items and if catheterised, the patients were asked to empty 
the bladder (or catheter bag emptied). The scales automatically take the reading 
when movement ceases, and this was then recorded to the nearest 0.1kg.
Percentage weight loss was then calculated using the formula:
% Weight loss = (Usual weight (kg) -Current weight (kg)) X 100
________________________ Usual weight (kg)___________________________
The accuracy of the percentage weight loss depends on the accuracy of the 
original weight estimation before the onset of weight loss. Many patients can give 
some estimate of their weight when well but the accuracy of the reported weight 
is questionable [224-226].
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Body Mass Index
BMI was calculated from 
Weight (kg)
Heighr (m)
Garrow and Webster (1985) [227]
Mid-Arm Circumference
Mid-arm circumference (MAC) is needed to calculate mid-arm muscle 
circumference (MAMC), which is a practical measure of nutritional status. Alone 
the MAC can be a guide to overall nutritional state, as it reflects both fat and 
muscle tissue, or it can be used serially to monitor changes. In this thesis it was 
used primarily to calculate MAMC, in order to assess muscle mass.
MAC was measured using a flat tape measure (CMS Weighing Ltd), with the 
subject sitting. If this was not possible, when the subject was bedbound, the 
recumbent measurement was taken. The non-dominant arm was used wherever 
possible; to ensure consistency and comparability of the results, because the 
dominant arm may have a greater muscle volume due to increased use.
First, the subject was asked to bend their arm at a right angle across their 
abdomen. The length of the upper-arm was then measured from the acromion 
process of the shoulder blade to the olecranon process of the ulna. The half way 
point was marked, then the subject was asked to relax their arm and let it hang 
down by their side, with the palm inwards. The circumference of the arm was 
measured at the marked mid point, keeping the tape horizontal and taking care 
not to compress the tissue, but to ensure the tape was not loose with gaps 
between the tape and the skin. This is often difficult in elderly subjects and 
patients who have lost significant weight, as they may have a lot of loose skin on 
their upper arm. In this case the tape was always tightened until the loose skin 
was gathered in and no gaps existed between the tape and skin. Every effort 
was still made not to compress the underlying tissue.
If a recumbent measurement was needed, the subject was asked to lie on their 
back. The mid point was identified as above, and then the arm was laid out
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away from the body palm up. The elbow was supported with a rolled up towel to 
raise the arm from the bed. The circumference could then be measured.
Readings were taken to the nearest 0.1cm and an average of two measurements 
recorded. Both measurements had to be within 0.5cm, if not further readings 
were taken, until two measurements within 0.5cm were obtained. The average 
was calculated from the two measurements within 0.5cm.
Triceps Skinfold Thickness
Triceps skinfold thickness (TSF) is also required to calculate MAMC, but it is also 
used as a measure of fat tissue. This measurement was chosen primarily to 
calculate MAMC, but also to provide information on body fat content, possibly 
allowing the identification of which compartments change during weight changes.
TSF was measured using Holtain Skinfold Calipers (Holtain Ltd., Crosswell, 
Wales), with the subject sitting. If they were unable to sit up, the measurement 
was taken while recumbent. The non-dominant arm was used whenever 
possible, as for the MAC. Firstly, the mid-point was found. In practice the MAC 
was measured first then the TSF taken using the same mid-point mark. The 
subject was asked to let their arm hang loosely by their side and a vertical pinch 
of skin and fat was grasped 1cm above the mid-point mark. This was done at the 
back of the arm in the mid-line, parallel to the long axis of the upper arm. The 
pinch was pulled away gently to ensure the muscle layer was avoided, then 
using the calipers the skinfold was measured at the mid point while maintaining 
the grasp with the fingers. Care was taken to hold the skinfold gently, so only 
the calipers were compressing the tissue. The reading was taken to the nearest
0.2mm two to three seconds after applying the calipers.
Three measures were taken, ensuring the pinch was released in between each 
measure. If the three readings were within 1 mm of each other, an average of the 
three measures was calculated. If not further readings were taken, until three 
were obtained within 1mm of each other.
If a recumbent measurement was needed, the subject was asked to roll on to 
their side, so their upper arm was resting along the side of their body. This gave
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access to the back of the upper arm enabling the measurement to be taken as 
above.
Mid-Arm Muscle Circumference
Mid-arm muscle circumference (MAMC) provides a guide to body muscle 
content. To estimate the arm muscle, MAMC was calculated from Tricep Skinfold 
Thickness (TSF) and Mid Arm Circumference (MAC) using the following equation 
[573]:
MAMC (cm) = MAC (cm) -  3.14 x TSF (cm)
Measurement Errors
Investigator error is classed as intra-observer error, which is the difference in 
repeated measurements by the same observer, and inter-observer error, which is 
the difference in measurements by two or more observers [574]. Investigators 
need to be well trained and practiced to produce reproducible measurements.
Functional Measures
It is also useful to study changes in a subject’s physical function in addition to 
observing changes in body size or composition. Functional measures give an 
indication of changes that will directly influence a person’s independence and 
well-being. Hand-grip dynamometry was used to measure hand and arm muscle 
strength.
Hand grip strength measures the muscle function of the hand and arm muscles 
by providing a measure of strength for the gripping action, and it has been shown 
to correlate well to other measures of muscle function, illustrating that handgrip 
strength can offer an indication of function and well-being.
There are a number of different types of tool available to measure grip strength 
including; hydraulic, pneumatic, strain gauge and mechanical [575].
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Pneumatic systems such as the Martin Vigorimeter or modified 
sphygmomanometer are much easier to use for people with hand weakness, 
pain or deformities, however, they have been criticised for measuring strength as 
a pressure rather than a force [576]. Pressure depends on the magnitude of the 
force applied and the area over which it is applied. This means someone with 
small hands may produce a greater pressure reading than a person of the same 
strength (equivalent force production) but larger hands.
Strain gauge dynamometers are not usually used in a clinical setting but have 
been used for research studies. These tools consist of a rigid and a flexible bar, 
when grasped the flexible bar bends and the transverse force within this bar is 
measured as it bends. These are very sensitive instruments and can record very 
small increments of force. They are however, not readily available as most have 
been individually designed by the investigators [575].
The last type of dynamometer is the mechanical type, which relies on the amount 
of tension generated on a metal spring, for example the Smedley, Harpenden or 
Takei Grip-D. The test-retest reliability has been found to be high for this type of 
dynamometer [575].
The use of grip strength in this thesis is confined to monitoring change, using a 
Takei Grip-D® dynamometer. This is a mechanical type of dynamometer, 
consisting of two handles with an adjustable inter-handle distance to 
accommodate differing hand sizes. The inner handle has to be pulled down 
towards the outer handle and in doing so pulls on the spring mechanism; the 
measurement is recorded in kilograms of force (kgf) on a digital display. The 
measurement range of this equipment is 5-1 OOkgf therefore readings less than 5 
are recorded as 0.
The grip strength procedure measures the peak or maximal force produced 
during a transient grip. The literature is divided over whether the dominant hand 
is stronger than the non-dominant [575], but when measuring an older population 
hand disability must be taken into account. Therefore, the subject was asked 
which their best hand was, and this hand was used rather than the dominant
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hand. A note was made which hand was used so serial measurements could be 
made with the same hand.
When measuring hand grip strength it is important that a standardised position is 
used for all subjects as the position of the body and arm flexion can influence 
results [575]. The protocol used ensured that all subjects were seated, their 
elbow flexed at 90°, with the forearm and wrist in supination (palm face up). 
They were then asked to grasp the instrument and when ready, squeeze the 
bars together with their maximal effort. The procedure was repeated three times 
and the maximum score recorded. A rest of about 15 seconds was allowed 
between repeated measurements. There is no standard inter-trial rest period in 
common use, and the time allowed may vary from two seconds to six minutes 
[575]. The authors [575] have suggested that four minutes are needed to ensure 
full recovery and eliminate fatigue effects. A shorter time was chosen in these 
investigations to reduce the duration of the assessment. This may have meant 
that patients did not always achieve the true maximal grip strength. However, 
the important factor was the change between two measurements, which would 
be reliable providing the consistent use of same protocol. Age specific norms for 
hand grip strength in table 2.2.3 [237, 577].
Table 2.2.3 Reference normal values for hand grip strength
Aqe range Female (kgf) Male (kgf)
* 65-95 years 19.5 33.8
§ 60-69 25.3 45.6
§ 70-79 23.7 42.4
§ >80 years 20.0 34.5
* (Bassey & Harries, 1993)[577], using custom built strain gauge dynamometer 
§ (Desrosiers et al, 1995)[578], using Jamar dynamometer
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Dietary Intake
Dietary intake was assessed pre-operatively and from the first postoperative day 
until discharge. Prior to the surgical procedure dietary intake was assessed 
using 24-hour dietary recall. Post-operatively, fluid and food record charts were 
the chosen means of recording food and fluid intake. Nursing and support staff 
were instructed to observe food eaten and to document the amount consumed in 
household measures i.e. one cup of milk, a half bowl of Cornflakes. Patients 
were allowed to choose their own food at mealtimes from the ward trolley and 
were given considerable encouragement to eat. All patients were questioned on 
their food and fluid intake over the previous 24-hour period to verify the food 
record charts. Studies conducted in an attempt to quantify the error in dietary 
assessment methods have found that most estimates using the 24-hour recall 
are accurate to ±10% of actual food intake [274] [275].
Biochemistry
Pre-operatively and daily post-operatively for the first seven days (as per routine 
surgical care pathway) serum samples were collected for biochemical analysis of 
sodium, potassium, urea, creatinine, albumin and C-reactive protein using 
routine analysis. These samples were sent to the hospital laboratories for routine 
analysis. If the admitting doctor had already ordered the blood test, it was not 
repeated.
On the 4-5th post-operative day, a 24-hour urinary collection was performed. 
Once again this was sent to the hospital laboratories for routine analysis.
The results were usually available within 24 hours on the hospital patient 
information system. All analysis was carried out using the Abbott Aerosets these 
instruments are supplied through Abbott Diagnostics USA and the kits used for 
the following tests are all Abbott CE marked kits.
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Nutrition Risk Index (NRI)
The nutrition risk index was calculated using the equation below:
Nutrition Veterans NRI=
Risk Index Affairs et (1.519x albumin, ql '1) +(0.417 current weight X 100
(NRI) al (1991) 
[278] usual weight
NRI >97.5 borderline malnutrition
NRI 83.5-97.5 mildly malnourished
NRI <83.5 severely malnourished
Health Related Quality of Life
In addition to indicators of disease, nutritional status and function, measurements 
of what the patient feels about their own health state have gained increasing 
interest over the last ten years [579-589]. This is termed ‘health related quality of 
life’ (HRQoL).
The World Health Organisation defines HRQoL as:
‘An individual’s perception of his or her position in life in the context of the 
culture and value systems in which he or she lives and in relation to goals, 
expectations, standards and concerns. It is affected in complex ways by 
the person’s physical health, psychological state, level of independence, 
social relationships and how the person relates to salient features of his or 
her environment ’
(World Health Organisation, 1998) [445] pg 1569
A primary aim of any treatment intervention is to enhance HRQoL by reducing 
the impact of disease, but people with severe disease (such as cancer) can still 
report good HRQoL. Therefore the relationships between health, illness and 
HRQoL are neither simple nor direct.
An assessment of HRQoL, which is in essence the patients’ subjective view of 
their own health state, adds another dimension to the evaluation of a treatment.
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By including this measure the treatment can be assessed more holistically, rather 
than by focusing solely on defined clinical outcomes.
Types of Health Related Quality of Life Measurements
There are two main types of measure; indices and profiles, and within these
categories, tools may be generic or disease specific. The tool chosen for use will 
depend on the purpose of the evaluation, the population to be studied and the 
resources available. More complex instruments take longer to complete and 
some require skilled interviewers. The simpler tools are easier to complete and 
thus the response rate may be better, but detail is lost as the information 
collected is limited. For the current RCT the SF-36 was used.
The SF-36
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It has 
8 aspects including questions on functional health and well-being scores as well 
as psychometrically based physical and mental health. It is a generic measure 
[590] [591].
The SF-36 questionnaire formed part of the initial assessment when subjects 
were recruited onto the study. The questionnaires were also completed at 6 
weeks, 12 weeks, 6 months and 12 months post-discharge. The follow up data 
was collected by postal survey, and sent to all subjects except those who died. If 
no response was obtained after one month, a second letter and questionnaire 
was sent. If no response was received from this letter the follow-up data was 
treated as missing. Subjects were asked to complete it themselves, or if they 
preferred they could complete it in the presence of a member of the research 
team to assist if they had any queries.
A few patients were unable to complete the questionnaire as they simply felt too 
unwell and did not wish to complete it without help. In this situation, the
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instructions and statements that made up the questionnaire were read aloud, 
and the form completed according to the subject’s responses. Care was taken 
not to prompt replies or make suggestions as to which response was most 
appropriate. It was important to emphasise that the responses related to how 
the subject felt on in the last week rather than in general.
The presence of a member of the research team prevented ambiguities, such as 
patients ticking more than one response in one dimension. There are limitations 
to this approach, as it is possible that the presence of a member of the research 
team may influence the subject’s responses. Subjects may be influenced in the 
answers they give due to an awareness of being observed or the supposed 
wishes of the researcher, known as the Hawthorne effect [592].
The process was also completed on the actual day of discharge or as near to the 
date of discharge, of the patients from the surgical ward.
Data Analysis of Health Related Quality of Life
The SF-36 questionnaires were manually collated on to the database. The data 
was then cleaned and checked and subsequently transformed using the ‘SF-36 -  
How to Score Version 2 of the SF-36 Health Survey [593].
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Cost Analysis
It is assumed that patients who have a prolonged LOHS have increased 
healthcare expenditure [594]. A key priority of healthcare organisations is to 
reduce healthcare expenditure whilst maintaining and improving quality clinical 
care.
A report from the USA, suggested that surgical services represent approximately 
40% of all hospital expenditure, thus, any interventions that can potentially 
reduced expenditure are important [595].
Therapies that lower morbidity and mortality have traditionally been perceived as 
effective by clinicians, regardless of cost. The two terms ‘effective’ and ‘clinically 
effective’ should be interchangeable however this is not always the case.
Recently, pragmatic clinical trials have included a financial analysis in the 
outcomes to determine if treatments are justified [12, 596]. Often, data on cost 
can be collected concurrently with other outcome data in a pragmatic RCT [597].
Cost effectiveness analysis compares the cost of the treatments with their 
relative effectiveness. If the costs of the intervention are less than the control, 
and its effectiveness is superior, then the intervention is ‘dominant’ and should 
be accepted. If the cost of the intervention is more than that of the control, and its 
effectiveness is inferior, then the control treatment is dominant and the 
intervention should be rejected.
If however, the intervention treatment is cheaper than the control or less 
effective, or vice versa, then there is a trade off and an assessment of the 
relative size of the difference in costs, compared to the difference in 
effectiveness is needed. An alternative approach is to measure the subjects’ 
health utility, in order to calculate ‘Quality Adjusted Life Years’ (QALYs).
There are several factors that need to be considered in a cost analysis, these 
include,
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1. Cost benefit analysis attempts to put a monetary value on the health benefits 
of a treatment. However, assigning monetary value to health outcomes is not 
always seen as appropriate by clinicians.
2. Costing is rarely straightforward as there are many factors that need to be 
taken into account when making cost comparisons. Assumptions need to be 
made that would probably be unacceptable across other scientific disciplines.
3. Capital costs include building, equipment costs and land and other capital- 
intensive items (expenditure on structural alterations).
4. Overhead costs are those resources related to the building (power supply, 
water rates etc) staffing costs and other costs of providing the service (catering, 
laundry, maintenance, cleaning, stationary).
5. Resource costs are those costs related to the treatment of the patients (use of 
investigations, biochemistry costs, and procedures, costs of drugs prescriptions 
and interventions.)
For the purpose of this RCT, a full health economic study was deemed 
inappropriate, as this would have required additional economic and staff 
resources to support the collection of the data and analysis. This was considered 
to be outside the remit of this RCT. Cost of capital, overhead and resource costs 
are considered to be the same for both groups of the study.
An alternative approach is to present arrays of outcomes alongside their costs 
and leave the reader to draw their own conclusions regarding the cost. This is 
termed the cost consequence analysis. This is the approach used in this RCT.
A cost calculation was performed based on the median and interquartile range of 
length of hospital stay and development of the statistically significant 
complications, for the two randomised groups. This has been used as an end 
point in other clinical trials as a crude indicator of cost [12, 13] but never the less 
is a general indication of cost comparison. In addition, the costs of treating the 
statistically different major complications for the two groups were also calculated.
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2.1.7 Reliability and Validity of the Study
Reliability and consistency of the study itself is also an important consideration in 
terms of clarity and accuracy of the final report. In qualitative terms reliability is 
referred to as consistency, repeatability, replicability or stability of the study [598- 
600].
In order to ensure good quality of the study a number of factors have been used 
to ensure rigor.
Care was taken throughout the study to ensure that no other intrinsic or extrinsic 
factors could influence the results within either of the groups. This was 
addressed with:
1. Stringent inclusion and exclusion that prevented changes in clinical 
interventions without discussion with the investigator.
2. The use of random allocation enabled all the subjects to have equal 
opportunity to be included in either the standard or treatment groups.
3. The use of reliable and valid assessment measures as outlined in the clinical 
outcome section.
4. Consistency of approach across all four hospitals sites, by only the Research 
assistant and PI collecting data and implementing the protocol.
5. A robust training and educational programme was set up prior to commencing 
the RCT.
6. Engaging the support of all relevant stakeholders to ensure the RCT protocol 
was adhered to.
7. Stringent data management programme as outlined in section 2.3.
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2.1.8 Summary
This section has outlined the trial design. It has discussed the aims and 
objectives of the current RCT that is presented in this thesis.
This was then followed by a detailed justification for the choice of Outcomes 
(both Primary and Secondary Outcomes) along with a clear definition that would 
be the basis for data collection and analysis.
In addition, an overview of the important issues that are required to be 
considered to ensure the reliability and validity of the study.
The next section will outline the study procedures for the trial progress of the 
current RCT.
154
2.2 Study Procedures for the Randomised Controlled Trial
2.2.0 Introduction
This section will present the study procedures for the RCT presented in this 
thesis. It will outline the principles of the trial design and trial progress. It will also 
detail methods for data management and data analysis.
2.2.1 Sample Population
The patients were recruited as a convenience sample. Thus, all patients who 
underwent major resection for upper gastrointestinal cancer under the remit of 
the South East Wales Regional Upper Gl cancer Network were eligible to be 
recruited into the study.
2.2.1.1 Inclusion Criteria
All patients admitted to the adult Upper Gastrointestinal and Hepatobiliary Unit at 
the 4 hospital sites with a suspected upper gastrointestinal malignancy and 
referred for major elective or semi elective operative resection, were eligible to 
enter into the trial on the approval of their Consultant Surgeon (no patients were 
refused entry by their Consultant).
2.2.1.2 Exclusion Criteria
Patients were excluded if any of the following existed:
1. They were unable or unwilling to give informed written consent
2. They had a pre-operative infection
3. They had a residual small intestine length of less than 100cms resulting from 
previous intestinal surgery
5. They were under 18 years of age.
6. They were pregnant
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2.2.1.3 Sample Size Power Calculation
Following discussion with two independent Statisticians, it was anticipated that 
80 patients in both groups of the trial would have an 80% power to predict a 3 
day reduction in length of hospital stay (total N = 160). This was based on the 
results of the pilot study (appendix II.I). The desired significance level was set at 
0.05%, therefore, the risk of a Type I error is 5%.
The power was set at 0.80, thus the study should have an 80% chance of 
detecting a treatment effect and the risk of Type II error is 20%.
2.2.2 Registration and initiation of the Clinical Trial
2.2.2.1 Ethical Approval
In order to proceed with the study ethical approval was obtained. Approval was 
obtained from the Local Ethics Research Committee, as all the hospital centres 
were located in the same ‘domain’. The approval was based on a “no local 
researcher” basis that meant that the PI had to perform all consenting and 
recruiting of patients in the RCT. The letter of permission from ethics committee 
is in appendix ll.ll.
As nutritional products are classed as borderline substances advice was sought 
from the Medicines for Human Use Regulations (MHRA) 2004 who regulate trials 
on medicines for humans. Following discussion and scrutiny of the research 
protocol by the MHRA, the consensus was that the use of nutritional support are 
not classified as drugs and the trial did not meet the criteria of the EU Clinical 
Trial Directive.
However, in line with ‘best practice’ the trial was conducted in line with the 
Research Governance framework and MRC guidelines for conducting clinical 
trials [601]
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In accordance with the Research Governance Framework [557], local Hospital 
Trust Research and Development approval was obtained at each of the 4 
hospital centres. The trial was subsequently registered on the National Research 
Register (NRR) [602].
The trial protocol was scutinised by the the Welsh Cancer Trial Network and the 
UK National Cancer Trials Network (NCTN) [603] and adopted and registered on 
the NCTN database of Cancer clinical trials.
In addition, the study protocol was peer-reviewed by experts in the field of 
surgical nutritional support during the grant application. External grant funding 
was obtained from the Health Foundation, London, UK [604] and also funding 
was secured by the Cardiff and Vale NHS Trust small grant award scheme. This 
enabled a pilot study to be conducted N=8 (appendix II.I). Amendments to the 
research protocol were made following the pilot study; these are detailed in 
appendix II.III.
2.2.2.2 Sponsorship of Study
The Research Governance Framework requires that all clinical trials have a 
‘Sponsor’. For this MCRCT the employing organisation of the Principal 
Investigator, Centre 1 provided sponsorship for the trial. The Sponsor acts to 
take responsibility for securing the arrangements to initiate, manage and finance 
clinical trials.
All relevant Stakeholders of the trial were kept fully informed of the progress of 
the clinical trial in order to ensure appropriate adherence to the protocol.
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2.2.3 Recruitment of Patients into the Trial
The PI approached eligible patients at least 48 hours after the diagnosis of a UGI 
malignancy or a suspected malignancy, which required surgical resection. A 
detailed verbal explanation of the trial was provided. The PI explained the 
purpose of the trial, and that all data provided would by kept anonymous and 
confidential. This was outlined in the patient information sheet (appendix 11. IV).
Patients were allowed a minimum time of 12-24 hours from being given the 
patient information sheet and signing the consent form.
After agreeing to participate in the trial the patient was asked to sign two copies 
of the consent form (appendix II.V), one was put in the medical notes and one 
was kept in a locked filing cabinet, along with the data collection proforma.
The PI also assured the patient that at any time they could withdraw from the trial 
and that all data collected would be kept in accordance with the Data Protection 
Act (1998) [605].
Patients were reassured that they could contact either the PI or the on-call 
surgical registrar to discuss further any aspect of the trial. The PI was aware of 
the sensitive nature of this trial and that these patients may require more time to 
give informed consent, after receiving their diagnosis of cancer.
2.2.3.1 Randomisation and Stratification
For the purpose of this RCT, stratification was based on each hospital centre, 
thus there were four separate randomisation sequences. The unit of 
randomisation was the patient. This study used an unrestricted method of 
random allocation. The randomisation was performed in blocks of 30 to ensure 
all patients are exposed to similar care and that alterations in care and staff have 
not changed.
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Fifteen pieces of paper with EEN written on and 15 pieces of paper with STD 
written on were placed in sealed opaque envelopes. These envelopes were then 
shuffled and then labeled 1-30. All envelopes were kept in a locked box in the 
main research site. Each envelope contained instructions as to whether the 
patient would receive standard management or receive early enteral nutritional 
support.
The randomisation envelopes were opened at the end of the operation after the 
PI was confident that a potentially curative procedure had been performed. The 
investigator conducted the randomisation in order to ensure that chance and not 
choice, determined the allocation procedure.
2.2.3.2 Blinding
Following discussion with the research team and the multidisciplinary team it was 
considered impossible to blind the groups in this RCT. Blinding was neither 
practical nor feasible in this clinical trial. This is discussed in the limitations of the 
RCT in the discussion chapter 4.0.
The patients were kept ignorant to which allocated group they had been 
randomised to for the first week after surgery, unless they asked specifically. 
This was made easier as the patients were often on the critical care unit and 
were typically unaware of the presence of the enteral feed.
2.2.3.3 Patients who declined Consent
All patients eligible for entry into the study had preliminary baseline data 
collected. This is important to determine if the reasons indicate that those who do 
not wish to participate constitute a separate sub group. This group was subjected 
to statistical analysis, in comparison with the responders to ensure they did not 
differ from the main study population.
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2.2.4 Non-Interventional phase
2.2.4.1 Pre-operative Stage
Following the patient being recruited to the trial, the following data were collected 
prior to surgery:
1) Oral dietary intake in kilocalories/day and oral dietary protein intake/day.
2) Current weight, self reported pre-illness weight, percentage weight loss
3) Body Mass Index (BMI)
4) Appetite changes, taste changes, swallowing and chewing ability
5) Tricep skinfold thickness, mid upper arm circumference, muscle strength 
(using hand-dynanometry)
6) Routine clinical biochemistry: liver, renal and bone profile, albumin and C- 
reactive protein
7) Sex and age of the patient
8) The SF-36 Health Related Quality of life questionnaire [606]
9) Medical and surgical history from doctor’s clerking
10) The diagnosis/stage of the primary malignancy and whether neo-adjuvant 
chemotherapy had been administered.
2.2A.2 Intra-operative stage
Patients were randomised at the conclusion of the laparotomy. All patients had a 
needle catheter feeding jejunostomy inserted by the operating surgeon. (A 
jejunostomy was inserted to ensure that if patients did develop complications 
preventing them from achieving adequate oral intake, enteral feeding could be 
commenced after 5-7 days.) The jejunostomy was inserted at 30-100cms distal 
to the Duodenal-Jejunal flexure. The type of jejunostomy was a 
Freka®Fresenius Fg 9 needle catheter jejunostomy.
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The following data were recorded whilst the patient was in the operating theatre: 
The case report forms (CRFs) are presented in appendix II.VI.
1) Type of anaesthetic used and method of post-operative analgesia
2) Estimation of intra-operative fluid Balance (in millilitres).
3) Intra-operative blood loss (in millilitres)
4) Duration of operative procedure (in hours). This was recorded as the time from 
induction of anaesthetic to the patient leaving the operating theatre.
5) The type of surgical procedure performed. These are classified as 
Oesophagectomy, Gastrectomy or Pancreatectomy.
Any patient who underwent a palliative resection was recorded and subsequently 
excluded from the RCT.
2.2.5 Interventional Phase
This section will outline a comparison of the intervention groups forming the 
basis of the RCT. There were two groups for comparison.
2.2.5.1 Choice of Interventions
For the purpose of this study the experimental intervention was early enteral 
nutrition compared with standard therapy.
Group A (Standard Therapy Group)
The patients in this group received standard treatment. The standard group 
received 10ml/hour of sterile water via the needle catheter jejunostomy. 
Hydration was maintained using intravenous fluids. This continued until the 
introduction of oral fluids and diet.
All patients in the trial continued to receive the appropriate clinical treatment as 
decided by their surgical and critical care teams. All patients had a radiological
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contrast swallow between days 7-10 days after the operation. It was following 
this ‘swallow’ test that patients were deemed ‘safe’ to swallow and then oral 
fluids and diet were gradually introduced over 2-5 days at the patients’ 
preference.
If the ‘swallow’ tests deemed the patient unsafe for initiating oral diet and fluids 
this was recorded. If oral intake had not resumed by day 8, patients in the 
standard group were reviewed as to the need for either enteral or parenteral 
nutritional support. This was administered at the discretion of the operating 
surgeon. Nutritional requirements were calculated based on 30 kcals per kg per 
day [572]. To mimic the introduction of oral diet the feed rate was gradually 
increased over 2-5 days.
Group B (Enteral Nutrition Group)
In addition to standard management, these patients commenced early enteral 
nutrition via a needle catheter jejunostomy (Freka® fg 9 Fresenius). Nutritional 
support was commenced within 12 hours of leaving the operating theatre. 
However, patients were not started on enteral nutritional support if they were 
clinically and haemodynamically unstable.
Feeding Protocol
The enteral nutrition group was started on enteral feed administered at 10 
ml/hour for the first 24 hours, via the needle catheter jejunostomy. On the first 
post-operative day enteral feed was increased to 20ml/hour for 12 hours and 30 
ml/hour for next 24 hours. The feed was then increased by 10mls/hour until the 
maximum target rate of feed of 80ml/hour was achieved. Nutritional requirements 
were calculated [572]. The enteral nutrition formulas were polymeric 1 kcal/ml 
commercial preparation for gastrectomy and oesophagectomy patients and 1.3- 
kcals/ml semi-elemental formula for the pancreactectomy patients.
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It was intended to achieve a minimum of half of nutritional requirements by day 5 
post-operatively.
Once oral intake had commenced, the patient was commenced on a 1.5 kcal/ml 
enteral feed. The patients were switched to receive overnight enteral nutrition (12 
hours) until it was deemed that the patient was achieving % of their nutritional 
requirements orally.
2.2.6 Post Operative Stage Data Collection
All patients were prospectively followed up and the following data was collected 
daily: (appendix II.VI).
1) Ward location
2) Type of feed administered
3) Rate of feed in millilitres
4) Percentage of nutritional requirements delivered via the jejunostomy per 24 
hours (Nutritional requirements were calculated using Elwyn (1980) [572]
5) Presence of nausea and vomiting.
6) Presence of abdominal distension.
7) Fluid balance in millilitres per 24 hours.
8) Passage of bowel motions (i.e. flatus, diarrhoea and constipation).
9) Frequency of peristaltic waves per minute as detected using ultrasound 
imaging
10) Presence of both major and minor complications (see appendix iv)
11) Routine post-operative biochemistry liver: renal and bone profile, albumin 
and C-reactive protein
12) Routine post-operative full blood count
13) Temperature from the nursing records. The highest daily temperature per 
day was recorded
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14) Pain score and Analgesia requirements was recorded using the nursing 
records
15) Stage of mobilisation
2.2.6.1 Discharge
On the day of discharge the following information was collected. All patients were 
discharged with their needle catheter jejunostomy in situ until their first outpatient 
clinic appointment at 2-6 weeks. On discharge the following data was collected 
(appendix II.VI):
1. Weight and percentage weight loss post-operatively
2. Mid Upper Arm Circumference, Tricep Skinfold Thickness and muscle function
3. Serum albumin
4. The presence of any minor or major complications
5. The need for home enteral nutrition
6. SF-36 Health Related Quality of life questionnaire [606]
7. The destination to where the patient was discharged.
2.2.6.2 Follow-up
Patients were reviewed at 6 weeks and 12 weeks post discharge at their routine 
outpatient appointment. The following information was collected (appendix II.VI):
1. Weight and percentage weight loss post-operatively
2. MUAC, TSF and muscle function
3. The presence of any minor or major complications
4. SF-36 Health Related Quality of life questionnaire [606]
5. Readmission to hospital rates and the duration of stay if applicable
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2.2.6.3 Close of Study
The patients were contacted when they attended outpatient clinic as near to one 
year as possible to prevent the patients having to be contacted independently of 
this appointment. The following information was collated at one year.
1. SF-36 Health related Quality of life questionnaire [606]
2. Survival rates
For the purpose of this thesis however, this data will not be included as it was still 
being collected when a cut off was made.
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2.2.7 Summary of Methods
Pre-operative outpatient clinic
Refused to 
Consent
Informed
Consent?
Patient 
information sheet 
aiven
Day 1 prior to surgery 
-  recheck consent and 
repeat data collection
Patient referred to SE Wales UGI Cancer 
Network with a suspected malignancy
Care Pathway Clinical investigations
Curative resection possible
Pre-operative data collection 
▼
Theatre
Confirmed curative intent resection 
Jejunostomy inserted
Palliative Surgery or palliative 
chemotherapy or palliative 
care
Randomisation
Standard group
Neo-adjuvant
nhflmnthfiranv
Palliative
procedure
performed
Early Enteral 
Nutrition group
2.3 Data Management
2.3.0 Introduction
The next section will detail the factors that were considered regarding the data 
management of the current Randomised Controlled Trial. It will outline the issues 
for quality control, data validity and cleaning and data analysis.
2.3.1 Quality Control
The data were entered by hand onto the case report forms (CRFs). The CRFs 
were developed in collaboration with the Trial Steering Committee. The database 
was developed in the statistical software package SPSS 12.0 (SPSS Inc., 
Chicago, USA)
The PI checked quality and consistency of data entry for every third patient. 
Following the securing of funding for a research assistant, the Research 
Assistant (RA) helped the PI with the data collection. A rigorous training 
programme was provided for the Research Assistant. This included spending 
time with other RAs in the Welsh clinical Trials units and attending several 
courses on data management and SPSS.
The PI verified at regular intervals that data collection was accurate and that 
CRFs had been completed correctly. Regular ‘spot’ checks of the data base and 
data collection sheets were conducted to ensure consistency and accuracy.
2.3.1.1 Data Validity and Cleaning
The first stage in the ‘cleaning’ process was to tidy up the database. All the 
variable names were checked to ensure they were easily understood and 
corresponded correctly with the data, and categorical variables had each 
category labeled correctly. In addition, each variable was checked to ensure it 
registered missing data correctly.
Once these checks were made, the subject numbers were examined to ensure 
they were all present and that all the numbers were the same for each section of 
data. Once completed many of the duplicate variables could be deleted to make 
the database more manageable.
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The next part of the process was the systematic cleaning of all the data. For 
many of the variables logical checks could be made for errors. Some variables 
should have no missing data, such as age, sex, ward, LOHS or randomisation 
group. Any missing data that could be obtained from the hospital patient 
database was added to the database. As length of hospital stay was the primary 
outcome indicator this was doubled check prior to the final data analysis. Once 
these logical checks had been made, additional variables were added. For 
example, to identify the patients who died and which arm of the study patients 
were in. Next, each continuous variable’s range was analysed and any results 
outside reasonable values were double-checked with the written CRF. For 
example, weight above 110kg and below 30kg, values outside this range could 
still be valid but were unlikely, so were verified as far as possible. No values 
were deleted at this stage but merely cross-checked. Some variables had set 
limits, in this case the original CRF was checked and if the correct figure was not 
apparent, the figure in the database was deleted and treated as missing.
Categorical data were checked to ensure only the appropriate categories were 
present, for example, appetite was scored from 1-5 therefore any number other 
than these was erroneous.
As the variables had all now been examined in detail for errors, derived variables 
could be calculated, such as the mean of multiple anthropometric measures, 
BMI, MAMC, and the changes between variables from the first and second 
assessments. In addition, time spans were calculated from dates to produce the 
variables such as length of stay and survival.
Once these were calculated the outliers were studied, in SPSS these are 
produced as the five most extreme values at either end of the distribution. Any 
‘impossible’ values were removed at this stage; the definition of ‘impossible’ was 
agreed through careful discussion with supervisors and others interested in the 
research project (see acknowledgements). In the event very little data needed to 
be removed, and these were mainly from the variables calculated to show the 
changes during the study. As an example, weight change for a subject who had 
gained 22.3 kg, which was impossible within the length of time they were on the
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study. The original data were checked to try to establish the correct values and if 
this was not possible all related values were deleted i.e. the weights from 
assessment one and two and the change value, as it was impossible to tell which 
of the two values was incorrect. During this screening process the data 
distribution was also observed to look for parametric and non-parametric 
distributions. A copy of the final database was burnt onto a CD and kept in a 
locked cabinet.
2.3.2 Data Analysis
The types of statistical methods are dependent on the design of the study and 
the type of data collected. Data analysis include descriptive statistics that 
describe the sample characteristics and inferential statistics that assist in making 
an inference regarding the population based upon the evidence from the study.
2.3.2.1 Intention to Treat Analysis
‘Intention to treat’ is a strategy for analysing the results of RCTs according to the 
original treatment allocation. This includes participants that did not receive the 
allocated treatment. There could be many reasons why patients may not have 
had received their allocated treatment: These included:
1. Non-compliance with treatment
2. Dropped out from follow up
3. Underwent co-interventions
4. Dissatisfaction with treatment allocation
All these reasons should be detailed on the CONSORT flow diagram, so all 
allocated patients can be accounted for.
The intention-to-treat approach is assumed to represent a ‘real life’ situation with 
respect to compliance and treatment errors [607] and it is thought to give a more 
realistic assessment of the treatment in usual clinical practice [550]. Failure to 
conduct ‘intention-to-treat’ analysis has been reported to overestimate the 
treatment effect [608]. The current RCT aimed to analyse the primary outcome 
on an ‘intention-to-treat’ basis and a Per Protocol Analysis.
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2.3.2.2 Per Protocol Analysis
This is often an alternative to ‘intention-to-treat’ analysis. Subjects are included 
for analysis only if they complete the treatment as per protocol, however Altman 
(1990)[541] criticised this analysis as leading to bias.
2.3.2.3 Interim Analysis
This is an analysis that is carried out before the trial has finished, usually to 
check safety, problems with recruitment and unexpected side effects for one of 
the arms. For the purpose of the current study an interim analysis was conducted 
at 12 months after the trial commenced.
As mentioned previously, this thesis reports the results of a pragmaic early 
analysis of the first 102 patients in the current RCT. This was due to the time 
constraints of the need to complete the thesis within the deadline of the 
University for submission.
2.3.2.4 Withdrawals and Drop Outs
Poor compliance with treatment and loss to follow up lead to the exclusion of 
patients after they have been randomised to their treatment groups. Dropouts 
and withdrawals were reported on the CONSORT flowchart [559] [558]. The 
reasons for reporting the exclusions in a robust manner centres on a paradox 
called the ‘Exclusion Paradox’ [609]. This states that if trialists do not report 
exclusions, the reader assumes the trial did not have any. Therefore this may 
bias the interpretation of the results of the study.
Missing data are inevitable in any clinical trial and there are several methods for 
dealing with it [610]. Firstly missing data can be ignored, secondly the last 
observed value can be carried forward, finally a regression method or imputation 
can be used. For this trial, the last observed value was used.
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2.3.2.5 Stages of Data Analysis
RCTs typically measure continuous, categorical and ordinal variables at 
baseline, which are then repeated at intervals after the introduction of the 
treatment intervention in two or more groups. Analysing the results can be 
divided into:
1.Baseline comparison of the two groups (descriptive statistics)
2. Primary analyses- intention to treat analyses of primary outcome
2.3.2.6 Baseline Comparison
Despite the randomisation process, which aims to produce groups, which are 
equal, there may be some baseline differences between the two groups 
occurring by chance. If this occurs then more complex statistical methods such 
as ANCOVA can be used. However these methods have been widely criticised 
[611]. Senn (1997) [611], stated that using these statistical methods at baseline 
complicate baseline comparability.
For the purpose of the current RCT, patient variables analysed included; age, 
gender, and other peri-operative treatment variables (type of operation, operative 
blood loss, operative duration, POSSUM score, use of neo-adjuvant 
chemotherapy) associated with influencing the primary outcome indicator [565, 
566] as outlined in section 2.1.6.1.
The randomised groups were compared at baseline (pre-operatively) to 
determine if the groups were similar for these confounding factors. The 
statistical analyses used for this were based on descriptive statistics such as 
means and medians, depending whether the variable was normally distributed. 
Pre-operative nutritional parameters were also compared at baseline for the two 
randomised groups. Once again descriptive statistics were used for these 
comparisons.
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2.3.2.7 Primary and Secondary Analyses of Outcomes
The primary outcome indicator (LOHS) was analysed on an intention-to-treat and 
per-protocol basis. Length of hospital stay was not normally distributed so it is 
presented as median with the range of inter-quartile points. Where data were 
normally distributed, mean and standard deviation (SD) were presented.
Univariate analysis was performed using the Mann-Whitney U test for continuous 
data that was not normally distributed. The Chi-squared test was used for 
categorical data and the Fischer’s exact test was used if the data sample was 
small, thus the assumptions for the chi-squared test could not be met. If the data 
were normally distributed a parametric test could be used, namely the two 
sample t-test. P< 0.05 was accepted as significant. All P- values reported were 
two tailed.
2.3.3 Summary
This section has detailed the procedures for conducting the RCT described in 
this thesis. It has discussed the sample population, the eligibility criteria and has 
reported the power calculation on which the funding and execution of the trial 
was initially based. It has presented the administrative procedures required to 
ensure the trial was ethical and registered according to the recommendations 
required in the Research Governance Framework.
It then presented how the recruitment and subsequent accrual was to be 
performed. This was followed by details of the randomisation and stratification 
procedures. It also presented the trial progress detailing both the interventional 
and data collection phases. The section then ended with the methods used for 
data management including, data cleaning, data checking, quality control and 
data analysis. The next chapter will present the results of the RCT.
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3. Results
3.0 Introduction
The purpose of this chapter is to present the results of an early analysis of the 
Multicentred Randomised Controlled Trial (MCRCT) of early enteral nutrition 
versus standard management for patients undergoing major resection for upper 
gastrointestinal cancer.
The chapter is subdivided into:
1. Trial Profile
2. Baseline Characteristics
3. Primary analysis of Results
4. Secondary analysis of Results
3.1 Trial Profile
Initially, the RCT was a Single Centre study, but evolved to become Multicentre 
during the RCT. Three additional hospital centres were enrolled to recruit 
patients. This was to:
1. Improve the accrual of patients
2. Enable the recruitment of all patients who had their surgical treatment 
performed by a surgical member of the Local Regional Upper Gastrointestinal 
Cancer Network.
All patients eligible for entry into the MCRCT had their optimum treatment option 
(i.e. surgical, oncological or palliative care) discussed at a weekly 
Multidisciplinary Team (MDT) meeting. Therefore the decision to perform 
elective curative intent resection was based on a consensus agreement within 
the MDT.
173
3.1.1 Descriptions of Referring Hospital Centres 
Centre 1: A University Teaching Hospital.
This centre was the base of the principal investigator and author of this thesis. 
The hospital is the main centre, serving a population of 1.3 million (WAG (2006)).
Surgical procedures performed at this site include oesophagectomy, 
gastrectomy, pancreatic and biliary resections. Recruitment was completed from 
November 2002 to July 2006. There were 3 operating consultant surgeons at this 
centre, referring patients to the MCRCT.
Centre 2: A District General Hospital
Centre 2 was located 12 miles from Cardiff. It serves a population of 560,000 
people (WAG (2006)). There was one upper gastrointestinal surgeon performing 
both oesophagectomy and gastrectomy. This site recruited for 8 months from 
October 2004 to May 2005. The operating surgeon then relocated to Centre 1, 
becoming the 3rd surgeon there. This centre subsequently stopped recruiting 
patients to the MCRCT.
Centre 3: A District General Hospital
Centre 3 was located 18 miles from Cardiff. This centre also had one referring 
upper gastrointestinal surgeon performing oesophagectomy and gastrectomy. 
This centre referred patients to the study for 20 months from December 2004 to 
July 2006.
Centre 4: A District General Hospital
Centre 4 had one operating surgeon performing both upper gastrointestinal and 
pancreatic resections. This centre did not recruit any patients successfully into 
the trial. During 3 months (January 2006 to April 2006) all patients eligible were 
deemed palliative at laparotomy.
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3.1.2 Referrals of Patients into the Trial from each Hospital 
Centre
The RCT recruited patients from November 2002 to July 2006. Recruitment by 
hospital centre is illustrated in table 3.1.
Table 3.1 Recruitment of patients in each of the Randomisation groups per 
hospital Centre.________________________________________________________
Hospital Centre No. of Months 
trial active
No. of Patients 
approached
No. of patients 
recruited
Centre 1 30 108 85
Centre 2 7 3 3
Centre 3 18 21 14
Centre 4 3 4 0
The number of patients recruited varied over the course of the MCRCT. The 
monthly recruitment rates are presented in figure 3.1. The months with a peak 
number of patients recruited was December 2003, October 2004, May 2005 and 
January 2006, each month recruiting 6-8 patients.
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Figure 3.1 Monthly Recruitment of patients in each of the Randomisation groups per hospital Centre.
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3.2 Trial Progress
The number of patients eligible for entry into the MCRCT at the point of cut off for 
this thesis was 169 patients. A total of 139 patients were recruited into the trial. 
The consent rate was 82.2%. Only patients who underwent curative intent 
surgery were eligible to be randomised. Therefore, it was inevitable that a 
proportion of the patients recruited would not be randomised following 
laparotomy and palliative surgery only. Thirty-seven patients were deemed 
palliative at open operation. Therefore, 102 patients were randomised for entry 
into the MCRCT.
Sixty patients were randomised to receive early enteral nutrition and 42 patients 
were randomised to receive standard management. There was an imbalance of 
18 patients between the two groups when the MCRCT closed for the analysis for 
this thesis. Whilst surprising, this can be explained by the block randomisation. 
Centre 1 did not complete the full third block of 30; and the other two centres 
recruited less than 30 patients. (The randomisation was performed in blocks of 
thirty by each centre as described in the methods chapter.)
The trial progress is summarised in the CONSORT diagram (figure 3.2).
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3.2.1 Sample Characteristics
All patients in the MCRCT were admitted for major upper gastrointestinal or 
hepatobilary surgery. The most frequently occurring diagnosis was oesophageal 
cancer, 47% (N=48). Twenty-nine patients (28%) presented with gastric 
carcinoma and 25 patients (24.5%) presented with pancreatic cancers. The 
median age of the population was 64 years (58-72 years).
The surgical procedures performed at each hospital centre were compared. 
Centre 1 carried out the majority of all surgical procedures (N=86). The number 
of surgical procedures in Centre 2 and 3 were too small for meaningful 
comparisons. Only centre 1 conducted pancreatic resection. The types of 
surgery are presented in table 3.2.
Table 3.2 Comparison of the Surgical Procedures Performed at each Hospital 
Centre
Hospital Centre
Centre 1 
N (%)
Centre 2 
N (%)
Centre 3 
N (%)
Transhiatal oesophagectomy 15 (83%) 0(0) 3(17)
Ivor-Lewis oesophagectomy 20 (69) 2(7) 7(24)
Partial Gastrectomy 15 (100) 0(0) 0(0)
Total Gastrectomy 11 (79) 1(7) 2(14)
3 stage oesophagectomy 0(0) 0(0) 1 (100)
Total Pancreactectomy 2(100) 0(0) 0(0)
PPPD 23(100) 0(0) 0(0)
Total 86 (84) 3(3) 13(13)
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3.2.2 Description of Patients who declined consent
Thirty patients declined consent for the MCRCT. Fundamental demographic and 
oncological data were collected on these patients to enable a comparison to be 
made with the randomised study population. The results are presented in table 
3.3.
Table 3.3 Baseline variables for patients who declined consent and patients who 
were randomised into the RCT
Declined
Consent
N=30
Randomised 
Group N=102
Chi (p)
Age median 62(53-76) 64 (58-72) NS
Gender N (%)
Male
Female
16(51.6) 
15 (48.4)
64(68) 
33 (32)
NS
Type of Tumour N (%) 
Oesophageal 
Gastric 
Pancreatic
10 (32.25)
11 (35.5) 
10(32.25
46 (47) 
28 (28) 
23 (23.7)
NS
Staging N (%) 
1
II
III
IV
9(29) 
15 (48.4) 
7 (22.6) 
0(0)
11 (11.5) 
43 (44.5) 
39 (40.5) 
3 (3.5)
7.59 (0.033)
Histology 
Adenocarcinoma 
Squamous Cell
25 (80.6) 
6(19.4) NA
There were no statistical differences for age, gender and type of tumour between 
the randomised patients and the patients who declined consent.
There was a statistical difference (Chi 7.59 p=0.033) for pre-operative staging of 
tumour. Thirty (40.5%) of the patients recruited and randomised presented with 
tumour stage III or above. This is compared to 22.6% of the patients who 
declined consent. This suggests that the patients in the RCT had more advanced 
tumours than the patients who declined to consent.
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Figure 3.2 CONSORT Diagram
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3.3 Baseline Sample Characteristics
The two randomised groups were compared at baseline. This section presents 
baseline comparisons of the demographic data, peri-operative factors, nutritional 
parameters and biochemical parameters.
This section did not undertake hypothesis driven analysis. If certain 
characteristics looked potentially different, then exploratory inferential analysis 
was performed. This was to limit the chance of a Type I error.
3.3.1 Baseline Comparison of Age and Gender
There were no differences between the two-randomisation groups for age and 
gender, in both groups the majority of participants were male (1:2 male: female) 
and the youngest participants were in their fifties. This data is shown in table 3.4.
Table 3.4 Age and Gender of the Randomisation Groups.
Variable STD group EEN group Total population
Aqe median (IQ range) 63.5 (56-73) 63.5 (58-72.25) 64 (58-72)
Male N (%) 29 (69) 35 (65) 64 (67)
Female N (%) 13(31) 19 (35) 32 (33)
IQ - interquartile range
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3.3.2 Baseline Comparison of Peri-Operative Factors
The randomised groups were compared for surgical and intraoperative factors 
i.e. type of surgical procedure, neo-adjuvant chemotherapy, intra-operative blood 
loss, duration of operation, ASA grade and POSSUM scores [612] . The results 
are presented in the following section and summarised in table 3.6 later in this 
section.
Neoadjuvant Chemotherapy
Thirty-six percent of the total study population received neo-adjuvant 
chemotherapy. The number of patients receiving neoadjuvant chemotherapy in 
the standard group was 18 (42.9%) and 18 (33.3%) in the enteral nutrition group. 
Despite the higher percentage in the standard group, the difference was not 
statistically significant.
Duration of Time in Theatre
There was no difference between the two groups for the mean duration of time 
spent in theatre. The standard group had a mean duration of 7.3 hours (SD 2.1 
hours) and the early enteral nutrition group had a mean duration of 7.0 hours 
(SD 2.0 hours).
Intraoperative Blood Loss
There was no difference in intraoperative blood loss between the two 
randomised groups. The mean blood loss in the standard group was 1396 
millilitres (SD 1195 mis) and 1168 millilitres for the enteral nutrition group (SD 
672 mis).
American Society of Anaesthesiology (ASA) Grade
No statistical differences were identified between the two groups for ASA grade. 
From observing the data (table 3.6) it appears that more patients in the enteral 
nutrition group had a higher ASA grade when compared to the standard group, 
(59% versus 40.5%). As there was only one patient with an ASA grade of 1, the
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statistical analysis was repeated excluding this patient. Once again the 
difference between the two groups was not statistically significant (Chi squared 
test p=0.098).
POSSUM Scores
The median POSSUM [612] scores were compared for the randomised groups. 
The results are presented in table 3.5. The groups were comparable for each 
predictive score.
Table 3.5 nMedian POSSUM scores for the two-randomisation groups at Baseline.
Possum
Score
Physiology 
Median (IQ)
Operative 
Median (IQ)
Morbidity 
Median (IQ)
Mortality 
Median (IQ)
P-Mortality 
Median (IQ)
STD
group
13(12-15) 24 (20-24) 63.8 (52.8-67.8) 16.2 (11.6- 
20.1)
3.5 (2.6-4.8)
EEEN
group
14(12-15) 24 (24-24) 67.5 (63.8-74.1) 18.3 (16.3- 
22.3)
3.5 (2.7-4.9)
IQ = Interquartile range
P-Mortallty is calculated using the Portsmouth POSSUM [572, 613]
To note, the predictive mortality from POSSUM for the sample population was 
between 16.2% for the STD group and 18.3% for the EEN group. This is higher 
than the predicted mortality from the P-POSSUM [572, 613], which is more in line 
with the reported mortality rates for UGI surgery from other centres [86, 132, 
153, 154].
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Summary of the Baseline Perioperative Risk Factors
In summary, no differences were highlighted between the two groups at baseline
for surgical or intraoperative risk factors as outlined above. The results are 
summarised in table 3.6.
Table 3.6 Summary of Surgical Characteristics of the Two Randomised Groups at 
Baseline
Standard Enteral Total Population
Group Group
Pre-op T umour stage 1 4 (9.5) 5(9) 9 (9.3)
N (%) II 18(43) 26 (48) 45 (46.9)
III 19(45) 21 (39) 39 (40.6)
IV 1 (2.5) 2(4) 3 (3.2)
Pre-op Chemotherapy N (%)
Yes 18 (42.9) 18 (33.3) 36 (36)
No 24 (57.1) 36 (66.6) 60 (64)
Tumour Diagnosis N (%)
Oesophageal Cancer 21 (50) 24 (44.5) 45 (47)
Gastric Cancer 10 (23.8) 18 (33.3) 28 (29)
Pancreatic Cancer 11 (26.2) 12 (22.2) 23 (24)
Surgical Procedure N (%)
Oesophagectomy 21 (50) 24 (45) 45 (47)
Transhiatal 7(16.6) 10(18.2) 17(17)
Ivor Lewis 13(31.0) 14 (25.5) 27 (29)
Three Stage 1(2.4) 0(0) 1 (1.4)
Gastrectomy 10 (24) 18(33) 28 (29)
Partial gastrectomy 1 (2.4) 1 (1.8) 2 (2.8)
Subtotal gastrectomy 5 (9.5) 8 (14.5) 13(13.5)
Total gastrectomy 4 (9.5) 9 (16.4) 13(13.5)
Pancreatic Resection 11 (26) 12(22) 23 (24)
PPPD 9(21.4) 8 (14.5) 17(17.7)
Total pancreactectomy 2 (4.8) 4 (7.3) 6 (6.3)
Mean hrs theatre (SD) 7.3 (2.1) 7. 0 (2.0) 7.15(2.0)
Mean Intraoperative Blood 
Loss mis mean (SD)
1395 (1195) 1167 (671) -
Mortality Possum Score (IQ 
range)
16.2 (11.6- 
20.1)
18.3(16.3-
22.3)
-
ASA grade (%) 1 0(0) 1 (2) 1 (1)
2 25 (59.5) 21 (39) 46 (48)
3 17 (40.5) 32 (59) 49 (51)
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3.3.3 Baseline Comparison of Baseline Nutritional Parameters
All baseline nutritional parameters are presented in table 3.7. All baseline 
parameters for the two-randomisation groups were similar with no clinical or 
statistical differences between the two groups highlighted. The mean pre-illness 
BMI and mean pre-operative BMI are in the overweight category. However the 
percentage pre-operative weight loss is indicative of nutritional risk.
Table 3.7 Summary of the Baseline Mean nutritional Parameters of the 
Randomised Groups ________________________________________________
Standard Group 
N=42 
Mean (SD)
Enteral Nutrition 
N=54 
Mean (SD)
Mean pre-illness BMI 27.4 (4.2) 27.9 (5.06)
Mean pre-operative BMI 25.2 (4.1) 25.6 (5.4)
Mean pre-op % weight loss 7.2 (7.3) 6.8 (7.5)
Mean Nutritional risk Index 99.8 (11.33) 100.0 (10.88)
Mean pre-operative Weight 
(Kg)
73 kg 74kg
Calorie intake per day 1393(415) 1508 (462)
Protein intake per day (grams) 58.1 (19.2) 57.8(18.8)
Equivalent Oral calorie 
intake/day/kg
19 20
Equivalent Oral protein 
intake/day/g
0.8 0.8
Triceps skinfold thickness (mm) 13.6 (8.07) 13.03 (5.3)
Mid upper muscle circumference 
(mm)
30.7 (4.23) 30.41 (6.89)
Hand dynamometry (mmHg) 33.4 (10.4) 31.2 (11.2)
A Calculated from calorie and protein intakes per day
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Pre-operative Oral Food Intake
The mean calorie intake per day was 1393 calories per day (SD=415.6) for the 
standard group and 1508 calories per day (SD=462) for the enteral nutrition 
group. (This equated to 19 calorie per kg per day and 20 calorie per day 
respectively. Recommended calorie intake should be 30-35 kcals per kg/day 
[572].
The mean protein intake per day was 58.1 grams per day (SD 19.2 grams per 
day) for the standard group and 57.8 grams per day (SD 18.8 grams per day) for 
the enteral nutrition group. This equated to 0.79 grams per kilogram per day and 
0.78 grams per kg respectively. The requirement is 1-1.5 grams protein/Kg/day 
[572].
Twenty six percent (N=11) of the standard group had a mean daily oral calorie 
intake of less than 1000kcals compared to 13% (N=7) in the enteral nutrition 
group (Table 3.8). The difference was not statistically significant. There was no 
difference for the protein intakes (table 3.8).
Table 3.8 Oral calorie in1takes per day at Baseline.
Mean calorie 
intake/day
Standard Group 
N (%)
Enteral Group 
N (%)
Less than 600 kcals 1 (2.4) 2 (3.7)
601-999 kcals 10(23.3) 5 (9.3)
1000 -1499 kcals 14 (33.3) 22 (40.7)
1500-1999 kcals 15(35.7) 20 (37)
Mean protein intake/day
Less than 20 g protein 1 (2.4) 1 (1.9)
21-35 g protein 3(7.1) 7(13)
36-50 g protein 13(31) 15 (27.8)
51-65 g protein 11(26.2) 13(24.1)
66-80 g protein 8(19) 11 (20.4)
More than 80 g protein 6 (14.3) 7(13)
Of clinical relevance, all the patients (N=5) who developed peri-operative major 
complications within 48 hours that required a return to the operating theatre had 
protein intake of less than 0.48 grams per kilogram per day. This is a third of
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normal protein intake pre-operatively. All these patients reported a good appetite 
pre-operatively.
Pre-operative Body Mass Index (BMI)
The m ean pre-illness Body M ass Index (BM I) for the total study population was 
27.5. The m ean pre-operative BMI remained in the overweight category for the 
total study population 2 5 .4  (S D  4 .8). Fifty-four percent of the total study 
population had a pre-operative BMI greater than 25 indicating that these patients 
are overweight. The incidence of obesity was 14.5 % in the total study 
population. Forty patients (4 1 .6 % ) in the total study population had a BMI in the 
normal range i.e. 20-24 . Five patients (5 .2% ) in the total study population had a 
BMI less than 18.
The m ean BMI w as similar for both randomised groups. More of the enteral 
nutrition groups, N =32 (59% ), had BMI over 25 (i.e. the overweight category). 
This compared to 21 (50% ) patients in the standard group. Ten patients (18 .5% ) 
in the enteral nutrition group compared to 4 (9 .5% ) in the standard group were 
morbidly obese pre-operatively.
Figure 3.3 Pre-operative Body M ass Index of the Two Random isation Groups.
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A relationship between BMI and surgical procedure was highlighted when the 
data were explored. Two oesophagectomy patients (4%), 7 (24%) gastrectomy 
patients (24%) and 3 (12%) pancreatic resection patients, had a BMI less than 
19 (i.e. underweight). The results are presented in table III.1.1 in appendix III. This 
suggests, that using BMI in patients undergoing gastrectomy were more
undernourished pre-operatively using BMI, when compared to the other surgical 
procedures. Twenty patients (42%) undergoing oesophagectomy were
overweight using BMI (BMI 25-30), compared to twelve (34%) gastrectomy 
patients and seven (28%) pancreatic patients. The incidence of morbid obesity 
(BMI greater than 30) was 19% - once again higher in patients undergoing 
oesophagectomy, compared to 14% in gastrectomy patients and 4% for 
pancreatic resection patients.
Percentage Weight Loss
The median percentage weight loss of the total study population was 6.3% (0.5- 
11%). Thirty-six patients (38%) in the total study population had lost more than 
10% body weight in the 3 months prior to admission for surgery.
The median pre-operative percentage weight loss was similar for the two
randomisation groups (table 3.9). Despite this, 38% (N=21) patients in the 
enteral nutrition group had lost more than 10% weight loss compared to the 33% 
(N=14) of the standard group. However, this difference was not statistically 
significant.
Table 3.9 Pre-operative Percentage Weight Loss of the Standard and Early Enteral 
Nutrition groups. __________________ _______________ __________________
% Weight loss Standard group 
N (%)
Enteral Group 
N (%)
Total 
N (%)
Less than 5% 20 (47.6) 26(48.1) 47 (48.9)
Between 6-9% 9(21.4) 7(13.0) 17(17.7)
Between 10-15% 11 (26.2) 13(24.1) 25 (26)
More than 16% 3 (4.8) 8 (14.9) 11 (11.4)
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A relationship between percentage weight loss and gender was identified when 
the data were explored. The median percentage weight loss for males was 4.5% 
(0-10.6)) and for females was 9.2% (0.6-12.3). (This was not statistically different 
U=889; p=0.114). The results are presented in table III.I.II appendix III. Twenty- 
five men (17%) compared to 21 women (65%) had lost more than 10% weight 
loss prior to admission in the previous 3 months. As with BMI, patients 
undergoing gastrectomy lost the greatest percentage weight with 62% (N=8) of 
the patients losing more than 10% weight loss pre-operatively.
Nutrition Risk Index
Patients were comparable at baseline for degree of malnutrition using the 
Nutrition Risk Index (NRI). The majority of patients in both groups were classified 
as borderline using the NRI (table 3.10).
Table 3.10 A comparison of Pre-operative Nutrition Risk Index Score between the 
two randomised groups____________________ ____________________________
NRI Standard group 
N %
Enteral Group 
N %
Severe PEM 4 10 6 12.5
Moderate PEM 4 10 2 4.2
Borderline PEM 32 80 40 83.3
Females were more nutritionally at risk prior to surgery with 21.4% (N=6) 
compared to 6.7% (N=4) males having a severe score for NRI. The results are 
presented in table lll.l.lll in appendix III.
Appetite and Pre-operative Oral Food Intake
Patients were asked to rank their appetite on a scale of 1-5 compared to usual 
appetite. The results for the two randomised groups are presented in table 3.11. 
This measure is subjective, but ‘appetite’ is an often-used clinical term and was 
deemed important to collect for the purpose of the trial.
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The median appetite scores were similar for the two randomised groups 4 (IQ 
range 2-4) and 4 (IQ range 3-4) respectively for the standard groups and for the 
early enteral nutrition group. Twenty one percent of the enteral nutrition group 
had a reduced appetite compared to 31.7% of the standard group.
Table 3.11 Appetite Scores for the Two Groups
Appetite Score Standard Group 
N (%)
Enteral
Group
N (%)
Total 
N (%)
1 (very poor) 3(7) 5 (9) 8 (8.3)
2 (reduced) 10(24) 6(11) 16(16.6)
3 (average) 8(19) 11 (21) 19(20)
4 (good) 14 (33) 21 (39) 35 (36.4)
5 (excellent) 7(17) 11 (20) 18(18.7)
Hand Grip Dynamometry
Handgrip dynamometry was compared at baseline for the two randomised 
groups (table 3.12). The mean handgrip dynamometry for the standard groups 
was 33.4mmHg and 30.9 mmHg for the enteral nutrition group.
Table 3.12 Comparison of the Randomisation groups for Pre-Operative 
Handdynanometry expressed as 85% of normal.___________________________
Handdynanometry less 
than 85% of normal
Standard Group 
N (%)
Enteral group 
N (%)
Test 
Statistic (p)
Yes 18(42) 23 (44)
NSNo 19(45) 22 (41)
Missing data 5(13) 9(15)
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Factors that have an Impact on Oral Food Intake
Comparisons at baseline of the factors that affect oral intake were made. The 
results are presented in table 3.13. The groups were similarly matched for all 
factors. The incidence of dysphagia was 18.8% for the study population. The 
incidence of diabetes (both Type I and II) was 47% for the total study population.
Table 3.13 Symptoms affecting food intake a comparison of randomised groups
Did the patient report 
and of the symptoms 
listed below?
Standard group 
N-42
N (%)
Enteral Nutrition 
group N=54
N (%)
Total Study 
Population
Dysphagia
Yes 9(21) 9(17) 18(18.8)
No 33 (79) 45 (83) 78 (82)
Nausea
Yes 14 (33) 13(24) 27 (28)
No 28 (67) 41 (76) 69 (72)
Vomiting
Yes 14(33) 11 (20) 25 (27)
No 28 (67) 42 (80) 70 (73)
Taste Changes 
Yes 10(23) 9(17) 19 9(20)
No 32 (77) 45 (83) 77 (80)
Chewing Problems 
Yes 2(5) 0(0) 2(2)
No 39 (95) 49 (100) 88 (98)
Bowel problems 
Yes 13(31) 16(30) 29 (31)
No 29 (69) 38 (70) 67 (69)
191
3.3.4 Baseline Comparison of Biochemical Parameters
The baseline biochemical parameters were comparable for the two- 
randomisation groups. The results are presented in table III.I.IV in appendix III. 
All mean parameters were in the normal clinical reference range at baseline.
3.4 Group Allocation and Equivalence
The chapter has so far explored the data from the two-randomisation groups at 
baseline prior to any study intervention. The baseline data from the SF-36 Health 
Related Quality of Life is presented later in this chapter.
No differences were found between the randomised groups for operative, 
demographic and nutritional characteristics. The standard group and enteral 
nutrition group were therefore considered suitable for the purpose of statistical 
analysis in the analyses of the primary and secondary outcomes.
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3.5 Analysis of Primary Outcome
The primary outcome for the MCRCT was a comparison of the length of hospital 
stay (LOHS) in days by group. This section will present the results of the analysis 
of LOHS.
3.5.1 I ntention-to-Treat Analysis
The results of the intention-to-treat analysis concluded that the median length of 
hospital stay for the STD group was 20 days (IQ range 14.75-28) compared to 16 
days (IQ range 13-22.75) for the EEN group. The difference between the groups 
was approaching statistical significance (U=999.70 p=0.65). The data was not 
normally distributed.
3.5.2 Per Protocol Analysis
In addition to the Intention-to-treat analysis a per-protocol analysis was also 
performed. Six patients were excluded for this analysis for the following reasons:
1. The need to return to theatre due to major complications within 24-48 hours 
post-theatre (N 3)
2. Died within 24-48 hours post-operatively (N=1)
3. Had a nasojejunal tube (N=2)
All the events leading to withdrawal were unrelated to enteral feeding, as they all 
occurred prior to the commencement of the enteral feed.
The results of the per-protocol analysis indicated that the median LOHS for the 
STD group was 20 days (IQ range 14.75-28 days) compared to 16 days (IQ 
range 13-22 days) in the EEN group (figure 3.4). The difference between the 
groups was statistically significant (U=822.50, p=0.021). The data were not 
normally distributed as illustrated by the QQ plot (figure III.II.I in appendix III.II). 
The results indicate that the null hypothesis of the MCRCT can be refuted.
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Figure 3.4 Length o f hospita l stay and inter-quartile ranges of the tw o randomised 
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There w ere five outliers in the per-protocol analysis of the primary outcome. 
Three outliers in the S TD  group and two in the EEN group; all had LOHS  
exceeding 40  days. These prolonged LO H S are attributed to the development of 
m ajor complications.
3.6 Analysis of Secondary Outcomes
The M C R C T  had multiple secondary outcomes. This section will present the 
results of the com parisons of the secondary outcomes, between the two 
randomised groups. All analyses are on a per-protocol analysis basis. Results 
will be presented for the differences in the:
1. Developm ent o f m ajor complications
2. Readmission rates at 6 and 12 weeks post-discharge.
3. Developm ent of minor complications
4. Fluid balance and prescription of intravenous fluids.
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5. Nutritional parameters
6 . Biochemical parameters
7. Health related quality of life scores
8 . Cost using length of hospital stay and development of major complications
3.6.1 Major Complications developed during Hospitalisation
This section will present the results of the development of major complications. 
The analyses for major complications were classified into:
1. Total number and mean number of major complications developed
2. Development of infective and non-infective complications
3. Percentage of LOHS with a major complication
4. A comparison of Complication Ratios [567]
5. Difference in number of major complications on discharge
Total Number of Major Complications Developed Between the Two 
Randomised Groups
The STD group (N=42) had a total of 69 major complications compared to 26 in 
the EEN group (N=54). The mean number of major complications developed per 
group was 1.64 (SD 1.8 8 ) for the STD group and 0.54 (SD1.0) for the EEN group 
(t=3.49; p=0.001). This suggests that the STD group developed 3 times as many 
major complications than the EEN group on average.
More patients in the EEN group had an uncomplicated post-operative recovery, 
when compared to the STD group (6 8 .8 % versus 39%). Similarly, ten patients 
(25%) in the STD group versus 1 patient (2.1%) in the EEN group developed 
more than 4 major complications post-operatively. The results are presented in 
table 3.14.
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Table 3.14 Total Number of Major Complications developed Post-operatively by 
Randomised Group_________________ ______________ ________________
Total no. of major 
complications
STD group
N (%)
EEN Group
N (%)
Total Study Group
0 14(34.2) 35 (66.0) 49
1 13(31.8) 11 (20.0) 24
2 1 (2.4) 4 (7.5) 5
3 3 (7.3) 2 (4.6) 5
4 6 (14.6) 1 (1.9) 7
5 3 (7.3) 0(0) 3
6 1 (2.4) 0(0) 1
Total 41* (100) 53* (100) 94
*There were two peri-operative deaths one in each group
The Classification of Major Compilations
The major complications results are presented in table 3.15. More patients in the 
STD group 28.5% (N=12) developed wound infections compared to the EEN 
group 5.5 % (N=3) (chi square=16.3, p<0.0001). Likewise, the standard group 
developed more chest infections 21.4% (N=9) versus 9.3% (N=5) in the enteral 
nutrition group (chi squared=6.03; p=0.05). The incidence of pleural effusion was 
similar for both groups.
There were differences in wound healing between the two groups. This was 
manifested by a reduction in open abdominal wounds and anastomotic leaks in 
the EEN group. Four patients (9.5%) in the STD group compared to one patient 
(1.9%) in the EEN group had an abdominal wound breakdown. This did not 
reach statistical significance.
For anastomotic leaks, 16.6% (N=7) of the STD group compared to 1.8% (N=1) 
in the EEN group developed a leak (chi squared=6.73; p=0.01). The 
development of anastomotic leaks occurred irrespective of the type of surgical 
procedure. Three patients with anastomotic leak had oesophagectomies, 2 
patients had gastrectomies and 2 patients had PPPD.
The incidence of respiratory failure (STD 6 % versus EEN 2.3%) and chylothorax 
(STD 2.1% versus EEN 0%) was higher in the EEN group. The results were not
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statistically significant. However, the numbers in each group are too small for 
reliable comparison.
Delayed gastric emptying occurred in patients who had pancreatic resection. 
More patients in the STD group 7.3% (N=3) versus 1.8% (N=1) in the EEN group 
developed delayed gastric empting. The differences with delayed gastric 
emptying should be interpreted with caution as the numbers for comparison are 
small, but it does refute one study [424] that concluded continuous enteral 
feeding via a needle catheter jejunostomy decreased gastric emptying in patients 
undergoing pancreatic resection.
Patients in the EEN group had fewer urinary tract infections (2.1% versus 7.3%; 
NS); fewer haemorrhages (0% versus 2%); and less myocardial infarction (0% 
versus 2.3%). However, caution is again advised when interpreting these 
findings, as the number of patients in each subgroup is very small.
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Table 3.15 Percentage and Number of Major Complications by Randomised Group
Type of Complication STD Group 
% (N)
EEN Group 
% (N)
Chi squared 
test (p)
Infective Complications
Wound Infection 28.5 (12) 5.5 (3) 16.3 (0.0001)
Chest Infection 21.4 (9) 9.3 (5) 6.025 (<0.05)
Urinary Tract Infection 7.3 (3) 2.1 (1) 1.92 (0.38)
Septicaemia 0 (0 ) 0  (0 ) -
Non infective Complications
Delayed Gastric Emptying 7.3 (3) 1.8 (1) 3.95 (0.11)
Myocardial Infarction 2.3(1) 0 (0) 2.61 (0.41)
Major Haemorrhage 4.9 (2) 0 (0 ) 3.23 (0.17)
Pleural effusion 17.1(7) 14.3 (7) 0.78 (0.84)
Chylothorax 0 (0) 2.1 (1) 2.29 (0.53)
Anastomotic Leak 16.6 (7) 1.8 (1) 6.73 (0.01)
Open abdominal wounds 9.5 (4) 1.9 (1) 2.78 (0.18)
CVA 0 (0 ) 0 (0 ) -
ARDS 0 (0 ) 0 (0) -
Respiratory Failure 2.3 (1) 11.1 (6 ) 0.85 (0.34)
Mortality Rate (30 day) 2.3 (1) 1.9 (1) -
Total complications 49 26
Percentage of Length of Hospital Stay spent with Complications
The next section will compare the two groups for the proportion of their LOHS
spent with a major complication. The results are presented in table 3.16.
Thirteen patients (34%) in the STD group spent more than half their post­
operative stay with a major complication compared to 3 patients (6.3%) in the 
enteral nutrition group. The results once again indicate that EN reduces the time 
post-operatively spent with a major complication as compared to the STD group.
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Table 3.16 Length of Time with a Major Complication as a Percentage of Hospital 
Stay_______________________________________________________
Percentage of LOHS with a 
major complication
STD Group 
N (%)
EEN Group 
N (%)
0% 14 (34.2) 35 (66.0)
1-10% 4 (9.8) 9(16.9)
11-20% 4 (9.8) 4 (7.5)
21-30% 1 (2.4) 1 (1-9)
31-40% 4 (9.8) 1 (1.9)
41-50% 1 (2.4) 0(0)
More than 51% 13(31.6) 3 (5.8)
Total patients (missing data) 41 (1*) 53 (1*)
* 2  peri-operative deaths one from each group
Complication Ratios
A study by McAleese and Oldling-Smee (1994) [567] determined complication 
ratios for major complications (see methods section). These ratios can be 
applied to length of hospital stay in surgical patients to establish how each major 
complication will increase LOHS.
Complication Ratio=
Mean* LOHS stay with complication / Mean* LOHS stay without complications
*The mean LOHS was used for this calculation as proposed by the authors [567]
For the purpose of this study, a comparison of enteral nutrition and standard 
management on the complication ratios was calculated. The results are 
presented in table 3.17.
The results suggest that the presence of any major complication increased 
LOHS by 1.47 times for the total study population. By using early enteral feeding 
post-operatively the complication ratio was 1.39 versus 1.55 for standard 
management.
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Complication ratios for each major complication were calculated (table 3.17). The 
STD group tended to have higher complication ratios as compared to the EEN 
group, indicating that EN reduces the severity of major complications and hence 
reduces LOHS.
Table 3.17 A Comparison of Complication Ratios* McAleese and Oldling-Smee by 
randomisation groups_______ _________________________ ______________
Type of Complication STD Group 
Mean ratio 
(LOHS)
EEEN Group 
Mean ratio 
(LOHS)
Total Group
Mean ratio 
(LOHS)
All Major Complications 1.55 (24.18;) 1.39 (20.19) 1.47 (22.2)
Infective Complications
Wound Infection 
Chest Infection
1.50 (23.46) 
1.66 (25.9) 
1.33 (20.8)
1.28 (18.6) 
1.14(16.6) 
1.42 (20.6)
1.45 (21.9) 
1.39 (20.9) 
1.51 (22.7)
Non Infective Complications
Delayed Gastric Emptying 
Pleural effusion 
Chylothorax 
Anastomotic Leak 
Open abdominal wound 
Respiratory Failure
1.35 (21.1) 
1.41 (22.1) 
1.81(28.3)
-(-)
1.9 (29.7) 
1.38 (21.6) 
1.6 (25.0)
1.29 (18.7) 
1.28 (18.6) 
1.66 (24.1) 
1.4** (20.3)
-(-) 
2.45** (35.6) 
0.96 (28.5)
1.32 (19.9) 
1.35 (20.3) 
1.75 (26.4) 
. 1.4(21.1) 
1.9 (28.7) 
1.55 (23.4) 
1.22(18.4)
*This is the predicted LOHS for each complication based on the actual LOHS for each 
randomisation group (standard group=15.64 days (7.4); enteral group=14.53 days (5.13) 
total study population = 15.08 days).
^Interpret with caution, n=1.
The results suggest that the development of a wound infection in the STD group 
will increase LOHS by 1.66 times; pleural effusion by 1.81 times and an 
anastomotic leak 1.9 times. The mean LOHS for the STD group patients who 
developed no post-operative complications was 15.64 days (SD 7.4 days). 
Therefore, the corresponding LOHS for each of the major complications 
developed would be 25.9 days for wound infection, 28.30 days for pleural 
effusion and 29.7 days for anastomotic leak.
The calculation of complication ratios in the EEN group, suggests that the 
increase in LOHS if a patient developed a wound infection was 1.14 and 1.66 for 
a pleural effusion. No comparison can be made for this MCRCT for patients with
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anastomotic leak as no patient in the EEN group developed one. The mean 
LOHS for the EEN group who developed no post-operative complications was 
14.53 days (SD 5.13 days). Therefore, the corresponding increased LOHS will 
be 17.7 days (range 10.72-22.41 days) for wound infection. For pleural effusion 
the LOHS would be 24.1 days (range 15.6-32.6 days).
The conclusions to be drawn so far from this early analysis are that if a patient 
develops a major complications, enteral nutrition may reduce LOHS by 16.5% for 
all major complications, may reduce LOHS by 20.7% for infective complications 
and may reduce LOHS by 11.1% for non-infective complications.
The EEN group however, had a higher complication ratio for chest infection, 
abdominal wound breakdown and chylothorax. The number of patients in the 
EEN group with abdominal wound breakdown and chylothorax was only one and 
consequently caution needs to be used when interpreting these results.
The authors [567] suggest that the complication ratio may also reflect the 
severity of major complications. According to the results of this RCT, the most 
severely impacting complications were pleural effusion, anastomotic leak and 
chylothorax. This was based on the complication ratios of the total study 
population.
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3.6.2 Presence of Complications on Day of Discharge
The presence and type of complications on the day of discharge were compared 
(table 3.18). Six patients (11.1%) in the EEN group reported complications on the 
day of discharge, compared to 14 patients (33.3%) in the STD group (Chi 
square= 8.56; p=0.0001).
Table 3.18 Types and frequency of Major Complications on Discharge
Group Developed no 
Complications 
N (%)
Chest 
N (%)
Wound 
N (%)
Anastomotic 
Leak 
N (%)
Other* 
N (%)
Missing
data
N (%)
STD 25 (59.5) 1 (2.3) 10(23.8) 3(7.1) 2 (4.7) 1 (2.3)
EEN 48 (88.8) 0(0) 3(5.5) 0(0) 3 (5.5) 2(1.9)
*Other= oedema, dysphagia secondary to vocal cord palsy, severe anorexia
3.6.3 Hospital Readmissions Rates
Patients were reviewed at 6  weeks and 12 weeks post discharge. Only 
readmissions related to the initial surgical procedure were recorded. Data were 
only recorded if the patient required a minimum of one night inpatients stay. The 
results of readmissions within the first 6  weeks after discharge are presented in 
table 3.19.
Six patients (14.3%) in the STD group required readmission within 6  weeks 
compared to 4 patients (7.6%) of the EEN group. The difference was not 
statistically significant.
Table 3.19 Readmission Rates between discharge and 6 Weeks by Randomisation
Readmission between 
discharge and 6 
weeks
Standard Group 
N (%)
Enteral Group 
N (%)
Chi square
Yes 6(14.3) 4 (7.6)
NSNo 36 (85.7) 48 (92.4)
Total 42 52*
* missing data N=2
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Two patients (4.8%) in the STD group compared to 1 patient (1.9%) in the EEN 
group required readmission at 12 weeks post discharge (table 3.20). The 
difference was once again not statistically significant.
Table 3.20 Readmission Rates between 6 weeks and 12 weeks by Randomisation 
Group__________________________________________________________
Readmissions 
between 6 weeks 
and 12 weeks
STD Group 
N (%)
EEN Group 
N (%)
Chi square
Yes 2 (4.8) 1 (1.9)
NSNo 40 (95.2) 51 (98.1)
Total 42 52*
missing data N=2
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3.6.4 Tolerance and Feasibility of Enteral Nutrition
This section will present the data regarding the tolerance and feasibility of enteral 
nutrition delivered in the immediate post-operative phase.
All results are comparisons between the two randomised groups unless 
otherwise specified.
Complications related to the Needle Catheter Jejunostomy
There were no reported complications associated with infection at the catheter 
site, leakage from the catheter or displacement of the catheter. There were no 
reported major jejunostomy related complications for the total study population.
There were two tubes blockages, one in either group. Neither of the blockages 
caused cessation of either enteral feed or water for more than 4 hours.
Volume of Enteral Feed Delivered
All EEN group patients commenced enteral feeding within 24 hours of their 
surgical procedure. The number of patients in the EEN group who had 
uninterrupted enteral feeding in the 1st week was 85.2% (N=46). The mean daily 
volumes of enteral feed delivered are presented in table 3.21.
Enteral nutrition was delivered to eight patients in the STD group within the first 7 
days post-operatively. The reasons for this are presented in table 3.23. All 
patients in the STD group who received EN were fed as per EEN group protocol. 
However, the mean volume of enteral feed delivered to the STD group did not 
exceed a mean volume greater than 95 mls/day (SD 242-458 mis) and 9.6% of 
their nutritional requirements for the 1st 7 days post-operatively. All patients were 
analysed on an intention to treat basis.
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Table 3.21 Mean volume of enteral nutntion delivered per day (millilitres)
Post operative 
Day
EEN Group 
Mean vol. (SD)
STD Group 
Mean vol. (SD)
ANOVA
1 317(172) 0(0) F 1,95=125.4 
(p>0.0001)2 615 (283) 0(0)
3 946 (389) 0(0)
4 1168 (577) 65 (242)
5 1294 (655) 45 (366)
6 1296 (747) 95 (458)
7 1450 (682) 244 (547)
The mean volumes of EN delivered in the STD group are for a7 patients in the STL
group and not the mean volumes for the patients who received EN.
The volume of EN and the percentage of nutritional requirements achieved by 
the EN varied each day. From the table 3.22 it can be seen that the maximum 
percentage of nutritional requirements achieved by the EEN group was 71.2% 
(SD 124.7%) occurring on day 4 post-operatively. 100% of nutritional 
requirements were achieved by some of the EEN group as indicated by the 
standard deviations.
Table 3.22 Mean (SD) Percentage of Nutritional rec
Post-operative
Day
STD Group
N=42
Mean % Nutritional 
Requirements (SD)
EEN Group 
N=46 
Mean % Nutritional 
Requirements (SD)
1 0(0) 13.6 (10)
2 0(0) 29 (19)
3 0(0) 44 (24.2)
4 3.9(14.1) 71.2 (124.7)
5 2.5 (14.2) 59.8 (32.6)
6 5.5 (23.4) 59.8 (31.7)
7 9.6 (28.3) 63.2(31.1)
uirements delivered per day
A summary of the delivery of enteral nutrition is presented in table 3.26. The 
mean time post-operatively that the enteral nutrition was commenced at was 
12.3 hours (SD 6.2 hours).
The mean rate of commencing the enteral nutrition was 17.92 mls/hour (SD 9.06) 
on day 1. The protocol advised that patients were commenced at 20 mls/hour, in
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line with the study feeding protocol. The variation is due to nursing 
documentation at ward level.
The rate of feed delivery on day 3 was 46.1 mls/hour (SD 16.7mls). The mean is 
in line with the protocol, but the standard deviation suggests that some patients 
were receiving enteral nutrition at a greater rate. The rate of feed on day 5 was 
57.9 mls/hour (SD 25.43). This is in line with the feed protocol.
By day 7, the rate of feed was 61.5 ml/hour (SD 26.8mls). This is the day the 
patients often had their gastrograffin swallows and hence the enteral nutrition 
would have been discontinued temporarily.
The mean number of days post-operatively that the EEN group received enteral 
nutrition was 12.4 days (SD 6.33 days). There was variation in the length of time 
the EEN group received the enteral nutrition, with two patients stopping on day 6  
(as they were ready for discharge) and one patient who was fed for 41 days 
(secondary to vocal cord palsy and dysphagia). This patient was subsequently 
discharged home with enteral feeding.
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Table 3.26 Summary of the delivery of enteral nutrition
Variable STD Group 
Mis/day
EEN Group 
Mis/day
Mean hours post op enteral 
nutrition commenced (SD)
N/A 12.3 (6.2)
Rate feed commenced mis (SD) 11.50 (water) 17.92 (9.06)
Volume of feed delivered day 3 
mis (SD)/day
50.71 (37.0) 959.9(381.0)
Rate of feed day3 
mis (SD)
9.8 (1.5) 46.1 (16.7)
Volume of feed delivered day 5 
mis (SD)/day
51.4 (234.3) 1333.8 (656.4)
Rate of feed delivered day 5 
mis (SD)
12.1 (98) 57.9 (25.43)
Volume of feed delivered day 7 
mis (SD)/day
229.7 (512) 1433.7 (702.44)
Rate of feed day 7 
Mis (SD)
7.8 (20.6) 61.5 (26.8)
No. of days enteral feed 
delivered
N/A 12.4 (6.33) 
range 6-40 days
Mean day post-op enteral 
nutrition stopped
N/A 13.7(16.3) 
range 6-41 days
Reasons why the Standard Group Commenced Enteral Feeding in the Early 
Post-Operative Period
A total number of 8  (19%) patients commenced EN in the STD group by seven 
days post-operatively. The reasons are given in table 3.23.
Two patients on day 4 commenced enteral feeding due to surgeon preference. 
One patient commenced enteral nutrition due to a suspected chest complication.
By day 7, three patients were commenced on EN due to anorexia and oedema. 
One patient commenced EN due to a suspected anastomotic leak.
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Tab e 3.23 Number of Standard Group Patients who received Enteral Nutrition post-operatively and the Reasons for starting
Operation
Type
Centre Day feed 
started
Reason Feed type No. Of days 
feed
Day oral diet 
commenced
LOHS
IL 1 4 Surgeon request Peptisorb 47 8 51
IL 4 Surgeon request Perative 2 0 14 26
Trans 1 4 ? Chest infection Osmolite 14 15 2 0
IL 5 Chest complication Osmolite 12 13 2 0
PPPD 1 7 Oedema/anorexia Perative 23 12 35
Transhiatal 1 7 Oedema/anorexia Osmolite 15 11 18
Transhiatal 1 7 Oedema/anorexia Perative 11 13 15
IL 1 7 Anastomotic leak Osmolite 27 2 0 35
IL- Ivor Lewis oesophagectomy, ? -suspected , LOHS- length of hospital stay; PPPD Pylorus preserving pancreaticoduodenectomy; 
Transhiatal=transhiatal oesophagectomy
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Table 3.24 Summary of the reasons why enteral nutrition was commenced in the
standard group _______ _________________________ ________ _______
Reasons for Enteral 
Nutrition
Day 4 Day 5 Day 6 Day 7 Day 9 Day
12
Clinical Error 0 0 0 0 0 0
Surgeon preference 2 2 2 2 3 3
Major complication 1 2 2 3 8 20
Minor Complication 0 0 0 3 3 1
Receiving enteral 
nutrition/day N (%)
3(7.1) 4(16.6) 4(16.6) 8(19) 14 (24) 20(48)
Reasons for Stopping Enteral Nutrition in the Enteral Nutrition Group
The number of patients who needed to have their enteral nutrition stopped or
interrupted in the 1st post-operative week was 16% (N=9). The reasons are 
outlined in table 3.25.
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Table 3.25 Reasons for Interruplting Enteral Nutrition delivery in the Enteral Nutrition Group
Operation
type
Centre Day
feed
stopped
Reason Action No. Of days 
feed stopped
Day enteral 
feed resumed
LOHS
IL 1 3 Chylothorax TPN 25 28 50
Gastric 1 5 ? chest Infection NBM 1 6 11
Gastric 1 4 Oozing wound NBM 2 6 7
Gastric 1 7 Abdominal pain NBM Not resumed N/A 16
Gastric 1 5 ? chest infection NBM 1 6 16
Gastric 2 6 ? chest infection NBM Not resumed N/A 13
Gastric 2 6 ? chest infection NBM 1 7 16
Gastric 1 5 ? chest infection NBM 1 6 14
PPPD 1 5 ? anastomotic leak NBM 1 6 17
IL=lvor Lewis oesophagectomy, PPPD= pylorus preserving pancreaticoduodenectomy, TPN=total parenteral nutrition, NBM= nil by mouth, 
? suspected diagnosis, N/A not applicable
Number of Patients receiving Enteral Nutrition on the Day of Discharge
On the day of discharge, 6  patients (14.2%) in the STD group were requiring
enteral nutrition and were subsequently discharged home on enteral nutrition. In 
comparison 1 patient (1.8%) of the EEN group were discharged home on enteral 
feeding.
Table 3.27 Number of patients requiring Home Enteral Nutrition
Type of feed required on 
discharge
Standard Group 
N (%)
Enteral nutrition group N 
(%)
No Feed 36 (8 6 ) 53 (98.2)
Water 0 (0) 0 (100)
Whole Protein 4 (9.5) 1 (1 .8 )
Semi-elemental 2 (4.7) 0 (100)
Missing 0 (0) 0 (0 )
The reasons for patients being discharged on home enteral nutrition are 
presented in table 3.28. Fifty percent of the STD group requiring home enteral 
nutrition remained nil by mouth post-discharge. The one patient in the enteral 
group requiring home enteral nutrition had vocal cord palsy and dysphagia.
Table 3.2I3 Patients discharged on Home Enteral Nutrition.
Patient
ID
Randomisation
group
Reason for HEF Nil by mouth?
43 Standard Anastomotic leak Yes
47 Standard Anastomotic leak Yes
81 Standard Anastomotic leak Yes
23 Standard Wound infection/poor appetite No
14 Standard Wound Infection/poor appetite No
3 Standard Poor appetite No
53 Enteral nutrition Dysphagia Yes
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3.6.5 Development of Minor Complications Post-operatively
The section will present the minor complications developed in the post-operative 
period by randomisation group. Differences in nausea and vomiting, nasogastric 
aspirates, abdominal distension, bowel function and pain will be presented.
Nausea and Vomiting
The incidence of nausea and vomiting in the 1st seven days post-operatively was 
analysed (table 3.29).
Fifteen patients (35.7%) in the standard group reported at least one episode of 
nausea in the 1st 7 post-operative days, compared to 15 (27.3%) in the enterally 
fed group (Chi square=8.82; p=0.06)
Vomiting in the first week occurred in 10 patients (23.8%) in the STD group and 8 
patients (14.5%) in the EEN group (Chi square=10.89; df 4 p=0.01)
Table 3.29 Number of patients reporting nausea and vomiting in the first week 
post-operatively_______________________ _______________________________
Presence of nausea in 
1* week
STD group 
N (%)
EEN Group 
N (%)
Chi square *(p)
Yes 15(35) 15(27.3) 8.82,
No 26 (62) 39 (70.9) (0.06)
Presence of Vomiting in 
1st week
Yes 10(23.8) 8 (14.5) 10.88, (0.01)
No 31 (73.8) 46 (83.6)
* Fischer exact test
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Nasogastric (NG) Aspirates
NG aspirates are frequently used in clinical practice to reflect gastrointestinal 
motility post-operatively. High NG aspirates are thought to reflect delayed gastric 
emptying and altered small bowel motility. Daily NG aspirates were recorded and 
the median daily results per randomised group are presented in table 3.30.
Table 3.30 Nasogastric Aspirates in millilitres (mis) by Randomised groups
Day post op STD group 
N (missing)*
STD
NG asps mis 
median (IQ 
range)
EEN group 
N
(missing)*
EEN
NG asps 
mis median 
(IQ range)
U
1 42 (0) 205 (0-375) 54(0) 2 0 0  (0-601) NS
2 36 (6 ) 127 (0-445) 44(10) 375 (163- 
325)
NS
3 37 (5) 212 (0-685) 50(4) 0 (0-375) p=0.081
4 38 (4) 200 (0-650) 47 (7) 0  (0-2 0 0 ) NS
5 37 (5) 79 (0-510) 45 (9) 0 (0-336) NS
6 37 (5) 0 (0-370) 46 (8) 0 (0-362) NS
7 36(6) 0 (0-494) 49 (5) 0  (0-182) NS
* number of missing patients, data not available on wards/recorded.
There was no statistically significant difference between median volumes of NG 
aspirates reported between the two groups. On day 3 the difference in median 
volumes was approaching significance (p=0.08) with the standard group having 
more NG aspirates than the enteral nutrition group.
Abdominal Distension
The development of abdominal distension is a side effect often reported with the 
early use of EN. The incidence of abdominal distension for the total study 
population was 12.5% (N=12). The presence of abdominal distension peaked on 
day 3-4 post-operatively for both groups. There were no differences reported 
between the groups in incidence of abdominal distension. The percentage of 
patients in the STD group that reported abdominal distension for the first 7 days 
post-operatively was 14.3% (N=6 ), for the EEN group 11.1% (N=6 ) patients 
reported abdominal distension.
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Bowel Function
Bowel function i.e. passage of flatus and stools are often considered by 
surgeons to be vital clinical stages in the post-operative recovery of surgical 
patients. However, as outlined in section 1.5.1.5 these do not reflect resumption 
of bowel function post-operatively.
The use of Ultrasound to Determine Return Of Peristalsis Post-operatively
As outlined in section 2.1.6.2 the use of ultrasound imaging (USS) at the bedside 
to detect the number of peristaltic waves in the small intestines was developed. 
The results are presented below.
A subgroup of consecutive patients (N=25) had their motility determined using 
USS (section 2.1.6.2). These patients were consecutively admitted from 
November 2002 to May 2003. The results are presented in table 3.31.
Table 3.31 Number of peristaltic waves/minute in the small intestines post 
operatively as determined using Ultrasound Imaging ______________________
Post op day STD group 
Mean (SD)
EEN group 
Mean (SD)
T test (p)
4 4.8 (2.6) 13.9(2.01) -4.039 (0.0001)
5 5.33 (2.08) 12.6 (5.3) -2.26 (0.050)
6 9.2 (1.72) 14.17(6.6) NS
From the table the results indicate that the EEN group had more peristaltic 
waves per minute on day 4, day 5 and day 6  post-operatively. The difference 
between the groups reached statistical significance on days 4 and 5. The mean 
frequency of waves for the EEN group was 13.9 (SD 2.01) on day 4 and this 
remained similar for days 5 and day 6  post-operatively. The mean frequency for 
the standard group gradually increased over days 4-6. However, the mean 
frequency never achieved the score of the EEN group.
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Passage of Flatus
The results from this MCRCT suggest an earlier passage of flatus in the EEN 
group compared to the STD group, with 20% (N=11) of the EEN group versus 
2.3% (N=1) passing flatus by day 4 post-operatively (Chi square=25.5; 
p=0.0001). The results need to be interpreted with caution as several patients 
reported passage of flatus after passing stools suggesting under-reporting of 
passage of flatus.
Passage of Stools
Comparison of the groups on day 4, suggests that EEN stimulated patients to 
pass stools quicker than STD management. Eight patients (97.7%) in the EEN 
group had opened their bowels compared to 1 patient (2.3%) in the STD group 
on day 4 post-operatively (Chi square=20.49; p=0.0001). Fourteen patients 
(26.4%) in the EEN group opened their bowels on day 5 post-operatively 
compared to 2 patients (4.7%) of the STD group (Chi square=17.47; p=0.001). 
By day 7, forty-two patients (61.3%) in the EEN group had opened their bowels 
compared to 11 patients (25.8%) in the STD group (Chi square =19.54; 
p=0.001). A summary of the results of patients who opened their bowels, in the 
first week post-operative for the two randomised groups are presented in table 
3.32.
Table 3.32 Number of Patients who reported Bowels opened in 1st week Post- 
Operatively____________________ ___________________________
Bowels opened in 1st 
week post-op
No. Of patients (%)
Standard Group
Yes 20 (46.5)
No 22 (53.5)
Enteral Group
Yes 32 (59.3)
No 21 (38.7)
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Incidence of Diarrhoea
The incidence of diarrhoea in the 1st week was reported in 12 (12.5%) patients in 
the total study population. The incidence of diarrhoea in the 1st week was 14% 
(N=6 ) for the STD group and 11.1% (N=6 ) for the EEN group. The difference was 
not statistically significant. The results are presented in table 3.33.
Table 3.33 Number of patients reporting diarrhoea by randomised group in the 
first 7 days
Diarrhoea reported in 1st 
week post-op 7
No. of patients
(%)
STD group
Yes 6 (14)
No 36 (86)
EEN group
Yes 6(11.1)
No 48 (88.9)
The differences between the two groups for the development of minor 
complications (nausea, vomiting, bowel function; diarrhoea and constipation) 
reduced prior to discharge, with no statistical differences between groups on 
discharge.
Comparison of Pain Scores
Pain scores were compared for the first seven post-operative days. The pain 
scores were ranked on a scale of 1-4. The scores were comparable for the first 5 
post-operative days. On day 6 , the difference in pain scores was approaching 
significance (Chi=10.9; p=0.07). The results are presented in table 3.34. The 
differences in pain scores for the two groups may have been attributed to quicker 
resumption of bowel function in the EEN group.
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Table 3.34 Pain scores for the first seven days post-operatively
Post op Day Standard Group 
N (%)
Enteral Group 
N (%)
Chi (p)
1
no pain 
mild
moderate
severe
8(19) 
11 (26) 
18(43) 
5(12)
17(31)
17(31)
1 2 (2 2 )
8(15)
5 .74  (0.44)
2
no pain 2(5) 3 (5.5) 3.75 (0.42)
mild 15(36) 25 (46)
moderate 12(28) 17(31.5)
severe 13(31) 9(17)
3
no pain 6(14) 12 (2 2 ) 9.74 (0.11)
mild 16(38) 18(33)
moderate 13(30) 9(17)
severe 7(17) 15(28)
4
no pain 13(31) 25 (46) 5.63 (0.39)
mild 13(31) 9(17)
moderate 11 (26) 14 (26)
severe 5(12) 6 (11)
5
no pain 9(21) 27 (50) 10.9(0.07)
mild 12(29) 11 (2 0 )
moderate 15(36) 8(15)
severe 6(14) 8(15)
6
no pain 8(19) 23(44) 9.91 (0.07)
mild 22 (52) 16(30)
moderate 8(19) 10(19)
severe 4(10) 4(7)
7
no pain 19(45) 32 (60) 6.48 (0.31)
mild 13(31) 7(13)
moderate 8(19) 11 (2 0 )
severe 2(5) 2(4)
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3.6.6 Post-operative Recovery of Mobility
The difference stages of mobilisation were compared for the first 12 post­
operative days (table 3.35). There were no statistically significant differences 
between the two-randomised groups.
Exploration of the data demonstrated a small trend for the STD group to mobilise 
independently more quickly than the EEN group by day 7 post-operatively 
(11.9% (N=5) versus 5.5% (N=3)).
This may be attributed to the EEN group being connected to the feeding pump, 
as at day 12, 14.2% (N=6 ) of the STD group compared to 18.5% (N=10) of the 
enteral group were mobilizing independently.
Table 3.35 Number of Patients (%) achieving different stages of mobilization in the
post-operative phase by randomised group
Stages of Mobilisation Day 3
N (%)
Day 5
N (%)
Day 7 
N (%)
Day 12
N (%)
Lying in bed
Standard Group 
Enteral Group
29 (69) 
26 (48)
7 (16.6) 
11 (20.3)
5(11.9) 
5 (9.2)
1 (2.3)
2 (3.7)
Sitting in Chair
Standard Group 
Enteral Group
9(21) 
22 (40)
14 (47) 
15(38)
12 (28.5) 
8 (14.8)
8(19)
6 (1 1 .1)
Mobilising around bed
Standard Group 
Enteral Group
3(7)
7(13)
4(13)
12(3)
3(7.1)
9(16.6)
7(16.6) 
4 (7.4)
Mobilising with assistance
Standard Group 
Enteral Group
1 (2 ) 
0 (0)
2 (6)
0 (0)
7(16.6) 
12 (34.5)
5(12) 
14 (25.9)
Mobilising independently
Standard Group 
Enteral Group
0 (0)
0 (0 )
2 (4.7) 
0 (0)
5(11.9) 
3 (5.5)
6 (14.2) 
10(18.5) I
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3.6.7 Post-operative Fluid balance
The mean fluid balance for the two randomised groups was compared post- 
operatively (table 3.36). The difference between the two groups for daily fluid 
balance reached significance over the first 7  post-operative days (F i >7o=766 .8 ;
p>0 .0 0 0 1 ).
The STD group was in a greater cumulative positive fluid balance for the first 7 
days post-operatively (5123 mis) when compared to the EEN group (4053 mis). 
The mean difference was 1070 mis.
Table 3.36 Mean da ly fluid balance (mil i litres)
Fluid Balance Standard Groups 
N-35 
Mean (SD)
Enteral Group 
N=45 
Mean (SD)
ANOVA
Day 1 1012 (1144) 1029 (1045)
Day 2 815(1158) 801 (1049) (Fi,78=148;
Day 3 264 (851) 913(1303) p>0 .0 0 0 1 )
Day 4 564 (1269) 530 (1040)
Day 5 695 (944) 139 (974)
Day 7 761 (1338 641(856)
Day 12 934 (1053) 397 (655)
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Figure 3.5 Mean daily fluid balance (millilitres)
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(F i,78=148; p > 0 .0001 ).
The use o f Intravenous (IV) Fluids
The daily volum e of intravenous fluids infused for the two-randomisation groups 
was collected daily for the first 7 days post-operatively (table 3 .37).
The m ean volume o f IV fluids prescribed was significantly higher in the S TD  
group for the first 7 days post-operatively when compared to the EEN  group. The  
volume of IV  fluids prescribed in the enteral nutrition decreased over the first 7 
days post-operatively.
This is attributed to the use of EN to provide fluid requirements in the EEN  group 
with subsequent reduction in the volume of intravenous fluid required.
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Table 3.37 Mean daily volume of intravenous fluids (millilitres) delivered a 
comparison of randomisation groups_______ ________________________
Post
operative day
Standard Group
N=35
Mean IV fluid vol 
delivered/day mis (SD)
Enteral Group
N=37
Mean IV fluid vol 
delivered/day mis (SD)
1 2713 (701) 2524 (911)
2 2960 (8 8 8 ) 2329 (762)
3 2593 (753) 2270 (1082)
4 2810 (8 6 8 ) 1889 (910)
5 2566 (937) 1726 (1150)
6 2620 (760) 1379 (1059)
7 3312 (4682) 1308 (1086)
Total
cumulative
intake
19574 mis 13425 mis
(Fi,70=766.8; p>0.0001).
The volume of intravenous fluids delivered increased throughout the course of 
the first week and averaged between 2500-3000mls/day in the STD group. The 
mean volume then increased to a mean of 3000 mls/day on day 7 (figure 3.6)
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Figure 3.6 Mean daily volume of intravenous fluids (millilitres) delivered
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(F i i70=766 .8 ; p >0 .0001).
The development o f Oedema
The developm ent of oedem a w as compared for the first 7 days post-operatively  
(table 3 .38 ). Fifteen patients (3 6 .6 % ) of the standard group compared to four 
patients (8 % ) of the enteral nutrition group developed oedem a (Chi 
square=12.0 ;p=0 .0001).
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Table 3.38 Number of patients and percentage who developed oedema in the 1st
week post-operative________________ _________________ _________________
Oedema in 1 st 
week?
Standard Group 
N (%)
Enteral Group
N (%)
Chi (p)
Yes 15(36.6) 4 (7.5)
1 2 .0 (0 .0 0 0 1 )No 26 (63.4) 48 (92.5)
Total 41 52
3.6.8 Nutritional Parameters
This section presents the results of the comparisons of the nutritional parameters 
post-operatively and post-discharge by randomised group.
Nutritional parameters have been used as surrogate outcome indicators in many 
clinical nutrition trials and are therefore important for use in the comparisons of 
efficacy of EN versus STD management. Results will be presented on the 
following:
1. Nitrogen balance
2. Weight
3. Mid upper muscle circumference
4. Handdynanometry
5. Oral intake and appetite
6 . Biochemical parameters
Nitrogen Balance
A subgroup of patients in the total study population had a 24-hour urine 
collection for nitrogen balance performed. Many of the samples collected were 
not analysed as in many cases the timing on the collection was at the weekend, 
and only emergency samples were analysed. Results for the subgroup (N=44) 
are presented in table 3.39, by randomised group.
The difference between the groups was statistically significant; with the entire 
STD group in a negative nitrogen balance on day 5 post-operatively compared to
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11 (47.8%) of the EEN group (Chi 22.2; p=0.01). Eight patients (34.7%) in the 
enteral nutrition group were in a positive nitrogen balance on day 5.
Table 3.39 Comparison of Nitrogen Balance on Day 5 Post-Operatively
Nitrogen balance Standard
Group
N (%)
Enteral
Group
N (%)
Total 
N (%)
More than 1Ograms-ve 8(38.1) 1 (4.5) 9(21)
6 -1 0  grams -ve 6 (28.5) 2  (8 .6 ) 8(18)
1-5.9grams -ve 7(33.4) 8 (34.7) 15(34)
Equilibrium 0 (0 ) 4(17.3) 4(9)
1-6 gram +ve 0 (0 ) 7 (30.4) 7(16)
More than 6gram +ve 0 (0 ) 1 (4.5) 1 (2 )
Total 21 (1 0 0 ) 23 (100) 44(100)
Weight
All patients in the study lost weight during their hospital stay (mean percentage 
weight loss of 4.2% from pre-operative day 1 to day of discharge). The results of 
the mean weight throughout the study are presented in table 3.40.
The mean weight on discharge of the STD group was 69.2 kg (SD 15.1 kg) and 
72.2kg (SD 17.1kg) for the EEN group (NS). The mean drop in weight for the 
STD group was 4.6 kg (6.2% weight loss) and the mean drop for the EEN group 
was 2.1kg (3% weight loss). None of the mean weights were statistically 
significantly different.
Weight (kilograms) Standard
Group
Mean (SD)
Enteral
Nutrition
group
t-test (p)
Pre-illness 79.2 (14.9) 79.4(16.4) NS
Pre-operative 73.8(16.0) 74.5(17.5) NS
Day 7 7 4 .5  (14.4) 74.8 (18.1) NS
Discharge 69.2 (15.1) 72.2(17.1) NS
6 weeks follow up 67.2 (14.3) 70.5 (16.9) NS
12 weeks follow up 66.9(13.9) 70.5(16.8) NS
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Table 3.41 shows the weight changes from pre-operatively to 6  weeks post- 
operatively were 6 .6  kg (SD 4.4kg) for the STD group and 3.9 kg (SD 4.5kg) for 
the EEN group (t=2.96; p=0.004). It is clinically relevant that weight loss in the 
enteral nutrition group appears to be accelerated post-discharge (figure 3.7). The 
mean weight loss post discharge in the EEN group was 7.5 kg (SD 6 .6 kg) versus 
2.0kg (SD 2.7Kg) in the STD group. This reached statistical significance (t=-2.09; 
p<0.05).
Table 3.41 Mean Changes in Weight (in Kilograms) over the study period and 
follow-up (kilograms)__________________ ___________________________
Changes in weight Standard Group
Weight change Kg 
(SD)
Enteral Group
Weight change 
Kg (SD)
t-test
(P)
Pre-op to 7 days 
post-op
-0.65 (4.9) -0 .2 2  (2 .2 ) NS
Pre-op to discharge 4.6 (3.5) 2.1 (3.2) 3.5, df 94 
(0 .0 0 1 )
Pre-op to 6 weeks 6 .6  (4.4) 3.9 (4.5) 2.96 df 94 
(0.004)
Pre-op to 12 weeks 1.7 (6.3) 3.8 (4.6) 2.89 df 94 
(0.005)
Discharge to 6  
weeks
2.0 (2.7) 1.7 (6 .6 ) -2.09 df 94 
(p<0.05)
Discharge to 12 
weeks
2 .2  (2 .6 ) 1.8 (3.3) NS
6  weeks to 12 weeks 0 .2  (2 .6 ) -0.04(1.6) NS
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Figure 3.7 M ean changes in w eight (kg) of the Random ised Groups over the  
duration o f the  study
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Oral food intake
Resumption of oral drinks and food post-operatively is a key stage used to 
indicate ‘recovery’ in surgical practice. Fluids and foods are usually reintroduced 
on day 4 -5  post-operatively for gastrectomy patients, day 7-8 for 
oesophagectom y and pancreatic resection. Patients typically undergo a contrast 
swallow prior to commencing oral fluids and diet to ensure the UGI anastomoses 
are intact.
Oral diet w as com m enced on the fifth post-operative day in one patient 
undergoing partial gastrectomy in the STD  group and two patients undergoing 
sub-total gastrectom y in the EEN group.
By day 7 post-operatively, eight of the STD group (18 .6% ) and 9 patients 
(16 .6% ) of the EEN group were commenced on oral diet. By day nine, 36%
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(N=15) of the STD group had commenced oral diet and 44% (N=24) of the EEN 
group had commenced oral diet.
By day 12, more patients in the EEN group were eating and drinking (60% 
(N=32) versus 22% (N=9)) than the STD group. Similarly, on day 15, twelve 
percent (N=5) in the STD group and 7.6% (N=4) in the EEN group remained nil 
by mouth. The reasons are outlined in table 3.42.
Table 3.42 Reasons Patients Remained Nil by Mouth on Day 15
Standard Group Enteral nutriition group
Pt ID 
no.
Operation Reason for nil by 
mouth
PtID
no
Operation Reason for nil by 
mouth
13 IL Respiratory
problems
67 GS Chylothorax
14 IL Leak 89 GS Leak
17 PG Leak 90 PPPD Delayed gastric 
emptying
28 P PPD Leak 91 PPPD Chest infection
40 P PPD Leak
Leak = anastomotic leak, IL= Ivor Lewis oesophagectomy, PG=partial gastrectomy; PPPD= 
pylorus preserving pancreaticoduodenectomy; GS= gastrectomy
The mean calorie intakes were compared over time. The EEN group consistently 
had a higher mean calorie intake as compared to the STD group.
The difference between the groups for mean oral calorie intakes over time was 
statistically significant (Fi, 86=1682.6;p<0.0001). The results are presented in 
table 3.43 below and illustrated in figure 3.8.
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Table 3.43 Mean oral calorie intake by Randomisation Group overtime
Oral calorie intake Standard  G roup  
N=38  
M ean intake  
calorie /day (SD)
Enteral Group  
N=50 
Mean intake  
calories/day  
(SD)
ANOVA (p)
Pre-operative 1429 (415) 1508(457) F-i,86=1682.6;
p<0.0001Day 9 post op 113(203) 218(203)
Day 12 post op 172 (231) 466(418)
Day of discharge 812(242) 1227(421)
6 weeks post discharge 1036 (334) 1544 ( 444)
12 weeks post discharge 1225(376) 1582(443)
Missing data= 4 in standard group; 4 in enteral nutrition group
Figure 3.8 M ean oral calorie  intake by R andom isation G roup over tim e
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Oral calorie intakes were categorized and analysed on discharge and at follow 
up. Eighty-three percent (N=35) of the STD group achieved a mean calorie 
intake less than 1000kcals/day at discharge. In comparison 30% (N=16) of 
patients in the EEN group were having a mean calorie intake less than 1000 
kcals/day (Chi squared =32.14; p<0.0001).
Table 3.44 Oral intake calories/day) on day of discharge by randomised gro
Oral intake on day 
of discharge
Standard Group 
N (%)
Enteral Group 
N (%)
Total Study 
Population
> 600 calories 4(10) 2(4) 6 (6 )
700-1000 calories 30 (73) 1 1 (2 1 ) 41(45)
1000-1500 calories 7(17) 31 (61) 38 (41)
1600-2000 calories 0 (0 ) 7(14) 7(8)
Total 41(100) 51 (100) 92(100)
Missing data = 1 in standard group and 3 in enteral nutrition group
Post discharge, mean oral intake for both groups showed they never achieved 
their full nutritional requirements calculated using Elwyn (1980) [572]. The 
maximum reported oral intake at both 6  and 1 2  weeks post-discharge was 1500 
kcals/day.
Appetite Scores
Appetite was compared on day of discharge (table 3.45 and figure 3.9). Ten 
patients (23.2%) in the STD group versus 27 patients (50%) in the EEN group 
reported good or excellent appetite on discharge. The majority of the STD group 
had an average appetite N=13 (30.2%) versus N=7 (13.5%) in the EEN nutrition 
group. The difference for appetites on day of discharge was statistically 
significant Chi square=9.5; p=0.049.
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Table 3.45 Reported Ap petites on Day of Discharge by Random ised Group
A ppetite reported on 
day o f discharge
Standard
Group
N (%)
Enteral Group
N (%)
Total Study 
Population N
(%)
Poor Appetite 3 (7 .1 ) 3 (5.6) 6 (6.3)
Reduced Appetite 11 (26.3) 4 (7 .4 ) 15(15.8)
Average appetite 18(43.3) 2 0 (37 ) 38 (39.5)
Good appetite 9 (2 1 ) 17(31.5) 26 (27)
Excellent Appetite 1(2.3) 10(18.5) 11 (11.4)
Total 42(100) 54(100) 96(100)
Chi =9.5; d f8 p = 0 .0 4 9
Figure 3.9 C om parison o f appetite  on day of discharge
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Mid Upper Muscle Circumference (MUMC)
Mid upper muscle circumference was compared peri-operatively. No significant 
differences occurred in mean M U M C  over time. The results are presented in 
table 3.46.
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Standard group 
N=34
Mean (SD)
Enteral Group 
N=48 
Mean (SD)
Total group 
N=82 
Mean (SD)
Pre-op 30 .7  (4 .9 ) 2 8 .8 (7 .2 ) 29.6  (6 .4)
Discharge 2 6 .3  (4 .4 ) 25 .3  (6 .3 ) 25.8 (5.6)
6 weeks post-op 23 .6  (3 .5 ) 24 .7  (5 .4 ) 24.3 (4 .7)
12 weeks post-op 2 2 .8  (3 .5 ) 24 .4  (5 .2 ) 23.7 (4 .6)
The mean changes in MUMC are presented in table 3.46 below. The STD group 
had more pronounced muscle loss than the EEN group on discharge, 6  weeks 
and 12 weeks post-discharge. Loss of muscle mass appeared to plateau at 6  
weeks whereas in the STD group muscle mass continued to decrease (figure 
3.10).
Table 3.47 Mean changes in Mid Upper l\fluscle Circumference Peri-operatively
STD Group
Mean changes
MUMC in mm 
(SD) N=34
EEN Group
Mean changes 
MUMC (mm) 
(SD) N=49
T test (p)
Pre-op to DC -4 .4  (2 .9 ) -3 .5  (2 .5 ) NS
Pre-op to 6 weeks -7 .0  (5 .3 ) -4.1 (4 .2 ) -4 .56 (<0.0001)
Pre-op to 12 weeks -7 .9  (6 .6 ) -4 .4  (5 .5 ) -1 .53 (<0.0001)
(DC= discharge; Pre-op= pre-operative)
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Figure 3.10 Mid U pper M uscle  C ircum ference (m m s) peri-operatively and at fo llow  
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Handdynanometry (HD)
All patients in the study had a reduction in HD and suggesting a reduction in 
muscle strength. The reduction in HD from pre-operative stage to discharge was 
statistically significant between the two groups (t=2.96;p=0.004). The EEN group 
had less reduction in hand-grip strength than the standard group (2.7 mmHg 
versus 5.72 mmHg).
Table 3.48 Mean changes in Handdynanometry (mmHg) readings from pre- 
operative period to discharge_____________ _____________ ___________
Handdynanometry
measurement
Standard 
Group mean 
(SD)
Enteral 
Group mean 
(SD)
t-test (p)
Pre-operative HD (m m H g) 3 4 (1 0 .8 ) 3 0 .7 (1 0 .8 ) NS
Discharge HD  (m m H g) 28 .2  (9 .7 ) 29 (9 .2 ) NS
Difference from pre-op to 
discharge (m m H g)
5 .7 2 (1 .1 ) 2.7 (1 .6 ) 2.96;
(p=0.004)
3.6.9 Biochemical Parameters
Serum Albumin
Serum albumin was assayed daily over the first 7 days post-operatively. As part 
of the normal care pathway, all patients post major UGIT surgery should have 
had daily albumin levels. In this RCT, twenty-four patients did not have daily 
bloods tests taken during this period. These patients were from both randomised 
groups.
There were no statistically significant between the two groups for the first seven 
days post-operatively. All patients in the total study population had a drop in 
serum albumin of 8-9g on Day 1 post-operatively. The mean serum level then 
gradually increased over the next 7 days (figure 3.11).
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Figure 3.11 Serum albumin concentration in the first seven days post-operatively
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Eighty two percent (N =79) of the study population successfully had serum  
albumin collected on discharge.
Fifty patients (79% ) in the S TD  and EEN group had a serum albumin greater 
than 30g/l on the day of discharge. The mean albumin level on discharge was 
32.2g/l (SD  5 .2 ) for the S TD  group and 33.9g/l (SD  4 .2 ) for the EEN group. Both 
levels were within the normal range. There were no significant differences in 
serum albumin on day of discharge (t=-1.70; p=0.092). The results are presented 
in table 3.49.
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Table 3.49 Serum a bumin concentration on day of discharge
Albumin level 
mmol/litre
Standard group 
N=41
N (%)
Enteral group 
N=53 
N (%)
Total study 
N=94 
N (%)
19-25 5(12) 1 (1 .8 ) 6 (6.4)
26-30 6(14.6) 7(13.2) 13(13.8)
31-35 18(44.4) 19(36) 37 (39.4)
Greater than 36 12(29) 26 (49) 38 (40.4)
C-Reactive Protein (CRP)
Sixty eight percent of the study population had CRP collected daily for the first 7 
days post-operatively. There were no differences between the two groups 
postoperatively for the first 7 days. The data from the total study population 
illustrates that CRP is synthesised during the 24-48 hours post-operatively, 
peaking on day 3 post-operatively (figure 3.12). There were no statistically 
significant differences between the two groups for CRP over the first 7 days post- 
operatively.
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Figure 3.12 Mean C-reactive protein (umols) for the first seven days post-
operatively
R a n d o m i s e d  G r o u p
 s t andard
 entera l  f eeding
1 5 0 .0 0 -
1 0 0 .0 0 -
6 5 0 .0 0 -
0 . 0 0 -
1 2 3 4 5 6 127p r e ­
op
P o s t o p e r a t i v e  d a y
3.6.10 Summary of Discharge Parameters
A sum m ary of both the continuous and categorical data recorded on the day of 
discharge are presented in the table 3.50. There were no significant differences  
between the two groups in terms of weight, appetite score, handdynanometry, 
mid upper arm circumference, albumin, bowel function, and nausea.
The difference on discharge for the presence of oedem a w as statistically 
different. More patients in the S TD  group were discharged with oedem a when  
compared to the EEN group. (Seven patients (37 .7% ) in the S TD  group 
compared to 2 patients (16 .6% ) in the EEN group (chi=4.54; p=0.033).
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There were no significant differences between the groups with regards to use of 
analgesia or ability to mobilise on discharge.
The majority of patients (92.5%) in the EEN group were able to mobilise 
independently on discharge. More patients in the STD group (16.7%) as 
compared to the EEN group (5.4%) were dependent on assistance to mobilise 
on discharge.
Table 3.50 Summary of Nutritional Parameters on the Day of Clischarge
Nutritional Parameters Standard
Group
Mean (SD)
Enteral
Nutrition
Mean
(SD)
Statistical 
test (p)
Weight (kilograms) Mean (SD) 69.2 (15) 71.5(16) NS
Oral intake (calories) Mean (SD) 830 (257) 1224
(445)
t=4.99 (>0.0001)
Handdynanometry Mean (SD) 28.4 (9.8) 28.0 (9.2) NS
Mid Upper Muscle Group Mean (SD) 26.3 (4.3) 25.3 (6.2) NS
Appetite mean scores Mean (SD) 2.86 (0.9) 3.4 (1.0) NS
Nausea day of Discharge N (%) 3(7.1) 1 (1.9) NS
Bowel Function day of discharge
Constipation
Normal stool
Loose Stools
Diarrhoea
N (%)
2 (4.7) 
35(83.3) 
0 (0 ) 
5(11.9)
5(9.3) 
42 (77.7) 
1(2 ) 
6 (11)
NS
Oedema present day of Discharge 
N (%) 7 (16.6) 2 (37.7) Chi = 4.54(0.033)
Analgesia Requirements N (%) 
No analgesia 
Paracetamol only 
Tramadol 
Missing data
1 (2.4) 
24 (57) 
7 (23.8) 
10(23.8)
0 (0 ) 
19(35.3) 
15(27.7) 
20 (37)
NS
Mobilisation day of Discharge N (%) 
Lying in bed 
Mobilising around bed 
Mobilising with assistance 
Mobilising no assistance
1 (2.4)
2 (4.8) 
7(16.7) 
31 (73.8)
0 (0)
1 (1.9)
3 (5.6) 
50 (92.5)
NS
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3.6.11 Estimation of Cost Differences
This section will present the results of the cost difference between the two 
randomised groups for the MCRCT. The aim is to provide an estimate of the 
differing costs associated with each group.
There were several assumptions for the calculation of costs for the two groups. 
These are listed below:
1) This cost estimation was based on the knowledge that the groups had similar 
costs for the delivery of the routine care pathway, for patients undergoing major 
UGI resection. Thus routine health expenditure was deemed similar for both 
groups.
2) The differential costs per group were used to determine the cost difference for 
the purpose of this RCT.
3) The differential costs were taken as the difference in LOHS and the costs of 
treating the significantly different major complications. These were considered to 
be the main cost drivers. The cost of LOHS has been used to calculate cost 
differences in other studies [12, 530].
4) All costs of equipment were calculated from manufacturers’ list prices.
5) The cost of drugs, dressings and enteral nutrition is based on the British 
National Formulary (BNF)[614].
6 ) The grades of medical and health professionals were taken as mean of pay 
scale, using current pay scales, based on Agenda for Change, Department of 
Health (UK) [615].
7) The jejunostomy tube is inserted as an adjunct to the operative procedure 
theatre time and was therefore not included in the costs. Only consultant and 
nurse time was calculated.
8 ) The cost of the feeding pumps was not included. These are supplied from the 
enteral nutrition companies as part of the Local Contractual agreement and are 
usually provided free of charge within the enteral feed contract.
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Cost of providing intervention
The cost of delivering enteral nutrition per patient was £270.11 per patient for 7 
days (table 3.51).
Justification of Costs
1) Consultant time.
The Consultant Surgeons each performed the insertion of the jejunostomy tube 
for the MCRCT. Each consultant was asked to record the time taken to insert the 
jejunostomy at the end of the main surgical procedure. The insertion time 
averaged 20 minutes for the four surgeons. The cost per hour of a Consultant 
Surgeon is £47.40 [615]. In addition, the cost of a theatre nurse was also 
calculated based on mean scale band 6  nurse for 20 minutes. The combined 
cost of insertion of the jejunostomy was calculated to be £60.
2) Cost of jejunostomy tube.
The jejunostomy tube used was the Fresenius Freka ® (Liverpool, UK) needle 
catheter jejunostomy. The cost per unit as reported by the manufacturer was 
£90.
3) Cost of dressing
The dressing used for the jejunostomy tube for patients in the study was 
Lyofoam® (7.5cm X7.5 cm). The BNF [614] price is 97p per unit. The dressing 
was changed every day.
4) Cost of giving sets
A giving set connects the needle catheter jejunostomy to the feed reservoir. In 
line with MHRA [616] recommendations, one giving set can be used for each 
patient for delivering sterile feeds per 24 hours. The unit price as per 
manufacturer was £3.76 per unit.
5) Cost of feeding pump
The cost of the feeding pump to administer the enteral feed was not included in 
the cost of administering the enteral nutrition. Most commercial enteral nutrition 
companies supply pumps as part of the local contractual agreement.
6 ) Nursing time
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The nursing time taken to set up the administration of the enteral feeding (flush 
the jejunostomy with sterile water, connect the enteral feeding) and check the 
percutaneous entry site (for leakage, complications and sign of infection) was 
estimated to be 20 minutes per day. The grade of nursing staff was taken as mid 
scale Band 5 (agenda for change) [615]. This equates to £28,000 gross costs 
per annum [615]. The hourly rate was £15 per hour. Thus for 20 minutes of 
nursing time, the cost is taken as £5.
7) Dietetic time
The dietetic time needed to determine nutritional requirements, monitor tolerance 
of enteral feed and calculate enteral nutrition regimen was estimated to be 30 
minutes per patient per day. The grade of dietitian was taken as Band 7 top of 
scale [615]. This was taken as £45,000 per annum gross cost. This equates to 
£23.07 per hour.
8 ) Length of time of Intervention
The length of time of the intervention was taken to be 7 days. Therefore the cost 
of delivering enteral nutrition to a patient in the enteral nutrition group was taken 
as £270.11.
9) Cost of Inpatient Stay
The cost per day for inpatient stay was based on figures from the Welsh 
Assembly Government [617] . The cost is £220 per patient per day. This is the 
cost of a general ward hospital bed only and does not include cost of diagnosing 
or treating the development of any minor or major complications.
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Table 3.51 The Calculation of Cost of Delivering Enteral Feed per Day to Study 
Patients
Cost Justification of cost Price
Insertion of jejunostomy 
tube
20 minutes of Consultant time
20 minutes theatre nurse time 
(Top of Band 6)
£20
£10
Cost of jejunostomy tube Fresenius list price [6181 £90
Cost of jejunostomy 
insertion
£120
Costs of dressing BNF price [615] 0.97 per unit
Costs of Giving set/day 
(single use)
Abbott Laboratories list price 
[619]
£3.76 per unit
Feed pumps Not included £0
Nursing time Top of scale Band 5 £5.00 for 20 minutes
Dietetic time Top of scale Band 7 £11.00 for 20 minutes
Cost of enteral feed per 
day
BNF price [615] for 
O smolite® (.Abbott 
laboratories)
£5.00
Total £25.73 day
Total for 7 days= £180.11 
+ tube insertion= £270.11
Cost Estimation Calculation
The cost of LO H S  was calculated using the median and interquartile range for 
LO HS determ ined from the results of this RCT. The calculation of the cost 
difference in L O H S  for the groups is presented in table 3.52.
The cost for the LO H S  for a patient in the enteral nutrition group was £3520  (IQ  
range £ 2 8 6 0 -£ 4 8 4 0 ). W hen  the cost of delivering enteral nutrition for the 7 day 
intervention period is added, the total cost attributed to the median LO HS is 
£3790.11  (£ 3 1 3 0 .1 1 -5 1 1 0 .1 1 ).
In comparison the cost of LO H S  for a patient in the standard group was £4400  
(IQ  range £ 3 2 4 5 -£ 6 1 6 0 ). Interventional costs for the standard group were not 
included, despite the cost of the increased intravenous fluids prescribed and 
administered. T h e se  costs w ere  considered minimal. The cost of delivering the 
enteral feed to the patients (n=6) who received enteral nutrition in the standard 
group was also not included in the cost estimation.
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Therefore, the cost difference for treating the differing LOHS for the two groups 
was £609.89 (114.89-1049.80) per patient when enteral nutrition used.
Table 3.52 Estimation of Cost for Length of Hospital stays for Both Randomisation 
Groups
Enteral Group
LOHS for the Enteral nutrition group median =16 days (Inter Quartile (IQ) range 13-22 days)
Cost of LOHS for the enteral nutrition group was £3520 (IQ range £2860-£4840 per patient 
+ Cost of Intervention =£270.11 per patient 
Total Cost of LQHS=£3790.11 (IQ range = £3130.11-£5110.11)
Standard Group
LOHS for the Standard group was 20 days (IQ range 14.75-28 days)
Cost of LOHS for the standard group was £4400 (IQ range £3245-£6160) per patient 
+ cost of intervention=£0 per patient 
Total cost of LOHS= £4400 (IQ range £3245-£6160)
Cost Difference between two groups
Cost Savina of £609.80 HQ ranae £114.80-£1049.891 per patient when enteral nutrition used
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Cost of Treating the Major Complications
The costs of treating the statistically significant different major complications 
were calculated. All other costs attributed to the development of non-significant 
complications were assumed to be similar for the two randomised groups. The 
costs are outlined in table 3.53. A more detailed table outlining the calculation of 
cost for each complication and a justification of these costs are presented in 
table lll.lll.l-lll.lll.lll in appendix III.
Table 3.53 Summary of the Costs of the Major Complications used in the cost 
estimation
Major Complication Cost per day
Chest Infection* £147
Wound Infection* £107
Anastomotic leak* £135-1157 per day
* Statistically significant complications, The cost of returning to theatre and 
radiology costs are not included in the cost of anastomotic leak.
The total costs of treating the significantly different complications in the standard 
group were £29,965.80-£179,151.24. This equates to £713.47-£4,265.51 per 
patient in the standard group. The major contributor to this cost is the 
expenditure associated with treating the seven patients who developed 
anastomotic leaks. These patients remained in hospital for a total of 142 
additional days as a result of this major complication. This averaged 3.4 days for 
every patient in the standard group (N=42). The patients may require a period of 
time on critical care for ventilatory support and may require a return to the 
operating theatre for further explorative surgery. Thus calculation and estimation 
of these costs is difficult. The treatment of anastomotic leaks varies in clinical 
practice. This is the reason for the variation in the costs calculation. All patients 
in this RCT returned to critical care after developing an anastomotic leak.
The cost of treating major complications in the enteral nutrition group was 
£4,480-£13,680. This equates to £82.30 to £253.33 per patient in the enteral
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nutrition group. Once again the variation in costs is attributed to the cost of 
treating the one patient who developed an anastomotic leak in the enteral 
nutrition group.
The cost difference of treating the major complications between the group was 
£631.17 to £4,012.18, if enteral nutrition was used. The calculations for the cost 
differences for the differences in major complications are presented in table 3.54.
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Table 3.R4 Calnulation nf nnsts for the differences in mainr nomnlinetinns
Cost per patients
: : ; : . .
£631.17-£4,012.18
Enteral Nutrition Group N=54, < , . of Treating Complications per day__ ___
£713.47-£4265.51 £82.30-£253.33
o n
:
Cost of W ound lnfection=£75-£107 per patient per day; Cost of chest infection = £115-£147 per patient per day;. Cost of treating anastom otic  
leak= £135-£1157 per patient per day.
£29965.80-£ 179151.24 £4480-£13,680
Wound Infection 
Chest Infection 
Anastomotic Leak
Total cost
28.5 
(12) 
21.4 (9) 
16.6 (7)
£7125-£10165 1
£3670.80-4692.24
2
£19170-£1642943
N of days 
for group 
with 
complication
No of 
days per 
patient in 
group
0.13
0.46
0.15
Cost of treating 
Complications
£525-£749 1 
£2875-£3675 2 
£ 1 0 8 0 -9 2 5 6 3
Total no. of 
days with 
complication
No. of 
days per 
patient in 
group
Cost of treating 
Complications
)
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The total cost estimation (based on LOHS and the statistically significant different 
major complications) is outlined in table 3.55. The total cost of the enteral 
nutrition group was £3709.52 (£3049.52 to £5864.96) per patient. The cost 
associated with the standard group was £5060.48 (£3905.48 to 10631.11) per 
patient.
The cost difference is £1350.96 (£855.96-£4766.15) per patient. This equates to 
the cost saving of using enteral nutrition post-operatively. The calculation for the 
cost analysis is presented in table 3.55.
Table 3.55 Cost Analysis Calculation______________________________________
Cost per patient of treating major complications per patient £713.47-£4,265.51 in the
standard group
Cost of LOHS=£4,400 (IQ range £3,245-£6,160)
Total cost for standard group per patient= £5,113.47 (£3,958.47-10,425.51)
Cost per patient of treating major complications =£82.30-£253.33 per enteral nutrition
patient
Cost of LOHS per patient = £3520 (IQ range £2,860-£4,840)
+
Cost of providing enteral nutrition for intervention period=£270.11
Total costs for enteral nutrition group per patient=£3.872.41 (£3.130.11-£5.110.11)
COST SAVING FROM USING ENTERAL GROUP= £1241.06 (£828.36-£5,315.40 PER
PATIENT
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Summary o f Cost Differences
This section has presented an estim ate of the potential cost savings that can be 
m ade with the incorporation of early enteral nutrition into a patient care pathway.
Several assumptions have been  m ade when calculating this cost estimate and it 
is important that reference again is m ade that this is not a health economic 
assessm ent of total cost expenditure. T he  sum m ary of the cost analysis is 
presented in table 3 .56.
Table 3.56 C ost A na lys is  S u m m ary  fo r  P atien ts  in C in ical Tria l
S tan d ard  G roup  
N=42
Enteral G roup  
N=54
Cost of intervention per 
patient for 7 days £0* £270.11 per patient
Cost of LOHS £4,400 (IQ range £3,245- 
£6,160) £3,520 (IQ range 
£2,860-£4,840)
Cost of treating 
significantly different 
major complications
£713.47-£4,265.51 £82.30-£253.33
Total per patient £ 5 ,1 13.47(£3,958.47- 
10,425.51)
£3,602.30 (£2,942.30- 
£5,093.33)
C ost Saving if enteral 
nutrition used per 
patient
g - 1 n J*'- - • ^  s| 3^ 5 52= f p f e f l f 3
£1421 .17  (£926 .17 -£5 ,242 .18)
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3.6.12 Results of Health Related Quality of Life
This section will present the results of the Health Related Quality of Life (HRQoL) 
questionnaires. HRQoL is an important outcome indicator. A comparison of 
HRQoL provides evidence of any potential benefit of the intervention in a holistic 
approach, and ensures any differences in clinical and financial outcomes do not 
convey deleterious consequences to the patient.
Response Rate
The SF-36 health related quality of life questionnaire was given to all patients 
pre-operatively, on discharge, at follow up at 6  weeks, 12  weeks, 6  months and 
12 months. As the trial was still recruiting, not all patients have reached the key 
time points. The response rate for the return of questionnaires is presented in 
table 3.57. The reasons why patients did not respond were not recorded, as it 
was deemed inappropriate to question the patients.
Table 3.57 Response Rates for Compleltion of Health Related Quality of Life
Administration of SF-36 HRQoL 
Questionnaire
Response N
Baseline (pre-operative) 81
Discharge 78
6 weeks 78
12 weeks 78
12 months 58
Results of Health Related Quality of Life
This thesis will only present the data relating to HRQoL until 12 weeks post- 
operatively. This is because full data sets were not available or transformed at 
the time of this analysis.
The data was transformed as per SF-36 manual instructions [593]. Data will be 
presented for changes in HRQoL using the mean values obtained for either 
group. In addition, a comparison between the groups will subsequently be 
presented.
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Baseline Comparison between the groups
The groups were compared at baseline (i.e. pre-operatively) for responses of 
HRQoL. The results are presented in table 3.58.
The groups were comparable for seven of the eight HRQoL factors pre- 
operatively. The scores for social functioning were however statistically different. 
The mean score was higher in the enteral nutrition group as compared to the 
standard group (t=-2.15; p=0.035).
Table 3.58 Comparison of Health Related Quality of Life scores at Baseline
HRQoL factor Enteral Group 
Mean (SD)
Standard group 
Mean (SD)
T test (p)
General Health Status 55.8(21.0) 59.4(19.9) 0.76 (0.45)
Physical Function 58.5 (27.9) 67.2 (28.6) 1.41 (0.16)
Vitality 56.7 (29.4) 50.4 (28.1) -0.97 (0.33)
Physical Role 29.3 (43.3) 25.0 (41.2) -0.45 (0.65)
Bodily pain 6 8 .8  (23.6) 59.1 (31.2) -1.62 (0 .1 0 )
Mental score 68.7 (22.00 69.4 (21.8) 0.13(0.9)
Emotional score 47.3 (48.4) 47.5 (44.4) 0.02 (0.9)
Social Functioning 63.3 (29.4) 48.3 (34.4) -2.15 (0.035)*
^statistically different
The changes in HRQoL data for the 8  factors by randomisation group are 
presented in table 3.59. The results are illustrated in Figures III.III.I to III.III.VIII in 
Appendix III.
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Table 3.59 Changes in Health Related Quality of Life Scores
HRQoL factor Enteral
Group
Mean score 
(SD)
Standard
group
Mean score 
(SD)
T test (p)
General Health Status
Score pre-op
Score on discharge
Score at 6 weeks
Score at 12 weeks
Difference pre-op to DC
Difference DC to 6  weeks
Difference 6  weeks to 12 
weeks
55.8(21.0) 
50.3 (20.3) 
47.8(19.0) 
51.3(10.8) 
-5.5 (22.7) 
-2.5(18.4) 
+ 3.5 (14.9)
59.4 (19.9)
47.9 (19.9)
49.9 (17.9)
49.9 (23.7) 
-11.5 (21.8) 
+2.0(15.2) 
+0.02 (23.2)
0.76 (0.45) 
-0.53 (0.59) 
0.49 (0.623) 
-0.26 (0.79) 
-1.16(0.25) 
1.18 (0.24) 
-0.76 (0.45)
Physical Function
Score pre-op 
Score on discharge 
Score at 6 weeks 
Score at 12 weeks 
Difference pre-op to DC 
Difference DC to 6  weeks 
Difference 6 weeks to 12 
weeks
58.5 (27.9) 
33.4 (22.9) 
46.2 (24.3) 
52.9(23.1) 
-25.1 (28.9) 
+12.8(23.7) 
+6.7 (20.3)
67.2 (28.6) 
35.7 (20.6)
44.3 (22.5)
49.3 (29.1) 
-31.5 (28.7) 
+8 .6  (2 0 .8) 
+5.0 (24.7)
1.41 (0.16) 
0.48 (0.63) 
-0.35 (0.73) 
-0.59 (0.55) 
-1.45 (0.15) 
-0.84 (0.40) 
0.45 (0.66)
Vitality
Score pre-op
Score on discharge
Score at 6 weeks
Score at 12 weeks
Difference pre-op to DC
Difference DC to 6  weeks
Difference 6 weeks to 12 
weeks
56.7 (29.4) 
32.4 (24.4)
37.8 (20.9) 
47.7(21.8) 
-24.3 (28.5) 
+ 5.4 (23.9) 
+ 9.9 (20.4)
50.4 (28.1)
25.1 (14.2)
36.2 (19.9)
44.4 (24.5) 
-25.3 (28.1) 
+11.1 (2 0 .0 ) 
+8 .2  (18.0)
-0.97 (0.33) 
0.16(0.11) 
-0.36 (0.72) 
-0.63 (0.53) 
-0.2 (0.84) 
1.11 (0.27) 
-0.47 (0.64)
Physical Role
Score pre-op
Score on discharge
Score at 6 weeks
Score at 12 weeks
Difference pre-op to DC
Difference DC to 6 weeks
Difference 6 weeks to 12 
weeks
29.3 (43.3) 
4.4 (17.9) 
22.0 (40.2) 
17.6 (35.6) 
-24.9 (42.9) 
+17.6(49.5) 
-4.4 (46.6)
25.0(41.2) 
0.69 (4.2) 
19.1 (41.7) 
10(24.3) 
-24.3 (39.1) 
+18.4 (47.5) 
-9.1 (46.5)
-0.45 (0.65) 
-1.21 (0.23) 
0.29 (0.77) 
-1.0 (0.29) 
0.84 (0.41) 
-0.98 (0.33) 
0.22 (0.83)
^Statistically significant difference; DC= discharge
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Table 3.59 Changes in Health Related Quality of Life Scores (continued)
HRQoL factor Enteral
Group
Mean score 
(SD)
Standard
group
Mean score 
(SD)
T test (p)
Bodily pain
Score pre-op 
Score on discharge 
Score at 6 weeks 
Score at 12 weeks 
Difference pre-op to DC 
Difference DC to 6  weeks 
Difference 6 weeks to 12 
weeks
6 8 .8  (23.6) 
44.0 (27.3) 
57.4 (28.2) 
63.6 (26.8) 
-24.8 (34.6) 
+13.4 (26.6) 
+6.2 (23.3)
59.1 (31.2)
37.4 (23.6) 
44.7 (22.9)
48.4 (29.6) 
-22.1 (32.3) 
+7.3 (19.8) 
+3.7 (21.1)
-1.62 (0 .10) 
-1.13(0.26) 
-2.17 (0.03)* 
-2.30 (0.02)* 
0.81 (0.42) 
-1.10(0.25) 
-1 .00  (0.28)
Mental score
Score pre-op 
Score on discharge 
Score at 6 weeks 
Score at 12 weeks 
Difference pre-op to DC 
Difference DC to 6 weeks 
Difference 6  weeks to 12 
weeks
68.7 (22.00 
60.5 (20.4) 
65.4(15.2) 
69.9(17.4) 
-8.2 (23.2) 
+4.9(17.1) 
+4.5 (16.9)
69.4 (21.8) 
58.9 (20.3) 
60.6 (18.9) 
66.0(21.5) 
-10.5 (25.6) 
+1.7 (18.5) 
+5.4 (16.6)
0.13 (0.9) 
-0.34 (0.74) 
-1.21 (0.23) 
-0.86 (0.40) 
-0.06 (0.96) 
0.78 (0.44) 
0.24 (0.81)
Emotional score
Score pre-op
Score on discharge
Score at 6 weeks
Score at 12 weeks
Difference pre-op to DC
Difference DC to 6  weeks
Difference 6 weeks to 12 
weeks
47.3 (48.4) 
34.6 (46.4) 
37.9 (45.2) 
56.0 (46.9) 
-12.7 (64.4) 
+3.3 (17.1) 
+18.1 (16.9)
47.5 (44.4)
24.9 (40.8)
36.9 (46.3)
39.6 (45.0) 
-22.6 (25.6) 
+12.0 (18.5) 
-0.3(16.6)
0.02 (0.9) 
-0.34 (0.74) 
-1.21 (0 .2 2 ) 
-0.86 (0.39) 
-0.06 (0.95) 
0.78 (0.44) 
0.24 (0.81)
Social Functioning
Score pre-op
Score on discharge
Score at 6 weeks
Score at 12 weeks
Difference pre-op to DC
Difference DC to 6 weeks
Difference 6  weeks to 12 
weeks
63.3 (29.4)
24.4 (26.7) 
42.1 (28.1) 
54.6 (31.9) 
-38.9 (33.2) 
+17.7 (28.1) 
+12.5(26.7)
48.3 (34.4) 
13.0(16.7) 
32.6 (24.6)
45.3 (29.7) 
-35.3 (38.5) 
+19.6 (22.6) 
+12.7 (25.5)
-2.15 (0.03)* 
-2.28 (0 .0 2 )* 
-1.6 (0 .12) 
-1.32 (0.19) 
0.82 (0.42) 
0.30 (0.76) 
0.03 (0.97)
‘ Statistically significant difference; DC= discharge
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Comparison of Health Related Quality of Life 
General Health Status
There were no statistically significant differences pre-operatively, at 6  weeks or 
at 12 weeks for General Health Status Factor. The mean values for each of 
group are presented in table 3.59.
On discharge the EEN group reported a mean higher score when compared to 
the STD group (50.3 (SD 20.3) versus 47.9 (SD 17.9)). The STD group 
deteriorated more post-operatively as compared to the EEN group (mean 
deterioration -11.5 (SD 21.8) versus -5.5 (SD 22.7) N.S). However, the EEN 
group deteriorated more post discharge as compared to the STD group (-2.5 (SS 
18.4) versus +2.0 (SD 15.2) NS). Both groups showed improvement between 6  
ands 1 2  weeks.
Physical Function
The groups had differences in mean pre-operative scores for physical function. 
The score for the STD group was higher than the EEN group (58.5 (SD 27.9) 
versus 67.2 (SD 28.6)). The difference did not reach statistical significance 
(t=1.38; p=0.172). The mean values for each of group are presented in table
3.59. There were no statistically significant differences in mean scores on 
discharge, 6  and 12  weeks.
Both groups had a large deterioration in physical function post-operatively; mean 
deterioration in scores was -25.1 (28.9) for the enteral group and -31.5 (SD 
28.7) for the standard group. Both groups reported an improvement in physical 
function post discharge, with the EEN group improving more quickly than the 
STD group. However, neither group returned to the level of physical function as 
reported pre-operatively.
Vitality
The patients reported differences in pre-operative scores for vitality. The mean 
score for the EEN group was higher than the STD group (56.7 (SD 29.4) versus 
50.4 SD 28.1)). The difference between the groups pre-operatively did not reach 
statistical significance (t=-0.405; p=0.687).
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The deterioration in mean scores suggests that all patients reported a loss of 
vitality whilst hospitalised. Both groups reported their mean lowest score for 
vitality on discharge. The STD group had a mean lower score on discharge as 
compared to the EEN group. The difference did not reach statistical significance 
(t=-1.63; p=0.107). The mean values for each of group are presented in table
3.59.
The mean change in scores in both groups from pre-operative to discharge was 
similar. Following discharge, both groups reported an improvement in vitality; the 
improvement was slightly quicker in the STD group, as compared to the EEN 
group.
Physical Role
There were no statistically significant differences between the two groups on 
discharge, at 6  weeks and 12 weeks. The enteral feed group reported a slightly 
higher mean score at baseline (29.3 (SD 43.3) versus 25 (SD 41.2)). The scores 
pre-operatively for physical role when compared to other HRQOL factors were 
‘low’ in both groups. The mean values for each of group are presented in table
3.59.
As expected following major resectional surgery, scores deteriorated after 
surgery. The scores on discharge were very ‘low1 for both groups with the 
standard group having a mean score of 0.69 (SD 4.2) and the EEN group having 
a mean score of 4.4 (SD17.9). Mean scores improved in both groups post 
discharge until 6  weeks but then both groups showed deterioration after 6  weeks 
to 12 weeks. The deterioration was greatest in the STD group. Mean scores 
were lower at 12 weeks than pre-operatively in both groups. This suggests that 
physical function takes longer to recover post discharge than other HRQoL 
factors.
Bodily Pain
The patients reported different mean pre-operative scores for bodily pain. The 
EEN group had a higher score as compared to the standard group.
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The mean scores for both groups decreased during hospitalisation. This 
represents more bodily pain. This is to be expected following major surgery.
Neither group showed a significant improvement in pain at 6  weeks, with scores 
only slightly higher than on discharge. However, the EEN group showed an 
improvement between 6  and 1 2  weeks reporting less pain as compared to the 
STD group. The scores for the groups were statistically different at 6  and 12 
weeks with the EEN group reporting mean higher scores, indicating less pain. 
The mean values for each of group are presented in table 3.59.
Mental Score
The mean scores for mental score were similar pre-operatively, on discharge, 
and at 6  and 12 weeks. The mean values for each of group are presented in 
table 3.59. The scores on discharge reduced for both groups, however, the 
decrease appeared to not be as marked as noted with other factors. Scores at 6  
weeks remained similar as on discharge, with a reported slight increase in the 
enteral nutrition group. Scores at 12 weeks in the enteral nutrition group returned 
to near baseline scores, with continued improvement noted in the standard group 
almost returning to baseline scores.
Emotional Score
There were no statistically significant differences between the two groups pre- 
operatively, on discharge and at 6  and 12 weeks. The mean values for each of 
group are presented in table 3.59. Mean scores in both groups deteriorated 
between surgery and discharge, with the STD group showing more deterioration 
on discharge as compared to the EEN group.
Post discharge the STD group reported a more rapid improvement as compared 
to the EEN group; however, this resulted in similar scores in both group at 6  
weeks. After 6  weeks, the standard group did not demonstrate any further 
improvement. The EEN group however continued to improve, with the mean 
score improving to be greater than pre-operative score.
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Social Functioning
The mean scores of the groups were statistically different at baseline with the 
enteral nutrition group reporting a mean higher score (63.3 (SD 29.4)) as 
compared to the STD group (48.3 (SD 34.4)), t=-2.15;p=0.035). This may be a 
chance finding but the statistically significant difference in baseline scores needs 
to be considered when making inferences about the results of the RCTs’ primary 
outcome.
The mean values for each of group are presented in table 3.59. Both groups 
reported a large deterioration in social functioning scores between surgery and 
discharge. Scores improved in both groups post discharge until 6  and 12 weeks. 
The difference in the mean scores was not statistically different. Mean scores did 
not return to that of baseline by 1 2  weeks.
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3.7 Summary of Chapter
This chapter has provided the results of an early analysis of an RCT. The results 
of the primary outcome suggests that the null hypothesis may be refuted and 
suggests that EEN delivered via a feeding jejunostomy within 12-24 hours post- 
operatively to patients undergoing major resection of upper gastrointestinal 
malignancy, may led to a reduction in length of hospital stay.
This chapter has also reported the results of the secondary outcomes, in 
summary:
1. Early Enteral Nutrition may reduce the development of major complications. 
The most noticeable reduction was in infective complications.
2. The Early Enteral Nutrition group had fewer readmissions between discharge 
and 6  weeks and between 6  weeks and 1 2  weeks post discharge as compared 
to the standard group.
3. Early Enteral Nutrition was safe and feasible for patients undergoing major 
resection surgery, as reported by no tangible differences between the two groups 
in terms of the development of minor complications.
4. The Early Enteral Nutrition group had marked improvements in nutritional 
status, as compared to the Standard group, post-operatively.
5. There were no statistically significant differences between the two groups for 
health-related quality of life; however there was a trend to an improvement in the 
enteral nutrition group.
6 . Early enteral nutrition provided a potential cost saving of £1,241.06 (£828.36- 
£5,315.40) per patient if delivered within 1 2  hours of leaving the operating 
theatre, as compared to patients who received standard post-operative 
management.
The following chapter will discuss the results of the RCT in the context of the 
previously reported literature. It will also discuss the generalisability of the RCT 
and options for implementation of the trials’ results.
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4. Discussion
4.0 Introduction
This aim of this study was to compare EEN with STD management in the post­
operative management of patients undergoing major UGI resection for cancer. 
Previous surgical clinical nutrition trials have not provided sufficiently robust 
evidence to determine which approach is better.
The current study was conducted as a RCT, the ‘gold standard’ for determining 
clinical efficacy and efficiency in healthcare treatments. This chapter will firstly 
discuss the trial design, the main findings will then be discussed in comparison 
with the relevant literature and in the final section recommendations will be made 
for further research.
4.1 Trial Design
Upper Gl resection for malignancy is a complex healthcare intervention with 
numerous extraneous and prognostic factors. It was therefore decided that the 
RCT was the most suitable trial design. The current RCT was a prospective 
multi-centre, randomised, pragmatic clinical trial. Pragmatic trials mimic clinical 
practice, compare two different healthcare interventions and use robust 
randomisation techniques with the aim of limiting bias.
As discussed in section 1.7.4 random allocation aims to reduce bias, by reducing 
the effects of extraneous variables so that the differences in outcome observed, 
between the randomised groups are due to the intervention.
The trial was initially single centred but due to relatively slow patient recruitment 
rates in the first year, further funding was obtained and the number of trial 
centres increased to 4 over the course of a year. These 4 centres form part of 
the regional UGI Cancer network. By involving patients from several centres, any 
conclusions have a broader, more representative base, than can be achieved in 
a single centre.
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4.1.1 The Hospital Centres
The four hospital centres had 5 consultant surgeons with patients eligible for 
inclusion in the study. There were 4 oesophago-gastric surgeons and 1 
hepatobiliary surgeon. Stratification was performed per hospital centre, as it was 
perceived that different pathways of care might occur in each centre. One 
example is the use of critical care management in the different centres. In centre 
3, the patients typically stay in critical care for up to 5-7days post-operatively. In 
contrast, centre 1 would traditionally keep patients in critical care for 24 hours. 
This has potential implications for trial outcomes.
The use of needle catheter jejunostomy (NCJ) was not routine in all 4 centres 
prior to starting the RCT. Therefore, measures were put in place for training staff 
regarding both the insertion and post-insertion care of the NCJ. These were the 
responsibility of the PI in conjunction with the lead surgeon at each centre.
The number of clinical ward based dietitians was also minimal in 2 of the centres. 
This resulted in several logistical problems, such as day-to-day management of 
the enteral feeds. Additional funding was obtained to allow allocation of a small 
amount of local dietetic time to administer the enteral feeds. Close liaison, 
education and training of the dietitians were required to ensure compliance with 
the study protocol.
4.2 Trial Progress 
4.2.1 Sample Population
This RCT focused on patients with UGI cancer undergoing major resections with 
curative intention. It is well documented that UGI surgery has high morbidity and 
significant mortality [19, 39, 153] in addition, these patients are unable to tolerate 
food and fluid orally for typically up to 10 days after surgical resection [59, 60]. 
Therefore, any supportive intervention that could enhance recovery and reducing 
the risks would be welcome.
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The study sample median age was 69 years (58-77 years) which is similar to that 
reported in the National Cancer Statistics in 1999 [102] (median age 64; 58-72 
years). The gender distribution was, as expected, approximately twice as many 
men than women in gastric and oesophageal cancer. The incidence of 
pancreatic cancer was similar in men and women.
4.2.2 Recruitment
As all participating consultant surgeons were actively referring patients to the 
study, it is assumed that all eligible patients were approached regarding 
recruitment into the study. A total of 139 patients were recruited to the trial. The 
average number recruited per month was 4.34 patients, below the anticipated 
recruitment of 6.4 patients/month outlined in the original protocol. Slower than 
anticipated accrual rates have also been reported in other RCTs [550].
It is not clear why recruitment was slower in the present study. It may be that 
fewer patients presented to their GP with symptoms of UGI cancer during the 
RCT, or that fewer patients were suspected to have UGI cancer by their GP and 
referral for specialist tertiary intervention in hospital was not made. However, 
there is no reason to assume that these occurred, especially in the light of a 
raised public awareness of the symptoms of cancers in recent years and the 
introduction of Cancer Standards for Wales (Welsh Cancer Intelligence and 
Surveillance Unit, 2005, Welsh Assembly Government)[617].
Another possibility is that the figures used as a basis for calculating the 
anticipated accrual rate were incorrect, maybe due to changes in clinical coding. 
Finally, the slower accrual rates maybe a result of fewer patients having surgery 
compared to several years ago when the trial was planned. This may be the 
result of improvements in radiological imaging detecting patients with non- 
curable disease who previously would have been submitted to surgery. This will 
be discussed later in this section.
The consent rate was 82.2%. Similar consent rates have been reported in other 
cancer trials [620]. There were no statistically significant differences between the
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patients who did not consent with the patients who did consent (table 3 .3 ). 
Information as to why the patients did not consent was not collected, as this was 
considered inappropriate and unethical. Several hypothetical reasons are 
detailed below. It may be that:
1. The patients and/or their relatives did not want to be burdened with more 
information and decisions at a time when they have just received a suspected 
diagnosis of cancer
2. They were already participating in a clinical trial
3. The Consultant Surgeon who first discussed the RCT with the patient may 
have influenced the patients’ decision. However, this is unlikely, as all 5
Consultants had appeared to have clinical equipoise regarding the trial.
Of the 139 patients who gave consent, 102 patients were subsequently 
randomised, as 37 patients were deemed palliative at operation. The majority of 
these palliative patients were pancreatic. This gives credit to the state-of-the-art 
radiology that accurately diagnosed the oesophago-gastric patients. However, 
radiology appears not to accurately predict the likelihood of pancreatic patients 
being able to have a curative resection.
It was the view of the operating surgeon that pancreatic tumours often involve 
the superior mesenteric vein or portal vein. Unfortunately, this is often only 
discovered during the dissection stage of the operation, as the adherence of the 
pancreas to the vessels is not always detectable by current radiological imaging 
(Puntis, personal communication, 2007). Therefore it was inevitable that a 
proportion of the patients recruited would not be randomised following
laparotomy, as they had a palliative (R1) operation.
Sixty patients were randomised to receive early enteral nutrition and 42 patients 
were randomised to receive standard management. There was an imbalance of 
18 patients between the two groups when the MCRCT closed for the early 
analysis for this thesis; this can be explained by the block randomisation. There 
were four hospital sites and each site was stratified and had its own set of
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randomisation envelopes. The randomisation was in blocks of 30. The reasons 
for this are presented in section 2 .2 .3 .1 .
The number of patients recruited from centre 1 was 85; therefore, this centre 
used 2 complete blocks of 30. Of the 3rd block there were 5 randomisation 
envelopes left. Centre 2, 3 and 4 did not complete a full series of randomisation 
envelopes. This is illustrated in table 4.1.
Because of the slower than expected accrual, the RCT continued to recruit 
patients following the ‘cut ofF for data analysis for this thesis. It is therefore likely 
that the allocation of patients to each randomisation group will become more 
balanced as the trial continues to recruit.
Table 4.1 Recruitment and use of randomisation envelopes for patients in each of 
the Randomisation groups per hospital Centre._________ _________________
Hospital Centre No. of patients 
recruited
No. of 
completed 
Randomisation 
blocks used
Randomisation 
envelopes 
remaining in block
Centre 1 85 2 5
Centre 2 3 0 27
Centre 3 14 0 16
Centre 4 0 0 0
Importantly, the imbalance of patients allocated to each group was not sufficient 
to affect the power of the study to refute the primary hypothesis. However, 
several of the secondary endpoints were not statistically significant, thus 
recruitment continued after the data analysis for this thesis, in order to ensure the 
power of the study.
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4.2.3 Baseline Comparison of the Two Randomisation Groups
The two-randomisation groups were equivalent for comparison in this RCT for 
age, pre-operative tumour stage, frequency of use of neo-adjuvant 
chemotherapy and POSSUM scores. Intraoperative factors such as operation 
duration and blood loss were also comparable. Interestingly, the two groups 
were not comparable for all of the factors on the HRQoL. The scores for social 
function were significantly different. The impact of this on the primary outcome is 
discussed in section 4.3.6.
It could be argued that having a heterogeneous group of patients (pancreatic and 
oesophago-gastric) is not ideal. The operations are obviously different, but the 
duration of the operation, the magnitude and complexity of the surgical 
procedures and the risk of post-operative mortality and morbidity are considered 
comparable [19, 39, 153].
The differing types of surgical procedures used are only relevant if the baseline 
groups are not similar for the distribution of these procedures. The study by 
Heslin et al (1997) [503] had a disproportionate number of oesophageal and 
pancreatic patients in each arm of the study. The difficulty is that these 
differences tend to become apparent only after closing the study and analysing 
the results.
Within each arm of the current RCT, there were no differences between the 
numbers of patients undergoing each procedure in each randomisation group. 
Therefore, the groups were considered sufficiently equivalent for meaningful 
inferences to be made.
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Baseline Comparison of the Randomisation Groups for Pre-operative
Nutritional Parameters
No differences were found in the pre-operative nutritional status of the enteral 
nutrition group compared to the standard group. This section will discuss the 
results from the current study of the pre-operative nutritional parameters in line 
with the previous literature in this area.
The total study sample had a pre-illness median Body Mass Index (BMI) of 27.5. 
The median BMI at presentation had dropped to 25.4. This is not surprising, as 
36% of the total study sample had lost more than 10% of their pre-illness weight 
in the 3 months prior to surgery. This is similar to findings by Windsor and Hill 
(1988)[282] who reported that 45% of cancer patients in their study had lost over 
10% of their pre-illness weight at presentation. The extent of the percentage 
weight loss and the timescale of the percentage weight loss are important. 
Studely (1936) [9] reported that surgical outcome was negatively influenced by 
increasing pre-operative percentage weight loss. This was also the finding of Roy 
et al (1985) [222] who concluded that a weight loss of >6 % of usual body weight 
more accurately predicted morbidity and mortality in surgical patients than other 
prognostic indices.
Based on the percentage weight loss, the current study sample had a weight 
loss, which was clinically relevant. As discussed in section 1.3, weight loss per 
se represents changes in body composition, with all body stores, i.e. glucose, fat, 
fluid and protein stores being affected. Unlike glucose and fat, there is no inert 
protein store. Therefore, any depletion of body protein stores will originate from 
lean body tissues and progress to altered organ function. This alteration, will 
become apparent at certain percentage weight losses [236] (table 1.4.1).
The use of different criteria to define malnutrition, as well as the inclusion of 
patients with differing stages of disease prevents the true comparison of the 
nutritional parameters between studies. Any future study should use nutritional 
parameters that are reproducible and reliable to aid comparisons between 
studies. Several studies [8 , 94, 176-178, 181] have reported the incidence of 
malnutrition in UGI cancer. Two studies [177] [178] used unintentional 
preoperative weight loss to define malnutrition. These two studies report an
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incidence of malnutrition of 57% and 58% respectively. If the same criterion was 
used in the current RCT sample, a similar incidence is evident, 51% (N=49). 
Table 4.2 shows the pre-operative nutritional data from this RCT in line with 
analyses performed in other clinical nutrition trials.
When interpreting the incidence of malnutrition it is important to remember that 
all patients in the current study had a stage of disease that was potentially 
curative by surgery. This is not the case in several other studies, which included 
patients receiving both palliative and curative intent surgery and modalities.
For example, the DeWys (1980) [176] study examined patients when their 
disease was beyond the scope of surgery. This is important, as the stage of 
disease has been reported to be one of the factors contributing to protein calorie 
malnutrition [180].
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He 4.2 A comparison of the baseline results of the incidence of malnutrition of this R<ZT compared with previous published studies
Author (year) Criterion used to Define 
Malnutrition
Incidence of Malnutrition in 
studies of Gl cancer patients
Incidence of malnutrition in current study 
if previous studies criterion is used
Persson et al (1999) [8] Subjective Global 
Assessment (SGA)
UGI cancers 80% Not recorded in this RCT
DeWys etal (1980) 
[176]
Weight loss > 5% in 6  
months
Pancreatic cancer 83% 
Oesophageal cancer 87% 
Gastric cancer 65%
Total sample 51%
Riccardi and Allen 
(1999) [94]
10% weight loss over 4 
months
UGI cancers 70% Total sample 36% (over 3 months)
Daly et al (2000) [177] Involuntary weight loss Oesophageal cancer 57% Total sample 51%
Martin etal(1999) [178] Involuntary weight loss Oesophageal Cancer 58% Total sample 51%
Rey-Ferro ef al (1997) 
[181]
Nutrition Risk Index (NRI) 
less than 97.5
Gastric Cancer 63% Total sample 18.5%
Thoresen et al (2002) 
[184]
Involuntary weight loss 
Weight loss > 10%
BMI >18
All Gl cancers 83% 
All Gl cancers 63% 
All Gl cancers 30%
Total sample 51.1% 
Total sample 36% 
Total sample 5.2%
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As mentioned, 51% of the sample population had lost weight pre-operatively. 
The reason for this was presumably due to the reported reduced calorie intake 
(1450 calories/day) prior to admission. Eighteen patients (18.8%) from the study 
population were eating less than 1000 calories per day. The recommended 
calorie intake (based on Elwyn (1980)) [572] is 30 calories per kilogram /day. 
The total study population was consuming less than the recommended calorie 
intake per day as measured by this recommendation.
Similar results were evident for protein intake. The mean protein intake for the 
total study population was 58 grams per day. This equates to 0.8 g protein per 
kilogram per day. The recommendation for non-hypermetabolic patients is 1 
gram per kilogram/day. Forty patients (42%) of the total study population were 
eating less than 50 grams protein per day. This is clinically relevant as a study by 
Shaw-Stiffel (1993) [344] suggested that reduced oral intake prior to surgery may 
lead to increased risk of complications. This correlation was not performed for 
presentation in this thesis, however, as this was not one of the objectives.
This study concluded that 25% of pre-operative patients had a reduced appetite, 
which is in line with the study by Murray (1979)[188]. One criticism of recording 
appetite is that it is very subjective. In this study patients were asked to recall 
how their current appetite compared to their usual appetite. The author 
appreciates that difficulties in recollection could have skewed the results. 
Nevertheless, it is still interesting that 25% of the total study population had 
anorexia.
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4.3 Discussion of Outcomes
Upper Gl surgery is associated with a high morbidity [19, 39, 153] which may be 
influenced by the patients’ physiological condition. Patients undergoing major 
UGI surgery are often malnourished prior to admission for their surgery [177] 
[178]. The patients in the current study were generally malnourished reflected by 
a median pre-operative weight loss of 6.3%.
In section 1.3 the deleterious effects of malnutrition on physiological condition 
were discussed. Pre-existing malnutrition deleteriously affects surgical outcome 
[5, 7, 10, 11, 170, 327, 336-338]. It could therefore be assumed that patients in 
the current RCT had a problematic post-operative recovery due to malnutrition. 
Logically, the use of nutritional support, which is designed to prevent and correct 
nutritional deficiencies and malnutrition [40], should optimise surgical outcome. 
However, few clinical nutrition trials have provided a consensus on whether the 
use of nutritional support post-operatively is beneficial to clinical outcome.
Patients undergoing major UGI surgery tend to have a long period of nil by 
mouth before recommencing ‘adequate’ oral diet [70]. This is because of 
reduced satiety and impaired gastric function [70]. Ryan et al (2006) [70] 
suggested that the use of EEN via a NCJ after UGI surgery allows time for the 
patients’ appetite to recover, ensuring adequate nutritional intake is delivered. 
This is particularly important in a patient who develops complications, which can 
markedly delay the onset of oral intake.
However, surgeons may argue that the use of a NCJ purely to provide adequate 
nutrition whilst appetite improves or in the event of a patient developing 
complications is not justified. This is especially so, when the clinical efficacy and 
effectiveness of EEN is not proven in the context of a RCT. Many surgeons 
prefer to use TPN in the surgical setting. This is because of lack of robust clinical 
trials and fear of EEN related adverse effects, inducing complications [532].
Studies indicate that EEN is more ‘physiological’ than TPN, preserving GIT 
function and preventing GIT structural alterations induced by starvation and or
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injury [621-625]. Alongside, EN is feasible immediately after major surgery, as 
small intestinal peristalsis recovers 6 -8  hours after surgical manipulation [384], 
the direct passage of nutrients in the GIT lumen early after major surgery or 
injury, increases splanchnic blood flow and stimulates Gl immune system all 
aiming to assist in improving clinical recovery [621-625]. EN is also less 
expensive than TPN [40]. Yet, as detailed in section 1.5, once again these 
benefits are not reflected in a consensus for the use of EEN.
The current RCT aimed to compare standard post-operative management with 
the immediate delivery of early enteral nutrition via a needle catheter 
jejunostomy within the framework of a pragmatic RCT. The next section will 
provide a summary of the main outcomes of the current RCT and then discuss 
these findings in the context of previously published work.
4.3.0 Summary of Outcomes 
Primary outcome
This analysis of this trial has indicated that:
1 Early Enteral Nutrition delivered via a feeding jejunostomy within 12-24 hours 
post-operatively to patients undergoing major resection of upper gastrointestinal 
malignancy, may lead to a reduction in length of hospital stay as compared to 
patients who continued to receive standard hospital management. The reduction 
of LOHS was 4 days with the use of EEN.
Secondary Outcomes
1. Early Enteral Nutrition may reduce the development of major complications. 
The most noticeable reduction was in infective complications.
2. Early Enteral Nutrition may lead to fewer readmissions between discharge and 
6  post-operative weeks, and between 6  weeks and 1 2  weeks, as compared to 
the standard group.
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3. Early Enteral Nutrition was safe and feasible for patients undergoing major 
resection surgery.
4. The Early Enteral Nutrition group appear to have a marked improvement in 
nutritional status, as compared to the Standard group, post-operatively.
5. So far, this analysis has indicated that no statistically significant differences 
between the two groups exist, for health-related quality of life.
6 . Early enteral nutrition may provide a potential cost saving of £1,241.06 
(£828.36-£5,315.40) per patient if delivered within 12 hours of leaving the 
operating theatre, compared to patients who received standard post-operative 
management.
269
4.3.1 Primary outcome
Early enteral nutrition delivered via a feeding jejunostomy within 12 hours 
post-operatively to patients undergoing major resection of upper 
gastrointestinal malignancy, may lead to a reduction in length of hospital 
stay when compared to patients who received standard hospital 
management
This early analysis has indicated that the use of EEN maybe superior to STD 
management in improving a patient’s clinical outcome as defined by a shortened 
LOHS.
The Per Protocol analysis concluded that the median LOHS for the STD group 
was 20 days (14.75-28 days) compared to 16 days (IQ range 13-22 days) in the 
EEN group. The difference between the groups was statistically significant 
(11=822.50, p=0.021). The intention-to-treat analysis concluded the same median 
difference, but the results were approaching statistical significance (U=999.8;
p=0.068).
Several EN versus STD management RCTs have used LOHS as a primary 
outcome measure. Of these, five have also concluded that EN reduced LOHS 
[12, 15, 16, 483, 518]. These studies, however, failed to reach statistical 
significance, presumably due to their small sample sizes. Thus, to date the 
literature for true comparison is sparse. There is one meta-analysis (studies 
N=11) of EN versus STD management, comparing patients undergoing all types 
of major Gl surgery. This analysis, Lewis et al (2001)[17] concluded that EN 
reduced LOHS by 1 day. Therefore, the findings of a 4 day reduction in LOHS is 
four times that found in the meta-analysis and has major implications for patient 
care and the NHS. There have been no Cochrane systematic reviews to date in 
this field.
4.3.1.1 The Definition of Length of Hospital Stay
Definitions of outcomes are very important in clinical trials. Readers must fully 
understand what criteria were used to determine outcome measures. By clearly 
defining what criteria the investigator used, readers are then able to make their 
own interpretation of the results. The precise definition of LOHS was therefore
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vital. Collins et al (1999) [564] (page 255), defined LOHS as, ‘the time from when 
the patient underwent the index operation to when discharged home’.
This definition does not take into account that patients often remain in hospital 
for many reasons other for than surgical and medical indications. Currently in the 
UK, with separate funding streams for healthcare and social care, delays in 
agreeing social care packages can delay a patient’s discharge from hospital 
even when they are medically fit for discharge. Without taking the external 
factors that can affect LOHS into account, misleading results can occur.
It was for this reason that for the purpose of this RCT, LOHS was defined as the 
time from the index operation to when the patients were declared medically fit for 
discharge. This definition can also be criticised without robust discharge criteria 
being available. The discharge criteria for this RCT are presented in section 
2.1.6 .2.
To date, there remains no consensus for a definition for LOHS (Blazeby, J, 
personal communication, 2008). One clinical trial by King et al (2005) [626] used 
length of hospital stay as a primary outcome. A total hospital stay including post­
operative hospital stay, convalescence stay and readmission stay supported this 
as a secondary outcome. Any future clinical trials in this field should aim to report 
both methods of defining LOHS. However, it is important to note that this method 
may limited when conducting multicentred trials, as each institution may have 
differing administrative procedures and management strategies for bed 
management, for both pre and post operative stay, making comparison across 
institutions more complex.
LOHS can be affected by many factors, including age, pre-operative physical 
status score, intra-operative factors such as blood loss, and duration of time in 
theatre, type of surgical procedure and the presence of co-morbidities. These 
factors have all been associated with prolonged LOHS [565, 566]. For the 
current RCT, pre-operative demographic and operative factors were comparable 
at baseline. Likewise intraoperative factors were comparable at baseline (Tables 
3.4-3.6 ). Interestingly, there was a baseline imbalance for social function, one of 
the eight factors on the SF36. This imbalance could be very important when 
interpreting the primary outcome. The higher mean score in the EEN group may
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have contributed to the shorter hospital stay [627]. This will be discussed later in 
this section (section 4.3.6).
To summarise, the use of length of hospital as a primary outcome can be 
criticised. It can be considered to be subjective and open to the risk of observer 
bias. However, length of hospital stay was considered to be the most appropriate 
primary endpoint, for true comparison with the previous literature [12, 13, 17, 
503], when the trial protocol was developed in 2002. What is imperative is that 
researchers clearly outline the definitions of both primary and secondary 
outcomes used in clinical trials. This allows the reader to make inferences about 
the validity and relevance of the outcomes for implementation in their own clinical 
practice.
4.3.1.2 Readmission to hospital
The use of LOHS as a primary outcome measure can be criticised if patients are 
discharged back into the community with complications. Information on the 
number of hospital readmissions is essential to support the result of the 
differences in length of hospital stay. Any RCT that reports LOHS as a primary 
outcome should report the number of patients requiring readmission to hospital. 
It is clearly not beneficial for a patient to be discharged early from hospital, to be 
readmitted at a later date. The EEN group had fewer readmissions between 
discharge and 6  weeks (7.6%) compared to the STD group (14.3%); and also 
fewer readmissions between 6  weeks and 12 weeks (1.9% versus 4.8%). 
Despite not being statistically significant the findings are nevertheless relevant.
Readmission to hospital may have a profound psychological effect on patients, 
affecting their HRQoL. This RCT has demonstrated that the EEN group had 
approximately half the readmission rate than the STD group. If these figures are 
annualised, then the cost saving would be considerable to the NHS. To our 
knowledge, no other published RCT in UGI cancer patients undergoing surgical 
resection has reported the impact of EEN versus STD on readmission rates to 
hospital.
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4.3.2 Secondary Outcomes
Secondary Outcome 2: Early Enteral Nutrition may reduce the development 
of hospital acquired major complications when compared to patients who 
received standard post-operative management.
Upper Gl surgery has a high morbidity and mortality associated with it [19, 39, 
153]. Therefore, it is anticipated that a proportion of patients will develop major 
complications. It is not clear why certain patients develop complications and 
others do not. The development of multiple complications suggests that a health 
care organisation maybe providing an inferior service [564]. Collins et al (1999) 
[564] stated that patients who develop complications are more costly. Thus, any 
intervention that can reduce the development of complications is beneficial for 
patients and the healthcare organisation.
The current analysis of this RCT suggested that EEN reduced the development 
of major complications compared to the use of STD management in patients 
undergoing major resection for UGI cancer. The STD group developed three 
times more major complications in hospital, compared to the EEN group (1.64 
versus 0.54 respectively).
The reduction of major complications was particularly striking for infective 
complications with the EEN group developing significantly fewer chests and 
wound infections. Other RCTS have reported similar results [46, 312]. Alongside 
this the EEN group had improved wound healing rates, presumably related to the 
fewer wound infections. Four patients (9.5%) in the STD group compared to one 
patient (1.9%) in the EEN group had impaired abdominal wound healing, 
characterised by a gaping abdominal wound of more than 3 cm. The results of 
this study are similar to findings by Schroeder et al (1991 )[16].
Anastomotic healing rates were also remarkably different for the two groups, with 
the EEN group having improved anastomotic healing. This supports the findings
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of four studies [68, 532, 533, 628] and one meta-analysis [17] which suggested 
that a jejunal infusion of EEN benefits anastomotic healing
To our knowledge, this analysis is the largest series of patients comparing EEN 
versus STD management in patients undergoing major resection for UGI cancer, 
to suggest that EEN maybe beneficial in anastomotic healing rates. The 
reduction in wound healing problems in particular anastomotic healing has major 
implications. Anastomotic leaks are a major concern for surgeons and patients, 
because of the increased LOHS and mortality associated with them.
Gastric emptying was improved in the EEN group. This was surprising as a study 
by Martignoni et al (2000) [424] concluded that EN delivered via a jejunostomy 
into the small intestine decreased gastric emptying. However, the numbers are 
small 7.3% (3/42) versus 1.8% (1/56) so meaningful conclusions are hard to 
draw.
Complication Ratio
McAleese and Oldling-Smee (1994) [567] introduced the concept of complication 
ratios. Complication ratios refer to the ratio to which LOHS will be increased if 
complications are developed by a patient. McAleese and Oldling-Smee stated 
that the development of any major surgical complications increased a patient’s 
average LOHS by 3.3 to 4.4 times, to that of a routine hospital stay. The use of 
complication ratios were used in the current RCT to compare the severity of the 
complications developed in each randomisation group. The results of the current 
RCT suggest a lower overall complication ratio of 1.39 for the EEN group and 
1.55 for the STD group (table 4.3).
There are several possible explanations:
1. The complications developed were more severe in the study by McAleese and 
Oldling-Smee [567]
2. The LOHS were typically shorter in the McAleese and Oldling-Smee study 
[567] therefore the complication ratio appears higher.
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3. The definition of LOHS used in the McAleese and Oldling-Smee study [567] 
was not clear. It is assumed that the authors used the actual LOHS, which, as 
discussed, can be misleading.
The differing outcomes of the complication ratio for the current study and the 
study by McAleese and Oldling-Smee [567] demonstrate the importance of 
detailed reporting of outcomes. The failure to adequately define outcomes allows 
the reader to make inferences about the results. Having stringent definitions of 
what constitutes a complication ensures meticulous data collection, promoting 
reliability and validity of the study and its results.
Table 4.3 Comparison of Complication Ratios of the current study with the 
Complications Ratios published by McAleese and Oldling-Smee (1994) [567]
Type of Complication Standard Group 
Mean ratio 
(LOHS**)
Enteral Group 
Mean ratio 
(LOHS**)
McAleese and 
Oldling-Smee 
Ratios
All major complications 1.55 (24 .18) 1.39 (20.19) 3 .3-4.4
Infective Complications 1.50 (23 .46) 1.28 (18.6)
Wound Infection 1.66 (25.9) 1 .1 4 (1 6 .6 ) 2.43
Chest Infection 1.33 (20.8) 1.42 (20.6) 1.99
Non Infective complications 1.35 (21.1) 1.29 (18.7) 3.4
Delayed gastric Emptying 1.41 (22.1) 1.28 (18.6) 1.99
Pleural effusion 1 .81(28 .3 ) 1.66 (24.1) -
Chylothorax 0 (0 ) 1.4* (20.3) 3.4
Anastomotic Leak 1 .9 (2 9 .7 ) 0 (0 ) 1.88
Open Abdominal W ound 1.38 (21.6) 2 .45* (35.6) 1.99
Respiratory Failure 1 .6 (2 5 .0 ) 0 .96  (28.5) -
* Only 1 patient in this group, therefore interpretaltion is limited
** The figure in the brackets refers to the predicted LOHS that would occur if the 
complication w ere developed. T h e  LO H S used for the calculation of the complication 
ratios is the actual median LO H S  for the S TD  and EEN group patients who did not 
develop a complication
Complications present on the day of discharge
At the cut off for this early analysis, fewer patients were discharged with 
complications in the EEN group compared to the STD group, six patients 
(11.1%) in the EEN group vs. 16 patients (33.3%) in the STD group) (Chi 
square= 8.56; p=0.0001; Cl >0.0001-0.045). This is manifested in a trend
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towards improved HRQoL in the EEN group reported on the day of discharge. 
Discharging patients into the community with complications has implications for 
primary care, community nursing, extra prescriptions for drugs or dressings, and 
extra visits to General Practitioners. Also, surgical complications may lead to a 
patient feeling socially isolated, as they may be unable to return to their normal 
activities of daily living, being more dependent on carers.
To our knowledge this is the first indication that the use of EEN versus STD 
management in patients undergoing major resection for UGI cancer may reduce 
the incidence of surgical complications in patients being discharged from hospital 
into the community.
4.3.3 Mechanisms of Early Enteral Nutrition Induced Benefits
The current study so far, has demonstrated a surprisingly clear improvement in 
the primary outcome and a reduction in major complications in the EEN group. 
However, there is almost certainly scope for refining the nutritional intervention to 
achieve the maximum benefit for patients with minimal risk and cost. In order to 
do this, efforts must be made to understand the details of the mechanism 
whereby nutritional interventions have their effect. It is becoming clear that these 
mechanisms are complex, interlinked and interdependent, and require extensive 
future study, which will be discussed in the next section.
Correction of Malnutrition
The use of EEN in improving clinical outcomes may be as simple as correcting 
the deleterious effects of malnutrition, or preventing these deleterious effects 
from occurring. Studies have illustrated how malnutrition deleteriously affects 
surgical recovery [5, 7, 155, 170, 327, 337, 338] and how malnutrition has a 
harmful affect on physiological function (section 1.4.2). Nutritional support is 
considered the only evidence-based modality capable of correcting the effects of 
malnutrition [40]. However, this would then infer that the use of any method or 
route of nutritional support (i.e. TPN or EN) is comparable, but this is not the 
case (table 1.6.3).
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Enteral Nutrition and the Modulation of the Immunological Response
EN and TPN are not comparable in improving clinical outcome [52-58, 279, 359, 
361,381,441,474-476].
The superiority of EN centres on its role in regulating the immune response both 
systemically [49, 312-314, 371, 372] and intestinally via the stimulation of Peyers 
patch cells lining the small intestines [46, 47]. Coupled with this, EEN has a 
‘trophic’ action on the small intestines improving GIT integrity, aiming to limit the 
translocation of bacteria into the systemic circulation [49, 313, 314, 372] (Section 
1.5).
Therefore, the role of EEN in enhancing immunity may be central in improving 
clinical outcome. This may explain why the current RCT demonstrated a 
statistical significant reduction in infective complications in the EEN group.
Attenuation of the Catabolic Response
The current study used nitrogen balance as a surrogate marker of catabolism. A 
sub-section of the study population (N=44) had nitrogen balance studies. The 
difference between the groups was statistically significant; with all those in the 
STD group in a negative nitrogen balance on day 5 post-operatively compared to 
11 patients (47.8%) in the EEN group (Chi 22.2; p=0.01). Eight patients (34.7%) 
in the EEN group were in a positive nitrogen balance on day 5. This is 
comparable to other studies in surgical patients [377-379, 483, 629].
Nitrogen balance is considered to reflect metabolic stress [268] a positive 
nitrogen balance is thought to indicate an attenuation of the APR. A positive 
nitrogen balance suggests a reduction in catabolism, optimising the free 
nitrogenous substrates available for wound healing and tissue repair.
The mechanisms as to why the EEN group had improved nitrogen balances are 
not clear, as these were not explored in the current RCT. Next the theoretical 
exploratory mechanisms will be detailed, all of which are interlinked. However, it 
will become evident that further studies are needed to substantiate these 
theories.
277
The EEN group actually received nutrients via the GIT. The STD group did not 
Circulation of nutrients in the systemic circulation initiates a fed state response. 
Insulin production is increased, diminishing catabolism, and inhibiting 
gluconeogenesis. A study by Hochwald et al (1997) [378] supports this theory, 
demonstrating an approximate two-fold increase in insulin levels in patients who 
received EN when compared to patients who received TPN. This was mirrored 
by a protein sparing effect, an improved nitrogen balance and a significant 
impact on protein loss coupled with a reduction in endogenous fat oxidation. 
Thus patients had improved muscle and fat mass.
What this study does not explain, however, is why TPN failed to increase insulin 
production to the same degree; TPN would provide a systemic supply of 
nutrients, therefore should initiate a fed state response. This is apparent as 
insulin was produced in the TPN group in the Hochwald study. What is 
interesting is that insulin production and hence attenuation of the APR did not 
occur to the same degree as the EN group. Maybe enhanced insulin secretion 
requires a supply of nutrients via the portal vein from the GIT? Does the liver 
have a pivotal role in this mechanism? These possibilities require further 
investigation.
2. The role of EN has been described in modulating the inflammatory and 
immuno-modulatory response [373-376]. In the current RCT, the EEN may have 
suppressed the APR, as reflected by an improved nitrogen balance. [46, 47, 
373].
The current RCT did not demonstrate any differences between the two 
randomised groups for two markers of the APR, albumin and CRP. This supports 
the finding of the study by Moore and Jones 1986 [483] who also used EN 
versus STD management in patients undergoing major emergency trauma 
surgery and reported no difference in these markers. However Peterson (1988) 
[374] suggested that EEN did improve serum albumin and decreased circulating 
levels of CRP.
There are possible explanations for the different findings in the studies. Firstly 
the current study and the Moore and Jones 1986 [483] study compared EEN
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versus STD management. The Peterson 1988 [374] study compared EEN versus 
TPN.
Secondly, it may be that the current RCT did not collect the assays for CRP and 
albumin at the correct times to detect the sensitive fluctuation in these markers. 
With more frequent assays subtle changes may have been detected. The current 
RCT relied on routine blood sampling, as more frequent assays were not 
available due to cost pressures of the trial.
Fluid Balance
More patients in the STD group developed oedema than in the EEN group (N=15 
(36.6%) versus N=4 (8%) p=0.0001). The STD group had a slightly higher 
cumulative positive fluid balance in the first post-operative week (+ve 5123 mis) 
compared to the EEN group (+ve 4053 mis). As expected the STD group had a 
mean higher volume of intravenous fluids administered in the first post-operative 
week compared to the EEN group. The slight difference between the two groups 
for fluid balance does not explain the marked difference between the two groups 
for the development of oedema.
Oedema has long been associated with deleterious clinical outcome in particular 
its negative impact on wound healing [255], thus the development of oedema 
was taken as an important surrogate outcome. The reduced oedema in the EEN 
group may have occurred for several reasons.
1. The enteral feed per se ensured a constant delivery of calories and nitrogen 
substrates that may have enabled adequate protein synthesis to maintain 
adequate blood oncotic pressure. However, as discussed previously, this was 
not reflected by marked changes in the serum albumin levels for the groups.
2. The EN may attenuate the acute phase response as reflected by an improved 
nitrogen balance in the EEN group. The APR alters fluid balance [255], causing 
fluid and electrolytes to be conserved. This is mediated by an endocrine 
response involving several hormones, including anti-diuretic hormone, 
aldosterone and rennin-angiotensin II system [630] which all lead to an increase 
in total body fluid volume. Concurrently, the release of inflammatory cytokines
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and mediators such as IL-6  and TNF-alpha, act as vasodilators, increasing 
capillary permeability. The net result is increased fluid distributed into the 
interstitial space [255], the magnitude of which is proportional to the extent of the 
stress stimuli.
The RCT concluded that the groups did not have a markedly different fluid 
balance for the 1st post-operative week. However, both groups had a positive 
cumulative balance exceeding 4 litres. Studies have illustrated that optimal fluid 
balance is essential in post-operative surgical management [255, 631]. However, 
the fluid balance management of surgical patients is challenging.
The prescription of intravenous fluids tends to be the responsibility of the pre­
registration house officers (PRHOs). The PRHOs will typically prescribe fluids 
based on the fluid balance chart, which is dependent on nursing records and 
documentation. The optimal prescription of fluids is dependent on a clear 
understanding of fluid balance by the prescribing doctor. The types of fluids used 
are critical, as the choice of colloids or crystalloid can radically influence clinical 
outcome [255, 632].
The issues surrounding the challenges of post-operative fluid management were 
highlighted in a survey by Lobo (2002) [631]. He concluded that current peri­
operative fluid and electrolyte management in the UK is suboptimal. With only 
16% of Consultants reporting that they felt their PRHOs had adequate 
knowledge in fluid management. As a consequence, only 30% of Consultants felt 
that postoperative patients received the appropriate amounts of water, sodium 
and potassium.
What is important is that fluid management needs to have more detailed 
attention and priority in the management of the surgical patients by clinical staff 
of all grades.
Prevention of Hyperglycaemia
A study [213] concluded that following surgery an insulin resistance type 
syndrome (similar to that seen in Type II diabetes) occurs, in the first few days
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post-operatively. Therefore the delivery of exogenous glucose (via nutritional 
support) can accentuate an already elevated blood glucose level. This may 
increase the likelihood of infections and provides a sub-optimal condition for 
wound healing.
Supporting this theory are two studies which have shown an increased 
complication rates in patients who received TPN [469, 470]. It has been 
previously discussed that patients who receive TPN have a lower production of 
endogenous insulin when compared to patients who received EN [378]. Coupled 
with this, TPN infusions tend to have a higher glucose load compared to EN, 
which may accentuate blood glucose levels.
The glucose delivery for the current study was slow as the EN was started at 10- 
20 mis and increased by 10 ml/hour every 12-24 hours, with the aim of delivering 
full nutritional requirements by day 5 post-operatively. Therefore, it is assumed 
that the concentration of glucose delivered was not excessive in the first 48-72 
hours. However, this study did not monitor blood glucose or insulin levels, so this 
cannot be confirmed.
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Secondary Outcome 3:
EEN was safe and feasible for patients post-operatively as demonstrated 
by no measurable differences between the two groups in terms of the 
development of minor complications.
4.3.4 Feasibility of Enteral Nutrition
The use of EN in the immediate post-operative period is often blamed for the 
increased reports of nausea, vomiting, abdominal distension, cramps and 
diarrhoea often seen in post-operative patients. Several studies [64, 6 6 , 70] [65, 
69, 358, 524] have shown that EN is not responsible for these symptoms, 
moreover, these complaints do not interrupt the delivery of EEN.
This was the finding so far of the current RCT. The number of patients who had 
uninterrupted enteral feeding in the 1st week in the current RCT was 85.2% 
(N=46). The results of this RCT are presented in line with previous studies in 
table 4.4.
Table 4.4. The number of patients who had uninterrupted enteral feeding in the 
current RCT as compared to the previously published studies _______________
Uninterrupted Feeding 
for the 1st week post­
op
Comments
This RCT 8 5 .2 (1 4 ) NCJ Feed commenced at 10ml/hr 
increased slowly* over 5 days
Biffi et al 
(2000)[64]
98.8 (79) NCJ Feed commenced at 15ml/hr 
increased over 5 days
Ryan et al 
(2006)[70l
92 (13) Colorectal patients
Braga et al
(2002)r66i
70 (455) NCJ Feed commenced at 15ml/hr 
increased slowly
Chin et al 
(2004)[65]
80 (64) -
Sarr (1999)[69] 85 (425) Used NCJ
Smith
(1985)f358]
56 (14) Foley catheter
DeGottardi[524] 82 (18) N =26 developed catheter related 
complications
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Jejunostomy Tube related Complications
The incidence of complications attributed to the needle catheter jejunostomy 
(NCJ) was 0% (N=0) in this early analysis of the current RCT. Other studies have 
reported the incidence of complications to be 0-40% [63-75]. The current RCT 
used the Fresenius freka NCJ that was inserted by one of the surgeons who 
conducted the main resection. The surgeons all reported that the zero 
complication rates were attributed to the technique of insertion of the NCJ. 
Therefore, the same dedicated surgeons using the same skilled technique was 
responsible for the very low complication rate.
However, this theory is refuted by one published cohort study [65]. This study by 
Chin et al (2004) had a complication rate of 12.9%. They used a dedicated 
surgeon for inserting the NCJ. DeGottardi (1999)[524] commented that it is the 
meticulous skilled insertion techniques and not just the use of a dedicated 
surgeon that was required to produce a low jejunostomy complication rate.
The type of feeding tube is also vital. As presented (table 1.6.6) there are a 
variety of tubes used in clinical studies, all with varying complication rates. Three 
studies [488, 503] [358] reported to use a Foley catheter as the jejunostomy. The 
reason why is not reported. Likewise it is not reported what the Foley catheter 
was manufactured from. This is important, as evidence suggest that the material 
used to manufacture the tube can cause differing rates of complications with the 
tube [633-635]. What is important to consider however, is that the choice of 
feeding jejunostomy is crucial and that it may be a major factor in the 
development of complications?
The insertion and type of the NCJ is not the only factor associated with the 
development of complications. The use of ‘aggressive feeding’ such as using 
high rates to initiate the enteral feed, coupled with the rapid increase in rate of 
the feed; along with the osmolarity of the feed are all important.
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Delivery of Enteral Feed
Previous studies have demonstrated that the use of ‘aggressive feeding’ caused 
serious and even fatal complications in patients feed via a jejunostomy [509-511, 
513-515]. The too rapid delivery of EN coupled with the overzealous use of 
opioids, which slow Gl peristalsis, [369] could lead to increased intra-abdominal 
pressure and exacerbate Gl oedema, reducing splanchnic blood flow increasing 
the likelihood of gastrointestinal ischaemia.
More studies are required to ascertain the nutritional requirements of surgical 
patients. It must be that differing requirements for nutrition are required at 
differing stages post-operatively. The equations by Elwyn (1980) [572] should be 
updated to reflect changes in surgical practices over recent decades.
The volume of EN delivered is vital. A study by Watters et al (1997) reported that 
EN delivered to nutritional requirements within 3 days in major surgical patients 
lead to respiratory problems secondary to increased abdominal distension. The 
maximum percentage of nutritional requirements achieved by the EEN group in 
the current study was 71.2% occurring on day 4 post-operatively.
The use of hyper-osmolar enteral feed has been reported as possibly 
contributory to both the intolerance of enteral feed and also the development of 
complications. Hyperosmolar feeds may cause a subsequent movement of both 
fluid and electrolytes into the Gl lumen, leading to a possible increased intra­
luminal pressure with its associated risks.
Feed aspiration is a potentially serious complication. No cases of aspiration were 
seen in the EEN group. The volume of NG aspirates was similar for both the 
enteral and standard group. It therefore seems logical that the slow and 
incremental delivery of enteral nutrition as used in the current RCT may have 
helped to prevent the accumulation of fluid in the stomach decreasing the risk of 
aspiration from occurring.
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Gastrointestinal Function
Clinicians often assume GIT function by the detection of bowel sounds, the 
passage of flatus, and whether a patient has passed stools. The auscultation of 
bowel sounds is a rather crude method. Much work has focused on correlating 
bowel sounds with small bowel motility [404-414, 636]. To date there is still little 
consensus that bowels sounds actual reflect GIT motility.
Studies as detailed in section 1.5.1.5 illustrate that small intestine motility is 
evident 6 -8  hours after surgical manipulation [384], however, this is not 
considered in clinical practice. Therefore, the qualification of GIT motility would 
undoubtedly prevent patients suffering from prolonged ‘nil by mouth’. There are 
few non-invasive techniques available to quantify gastrointestinal motility.
The use of ultrasound imaging for the quantification of GIT motility has not 
reportedly been used in clinical or research practice. By using USS imaging in a 
sub section of patients in this RCT, it is apparent that EEN stimulates GIT 
activity. The EEN group had more peristaltic waves per minute on day 4, day 5 
and day 6  post-operatively compared to the STD group. The difference between 
the groups reached statistical significance on days 4 and 5. This is a very 
exciting development and will be the subject of further investigation.
This study has shown that the use of EEN as compared to STD management 
stimulates GIT motility, which is also illustrated by a faster transit time and 
passage of flatus and stool in the EEN group. Several studies [12] [6 8 , 415] have 
also concluded that EN stimulates the passage of stool and flatus, as compared 
to STD management. The mechanisms governing the increased Gl motility in the 
EEN group are complex. The next section will detail the theoretical reasons as to 
why the EEN group had increased GIT motility.
Firstly, the delivery of nutrients (via the EN), directly elicit a fed state motility 
response [418], characterised by propulsive segmental peristaltic movements 
(section 1.5.1.5).
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Secondly, the increased small intestinal motility in the EEN group may have 
been secondary to the improved distribution of fluid in the EEN, indicated by the 
fewer cases of oedema discussed previously. Research has shown that a 
positive fluid balance and presence of oedema negatively affect Gl motility [570].
Thirdly, Mythen (2005) [383] concluded that PGID occurs in 90% of surgical 
patients. PGID is characterised by the inhibition of propulsive bowel motility. It is 
not however apparent from the paper by Mythen (2005) [383] what method of 
nutritional support was used, if at all. Likewise, if nutritional support was used, it 
is not clear whether it was enteral or parenteral nutrition. This is imperative as 
the use of differing types and routes of nutritional support affect the GIT in 
differing ways.
As discussed in section 1.5.1.5 the pathogenesis of PGID stems from the 
activation of a cytokine cascade by the surgical injury. The cytokines activate the 
enteric nervous system and the autonomic nervous system to alter Gl motility, 
reducing Gl transit time [384, 393, 394]. Coincidentally, the delivery of EEN 
dampens the GIT inflammatory response [46, 47, 473] as detailed in section 
1.6.7. Therefore, the role of EEN in promoting GIT motility may be cytokine 
mediated.
Pain
Pain scores were comparable in both groups for the first 4 days post-operatively. 
However, on day 5 the enteral nutrition group had lower pain scores compared to 
the standard group (t=2.655 df 95; p=0.009). On day 6 , the difference in pain 
scores was approaching significance (t=3.970 df 72; p=0.053). This difference 
may have been attributed to quicker resumption of bowel function in the enteral 
nutrition group.
Nausea and vomiting
Nausea and vomiting have been considered as symptoms of delayed 
gastrointestinal motility that occur post-operatively. Traditionally, in clinical
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practice there is a view that patients who receive EEN have higher risk of nausea 
and vomiting. Several studies have refuted this concept [13, 14].
In this analysis, 15 patients (35.7%) in the standard group reported at least one 
episode of nausea in the 1st 7 post-operative days, compared to 15 patients 
(27.3%) in the enterally fed group (Chi=8.82; p=0.04). Vomiting in the first week 
occurred in 10 patients (23.8%) in the standard group and 8  patients (14.5%) in 
the enteral nutrition group (Chi=10.89; p=0.01). The incidence of nausea is 
higher than the incidence of vomiting. This is expected as nausea is subjective 
and often precedes vomiting.
The incidence of nausea and vomiting in the current RCT was higher when 
compared to a study by Biffi et al (2000) [64]. They reported that 1.25% of their 
patients developed nausea and vomiting. A similar cohort study reported that the 
incidence of nausea and vomiting was 15% [69]. These studies should be 
interpreted with caution. Nausea and vomiting is caused by many others factors 
such as inadequate gastric decompression, inappropriate use of antiemetics, 
analgesia and anesthetic are also contributory. It can be assumed that gastric 
decompression was similar for the two groups as similar volumes of nasogastric 
aspirates were recorded for the first 5 days. Likewise the use of analgesia and 
anesthetics are assumed to be similar in both arms of the current study as the 
same anesthetists are used for UGI resections.
It can be concluded that enteral nutrition does not accentuate nausea and 
vomiting as discussed in the previous literature.
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Secondary Outcome 4: There were marked improvements in the nutritional 
status in Early Enteral Nutrition group post-operatively.
4.3.5 Improvement in Nutritional Status
As discussed in section 1.4, starvation and malnutrition lead to deleterious 
effects on physiological outcome. Keys et al (1950) [236] illustrated that 
depletion of body proteins will progress to impaired organ function.
This analysis suggests that the EEN group lost less weight, lost less muscle 
mass and function as compared to the STD group. This may well explain the 
marked reduction in the development of major complications seen in the EEN 
group. The next section will discuss the nutritional parameters in the context of 
the previous literature.
Weight Loss
All patients in this analysis lost weight post-operatively; the mean percentage 
weight loss was 4.2% from pre-operative stage to discharge. However, the EEN 
group lost less weight compared to the standard group (3% versus 6.2%) from 
pre-operative stage to when discharged from hospital. This was similar to the 
findings of the several studies [15, 16, 357, 358] [70, 291, 354-356] with the 
exception of the study by Watters et al (1997) [14] who refuted the fact that 
enteral nutrition post-operatively maintains the weight of post-operative patients.
These studies all had a calorie intake of 1138-1400 from the feed per day, which 
is comparable to calorie intakes, seen in the current RCT. Interestingly, none of 
these studies reported the incidence of oedema in the randomised groups. If 
weights were adjusted for the oedema, with dry weights reported the STD group 
might actually have lost more weight.
Feeding the Obese Surgical Patient
Forty-four percent of the sample was overweight or obese. This is similar to the 
series of UGI surgical patients reported by Ryan et al (2006) [70]. Obese patients
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undergoing high risk surgery bring with them both technical difficulties for the 
surgeon as well as longer operating times, impairments in immune function, 
abnormal cardio respiratory function, metabolic derangements, abnormal 
homeostasis and higher incidence of post-operative complications [70].
Interestingly, obese patients tend to lose more weight peri-operatively. This is an 
interesting concept and really opposes the view held traditionally that obese 
patients can ‘live off their excess fat’ as a primary fuel after surgery and that in 
some way this is beneficial. Obese patients experience a block in both lipid 
metabolism and utilisation that causes them to use their lean tissues for the 
synthesis of glucose [637]. This predisposes an obese patient therefore to lose 
more lean body mass as compared to non-obese patients and therefore feeding 
is even more important in an obese or overweight surgical patient.
Muscle Mass and Function
Not surprisingly both groups had a reduced muscle mass and function post- 
operatively. However, the EEN group maintained more muscle mass (using 
MAMC) when compared to the STD group at discharge, 6  weeks and 12 weeks.
Similarly the EEN group maintained muscle strength (using HD) when compared 
to the STD group. The attenuation of muscle strength has been reported in 
several other studies [13, 14, 16, 361]. These studies used handdynonometry. 
One trial studied concluded that EN did not alter the strength of respiratory 
muscle function [14].
To date no published trials have studied both the loss of muscle mass using 
MAMC and function using HD to date. The theory being that the loss of muscle 
mass from peripheral muscle as indicated in this RCT may reflect loss of other 
types of muscle namely cardiac and other organ muscle. However this is merely 
hypothetical and would require further research to substantiate this theory.
The mechanism as to why the EEN lost less muscle mass and function, may 
pivot on the previously discussed theory, that EEN leads to increased production 
of insulin. Insulin is an anabolic hormone. It is antagonistic of the stress 
response, thus leading to possible attenuation of the stress response.
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Resumption of oral Intake
This study has clearly indicated that the EEN group had an increased oral intake 
post-operatively. By day 7 post-operatively, 19% (8/42) of the STD group and 
16.6% of the EEN group (9/54) had resumed oral intake. The whole EEN group 
appeared to progress to oral intake quicker than the STD group, with 60% of the 
EEN group and 22% of the STD group having oral diet by day 12. This is similar 
to findings from five studies [12, 16, 357, 360, 361] that have reported that EN as 
compared to standard management improved oral intake post-operatively.
As expected, the corresponding mean calorie intakes were higher in the EEN 
group throughout the study duration. However, both groups had an inadequate 
oral intake on day of discharge (1227 calories/day for the EEN group versus 812 
calories/day for the STD group). The reason for reduced calorie intake is unclear. 
Presumably, lack of confidence with resuming oral intake after surgical resection 
and apathy could be responsible.
Appetite was reduced in 62% of the total study population on discharge, with 
50% of the enteral nutrition group and 23.2% of the standard management only 
reporting good appetite on day of discharge. This corresponded with post 
discharge oral intakes remaining inadequate in both groups with 83% (N=35) 
standard group and 30% (N=16) enteral group eating less than 1000 calories per 
day.
This is similar to reports in another study, Ryan et al (2006) [70]. They reported 
that 60% of their patient’s undergoing UGI resection had suboptimal food intake 
on and following discharge.
There are several suggestions why this RCT has demonstrated an increased 
oral intake and appetite in the EEN group:
1. The possible attenuation of the Acute Phase Protein Response as illustrate by 
improved nitrogen balance in the EEN group. However, as discussed this is not 
supported by the visceral protein and CRP.
2. Jejunal feeding bypasses the stomach and therefore does not cause satiation.
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3. Reduction in complications and infections seen in the EEN group, increased 
appetite quicker than the STD group.
Number of Patients requiring Home Enterai Nutrition
On the day of discharge, 6  patients (14.2%) in the STD group required EN and
were subsequently discharged home on EN. In comparison, only 1 patient 
(1.8%) of the EEN group was discharged home on enteral feeding. The main 
determinant of the need for home enteral feeding (HEF) was nil by mouth 
secondary to anastomotic dehiscence. The reported incidence of HEF in this 
study corresponded with the findings of the audit by Ryan et al (2006) [70]. They 
reported that 14% of their patients required HEF via a NCJ. The authors 
commented that the use of HEF was essential to maintain optimal nutritional 
status post discharge. The series by Ryan et al (2006) [70] stated that as 60% of 
their patients had suboptimal oral intake on discharge then the use of 
jejunostomy feeding should be much higher. To date the evidence to suggest 
that the use of HEF in patients post discharge is clinically effective is limited. It 
would seem logical that if a patient is nil by mouth then the use of HEF allows the 
patient to be discharged home, as continuing to keep a patient who is nil by 
mouth because of a complication without adequate nutritional support is clearly 
unethical. The issue however of routine HEF for patients who are anorexic and 
unable to achieve adequate nutritional intake orally requires further study. In the 
current study one patient was discharged home on HEF as a supplement to oral 
intake.
To date, no other RCTs have reported the need for home enteral nutrition post 
discharge in patients undergoing major UGI resection for cancer.
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Secondary Outcome 5: There were no statistically significant differences 
between the two groups for Health Related Quality of Life; however there 
was a trend to an improvement in the Enteral Nutrition group.
4.3.6 Health Related Quality of Life
Measurement of HRQoL was considered to be an important secondary outcome 
for this RCT. HRQoL is a reflection of how a patient perceives his or her own 
health [579-589]. The personal burden of illness cannot be fully described by 
objective measurements of disease status alone. Studying HRQoL involves 
gaining information on several factors that influence well-being.
To date, the body of evidence suggesting that post-operative EN in surgical 
patients impacts on HRQoL is limited. To our knowledge this is so far the largest 
series of patients to compare HRQoL in patients who received either EEN or 
STD management in patients undergoing major UGI resection for cancer.
The SF-36 was used for a comparison of HRQoL. This questionnaire was 
chosen as it has been intensively used in previous studies and has been found 
to have high validity and reliability [590, 591]. The SF-36 asks about general 
health and offers response options (1=excellent to 5= poor).
Baseline Assessment of Health Related Quality of Life
The response rate for the baseline assessment of HRQoL was 81%. The 
reasons for not responding were not recorded. It is not unreasonable to assume 
that patients may not have completed their questionnaires for several reasons, 
including feeling anxious prior to surgery, feeling unwell or feeling overburdened. 
Not having access to the reasons for non-responding can affect the 
representation of the data set. Therefore once again it is important to state this in 
the reporting of this data in future publications, once again allowing the reader to 
make their own inferences on the validity of the outcomes
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For this early analysis, the groups were comparable at baseline for seven of the 
eight HRQoL factors pre-operatively. However, the scores for social function 
were not comparable. The mean score was higher in the enteral nutrition group 
as compared to the standard group (t=-2.15; p=0.035).
The difference between the two groups for social function may have occurred by 
chance, as the other baseline HRQoL factor scores were similar. However, this 
could alternatively be an important finding, as it could be argued that the higher 
baseline score for social function in the EEN group may have contributed to the 
difference between the two groups for the primary outcome. A study by Blazeby 
et al (2005) [627] concluded that pre-treatment social function in particular was 
significantly associated with length of hospital stay (p=0021). The authors 
suggested from their studies that a reduction in social function by 1 0  points 
(using the EORTC questionnaire) corresponded to an increase in length of 
hospital stay by 0.93 days. The difference in scores for social function for the 
current study was 63.3 (SD 29.4) in the EEN group compared to 48.3 (SD 34.4)) 
in the STD group (t=-2.15; p=0.035). Therefore the difference between the two 
groups is 15 points. This difference could correspond with a LOHS of 1.4 days, if 
the results of the study by Blazeby et al (2005) [627] are conveyed to the current 
RCT. However, it is important to note that the two studies are using different 
HRQoL questionnaires.
Nevertheless, baseline quality of life scores for the different factors have been 
demonstrated to be independently prognostic of clinical outcome [627]. It is 
therefore important that the data is presented and the reader is able to make 
inferences regarding the impact on the primary outcome.
Post-Operative Assessment of Health Related Quality of Life
Post interventional analysis of the health related quality of life scores concluded 
that overall, UGI resection for malignancy has a negative impact on HRQoL as 
indicated using the SF36. The mean values for both groups, for all factors 
deteriorated post-operatively. This should be taken into account during patient 
selection for UGI resection, as the results of the HRQoL scores for the current
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study suggest that HRQoL takes longer than 12 weeks to return to pre-operative 
scores.
Comparisons of the randomised groups indicate that there were no differences 
for seven of the eight factors. The only statistically significant difference between 
the two groups was for bodily pain. The EEN group had less bodily pain at 6  
weeks and 12 weeks post discharge when compared to the STD group. This is 
an interesting finding. Possible reasons for this could be that the EEN group had 
less pain as a result of improved wound healing and hence less scarring. Better 
absorption of oral analgesia may be a possibility. Alternatively, it could be related 
to the APR, but typically this should have returned to a pre-operative state by 6  
weeks post-operatively. Whatever the reason, this is an interesting finding and 
requires further investigation.
The SF-36 is a general health status questionnaire. It may be that it was not 
specific for patients with a diagnosis of cancer. Other disease specific 
questionnaires may have reported a difference in HRQoL. This may be the 
reason why the EEN group did not show more of an improvement in HRQoL as it 
is not unreasonable to assume that any intervention that reduced LOHS, 
reduced the development of major complications, and was generally well 
tolerated by the patients who received it, should have had a more positive impact 
on a patient’s HRQoL.
Frames of Reference
Fayers and Sprangers (2002) [638] illustrated that the response given to HRQoL 
questions is dependent on what the patient has in mind when they are due to 
respond. For example, “ What is your overall quality of life during the past 
week?” This seems a simple question, but the response is very much dependent 
on what the patient is comparing it to. The authors [638] suggested that patients 
may employ differing frames of reference, which result from responses that are 
derived from implicit comparisons with various peers groups or with themselves 
before they were ill. The patient may respond, “Compared to others (in hospital 
or in clinic) who are very ill I am doing very well”. Thus, it could be argued that if 
a patient is in clinic or just admitted for surgery and sees others around, they
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may well think they have a reasonably HRQoL. A study Fayers et al (2007) [639] 
concluded that patients varied in the comparisons they used when completing 
HRQoL questionnaires. The results showed that 1/4 of patients compared 
themselves to before they were ill; 1/4 compared themselves to healthy peers; 
1/3 compared themselves to I year ago. The authors reported that these 
proportions were similar at all time points for data collection. As expected these 
respondents had markedly different HRQoL scores. This is termed reference 
frame utilisation.
In many RCTs it may be expected that the reference frame utilisation will be 
randomly balanced across the study arms. The main consequence of this will be 
loss of efficiency because of extra variability that has been introduced.
For this RCT it may have been useful to ask the patients what they were basing 
their comparison on when they report for their HRQoL, in an attempt to try to 
understand the variations in responses for the two arms of the study. 
Investigators have used questions such as “ compared to others of your age” 
and used this a basis for completion of HRQoL questions [640]. Any future 
studies conducting should attempt to standardise the basis of patients when they 
are answering HRQoL questions.
Re-Calibration
Recalibration of individuals following a diagnosis of cancer may also be a reason 
why they were no differences reported between the two groups in terms of 
HRQOL. Re-calibration suggests that patients redefine for themselves what is 
important to them [641].
It may be that following a diagnosis of a potentially life threatening disease and 
the knowledge that a major surgical resection is required may produce an 
individual to reprioritize what is important to them. Therefore they may well 
present their HRQoL in a more positive way then they may have previously. A 
respondents’ response may be dependent of life experiences and contact with 
other people [641].
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Location of Patient
Criticisms could be made of studies if the patients in each randomisation group 
attend different clinics. This could be stated for a study that compared surgical 
intervention for UGI cancers with oncological treatments. These differing 
healthcare treatments would be delivered in differing clinical settings and would 
have implication for the results of HRQoL questionnaires. This was not the case 
in the current RCT as all patients were treated in similar clinical surroundings 
and attended the same clinics.
Contact with Research Team
It may be suggested that any improvement in HRQoL in an RCT in the 
interventional arm may reflect bias; attributed to the increased patient contact 
between a member of the research team and the patient. However, it is assumed 
that each group had the same number of follow up appointments and there were 
no additional visits or time spent with either the STD group or EEN group.
Positive Response to Treatment intervention
Another source of bias could be the awareness of the patient that the research 
team expected a positive response from the enteral nutrition and hence patients 
may have produced a more favourable response. Similarly, ‘resentful 
demoralisation’ may have occurred in the control group. As there were no 
statistically significant differences between the two groups for 7 out of the 8 
factors it is unlikely that these biases were an issue of concern in this RCT.
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Secondary Outcome 6: Early enteral nutrition provided a potential cost 
saving of £1,241.06 (£828.36-£5,315.40) per patient if delivered within 12 
hours of leaving the operating theatre as compared to a patient who 
received standard post-operative management.
4.3.7 Cost Benefit
Very few RCTs have been designed to compare the financial costs of using EEN 
versus standard hospital management post-operatively. The results of this RCT 
are in line with findings of a study in USA by Hedberg et al (1999) [530]. This 
study [530] concluded that EEN delivered via a needle catheter jejunostomy 
feeding tube within 1 2  hours of major surgery as compared to standard care led 
to a cost saving of $4,450 per patient in the early EN group in patients post major 
GIT resection. Other studies [12, 13] have surmised that delivering enteral 
nutrition lead to a 50% cost saving as compared to the use of STD management. 
These results are once again in line with the findings of this RCT.
Moreover, using EEN avoids the need to use TPN with its attendant risk and 
expense [40, 642]. In addition to providing a safe effective route for enteral 
nutrition and avoids the need for parenteral preparations and intravenous drugs 
reducing real costs in terms of nursing time and drug costs.
For simplicity, the current RCT calculated the costs of the differing LOHS and the 
costs of treating the significantly different major complications of the two- 
randomised groups. The rationale for this was that these two costs were the 
main differential cost drivers. In an ideal world, this study would have performed 
a rigorous cost analysis, taking into account absolute costs. This would have 
meant more sophisticated data collection of exact drugs (including dosages and 
frequency of administration), ward stay and level of dependency of care, exact 
costing of theatre time and care, and allied healthcare profession input. This was 
deemed outside the remit of this thesis and RCT. Coupled with this, today’s bed 
pressures with critical care beds, the actual location of a patient does not clearly 
reflect the level of dependency of that patient and the nature of the treatment that 
patients should be receiving.
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4.4 Methodological Issues of the Study
A research trial should have the aim of answering a specific question, however, 
practical constraints will limit the trials conduct. This next section will discuss the 
methodological issues and potential limitations of the current RCT.
4.4.1 Trial Design
‘The RCT is a very beautiful technique of wide applicability, but as with 
everything else there are snags. When humans have to make observations there
is always the possibility of bias”
CONSORT STATEMENT[560]
Sample size/Early Analysis
The sample size of this early analysis was 102 patients. It was intended to recruit 
160 patients but due to slower than anticipated accrual, it was necessary to 
perform an early analysis of the dataset to meet the submission deadline of the 
University for completion of the thesis.
Recruitment did, however, continue after the early analysis for this thesis, as 
funding was available, and the investigator was concerned that one of the main 
criticisms of previous studies has been inadequate sample size to yield adequate 
statistical power (i.e., 80% power), leading to Type II error. However, performing 
an unplanned early analysis of the dataset has several limitations [560,601]. 
These include:
1. An interim analysis should be planned and outlined in the initial trial 
protocol. The main reason for performing an interim analysis is usually for 
patient safety, but sometimes the analysis is used to check the potential of 
the study to be adequately powered to establish efficacy. The early 
analysis of the current RCT was not planned but was conducted for 
pragmatic reasons regarding the need to meet submission deadlines; the 
use of term ‘interim analysis’ was felt to be misleading.
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2. The analysis for this thesis therefore deviated from the scheduled analysis 
in the original protocol: consequently, there is a potential to weaken the 
confidence of the inferences drawn by from the RCT. The results of this 
analysis should be interpreted with caution, as there is a risk of the 
treatment effect being overestimated.
3. The results of an interim analysis should be kept confidential. This is to 
maintain clinical equipoise amongst the trial and clinical team. The PI and 
independent statistician (supervisor) were the only individuals to see the 
results of the early analysis before the data collection for the main study 
was finalised. The results of the early analysis were therefore not 
cascaded to the surgeons or clinicians involved in the trial: subsequent 
presentations to this group were based on the results of the fully 
completed trial only.
The MRC now recommends the appointment of a Data Monitoring and 
Ethics Committee (DMEC) as a way of limiting potential bias within the 
data management and analysis of a trial, particularly for large scale, multi­
centre trials. A DMEC would normally be composed of experts in the field 
who are external to the Sponsoring organisation: the main task for such a 
group is to supervise decisions about interim analysis and establish the 
stopping rules for a study based on safety or efficacy issues. A Data 
Monitoring Committee was not established for the current trial as this was 
perceived to be a small-scale clinical trial based in a single region when 
the protocol was first developed: however, in line with more recent 
developments in the quality assurance of trials, the establishment of a 
DMEC is recommended for future studies.
Stratification and Randomisation
Stratification for this RCT was by hospital centre. This is typical as multicentred 
RCTs often have separate randomisation blocks for each centre to limit the 
differing ward-based procedures in each centre affecting the trials’ outcome.
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As discussed in section 2.2, the goal of randomisation is to prevent bias. To be 
truly effective the design and conduct of the clinical trial should ensure that the 
investigator, the clinical team and the patient are unaware of the treatment group 
to which the next patient is assigned. If this can be predicted, bias is introduced.
Many trials of nutritional support have not described their allocation sequence or 
randomisation technique. Therefore judgments cannot be made regarding the 
quality of the trial. These trials should be interpreted with caution.
The current RCT used block-stratified randomisation. The reasons for this are 
presented in section 2.2.3.1. Critics may argue that the process for 
randomisation in this RCT was not sufficiently robust. The use of blocks of 30 
was decided after discussion with a statistician. In hindsight maybe smaller 
blocks would have been more appropriate. This would have possibly prevented 
the imbalance in the two groups. Concurrently, the use of remote telephone 
randomisation services may have been the optimum. Due to the relatively small- 
scale nature of the current RCT this was not considered practical or financially 
viable. Any future studies would use the resources now available for remote 
telephone randomisation as a result of the establishment of the Welsh Cancer 
Trials Unit [603]. This facility was not available at the time when this RCT was 
being developed.
Blinding and Placebo
Whilst developing this RCT, the feasibility of blinding and using a placebo were 
considered in the development of this RCT. Blinding would have involved the 
patients receiving placebo via an enteral feeding system, which would have 
needed to be specially manufactured to be opaque. Usually, the enteral feeding 
systems are transparent so ward staff and investigation team would see if enteral 
feed solution were passing through it. To commission specially manufactured 
feeding systems, would have been costly, and impractical for this trial.
In conjunction, the effect of the placebo itself could bring forth its own 
physiological affect, giving false results not typically associated with STD 
management. One study [12] used a placebo of saline versus enteral feeding.
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The placebo group had a high complication rate, which might have been 
associated with the lack of enteral feed or the use of saline.
Also the effect of using water as a placebo could have more serious 
complications. A study by Schloerb et al (2004) [516] from a series of patients 
who had jejunostomy inserted, and received water only, concluded that water 
may have predisposed the patients to a high risk of small bowel necrosis.
These reasons alone, suggest that the use of placebo requires careful 
consideration and for the current RCT, it was not considered beneficial or useful 
to use placebo. It was believed that by using a placebo, confusion would have 
occurred, as the aim of the hypothesis, was to compare STD management with 
EEN. Fundamentally, pragmatic clinical trials aim to mimic clinical practice, and 
rarely use blinding or placebos.
Patient selection
The sample of patients included in the current RCT had UGI cancer. This trial 
sample is considered to be homogenous. The meta-analysis by Lewis et al 
2001 )[17] compared patients with all types of Gl conditions, colorectal and UGI, 
including both benign and malignant disease.
Initially, the pilot RCT originally set out to recruit all Gl patients. It became 
apparent that the consent rate for the colorectal patients was reduced.
The poor consent rate was probably attributed to the need for the colorectal 
patients to receive their EN via a nasoenteral feeding tube, placed prior to 
surgery. The use of nasojejunal tubes rather than NCJ was considered 
preferential in the colorectal group, as the duration of nil by mouth in colorectal 
patients tends to be shorter than UGI surgical patients. It was therefore 
considered inappropriate to insert a percutaneous tube. The tubes were also 
inserted prior to surgery to allow migration of the tube into the small bowel with 
normal peristalsis present pre-operatively. Compliance with this procedure was 
poor as shown another study by Lia et al (2003)[643].
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Over recent years, the Enhanced Recovery after Surgery programme (ERAS) 
[529] suggested that patients having major colorectal surgery can be orally fed 
immediately post-operative, therefore the routine use of enteral tube feeding is 
no longer necessarily relevant.
Small amounts of demographic and surgical data were collected on the patients 
who did not consent to the RCT. This was to ensure that the study sample was 
not markedly different from the patients who did not consent. As presented in 
table 2.4.3 the baseline characteristics for the study sample and the non- 
consenters were not different. There were no statistical differences for age, 
gender and type of tumour between the randomised patients and the patients 
who declined consent. More patients, however, in the RCT had tumours that 
were stage III and IV compared to the patients who declined consent. Therefore, 
it could be said that the trial consisted of patients with more advanced disease. 
Many RCTs have not collected data on patients who decline consent. Therefore, 
it is hard to make any assumptions on the generalisability of the findings.
4.4.2 The Treatment Regimens 
Standard management
The STD management used in this RCT was defined as nil by mouth until the 
operating surgeon deemed the patients safe to tolerate oral diet and fluids. This 
was typically 7-10 days post-operatively. Whilst, this is based on routine post­
operative management, it is still ambiguous. Some surgeons allow their patients 
to drink sooner than others, but this was not considered problematic as patients 
often had a gastric decompression tube. Thus, the contribution of this fluid to 
actual nutrient intake was considered to be negligible.
As the trial evolved, the gastrectomy patients tended to commence oral fluids at 
5  days, once again dependent on the surgeon preference.
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These variations in clinical practice only reflect the complexity involved with 
conducting clinical trials of this nature. Once again, if meticulous randomisation 
procedures have been used, these variations do not alter the trial’s findings.
Early Enteral Nutrition
The current RCT used enteral nutrition delivered in to the jejunum. There is 
much confusion in the literature with many authors reporting simply the use of 
enteral nutrition. They have either not considered, or have considered but not 
appreciated, that differing modes, routes and types of enteral nutrition have 
potentially differing effects on clinical outcome. The timing of commencing 
enteral nutrition, the amounts of enteral nutrition delivered and for how long, are 
all relevant and need to be reported in detail.
Two studies, did however stress the importance of reporting the time of 
commencing, the route, the type, the duration and volume of enteral nutrition in 
clinical nutrition trials [447, 644].
Time of Commencement of Enteral Nutrition
It is apparent that there is variation as to when the nutritional support is 
commenced post-operatively, with some commencing EN immediately after the 
patient returns from the operating theatre [12] [13], some starting within 24 hours 
[503, 521] [16], and some commencing within 24-48 hours [357]. One study 
commenced EN after 3 days [358]. The delay in starting the EN is relevant.
A study [538], concluded that for EN to be beneficial it needs to be both early 
(within 12 hours) and delivered in sufficient amounts. The authors concluded this 
might be the reason why many trials do not show any benefit with early enteral 
nutrition. The time when enteral nutrition was commenced for this RCT was 
standardised. Enteral nutrition was routinely commenced between 6 pm and 8  am 
after the patients returned from the operating theatre.
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Feeding Regimen
For this trial, the feed rate commenced at a low rate and incremented slowly. The 
mean feed volume never exceeding 80mls/hour and 7 5 % of nutritional 
requirements as calculated using the Elwyn equation [572].
The results of the current RCT indicate that delivering feeds to achieve nutritional 
requirements may not be necessary and that lower rates of feed may be 
sufficient.
However, similar outcomes as seen in the current RCT, may be achieved with a 
lower volume of EN. Similarly, a better outcome may have been achieved with a 
higher volume of feed. Only by exploring the technicalities of delivering the EN in 
future studies will this be concluded.
Clinical staff need to be educated on the optimal method of enteral feeding. This 
education needs to emphasise the importance of:
1. Enteral nutrition should be commenced early, i.e. within 12 hours of the 
surgical procedure or sooner, if practical.
2. The initial rate of commencing the enteral nutrition needs to be low i.e. 10-20 
mls/hour.
3. The enteral feed rate should be increased slowly i.e. 10 mls/hour every 12 
hours as delivered in this RCT.
4. Enteral nutrition does not need to be delivered to achieve nutritional 
requirements. The current RCT did not deliver EN higher than 70% of calculated 
nutritional requirements [572].
5. The insertion of the jejunostomy requires a skilled surgeon with meticulous 
technique.
Type of Enteral Feed
There are many types of EN available on the commercial markets. These can be 
categorised into whole protein, semi-elemental (pre-digested), elemental, 
disease specific and immuno-nutrition feeds. It is not evident in several studies
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the type of feed that was used. The current CT used a whole-protein 
commercially prepared enteral feed for oesophageal and gastric patients, and a 
pre-digested semi-elemental enteral feed for pancreatic patients. Different 
brands were used in each centre, depending on that hospital centres enteral 
feed contract. All brands had comparable nutrient composition and were 
equivalent.
Duration of nutritional support given
The patients in the EEN group received EN for an average of 14 days. The EN 
was delivered until the patient was eating 3A of their calculated nutritional 
requirements. As a result there was variation in the duration of time the EEN 
group received the EN. This was not considered problematic and just reaffirmed 
the need to study these patients in a pragmatic approach, as variations are 
inevitable.
4.4.3 Complication Rates of the Sample
Most surgical procedures are aimed at reducing patient suffering and improving 
functionality. Therefore, the development of a surgical complication is an 
unexpected and unfavourable result. Complications are considered as an 
important reflection of quality of care [645].
The validity of reporting of surgical complications is dependent on two issues. 
These are the definitions used and the validity of the recording systems. These 
will be discussed in the following section.
Over recent years, surgical morbidity has been categorised into major and minor 
complications, but crucially ambiguity remains as to how these are defined [579]. 
Rampersaud et al (2006) [646] stated that ‘presently there is no clear consensus 
on definition of complication in the surgical literature’.
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As presented in section 2.1.6.2 (table 2.2.1), the current RCT had clear 
definitions for complications. These were based on definitions used in a previous 
enteral feeding study [338].
In 2004, Dindo et al (2004) [647] published a classification system for surgical 
complications. Complications were classified into five categories depending on 
the intensity of the treatment required for the complication. Future surgical 
clinical trials should aim to use such a classification system, in an attempt to 
standardise the repoting of complications. This will improve the comparison of 
the incidence of complication rates across institutions. This is considered a 
common problem in surgical research at present [647] [645, 646].
The reporting of complications in clinical trials can therefore be criticised. It is for 
these reasons that the incidence of major complications was not chosen as a 
primary outcome, unlike many other clinical nutrition trials [12, 14, 503].
The current RCT used a prospective data collection for recording of the surgical 
complications. This ensured they were recorded as they developed, ensuring all 
complications were recorded, which was considered essential to gain an 
accurate incidence of all complications. The use of retrospective data collection 
for monitoring complications is dependent on stringent documentation in medical 
and nursing records, and reliable and accurate use of terminology by clinical 
staff.
The acceptable complication rate for UGI surgery is approximately 20%; with 
60% of patients reported to develop minor complications [30, 579]. The overall 
major complications rate for UGI surgery should not exceed 20% [19].
The total number of major complications developed in this RCT by the sample 
population was 95. This equates to nearly every patient in the RCT developing a 
major complication, on average. The current RCT reported the total number of 
major complications developed. Several patients developed more than one 
complication. Therefore the sample for the current RCT appear to have
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developed more major complications than reported elsewhere in the literature 
[19, 579]. There are several reasons to explain this.
1. Firstly, did the authors of previous studies equate the development of multiple 
complications by a patient to one complication or several complications? This will 
clearly affect the complication rate reported.
2. Secondly was stringent reporting of complications used in clinical trials? This 
is dependent on both the definition of the complication used, and the frequency 
monitoring by the trial team.
4.4.4 Concordance
Patient concordance is often a problem for researchers. An adequately powered 
trial can be planned, but if a large proportion of the patients in the treatment 
group fail to tolerate it, the results will be affected. A number of investigators 
have further divided patients into compliant and non-compliant for the final 
analysis [648-650], while others have simply withdrawn those who fail to comply 
[539].
Patient concordance was not a significant problem in the present RCT, as the 
EN was delivered via a NCJ and was generally well tolerated (section 3.6.5). The 
main issue of protocol compliance was from clinical staff.
Eight patients in the standard group (19%) were commenced on enteral feeds 
prior to 7 days post-operatively, in the current RCT. This was because clinical 
staff had a belief that this was beneficial for the patient. Concomitantly, 9 patients 
(16%) in the EEN group had their enteral feed stopped in the first post-operative 
week. The reasons are presented in table 3.25.
Of the 9 patients who commenced on EN, 5 of the patients had a suspected 
chest infection. As evident from the LOHS of these patients, none of these 
patients had a particularly complicated hospital stay. The clinical practice of 
stopping the EEN was based on the surgical teams assuming that stopping the 
EEN would benefit the patient. As discussed throughout this thesis, the crucial 
and reportedly optimal time for the delivery of the EN is when the patient is
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stressed and hypermetabolic, as occurs in the present of an infection. Had the 
patients subsequently developed a chest infection, this may not have been 
optimal treatment for the patient.
One of the patients had their EEN stopped because of developing a chylothorax. 
This patient consequently was commenced on TPN. Evidence supports the 
continued use of EN in patients who developed chylothorax, however, the 
knowledge of this option being available may not be widespread amongst 
surgical staff.
The patients who ‘switched’ groups were analysed on an intention to treat basis. 
Whilst this is a limitation of this RCT it serves to highlight the actual benefits of 
EN, as the STD group probably benefited from the use of EN.
Concordance is always going to be an issue in clinical trials. An alternative view 
is that poor compliance represents the true situation in real clinical practice, and 
therefore is not a major methodological problem. If good compliance cannot be 
achieved in a research trial, where patients are usually more closely monitored, it 
is unlikely to happen in routine practice. This means the results are applicable to 
the real situation in hospital.
4.4.5 Health Related Quality of Life
As presented in the methods section the SF-36 health related quality of life 
questionnaire was given to all patients pre-operatively, on discharge, at follow up 
at 6 weeks, 12 weeks, 6 months and 12 months. The score for social function 
was statistically significant at baseline between the two-randomisation groups. 
Any future analysis should adjust for this difference at baseline to determine the 
impact (if any) on the primary outcome. This could be conducted using sensitivity 
analysis.
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4.5 Generalisability
4.5.1 The Clinician as Principal Investigator
Some critics may have concerns about the principal investigator being a dietitian 
with a natural enthusiasm for the ‘new treatment’ i.e. early enteral nutrition may 
have affected the judgment of patients. This notion would be a particular issue if 
subjective outcome markers were used, but as the current RCT had a robust, 
objective primary outcome, which was clearly defined, this was unlikely to be a 
limitation in the current RCT. In addition, multiple safeguards were put in place to 
prevent this from occurring as discussed in the data management section (2.3.).
4.5.2 Generalisability of findings
The generalisability of a trial describes how the outcomes of a research trial can 
be used in other healthcare organisations or settings. Generalisability cannot be 
assumed, however. A RCTs’ capacity to promote change in clinical practice and 
healthcare policy centres on how closely the trial’s sample resembles the general 
population of patients with the same diagnosis that has been investigated. The 
CONSORT criteria provide a framework for empirically assessing and reporting 
generalisability. There are two main issues, these are
1. Is the patient population representative of the broad target group?
2. Can the results be generalised to an individual or group that differ from those 
in the study, with regard to age, sex, severity of condition or disease and co- 
morbid conditions.
Is the treatment package acceptable?.
Representation of Patient population
The main advantage of pragmatic trials over explanatory trials is that they 
increase external validity or generalisability of the findings; this is because the 
conditions that the trial was conducted to mimic the actual clinical surroundings 
and healthcare settings where the intervention is typically delivered. The current
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RCT used minimal eligibility criteria, as typical in pragmatic clinical trials. This 
ensures that the study population is diverse, with numerous confounding factors.
Providing a detailed outline of the baseline characteristics of both the study 
population and the randomised groups, allows the readers to decide whether the 
sample population resembles the general patient population with the condition. 
The current RCT baseline characteristics are presented in section 2.4.3. 
Similarly, presenting data on patients who were and were not enrolled in the trial 
is important, as presented in table 2.4.2.2. If the two populations are similar, the 
generalisability of the trial is increased. The current RCT participants are 
assumed to be reflective of most patients undergoing major UGI resectional 
surgery for cancer.
Generalisability of Treatment Packages
The generalisability of a treatment packages is crucial. There are three factors 
that determine this; feasibility, acceptability and effectiveness. These will be 
discussed next.
Feasibility
Feasibility is essential. Providers of healthcare will only implement a feasible 
intervention. The results of the current RCT conclude that EEN is feasible via a 
NCJ as detailed in section 2.4.6.4.
Feasibility will however vary across differing organisations. The presence of local 
“champions” have an influence. These “champions” must educate others 
regarding the crucial factors needed to make the intervention feasible. Failure to 
deliver on one of these factors could affect the efficacy of the intervention. 
Feasibility also has a cost dimension; an unaffordable intervention lacks 
feasibility, being cost ineffective. The costs associated with the delivery of the 
actual enteral feed are relatively small (table 3.51).
Acceptability
An intervention must be acceptable before its use becomes routine in clinical 
practice The current trial did not ask patients about their satisfaction with the 
EEN or the STD management.
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Acceptability amongst the multidisciplinary (MDT) members is also crucial. A 
positive view of the treatment promotes its use. For the current RCT, some MDT 
members did have a negative attitude to the use of EEN, however this subsided 
as the trial continued. Once again, education and training are vital to ensure 
clinical staff have confidence in the results of the research.
Effectiveness
For an intervention to be effective the recipients of that treatment must have 
capacity to benefit from the intervention. Conducting high quality RCTs 
comparing two differing treatment will provide the evidence that an intervention is 
effective. More high quality RCTs are needed in the field of nutritional support, to 
determine its effectiveness in other specialties.
4.6 General Interpretation of the Results
This early analysis of an ongoing multi-centred RCT of 96 patients indicated that 
the use of EEN in post-operative patients maybe beneficial when compared to 
STD management i.e. nil by mouth, in reducing LOHS which was the primary 
outcome indicator. Whilst LOHS has limitations, it does give an insight into 
improvements in clinical outcome. It is the ‘yard stick’ by which hospital 
managers and commissioners of healthcare services substantiate the complexity 
and severity of surgical procedures.
The EEN group developed three times fewer major complications than the STD 
group. Despite the multifactorial origin of complications, which include issues 
with the actual surgical technique, the anaesthetic, or the postoperative 
management such as fluid balance and analgesia prescription, these 
confounding factors should be evenly distributed with meticulous randomisation.
The baseline groups were equivalent for many confounding factors as detailed in 
the discussion. However, the difference in the baseline scores for social function 
needs to be considered when interpreting the results of this analysis.
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4.7 The Implications and Implementation of Findings
One of the main criticisms of clinical research is the difficulty of incorporating the 
findings into clinical practice. The successful dissemination of results is essential 
if current clinical practices are to change. The introduction of Clinical 
Governance [615] should help to assist in the implementation of the RCT results. 
Clinical governance is:
“The system through which NHS organisations are accountable for continuously 
improving the quality of their services and safeguarding high standards of care, 
by creating an environment in which clinical excellence will flourish
Any intervention that reduces LOHS is useful. The employment of clinical 
dietitians are needed to ensure the safe and feasible delivery of EN to yield the 
results demonstrated in the current RCT. Unfortunately the number of funded 
dietitians currently working in surgical units, is limited, across the UK. Allocation 
of funding and subsequent recruitment of dietitians is imperative. Convincing 
hospital managers of the benefits of allocating funds for dietitians is central to the 
success of implementation of these results. The reinvestment of any potentially 
released monies, resulting from the reduced LOHS and major complications, 
seems sagacious.
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4.8 Summary and Recommendations for Future Work
This thesis set out to compare the effects of EEN versus STD post-operative 
management in patients undergoing major UGI resection for cancer. The 
conclusions from this early analysis imply that patients do benefit from the use of 
EEN post-operatively and this yields a cost saving for healthcare organisations.
Whist conducting and analysing the results and debating these in the discussion 
several questions have arisen which require further investigation. These will be 
detailed in the next section.
1. In the current RCT EEN was commenced within 12-24 hours of leaving the 
operating theatre. Future studies could explore whether initiating nutritional 
support pre-operatively and continuing the EEN through the surgical resection 
can intensify the effect of EEN. Evidence from studies [427-431] suggest that 
GIT mucosal integrity is altered after initiation of an APR. Cummins et al (1995) 
[439] concluded that EEN is less effective at maintaining GIT mucosal integrity 
after the initiation of an APR. The authors suggested that there was a crucial 
window i.e. within 12 hours of theatre that EEN is most beneficial. Future studies 
should explore whether EN commenced in the immediate pre-operative period is 
better than EEN commenced post-operatively.
2. The actual prescription and delivery of the EEN is essential. A previous study 
[14] has demonstrated that the use of ‘aggressive feeding’ can lead to 
complications with the jejunostomy tube and increases the incidence of 
distension and abdominal bloating. The current RCT commenced the EEN at IQ- 
20 mls/hour and then subsequently slowly increased the EEN by 10mls/hour per 
day over the first 5 days post-operatively. Future work could explore whether the 
EEN actually needs to be increased in the first post-operative week above 20 
ml/hours, whilst the patient is catabolic. The theory may centre on delivering 
sufficient EEN to prevent GIT mucosal atrophy; but not increasing EEN may 
prevent any increase in luminal pressure, which may cause GIT complications.
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Likewise not increasing EEN above 20mls/hour may prevent hyperglycaemia 
that once again may further decrease complications.
3. This RCT has studied the delivery of EEN via a needle catheter jejunostomy 
inserted at open laparotomy at the time of the resectional surgery. Whilst this 
RCT reported no major or fatal complications attributed to the NCJ other studies 
have reported both major and fatal complications [358] [488] [500, 503, 505, 507, 
527]. Future studies could compare the use of nasojejunal tubes or double lumen 
gastro-jejunal tubes to deliver the EEN so perforation of the small intestine was 
not necessary. One study reported that the use of Jejunostomy is considered a 
‘small bowel stress test’ [500]. The theory may centre on the action of perforating 
the small intestinal luminal wall may deleteriously affect the immunological 
response initiated from the Peyers patches [46, 47].
4. The sample population of this RCT so far had a reduced oral intake (both 
protein and calories), prior to surgery. Previous studies have confirmed that post­
operative recovery and hence length of hospital stay may be proportional to pre­
operative nutritional intake. Future studies could aim to correlate whether oral 
intake has a negative affect on recovery and whether pre-operative enteral tube 
feeding is beneficial in improving post-operative recovery. Future studies should 
possibly stratify for pre-operative oral food intake. Likewise a retrospective study 
using correlations of pre-operative oral protein and calorie intake may provide 
some evidence.
5. This study has concluded that EEN is beneficial for patients with UGI cancer 
undergoing major resectional surgery. The beneficial effect of EEN (section 1.5) 
may centre on the optimisation of the immune response mediated by the Peyers 
Patches in the small intestine. It may be therefore that the use of EEN may 
benefit other groups of major surgical patients. Future studies should explore 
the use of EEN versus standard post-operative management in the following
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cohorts of patients; gynaecology, cardiac, head and neck, thoracic, vascular and 
in paediatric surgery.
6 . Hyperglycaemia is detrimental to post-operative outcome predisposing to 
increased risk of complications particularly infective complications [651]. A study 
in critical care patients [652] demonstrated that ‘tight glucose control’ using 
exogenous insulin improved clinical outcome. It would be useful to explore 
whether tight glucose control improves clinical outcome in post-operative 
patients having EEN. The use of exogenous insulin infusions for the first post­
operative week compared to routine post-operative management to determine 
the effect on differences in major complications would be interesting.
7. Future studies should compare the use of post discharge enteral feeding 
compared to the use of oral diet alone. Ideally, the enteral nutrition should be 
continued throughout the post-operative phase and then patients could be re­
randomised to either post discharge feeding or oral diet alone. This study has 
confirmed that the EEN group maintained their body weight as compared to the 
STD group. However following discharge the EEN lost more weight than the 
STD. This equated to 7.5 kilograms in the first 6  weeks and total 9.3 kilograms at 
12 weeks post discharge. The reasons for this loss maybe secondary to reduced 
oral calorie intake up to 6  and 12 weeks post discharge. The mean oral calorie 
intake of the sample population was less than 1500 calories per day. What is not 
clear is why the EEN group had a higher calorie intake at each time point when 
compared to the STD but yet lost more weight. It may be that the EEN group had 
in someway adapted to need a higher calorie intake and once the enteral feed 
was discontinued, the weight loss was more extensive.
8 . The current study has provided the evidence that EEN is superior to standard 
post-operative management in patients undergoing major UGI resection for 
cancer. This was conducted as a clinical trial. What is now important to 
determine is why EEN is beneficial. A study of cytokine response to both EEN
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and STD management is essential however ethically this may not be possible in 
patients, as it may no longer be ethical to withhold a beneficial treatment to study 
the mechanism as to why it may be beneficial. As a result this study may need to 
be conducted in other types of patients and the results then extrapolated to the 
type of patients studied in the current RCT.
9. The fluid balance of a patient greatly impacts on their clinical outcome [255]. 
The current RCT has reported that the STD group developed more oedema 
compared to the EEN group. Future studies should aim to explore the reasons 
for this difference. Is the increased report of oedema in the STD group a result of 
the lack of nutrition delivered or is it a result of the increased quantity of 
intravenous fluids? This study did not report the types of IV fluids delivered in 
either randomisation group, this data will be analysed for future studies and 
publications.
Another possible reason for more patients in the STD group developing oedema 
could centre in the APPR. All these possible factors should be explored in further 
prospective studies in an attempt to answer this important question.
10. The study has demonstrated that the use of EEN stimulates Gl peristalsis as 
compared to the use of STD management. Once again the mechanism for why 
this occurs is not answered by this clinical trial.
Further investigations are therefore required centering on the activation of 
proinflammotory cytokines, which have been postulated to be central in 
mechanism of altered Gl peristalsis [390-392]. Intestinal surgery is thought to 
activate the macrophage network in the intestinal luminal wall setting up an 
inflammatory reaction. These macrophages express CD11A and 11b/CD18 and 
interleukins IL-1, IL-6  and TNF alpha. These act locally to initiate morphological 
changes in the bowel wall. In addition, these immunological cells cause an 
increase in free radical production, which disrupts the membrane ion-channels 
(potassium and calcium) that regulate smooth muscle contraction and rhythm. 
The result is a decrease in circular muscle contraction and thus a reduced 
intestinal transit time. Subsequently, systemic cytokines, prostaglandins and 
catecholamines are released which activate the autonomic nervous system. This
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produces the inhibitory effects altered motility and reduces mesenteric blood 
flow. This was eloquently illustrated in an animal studies [393] [394] [384]. This 
should now be explored using USS imaging as detailed in the current RCT and 
correlating this with cytokine studies.
11. To date no RCT has studied the effect of using EEN and STD management 
on survival in cancer patients undergoing major resection. If EEN had an 
immunological response, it may be possible that it may affect survival. Future 
studies should aim to quantify any possible effect.
12. A study [627] demonstrated that pre-operative baseline factors of HRQoL 
correlate with both short-term outcome i.e. post-operative complications and 
length of and long term and survival. Future studies should aim to correlate 
baseline results of HRQoL from the current RCT and clinical outcome and 
survival.
13. Future work should focus attention on patients deemed palliative and 
therefore not eligible for curative intent resection. The benefit of enteral nutrition 
may well have considerable benefits on patients either undergoing palliative 
surgery or palliative chemotherapy or radiation therapy, having a potential impact 
on survival and HRQoL.
14. As discussed throughout this thesis, to date there has been no Cochrane 
systematic review of the use of peri-operative nutritional support. This should be 
conducted in the near future.
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5. Conclusions
The provision of early enteral nutrition delivered via a needle catheter 
jejunostomy within 12-24 hours of leaving the operating theatre may improve 
clinical outcome by reducing length of hospital stay in patients undergoing major 
upper Gl resection for cancer.
No differences were found between the EEN group and the STD group or 
HRQoL but patients in the EEN group did develop substantially less major 
complications in hospital. As a result there was an estimated cost saving in the 
region of £1800 per patient is EEN was used.
The results of this early analysis of an ongoing RCT have potentially important 
clinical connotations.
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Nutrition is considered so basic to life that to withhold it requires special and 
profound circumstances. By withholding medical treatments this may allow the 
disease process to progress; withholding nutrition can create a fertile ground for
disease occurrence and progression”
Scott Berry and Joseph Lacy, 1996 [653]
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Appendices
I. Appendices to supplement the Literature Review
1.1 Gastrointestinal Motility 
Gastric Motility
Regulation of gastric emptying is controlled by receptors in the duodenal and 
jejunal mucosal that detect changes in acidity, osmotic pressure and fat content.
Peptides, fatty acids and amino acids in the duodenum decrease the rate of 
gastric emptying. They also stimulate the production of cholecystokinin (CCK) 
and glucose insulinotropic peptide (GIP) hormone, both of which also decrease 
gastric emptying. Peptides in the duodenum and jejunum release gastrin from 
the mucosal lining in the stomach and duodenum. Gastrin acts to increase the 
contraction in the antrum and cause the pylorus to constrict further
In addition the presence of hypertonic solutions such as chyme in the small 
intestine, stimulates a feedback mechanism inhibiting gastric emptying. In 
addition the presence of acidity (pH <3.5) in the duodenum slows gastric 
emptying (some enteral feeds are acidic) the inhibition of gastric emptying in 
response to acids has both a neural and endocrine component. The hormone 
secretin is released from the central nervous system and Gl plexus neurons 
along with CCK and GIP and gastrin to act as neurotransmitters and 
neuromodulators. They inhibit antral contraction directly, but also increase the 
production of pancreatic and liver bicarbonate which neutralise the pH of the acid 
gastric chyme in the duodenum allowing the quicker activation of pancreatic 
enzymes which function optimally at a neutral pH.
The above effects result in fat not being emptied into the small bowel at a rate 
greater than it can be emulsified by bile salts. In addition gastric acids are 
inhibited from being delivered into the duodenum too quickly so that the acidity 
can be neutralised by pancreatic and duodenum secretions.
I
Motility of the Small Intestine
The small bowel is the largest segment of gastrointestinal system. It is 
approximately five metres in length, and chyme (undigested food) normally takes 
2-4 hours to pass through to the small intestine. The first 25 cm is the 
duodenum, which has no mesentery and is thus easily distinguishable from the 
rest of the small intestines. The jejunum is approximately 40% of the small bowel 
and the distal segment, the ileum, makes up the remaining 60%. The small 
intestines are where the majority of digestion and absorption occurs, with chyme 
and secretions being mixed and ‘pushed’ into contact with the absorptive 
intestinal lumen wall.
Normal small bowel motility consists of segmentation, which is determined by 
contractions of the circular muscle of the intestine. Segmentation is 
characterised by localised contractions of circular smooth muscle which divide 
the small intestine into oval segments, when the recently contracted segment 
contract neighbouring segments relax and so on.
The chyme is pushed towards the large intestine (colon) by cyclical rhythmical 
contractions called peristalsis.
Normally, regular slow waves of peristalsis occur along the entire length of the 
small intestine, ranging from 11-13 contractions per minute in the duodenum to 
8-9 contractions towards the end of the ileum.
The duodenum tends to follow the contractile activity of the antrum of the 
stomach the reason for this is to prevent the reflux of contents back onto the 
stomach
When a bolus of material (for example food or enteral feed) is delivered to the 
small intestine, the intestine responds by contracting proximal to the bolus and 
relaxing distal to the bolus, the aim being to propel the bolus further down the 
intestines.
Over distension of the small bowel is characterised by a corresponding reflex, 
which prevent further delivery of contents in to the small intestines from the 
stomach. It is thought that this is controlled by the hormone gastrin, which also 
works to increase distal small intestine motility to alleviate the over distension.
II
Colonic Motility
Large bowel motility is characterised by segmental contraction with non- 
propulsive activity. This allows mixing the contents and maximised the time for 
absorption. Several times a day high-pressure propulsive peristalsis waves 
propel colonic contents towards the rectum. In normal subjects a meal will be left 
in the colon for 3 days after eaten.
Stimulation of Gastrointestinal Motility
Historically it was thought that the gastrointestinal tract was innervated by the 
autonomous nervous system alone. More recently studies have shown that the 
Enteric Nervous system (ENS) has a vital role in Gl motility [654]. The ENS can 
act independently of the brain and controls peristalsis, local changes in blood 
flow and secretion of water and electrolytes [655] The ENS is an important 
influence on the body’s immune response [655].
Neuropeptides are the neurotransmitters of the ENS, they are produced by the 
entero-endocrine cells. These cells extend along the entire length of the GIT and 
respond to changes in levels of bacterial toxins, pH, osmolarity and lipids in 
addition to direct contact. In addition, the production of these neuropeptides 
seems to be influenced by cytokines, hormones and drugs [384, 393, 394, 636].
Fasting and its effect on gastric and small bowel motility
When humans are in a fasted state, three phases of gastrointestinal motility
occur:
1. Phase I -  there is no activity
2. Phase II- irregular activity occurs
3. Phase III- Strong rhythmic contractions starting in the stomach spread distally. 
This phase is known as the migrating motor complex (MMC). It occurs every 90 
minutes (range 50-140 minutes) and each contraction lasts for 5-10 minutes in 
any one area [384, 393, 394].
The MMC has the important role of propelling the residual of the last meal eaten 
into the distal part of the small bowel and colon. Failure of the MMC leads to 
bacterial overgrowth.
Ill
Fed State and Its effect on gastric and small bowel motility
The presence of nutrients in the stomach elicits peristaltic waves, which start in
the mid stomach and propel the food from mid stomach to the pylorus. This 
occurs every 20 seconds. Liquids start to empty as soon as they reach the 
stomach. Liquids empty from the stomach much faster than solid foods. These 
slow waves are thought to originate from the interstitial cell of Cahal [384, 393, 
394] and range from contraction activity in the jejunum at 12 contractions per 
minute to 8  per minute in the ileum. Small bowel contractions can be segmental 
or peristaltic with peristaltic waves occurring mainly in the duodenum and 
segmental occurring in the jejunum and ileum.
IV
I.II Methodological Quality Criteria for Reviews of Trials
The following criteria were used when comparing the clinical trials.
Patient Selection
Were the eligibility criteria for the trial specified?
Treatment Allocation
Was the trial randomised?
Was treatment allocation concealed?
Were the groups similar at baseline with respect to the most important prognostic 
indicators?
Interventions
Were the interventions explicitly described?
Was the care provider blinded to the intervention?
Was the compliance acceptable in all groups?
Was the patient blinded to the intervention?
Outcome Measures
Were the outcome measures relevant?
Were adverse events reported?
Was the withdrawal and drop out rate acceptable?
Was the timing of the outcome assessment in both groups comparable?
Statistics
Was the sample size for each group described?
Did the analysis include an intention to treat analysis?
The above criteria were used as a basis when reviewing the clinical trials. If not 
recorded in the clinical paper an assumption can be made that it was not 
recorded or reported.
V
II. Appendices to Supplement the Methods
11.1 Pilot Study
A pilot study was conducted. The purpose of this was to highlight any 
organisational issues, which could be encountered during recruitment for the 
main study. It was also to check the protocol was robust and easy to follow and 
adhere to.
Protocol Design
A literature search was perfomed using Medline and Cochrane databases. A 
well-researched clinical trial protocol was developed.
Sample Size
N= 8
Aim
To check that the protocol is robust and the trial isfeasible. All gastrointestinal 
cancer patients undergoing major resction were approached to enter into the 
pilot study.
Methods
All the appropriate ethical and research governance forms were completed in 
accordance with Researh Governance Framework [557].
Patients were referred to the RCT from the surgical multi-disciplinary team 
following the diagnosis of a suspected Gl malignancy. Patients were given the 
information sheet (see appendix 11. IV) and informed written consent (appendix
II.V) was obtained.
Nutritional, biochemical and anthropometric information, both at diagnosis and 
prior to surgery, is collected. The patient is then randomised to either the early 
EN group or the standard group.
Group A (Standard therapy group)
In keeping with standard practices, patients are kept on intravenous fluids until 
instructed by the surgical team.
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Group B (Treatment group)
In addition to standard management, these patients will commence an enteral 
feed via a jejunostomy within 24 hours of surgery at the rate of 10ml/hour. The 
rate of EN will be increased by 10ml/hour every 12 hours, to achieve full 
nutritional requirements by the 5th post-operative day.
Patients will be allowed to drink and eat once instructed by the surgical team, as 
with the standard group.
The patients were followed up daily for the first 7 days and then at day 9, 12, 15, 
2 0  and day of discharge.
Results
The consent rate for the pilot study was 90% in the Upper Gl and Hepatobilary 
group. The consent rate for the colorectal patients was 15%.
Twelve patients were recruited into the pilot study. The protocol was robust and 
well adhered to.
The mean LOHS for the enteral nutrition group was 19 days compared to 22 
days in the standard group. No statistical analysis was conducted in view of the 
small sample size.
VII
11.11 Amendments to Study Design after Pilot Study
Recruitment was not as successful in the colorectal group. This was attributed to 
the fact that these patients required naso-jejunal enteral feeding tubes, which 
lead to a reduction in compliance. In addition there was a change in surgical 
technique from moving to opt to laproscopic colectomy as opposed to an open 
procedure. These changes in surgical procedure lead to a shorted LOHS and 
hence it was decided that these patients should no longer be referred to the main 
RCT.
There was also a lack of Intensive care beds, which lead to patients being 
cancelled for their major surgery. In addition, the pilot study coincided with winter 
and hence the annual winter bed pressures also lead to cancellations of elective 
surgical procedures.
To resolve these issues, the RCT was planned to be extroplotated across 
neighbouring hospital centre in the South East Wales Network of Upper Gl 
surgery. The aim of this is to improve the accrual rate. Therefore the proposed 
sample size should be achieved in 2 years. The protocol was ammended as 
outlined in the current RCT.
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II.IV Patient information Sheet
To be issued on the Hospital Trust headed paper
Version 2 date 20/9/02
A RANDOMISED CONTROL TRIAL OF EARLY ENTERAL NUTRITION 
AFTER MAJOR GASTROINTESTINAL SURGERY
Before you decide to take part in this study you should read this information
sheet carefully. It gives details of the research in which you are being invited to
participate. Your doctor will also discuss the study in detail with you. If, after
reading this sheet and discussing the study with the doctor you feel you would
like to take part, please sign the consent form and return it to the doctor. You
should keep this information sheet in order that you may refer to it in the future.
Why is this research being done?
We are doing this research to see whether nutrition given through a feeding tube 
is helpful in improving the ability to recover from surgery. Traditional 
management following surgery involves ‘resting’ the gut to prevent foods 
aggravating the site of the operation. Foods are usually introduced after 
approximately five to seven days. Over the past few years, new medical 
evidence has suggested that the early delivery of nutrients via a feeding tube 
given directly into the intestines may improve the ability to recover from surgery. 
However this evidence is not yet sufficient to persuade a radical change in post 
surgical practices. The trial into which you are being invited to enter will hopefully 
provide this evidence or clarify that we should continue with our current post 
surgical management.
Approximately 180 patients will be included in this study.
How is the nutrition given?
After you have consented to be in the trial, you will be allocated in to either the 
treatment group or the control group. If you are in the treatment group, nutrition 
will be given through a feeding tube inserted in your abdomen (tummy) at 
surgery. If you are in the control group, you will receive our current management, 
which is to remain ‘nil by mouth’ until your surgeon says that you are able to eat.
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What does participation in this study involve?
The Research Dietitian will introduce herself and explain fully about the trial. If 
you need more time to decide this will be fully respected.
Participation in this study requires that you answer some simple questions after 
your surgeon has informed you that you will possibly require an operation. 
These questions are about your normal eating habits, weight and any weight loss 
and your current quality of life. This will take place in the outpatient department.
When you come in for your operation. I will meet you again, this time on the ward 
and I will explain step by step what the trial involves.
Before your operation, routine information will be collected about any changes in 
your weight and blood chemistry. You will be asked to have one additional blood 
test taken when you have your routine bloods checked -this is to determine your 
immunity levels on your blood.
If you are having any operation for a bowel problem, you will have a feeding tube 
passed up your nostril and into your tummy before you have your operation. This 
helps to ensure that the tube is positioned correctly in to the bowel before you 
have your operation, preventing the need to have to stay in the operating theatre 
longer than necessary after your operation (as would be the case if the tube 
was placed in theatre). This is a routine procedure that is used frequently in 
hospitals.
If you are having your operation for a gullet, stomach or pancreas problem, then 
a feeding tube will be placed into your tummy at the time of your operation. Prior 
to your operation you will have one additional blood test taken (this will however 
be taken when you have all your other tests so that you should only need one 
needle.) in addition you will be given a questionnaire to complete (this can either 
be completed at home or with the Research Dietitian or Specialist Nurse.
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If you are randomised into the feeding group, nutrition will be commenced as 
soon as your Consultant agrees, usually within 24 hours. If you are randomised 
to the conventional group you will remain ‘nil by mouth’ for the first 3-7 days 
depending on your consultants instructions.
You will be monitored closely throughout your hospital stay. You will have an 
additional ultrasound scan after 2-3 days after your operation. This is to 
determine the movement in your intestines. Oral food will be introduced to you 
once again as soon as your Consultant is happy. The feed through the tube will 
be stopped when you are able to eat enough food and fluids to warrant doing so.
If for any reason you are in the control group and you are not able to eat 
sufficient foods at this time, nutrition will be given to you via your unused feeding 
tube. This nutrition once again can be given until you are able to eat enough 
foods.
Once you are fit enough to go home, you will be ask to answer some more 
simple questions similar to that already ask in the initial visits.
You will be followed-up at your routine Consultant outpatient clinic after 
discharge.
This clinic visits at 4 to 8  weeks will be very similar to the first visit.
Do I have to participate in the study?
Participation in the study is entirely voluntary. If you decide not to participate in 
this study your medical care will not be affected in any way. If you decide to take 
part, but then change your mind, you may withdraw from the study at any time. 
You do not need to give a reason for withdrawing, but it would be helpful if you 
could. Again, the fact that you withdraw will not affect your medical care in any 
way either now or in the future. Your doctor might decide to withdraw you from 
the study if he/she thinks that it is in your best interest to do so but he/she will 
discuss this with you first and will give his/her reasons for doing so.
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Are there any risks or benefits to participating in the study?
In general people who receive nutrition after surgery have very few side effects. 
The only symptoms noted in the previous studies were nausea, which can be 
treated by your doctor. If you feel unwell please inform your doctor.
What happens to the information collected about me on the study?
If you agree to take part in this study, your case notes and other information 
collected about you during the study may be consulted by the investigator. In the 
information collected for the study you will be referred to only by your initials and 
a unique study number and never by your full name. All information will be 
treated in the strictest confidence.
Other information
Your General Practitioner will be informed, with your permission, about your 
participation in this study if you decide to take part.
The results of the study are expected to be available late in the year 2006.
Whom can I contact if I need to?
If you wish to discuss any aspect of the study with you should use the following 
contact numbers;
3) On-call Surgical Registrar
Via bleep from switch board
University Hospital of Wales
2920 747747
Thank you very much for considering taking part in our research. Please feel 
free to discuss this information with your family, friends or General Practitioner if 
you wish before reaching a decision.
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II.V Patient consent form
Version 2 date 20/9/02
To be issued on Hospital Trust headed paper
A STUDY COMPARING TWO TYPES OF NUTRITION AFTER MAJOR
SURGERY
1 . I (name of patient)
Of (address of patient)
Voluntarily agree to participate in this study.
I confirm that I have been given a full explanation of the purpose of the study by 
my doctor and/or the lead investigator and have had adequate opportunity to ask 
questions. I have been made aware of the procedures involved, any potential 
risk to my health and well-being and what is expected of me during the study.
I understand that I am free to withdraw from this study at any time, without 
explanation, and that such withdrawal will not affect my future treatment.
I understand that all reasonable steps will be taken to protect my confidentiality 
and that my name will not be disclosed to any unauthorised person or to be 
referred to in any report concerning this study.
I agree to my doctor informing my GP about my participation in the trial.
XIV
SIGNATURE OF PATIENT
Signed ------------------------------------------------------------------------
Dated ------------------------------------------------------------------
Name ------------------------------------------------------------------
SIGNATURE OF INVESTIGATOR
Signed----------------------------------------------------  Date
SIGNATURE OF WITNESS
Signed ------------------------------------------------------------------
Dated---------------------------------------------------------------------
Name---------- ----------------------------------------------------------
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II.VI Case Report Forms
Nutritional Assessment
At Diagnosis -  Data Collection
Kcal/day Protein/day Weigh
t
O Pre illness
3  weight
>
Pre illness 
BMI
%weig BM Appetit y 
h tlo ss  I e
normal
n
Taste changes Swallowing/chewing
difficulties
Anthropometric
TSF MUAC Hand 85% less than 
Dynamometry normal
y  n
Biochemical
Albumin N a K Urea Creatini 
ne
Mg
Selenium PO
4
Calciu
m
Alb Lympho 
cyte
Hb
Socio-economic Assessment
XVI
Salary <£1200 £12000- £16000- £20000 -
Range 0 £16000 £20000 £25000
Demographic Information
Male Female Age Postcod
e
Quality o f Life Questionnaire
£25000 +
PMH
Diagnosis
Occupation
Units Alcohol/week Ex-drinker Heavy alcohol use Alcohol dependency
Cigarettes/day Ex-smoker For how long stopped smoking?
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Inpatient Data Collection
Nutritional Information 
Height TSF MUAC Handdynomet 85% y
ry normal
n
NA K Urea Creatini
ne
Magnesiu
m
P 0 4‘ Seleniu
m
Calciu
m
Albumi
n
Hb
Lymphocyt
e
Glucose
Immunological Information 
White cell count 
Theatre information
CRP
Copper Zinc
Pyrexia
Fe
Apyrexia
1
CD11
b
Theatre time Blood loss Asa grade Diagnosis Surgical
procedure
Drugs in 
theatre
IV  fluids in 
theatre
UO in theatre
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Post O p  Monitoring Form 1
Day WaRD Volu
me
of
feed
Rate 
of feed
Oral
Fluids
Oral
Diet
Temper
ature
WCC CRP Total
lympho
cyte
count
U +
E’s
Albumi
n
N2
bal
GLUC MG
P04
HB
1
2
3
4
5
6
7
9
12
15
20
Discha
rge
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Post Op Monitoring Form 2
D a y s N a u s e
A
V o m it in g N G  A sp ir a t e s D ia r r h o e a F l a t u s C o n s t ip a t io n A b d o m in a l
D ist e n sio n
Pa t ie n t  
R e f u s in g  F e ed
URINE OUTPUT FLUID BALANCE IV
FLUIDS
1
2
3
4
5
6
7
9
12
15
20
D is c h a r g e
XX
Post Op Complications Monitoring Form
DAY p a in
SCORE
ANALGESIA
REQUIREMENT
WOUND
INTACT
WOUND
INFECTION
PE CHEST
INFECTI
ON
ANASTOMOTIC
LEAK
CONSERVA
TIVE
MANAGEM
ENT
THEATRE
NEEDED
DVT MOTILITY WE
1G
HT
1
2
3
4
5
6
7
9
12
15
20
D is c h a r g e
XXI
POST-OP DRUGS MONITORING FORM
DAY ENTERAL DRUGS IV DRUGS
1
2
3
4
5
6
7
9
12
15
20
DISCHARGE
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Health Economy Data Collection
Theatre operation
time
Post Op Dietitian 
Time
Length o f  Hospital Length o f  ITU Length o f  HDU
stay stay stay
Control Group IV 
Drugs
Treatment Group IV 
Drugs
Jejunostomy insertion 
time
Volume
Dose
Duration
Volume
Dose
Duration
Enteral Drugs
Patient Developed
infection ^ n
If yes antibiotics needed y n
Chest physio needed y n
Wound infection y n
Special dressing needed y n
Special mattresses needed y n
Changes in drug prescription on discharge:
What Type? 
What Type?
Duration 
Number o f visits
If  yes what
If  yes what duration
II.VI Letter to General Practitioner
To be issued on the Hospital Trust headed paper
Version 2 date 20/9/02
LETTER TO GENERAL PRACTITIONER
Date
Dear Dr..................................
Re: A RANDOMISED CONTROL TRIAL OF EARLY ENTERAL NUTRITION 
AFTER MAJOR GASTROINTESTINAL SURGERY
Your patient ____________________________________________
Has agreed to participate in a randomised controlled clinical trial to study the 
effect of enteral nutrition on surgical outcome.
The study is as detailed in the attached Patient Information Sheets and the study 
schedule is reproduced overleaf for your information. Briefly, patients will be 
randomised to receive either enteral nutrition via a feeding tube of remain nil by 
mouth until passage of flatus.
Your patient has been given a copy of the Patient Information leaflet and has 
given written informed consent (copy enclosed for your records).
If you have any queries concerning this trial please do not hesitate to contact me 
at the number below.
Signed:   Date:_____
RACHAEL BARLOW 
RESEARCH DIETITIAN
DEPARTMENT OF SURGERY, UNIVERSTITY HOSPITAL OF WALES 
02920 744294/bleep 07623 906116
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I1.V1I Nutritional Composition of Enteral Feeds
Nutritional 
information/100m I
Nutrison
Standard
Osmoiite Perative
Energy (kcal) 100 101 131
Protein (g) 4 4 6.7
Carbohydrate (g) 12.3 13.6 17.7
of which sugars 1 .0 0.69
Fat (g) 3.9 3.4 3.7
Fibre (g) 0 0 0
Sodium (mmol) 4.3 3.83 4.5
Potassium (mmol) 3.8 3.79 4.4
Osmolality 
(mosm/kg H20)
310 288 308
Nutritional information/100ml
III. Appendices to Supplement the Results Chapter
III.I Supplementary Baseline Results
Table III.1.1 presents the number and percentage of patients with a differing 
surgical procedure in the current RCT with a pre-operative weight loss of more 
than 10%. The results suggest that more patients undergoing gastrectomy 
(partial, subtotal and total) lost more than 1 0 % weight loss prior to surgery than 
other types of surgeries
Table lll.l.l Number of patients by surgical procedure with a pre-operative
percentage weight loss greater than 10%
Type of Surgical Procedure N %
Transhiatal O esophagectom y 1 5.5
Ivor Lewis oesophagectom y 10 34
Partial gastrectom y 1 50
Subtotal Gastrectom y 8 62
Total gastrectomy 6 43
PPPD 8 42
Total pancreactectom y 2 33
Total of study population 36 38
Table 111.1.11 presents pre-operative percentage weight loss by gender. It appears 
that women lose more weight pre-operatively with 2 2 % of females losing more 
than 16% of the pre-illness weight in the 3 months prior to surgery.
Table III.I.II Pre-operative weight loss compared by Gender
Percentage 
weight loss
Male
N (%)
Female 
N (%)
Test
Statistic
(P) _
Less than 5% 35 (55) 11 (34) CHI=13.23
6-9% 8 (12.5) 8 (25) . . (0.01)
10-15% 18(28) 6 (19)
16-20% 2(3) 1(3)
More than 21% 1 (1.5) 6 (19)
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The results for pre-operative Nutritional Risk Index are similar to pre-operative 
percentage weight loss. Significantly more women were either moderately or 
severely at risk of malnutrition as compared to the men. The results are presented 
in table lll.l.lll.
Table lll.l.lll Results of male and female pre-operative nutriltional risk index
NRI Male 
N (%)
Female 
N (%)
U(p)
Severe PEM 4 (6.7) 6(21.4) U=636 (0.004)
Moderate PEM 2 (3.3) 4 (14.3)
Borderline PEM 54 (90) 18 (64.3)
PEM- Protein Energy Malnutrition
xxvm
Table III.I.IV Results of Baseline Biochemical Parameters for the two
randomisations groups
STD
Group
EEN group Reference range
Albumin (g/l) 41 41 35-50
C reactive protein (mg/l) 7 8 0-10
Haemoglobin (g/dl) 32 36 13-18
WCC 10 "/litre 35 46 3.5-11.0
Calcium mmol/L 2.3 2.3 3.5-11.0
Selenium umol/l 0.7 0.7 0.8-1.4
Magnesium mmol/L 0.8 0.8 0.65-1.05
Phosphate mmol/L 1.19 1.09 0.87-1.45
Sodium mmol/L 140 138 135-150
Potassium mmol/L 4.0 4.1 3.3-5.1
Urea mmol/L 5.0 5.0 1.7-8.3
Creatine umol/l 80.8 85.0 44-101
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III.II Supplementary Results for Primary Outcomes
As discussed in the results chapter the data for length of hospital stay was not 
normally distributed. The QQ plot is presented below
Figure lll.ll.l QQ plot showing the distribution of data for LOHS 
Normal Q-Q Plot of LOHS(days)
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III.Ill Supplementary Results for Secondary Outcomes
/ / / . / / . / /  Supporting Information for Cost Analysis 
Table III.III.I Cost of Treating a Chest infection_____
Cost Cost per day Justification of Cost
Medical time 20 mins/day= £40 Time for junior medical team to 
review patient on ward round daily
Nursing time 30 mins/day= £15 Extra nursing time for 
administration of drugs +/-oxygen, 
taking patient to x-ray
Chest X-Ray £40 one off cost Only one X-Ray was included
Physiotherapy 30 min/day =£20 Top of scale band 7 physiotherapist
Antibiotics
(Intravenous)
£10-£32/day BNF price of Intravenous 
clarithomycin
Total £115-£147
BNF-British National Formulary
Table lll.lll.lll Cost of Treating a Wound infection
Cost (£) Cost per day Justification of Cost
Medical Time 20 mins/day= £40 Time for junior medical team to review 
patient on ward round daily
Nursing Time 30 mins/day= £15 Nursing time to dress wounds (sterile 
technique)
Dressings £10 /day BNF price Kaltostat Packings £6.78 
Tegaderm £2.34
Antibiotics £10- £32 BNF price of Intravenous 
clarithromycin. IV used as patient 
NBM
Total £75-£107 per day
BNF-British National Formulary
XXXI
Table lll.lll.lll Cost of treating an anastomotic Leak
Cost (£) Cost per day Justification of Costs
Critical Care 
stay
£0-£1000 The range in cost is dependent on 
whether the patients are readmitted to 
Critical care. The WAG (2005) figure 
for cost of 1-day critical care stay is 
£1000.
Medical Time 20 mins/day= £100 The cost of Consultant Surgeon and 
the junior medical team to review 
patient on daily ward round
Nursing Time 30 mins/day= £25 The cost of critical care stay includes 
intensive monitoring and nursing care 
of the patient.
However, this is the extra care for 
managing a patient with an 
anastomotic leak either on a ward or 
on critical care. This figure was 
calculated after asking the senior 
nurses on the wards to estimate the 
time taken per day.
Return to 
theatre
2 hours @ £300=£600* This is an optional cost and is 
dependent on whether the patients 
necessitate a return to the operating 
theatre. All patients in this RCT 
returned to theatre for exploratory 
surgery after developing an 
anastomotic leak.
Antibiotics £10- £32 BNF price of Intravenous antibiotics.
Radiology
Costs
Gastrograffin swallow* 
£150
Chest X-ray*
£40
To diagnose an anastomotic leak, 
patients often have a gastrograffin 
swallow and a minimum of one Chest 
X-Ray. These costs are taken from the 
WAG (2005)
Total £135-1157 per day
*refers to one off costs for treating an anastomotic leak such as returning to 
theatre, gastrograffin swallow and chest X-Ray which for simplicity are not 
included in the costs for treating an anastomotic leak.
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III.III.II Supporting Information for Health Related Quality o f Life
Figure lll.lll.l Time Series of Health related Quality of Life Factor-General 
Health Status by randomised group
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Figure lll.lll.lll Time Series of Health related Quality of Life Factor-Vitality
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Figure III.III.V Time Series of Health related Quality of Life Factor- Pain
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Figure III.III.V I! T im e Series o f H ealth  related Q uality  o f Life Factor - 
Social Function ing
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Specialty Manager: Stephanie Heaton
TELEPHONE: 020 7304 4773 at The Royal College of Surgeons of England
MEMBERSHIP: 020 7973 0303 35/43 LINCOLN’S INN FIELDS
Fax: 020 7430 9235 LONDON, WC2A 3PE
EMAIL: stephanie@asgbi.org.uk
23 October 2007
Dear Ms Barlow,
BJS Best Paper Prize- AUGIS Scientific Meeting, Cardiff 2007.
We are writing to congratulate you on your winning presentation during the Best Paper Session at the 
recent AUGIS meeting in Cardiff.
The 10 abstracts featured in the BJS Best Paper category scored the highest marks from the abstracts 
submitted for the conference, therefore to have been selected as the BJS prize winner is a true 
achievement. Your success was reflected in the extremely high standard in which your paper was 
presented.
Please find enclosed a token of your achievement.
Thank you for all the hard work - congratulations again on a job well done.
Kind Regards
Mr Merv Rees 
AUGIS President
Mr Rowan Parks 
Scientific Committee Chair
REGISTERED CHARITY NO. 1093090
